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Abstract
The stability of the genome is constantly challenged by both endogenous and exogenous
DNA damaging agents. DNA damage, if left unrepaired, can give rise to permanent genetic
alterations that ultimately increase our risk of cancer and other diseases. To combat these
threats, eukaryotic cells activate a DNA damage response (DDR) that coordinates a wide variety
of cellular processes including cell cycle progression, DNA repair, or in the case of
severe/irreparable damage, apoptotic cell death. In addition to its role in cancer prevention, the
DDR is fundamental in cancer treatment as noted by the numerous DNA damage-based
chemotherapies. Thus, understanding how cell fate is determined by consequences of DDR is
important for basic biological science and for medical applications.
Alkylating agents comprise a major class of DNA damaging chemotherapeutics. The
o MeG DNA lesion is a highly mutagenic, carcinogenic, and cytotoxic lesion produced by SNl
methylating agents. Additionally, persistent O6MeG lesions induce apoptosis in an O6MeG
DNA methyltransferase (MGMT) repair- and mismatch repair (MMR)-dependent manner. Here,
we examine the DNA damage response induced by the O6MeG lesion at both the molecular and
cellular level after treatment with the SN1 methylating agent N-methyl-N'-nitro-N-
nitrosoguanidine (MNNG). A systems-level approach combining various experimental
techniques was used to quantitatively monitor the temporal regulation of DDR network proteins
and, in parallel, phenotypic responses (cell cycle arrest, DNA replication, and apoptosis) induced
by 06MeG lesions. Through this approach, we have shown that TK6 human lymphoblastoid
cells undergo cell cycle delay through both the first and second cell cycle post treatment.
Furthermore, we demonstrate that 06MeG triggers an intra-S-phase arrest in the second S-phase
that ultimately leads to cell cycle progression and survival in cells with low/repairable amounts
of damage or apoptosis in cells with high/irreparable amounts of damage. Based on the signaling
and phenotypic data acquired, we developed a conceptual model for MMR's role in triggering
cell cycle arrest and cell death. In addition, exploration of the global transcriptional response
provided an unbiased approach to further elucidate previously unrecognized biological processes
involved in the response to MNNG-induced damage. Taken together, our results have enhanced
our understanding of the cellular response to alkylation-induced damage and will contribute to
the development of personalized chemotherapeutic treatments in the future.
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Chapter 1
Introduction
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Overview: DNA Damage Response
The genome is continuously exposed to DNA damaging agents found in our environment (e.g.
ultraviolet light from sunlight and chemicals found in cigarette smoke), as well as to endogenous
sources of DNA damage (e.g. reactive oxygen species formed as by-products of normal cellular
metabolism, spontaneous base hydrolysis, etc.) [4]. If left unrepaired, DNA damage can lead to
permanent genetic alterations such as mutations and chromosomal aberrations that ultimately
increase our risk of cancer, aging, and other diseases [6]. In order to maintain genomic integrity,
a cell activates a DNA damage response (DDR) that aims to slow down cell cycle progression
and repair the damage before such mutations are formed or, in the case where damage is too
severe or irreparable, to activate a programmed cell death response resulting in removal of the
cell from the population [7] [8]. The importance of the DDR in cancer prevention is highlighted
by a large number of hereditary DDR defects that predispose to cancer (highlighted in Table 1.1;
for more detail see reference [4]). Recently, the DDR has emerged as an important barrier
against tumorigenesis in precancerous lesions; in this model DNA double strand breaks (DSBs)
caused by oncogene-induced replication stress activate the DDR leading to growth arrest and cell
death [9] [10] [11]. With that being said, an understanding of the DNA damage response will
not only have important implications on our ability to prevent tumorigenesis, but since current
chemotherapeutics rely on the ability of DNA damaging agents to kill cancer cells, it will also
have important implications on our ability to improve cancer treatment (highlighted in Table 1.2;
for more detail see reference [3]).
A number of mechanisms exist for the repair of DNA lesions to prevent genetic alterations.
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These include direct DNA damage reversal, multiple excision repair pathways (base excision
repair, nucleotide excision repair, and mismatch repair), interstrand crosslink repair, single-
strand break repair, and double-strand break repair (nonhomologous end joining and homologous
recombination) [12]. The choice of repair process depends on many factors including the type
and location of damage, the cell cycle phase when the damage is incurred, and the specific cell
type. In particular, the inhibition of replication fork progression, whether by direct or indirect
mechanisms, represents a serious consequence of many DNA lesions. Therefore, in addition to
the DNA repair mechanisms listed above, damage tolerance mechanisms exist that allow the cell
to bypass damage encountered during DNA replication. Multiple strategies exist to relieve the
inhibition of replication including translesion DNA synthesis by specialized DNA polymerases,
recombination repair, and replication fork regression [13]. This thesis focuses on the response to
the 0 6-methylguanine (06MeG) DNA lesion. Two repair pathways that are critical determinants
of how cells respond to 06MeG are the O6MeG DNA methyltransferase (MGMT) repair protein
and the DNA mismatch repair (MMR) pathway. These repair pathways are discussed in more
detail later in this chapter.
While DNA repair is central to maintaining the integrity of the genome, efficient repair requires
its coordination with many other biological processes within the cell. In response to DNA
damage or replication stress, a DDR signaling network is activated that controls a wide variety of
cellular responses including cell cycle progression, DNA repair, and cell death (Figure 1.1) [7]
[8]. Although highly interconnected, the DNA damage signaling response can be thought of as a
signal transduction pathway composed of sensors that detect the damage and initiate the
signaling response, mediators that localize to and amplify the signal, and transducers that then
12
relay the signal from the site of damage to downstream effector proteins that directly regulate
cell behavior. In the following section I will highlight the major players in the DNA damage
signaling pathway and their biological roles.
DDR Signaling Network
Proteins such as ATM (ataxia-telangiectasia mutated), ATR (ataxia-telangiectasia and Rad3-
related), DNA-PKcs (DNA-dependent protein kinase catalytic subunit), and PARP- 1 (poly(ADP-
ribose) polymerase- 1) are classified as DDR sensors due to their ability to recognize and initiate
a signaling response following DNA damage. Mismatch repair (MMR) proteins have also been
proposed as a general sensor of DNA damage given their role in recognizing various lesions
(0 6MeG, cisplatin-, and IR-induced base lesions) and their potential in mediating downstream
signaling [1]. The role of MMR in DNA repair and 06MeG signaling will be discussed in detail
later. PARP-1 regulates diverse biological processes within the cell through the post-
translational modification of partner proteins via poly(ADP-ribosyl)ation [14]. Among its many
roles, PARP- 1 is a molecular sensor of single-strand breaks and is an important player in single-
strand break repair and base excision repair. The other members of this group, ATM, ATR, and
DNA-PKcs, are members of the phosphatidylinositol 3-kinase (PI3K)-like protein kinase (PIKK)
family. The PIKK family is made up of high molecular weight serine/threonine protein kinases
that participate in signaling following various stress responses [15]. Of the six mammalian
PIKKs, ATM, ATR, and DNA-PKcs are well known for their role in the DNA damage response;
in response to genotoxic stress, ATM, ATR, and DNA-PKcs, aided by partner proteins, are
rapidly activated and recruited to the site of damage where they phosphorylate their target
substrates [16]. DNA-PKcs, along with Ku70 and Ku8O, is known mostly for its essential role in
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double-strand break repair by non-homologous end joining although it has also been implicated
in a number of other cellular processes including telomere maintenance, transcription control,
and the regulation of apoptosis through p53 phosphorylation [17]. Of the sensors mentioned,
ATM and ATR have emerged as the major DNA damage signaling kinases with substrates that
cover a wide range of biological processes. In a recent large scale proteomic study, Matsuoka et
al. identified over 900 regulated phosphorylation sites on over 700 proteins that mapped to a
wide range of cellular processes including signal transduction, cell cycle control, DNA
replication, DNA repair, chromatin modification, transcription, and cell death to name a few
[18].
ATM and ATR: Activation and Function
ATM and ATR have emerged as central players in the DDR network due to their ability to sense
DNA damage and activate signaling cascades that regulate, through both transcription-dependent
and transcription-independent mechanisms, various cellular responses including DNA repair, cell
cycle arrest, and cell death. While ATM is primarily activated by double strand breaks (DSBs),
ATR responds broadly to lesions that give rise to single-stranded DNA coated by replication
protein A (RPA) [19] [20]. A common feature of activation is the recruitment of ATM and ATR
to sites of DNA damage through their accessory binding proteins. ATM is localized to DSBs
through interaction with the Mre 11-Rad50-Nbsl (MRN) complex that binds DNA ends, while
ATR in complex with ATRIP recognizes single-stranded DNA (ssDNA) bound by RPA [21]
[22]. In response to DSBs, local disruption of chromatin structure leads to the rapid
intermolecular autophosphorylation and dissociation of inactive ATM dimers into active
phosphorylated monomers [23]. Following recruitment of ATM to DSBs by the MRN complex,
14
ATM phosphorylates the histone H2A variant H2AX to form yH2AX. yH2AX is a central
mediator in the DNA damage response, facilitating the assembly and retention of numerous
DNA repair/signaling factors to the site of damage [24]. The accumulation of DNA damage
signaling and repair proteins into ionizing radiation-induced foci (IRIF) has been shown to be a
highly coordinated process both temporally and spatially involving a variety of post-translational
modifications; it is briefly summarized here [25] [26]. The phosphorylation of H2AX leads to
the recruitment of MDC 1 along with its binding partners, the MRN complex and the ubiquitin
ligase RNF8. RNF8, through its E3 ligase activity, poly-ubiquitinates yH2AX leading to the
recruitment of additional factors including the ubiquitin ligase RNF168 and the DNA repair
factors BRCA1 and 53BP1 (described in more detail in [27]). Although the function of these
foci is still unclear, the recruitment of DDR factors to the site of damage could serve to amplify
the DNA damage signal and promote efficient repair. While a majority of the work towards
understanding these events has been done with regard to DSBs (and ATM), other forms of
damage are known to trigger a robust DDR via the activation of the ATR protein kinase. As
stated previously, ATR is activated by various types of damage that result in replication protein
A (RPA)-coated single-stranded DNA, such as replication blocking lesions and DSB resection
intermediates [20]. As opposed to ATM, the molecular events marking ATR activation are not
as well established. A recent study by Liu et al. demonstrated that ATR is autophosphorylated at
threonine- 1989 after DNA damage and that this phosphorylation is critical for ATR function
[28]. Additionally, activation of ATR is directly stimulated by TOPBP 1 upon colocalization at
sites of DNA damage or replication stress [29]. While ATM and ATR are activated by different
mechanisms, both are critical for maintaining genomic integrity after DNA damage. ATM is
required for proper DNA repair and cell cycle control in response to DSBs. Cells deficient in
15
ATM are defective in multiple cell cycle checkpoints (G 1 /S, intra-S and G2/M) and double
strand break repair following treatment with ionizing radiation, accounting for the increased
radiosensitivity and genomic instability observed in ATM deficient cells [19]. ATR, while it
phosphorylates various substrates involved in cell cycle checkpoints and DNA repair, is
particularly important for fork stability following replication stress. In the absence of ATR,
stalled forks can collapse and form DSBs, ultimately leading to cell death [20].
CHK1 and CHK2 Checkpoint Kinases
Among the more prominent ATM and ATR substrates are the serine/threonine protein kinases
CHK1 and CHK2. CHK1 and CHK2 act as transducer kinases to relay the damage signal from
the upstream ATM/ATR protein kinases to effector proteins involved in DNA repair, cell cycle
arrest, and apoptosis [30] [31]. While CHK1 and CHK2 have overlapping functions, they are
activated through distinct pathways. Whereas CHK1 is activated by ATR in response to various
forms of genotoxic stress such as stalled replication forks and UV- and IR-induced DNA
damage, CHK2 is activated by ATM in response to DSBs [32] [33]. Active ATM
phosphorylates CHK2 on threonine-68; this event leads to dimerization and subsequent
autophosphorylation of CHK2 at threonine-383 and threonine-387, modifications required for
full kinase activation [34]. The mechanism of CHK1 activation is less clear. CHK1 activation
requires phosphorylation by ATR on serine-317 and serine-345 as well as its interaction with the
mediator protein Claspin [35] [36]. In both cases, CHK1 and CHK2 are transiently localized to
the site of damage where they are phosphorylated and activated; upon phosphorylation the
checkpoint kinases are released from chromatin and redistributed throughout the nucleus where
they phosphorylate their target substrates [37] [38]. The CHK1 and CHK2 protein kinases are
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critical regulators of the cell cycle checkpoint response [39]. In response to DNA damage,
CHKl/CHK2-dependent phosphorylation of the effector proteins p53 and CDC25 phosphatases
ultimately results in the inactivation of cyclin-dependent kinase (CDK) activity, consequently
arresting cells at various stages of the cell cycle (G1-S, intra-S, and G2-M) [40]. In addition to
its role in damage-induced cell cycle checkpoint control, CHK1 contributes to the regulation of
DNA replication in unperturbed cells, possibly contributing to the essential nature of this protein
[32]. CHK2, on the other hand, is not essential for cell survival; however, CHK2 defects
predispose to cancer and, at the cellular level, loss of CHK2 leads to defects in p53 function,
checkpoint responses, and apoptosis in response to ionizing radiation [30].
p53 Tumor Suppressor
A critical effector protein in the DDR network is the p53 tumor suppressor protein [41]. In
response to DNA damage and various other cellular stresses, p53 regulates the transcription of a
large number of target genes involved in DNA repair (e.g. DDB2, GADD45a) , cell cycle arrest
(p2 1 , TP53I3), and apoptosis (e.g. FAS, BAX) [42]. The stabilization and activation of p53 in
response to genotoxic stress is mediated in large part by a number of post-translational
modifications on the p53 protein itself and on its negative regulator MDM2 [43]. Among the
most recognized p53 modifications in response to DNA damage are the ATM/ATR-mediated
phosphorylation at serine-15 [44] [45] and the CHKl/CHK2-mediated phosphorylation at serine-
20 [46]. Depending on the cellular context and the nature of the stress signal, p53 activation can
lead to various cellular outcomes from DNA repair and survival to cell death or senescence; that
said, the precise mechanism by which p53 mediates the decision between life and death is still
under investigation [47].
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Overview: DNA Alkylation Damage
Alkylating agents are an important class of chemical DNA damaging agents that exist both
endogenously and exogenously [48]. While these agents are powerful mutagenic and
carcinogenic compounds, they are commonly used as chemotherapeutic agents due to their
cytotoxicity. Therefore, an understanding of how both normal cells and cancer cells respond to
such agents will have important consequences on the development of more effective cancer
prevention strategies and cancer treatments. This thesis work is focused on the cellular response
to DNA damage produced by the monofunctional SN1 type methylating agent N-methyl-N'-nitro-
N-nitrosoguanidine (MNNG). Monofunctional methylating agents have the ability to transfer a
single methyl group to nucleophilic sites in DNA, RNA, protein, and other macromolecules
within the cell [49]. Over a dozen different nucleophilic sites exist in DNA and the proportion of
methylation that occurs at the different sites depends on the mechanism of reaction (SN I or SN2
nucleophilic substitution) of the methylating agent [5]. While SN1 type methylating agents give
rise to both N-alkylated and 0-alkylated bases as well as alkylphosphotriesters in the DNA
backbone, SN2 type methylating agents attack mainly base nitrogens. The spectrum of lesions
produced by these two types of agents is illustrated in Figure 1.2 which summarizes the
distribution of methylated adducts in the DNA of cultured cells following treatment with two
commonly used laboratory methylating agents, N-methyl-N-nitorsourea (MNU) and methyl
methane sulfonate (MMS). These adducts can also give rise to secondary damage such as abasic
sites, strand breaks, and replication blocks. Thus, it is not surprising that the majority of known
repair mechanisms are important in modulating the cellular response to simple methylating
agents [49].
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MNNG
In this thesis, we use N-methyl-N'-nitro-N-nitrosoguanidine (MNNG) as a model SN I compound
to study the cellular response to an important class of methylating agents that target the 06
position of guanine, including the chemotherapeutic agents temozolomide, streptozotocin,
procarbazine, and dacarbazine [50]. MNNG is broken down in the cell into a reactive
methylating intermediate, CH 3 N2t , which modifies DNA through an SN I mechanism producing a
similar spectrum of adducts to that shown for MNU in Figure 1.2 [51]. The most abundant
lesion produced, N7-methylguanine (7MeG), is not directly mutagenic or lethal; however, its
susceptibility to spontaneous depurination can result in the formation of abasic sites that, if not
repaired, are potentially harmful to a cell. Following 7MeG in abundance are the 06_
methylguanine (O 6MeG) and N3-methyladenine (3MeA) lesions that make up approximately 8%
and 4% of the total alkylation generated by MNNG, respectively. 3MeA is a biologically
important DNA lesion as it is considered the major cytotoxic lesion produced by SN2 type
methylating agents. 3MeA, if not repaired, has been shown to slow S-phase progression, induce
sister chromatid exchanges and chromosome aberrations, and trigger apoptosis [52]. The main
repair pathway for 3MeA is base excision repair initiated by the alkyladenine DNA glycosylase
(AAG) [53] although other repair mechanisms (nucleotide excision repair, recombination repair,
and lesion bypass) have been shown to play a role in the response to this lesion [54] [55] [56].
The focus of this thesis, 06MeG, is a critical base lesion formed by SN 1 type methylating agents
and will be discussed in more detail below.
O'MeG
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Although it amounts to only 8% of total DNA methylation, 06MeG is the major mutagenic,
carcinogenic, and cytotoxic lesion produced by the methylating agent MNNG. 06MeG is
repaired by the O6MeG DNA repair methyltransferase (MGMT) protein using a direct damage
reversal mechanism (described below). In vitro and in vivo studies have demonstrated that
06MeG is preferentially mispaired with thymine during replication giving rise to G:C to A:T
transition mutations [57]. Studies in E. coli have shown that 06MeG is nearly 100% mutagenic,
with thymine almost always placed opposite the lesion during replication [58] [59]. Despite
having a reduced mutation frequency, similar studies in mammalian cells have also revealed
06 MeG-induced mutations to be almost exclusively G:C to A:T transition mutations [60] [61].
In addition, the persistence of 06MeG is potentially lethal to a cell. 06MeG-induced cytotoxicity
requires a functional mismatch repair (MMR) pathway as cells deficient in MMR are resistant to
killing by SN1 type methylating agents even in the absence of O6MeG repair by MGMT [62]
[63]. Cells that have lost MMR become tolerant of methylation damage, escaping cell death but
remaining sensitive to mutagenesis by 06MeG [64]. In addition to cell death, O6MeG induces
cell cycle arrest, sister chromatid exchanges, and chromosomal aberrations in a MMR-dependent
manner [65]. Several hypotheses exist for the role of MMR in mediating these outcomes and
will be described in more detail below.
MGMT
The human methyltransferase protein, 0 6-methylguanine DNA methyltransferase (MGMT),
restores O6MeG to its correct base through a direct damage reversal mechanism. MGMT
transfers the methyl group from the 06 position of guanine onto an internal cysteine residue
leading to inactivation and ubiquitin-mediated degradation of the protein [66] [67] [68]. The
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only other methyl substrate of MGMT, 0 4-methylthymine (0 4MeT), is repaired by MGMT with
very low efficiency, approximately 100-fold less well than 06MeG [69]. Rather than promoting
repair, studies have shown that MGMT actually inhibits the repair of 04MeT by the nucleotide
excision repair pathway [70]. Although this thesis deals with DNA methylation damage, it is
important to note that MGMT can also repair longer alkyl groups from the 06 position of
guanine including ethyl, n-propyl, n-butyl, and 2-chloroethyl groups [66]. Due to the specificity
for 06MeG, MGMT provides protection against the many potential biological effects of SN l type
methylating agents (i.e. toxicity, mutations, and carcinogenesis) and therefore plays an important
role in cancer prevention as well as in cancer treatment [71] [72] [73]. The importance of
MGMT in this regard is highlighted by the fact that MGMT promoter hypermethylation, leading
to loss of MGMT function, is a common epigenetic change in a variety of human tumors and that
methylation-mediated silencing of MGMT improves disease prognosis after treatment with
alkylating agents [74]. With that in mind, the inhibition of MGMT in tumors and the
overexpression of MGMT in normal tissue are current approaches being used in the clinic to
improve the effectiveness and reduce the toxic side-effects of chemotherapeutic alkylating agents
[68].
MMR
Mismatch repair (MMR) is responsible for the repair of base pair mismatches and
insertion/deletion loops resulting from errors during DNA replication [75]. The role of MMR
proteins is to recognize the mismatch, identify the newly synthesized strand, and replace the
misincorporated base with the correct base. This process is depicted in Figure 1.3 and
summarized here. MMR is initiated by the MutSa heterodimer (MSH2/MSH6) which
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recognizes and binds to the mismatch. The mismatch bound MutSa recruits the MutLa
heterodimer (MLH1/PMS2) and undergoes an ATP-dependent conformational change that
allows it to release the mismatch and translocate along the DNA in the form of a sliding clamp.
Strand discontinuities formed during DNA replication are encountered by the MutSa/MutLa
complex and are thought to direct repair to the newly synthesized daughter strand.
Reconstitution of an in vitro nick-directed mismatch repair system demonstrated that, in addition
to MutSa and MutLa, the components required for repair include the exonuclease EXO 1,
replication protein A (RPA), proliferating cell nuclear antigen (PCNA), replication factor C
(RFC), and DNA polymerase 6 [76]. In the current model, the endonuclease activity of MutLa
[77], guided by its interaction with PCNA [78], generates nicks spanning the mismatch in the
strand containing the pre-existing break. These nicks then serve as initiation sites for EXO 1-
mediated (5' to 3') degradation past the mismatch. Subsequently, the region of single-stranded
DNA is coated and stabilized with replication protein A (RPA). After removal of the mispaired
base, a replicative polymerase can then resynthesize the degraded region followed by sealing of
the nick by DNA ligase.
MMR-Mediated O6MeG Sensitivity
The methylating agent MNNG is known to induce cell cycle arrest and programmed cell death in
an 06MeG- and mismatch repair-dependent manner. Two models have been proposed to
describe the mechanism of mismatch repair-mediated sensitivity to this methylating agent, a
direct signaling model and a futile repair model (Figure 1.4). Replication past unrepaired
06 MeG lesions gives rise to 06MeG /T mismatches that are recognized and bound by MutSa
leading to the subsequent recruitment of MutLa. In the direct signaling model, the recruitment
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of MutSa/MutLa to the mismatch is thought to directly activate signaling that controls
downstream events such as cell cycle arrest and apoptosis. Alternatively, it is thought that the
unsuccessful processing of 06MeG /T mismatches by mismatch repair is the trigger for
activation of the DNA damage response. Following recognition of the mismatch by MMR
proteins, mismatch repair initiates the removal and reinsertion of the mispaired base in the
newly-synthesized daughter strand. Given that 06MeG resides in the template strand, a futile
repair cycle takes place generating secondary lesions including nicks and single strand gaps. It is
hypothesized that these gaps are encountered by replication forks in the following S-phase of the
cell cycle resulting in the blockage or collapse of DNA replication forks and double strand break
formation. These events in turn trigger a signaling response that activates the cell cycle
checkpoint and apoptotic signaling pathways. Evidence for both models exists and each will be
discussed in more detail in the following chapters in relation to this thesis work.
The goal of this thesis work has been to determine the molecular and cellular processes involved
in mediating cell survival and cell death decisions in response to the chemotherapeutically
relevant 06 MeG DNA base lesion. Various experimental approaches were developed to
quantitatively monitor the temporal regulation of DDR network proteins and, in parallel, the
phenotypic responses (cell cycle arrest, DNA replication, and programmed cell death) induced
by this DNA lesion. In this thesis, we will discuss the results obtained from such an approach.
We take a close look at the relationship between cell cycle progression and cell survival in
response to various levels of DNA damage. In addition, we discuss a model for MMR's role in
triggering cell cycle arrest and cell death based on the signaling and phenotypic data acquired.
Further, to gain a more general understanding of the biological processes that govern the cellular
23
response to DNA methylation damage, we explore the global transcriptional response induced by
the methylating agent MNNG.
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Figure 1.1 DNA Damage Signaling Response Figure from Nyberg et al. (2002) [2]
In response to DNA damage or replication stress, cells activate a DNA damage signaling
response that coordinates various cellular processes including cell cycle progression, DNA
repair, and apoptotic cell death. The ATM and ATR protein kinases are central players in this
response due to their ability to sense specific types of DNA damage and relay the damage signal
to a large number of downstream target proteins that control cell behavior. Key molecular
players in the DNA damage signaling response and their biological functions are discussed in
more detail in the text.
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Figure 1.2 DNA Alkylation Damage
(A) Susceptible nucleophilic sites of alkylation on DNA bases. Not shown are phosphotriesters
which can also be alkylated. (B) Distribution of alkylated adducts in the DNA of cultured cells
after treatment with the methylating agent MMS or MNU. nd = reported but not detected
(extracted from Beranek et al. (1990) [5])
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BA
Figure 1.3 Mismatch Repair Figure from Stojic et al. (2004) [1]
The repair of base pair mismatches by the mismatch repair (MMR) pathway is illustrated here
and described in more detail in the text. MMR is initiated by the MutSa heterodimer
(MSH2/MSH6) which recognizes and binds to the mismatch. The mismatch bound MutSa
recruits the MutLa heterodimer (MLHl/PMS2) and undergoes an ATP-dependent
conformational change that converts it to a sliding clamp capable of translocating along the
DNA. Strand discontinuities formed during DNA replication are encountered by the
MutSa/MutLa complex directing repair to the newly synthesized daughter strand. The
endonuclease activity of MutLa, guided by its interaction with PCNA, generates a nick 5' to the
mismatch. This is followed by EXO1-mediated (5' to 3') degradation past the mismatch.
Subsequently, the region of single-stranded DNA is coated and stabilized with replication protein
A (RPA). After removal of the mispaired base by EXO 1, a replicative polymerase resynthesizes
the degraded region and DNA ligase seals the nick.
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Figure 1.4 Models of 06MeG/MMR-dependent cell cycle arrest and apoptosis
Two models have been proposed to describe the mechanism of mismatch repair-mediated
sensitivity to the 06MeG lesion, a direct signaling model and a futile repair model. Replication
past unrepaired 06MeG lesions gives rise to 06MeG /T mismatches that are recognized by the
MutSa/MutLa complex. In the direct signaling model, the recruitment of MutSa/MutLa to the
mismatch directly activates protein signaling events that control cell cycle arrest and apoptotic
cell death. Alternatively, the unsuccessful processing of O6MeG /T mismatches by mismatch
repair is the trigger for activation of the DNA damage response. Following recognition of the
mismatch by MMR proteins, mismatch repair initiates the removal and reinsertion of the
mispaired base in the newly-synthesized daughter strand. Given that 06MeG resides in the
template strand, a futile repair cycle takes place generating secondary lesions including nicks and
single strand gaps. These gaps are encountered by replication forks in the following S-phase of
the cell cycle resulting in the blockage or collapse of DNA replication forks and ultimately the
formation of double strand breaks. These events in turn trigger a signaling response that
activates the cell cycle checkpoint and apoptotic signaling pathways.
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Table 1.1 List of hereditary syndromes that predispose to cancer and their associated DDR
defects (extracted from [4] and references within)
Syndrome Mutated Gene DDR Defect Cancer Phenotype
Xeroderma XPA-G, POLH NER Squamous and basal cell
pigmentosum (XP) carcinoma, melanoma
Fanconi anemia (FA) FANCA-C, FANCD1, ICL repair, HR AML, myelodysplasia,
D2, FANCE-G, FANCI, squamous cell
J, L-N carcinoma
Familial breast cancer ATM, BRCA1, BRCA2, HR, damage signaling Breast cancer, ovarian
BRIPI, CHK2, NBS1, cancer (BRCA1, BRCA2,
PALB2, RAD50, RAD51 C)
RAD51C
Bloom syndrom (BS) BLM HR Carcinomas, leukemias,
lymphomas
Rothmund Thomson RECQL4 BER, HR? Osteosarcoma, skin
syndrome (RTS) cancers
Werner syndrome (WS) WRN HR, BER, telomere Sarcomas
maintenance
Dyskeratosis congenita DKC1, TERC Telomere maintenance Carcinomas
(DKC)
MYH-associated MYH BER, oxidative damage Colorectal cancer
polyposis (MAP) repair
Hereditary nonpolyposis MSH2, MSH6, MLH1, MMR Colorectal cancer,
colorectal cancer PMS2 carcinomas
(HNPCC)
Ligase IV syndrome LIG4 NHEJ ALL, lymphomas
Radiosensitive severe ARTEMIS NHEJ Lymphomas
combined
immunodeficiency
(RS-SCID)
Ataxia telangiectasia ATM Damage signaling, DSB Lymphomas, leukemias,
(A-T)
Li-Fraumeni syndrome TP53
(LFS)
Nijmegen breakage NBS1
syndrome (NBS1)
repair, oxidative stress breast cancer
DNA damage signaling, Brain and breast cancer,
DSB repair sarcomas
Damage signaling, DSB B cell lymphoma
repair, replication fork
repair--
Seckel syndrome (SS) ATR, PCTN, SCKL2, Damage signaling, DSB AML?
SCKL3 repair, replication fork
repair
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Table 1.2 Examples of DNA-damaging chemotherapeutic drugs (extracted from [3] and
references within)
Cancer treatment
Ionizing radiation
Bleomycin
Alkylsulphonates
Temozolomide
Mitomycin C
Cisplatin
Camptothecins
Etoposide
Aphidicolin
Hydroxyurea
Types of DNA lesions induced
SSBs, DSB, base damage
Base damage, replication lesions, bulky DNA adducts
DSBs, DNA crosslinks, replication lesions, bulky DNA adducts
DSBs, SSBs, replication lesions
DSBs, replication lesions
42
Chapter 2
O6Methylguanine induces an intra-S-phase arrest from which cells
exit into apoptosis
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Abstract
DNA damage, if not repaired, can lead to mutations and chromosomal aberrations that ultimately
increase our risk of cancer. The DNA damage response is a protective mechanism that aims to
correct the damage before such deleterious events occur by delaying progression through the cell
cycle and repairing the damage or, in the case of severe damage, inducing cell death. One lesion
in particular, the 0 6-methylguanine (06MeG) lesion, is well known for its mutagenic,
carcinogenic, and cytotoxic properties. As current chemotherapeutics rely on the ability of
06MeG to induce cell death specifically in cancer cells but not in normal cells an understanding
of how a cell deals with this damage is of critical importance for improving current cancer
therapy. Research has shown that the cytotoxic nature of O6MeG is dependent on mismatch
repair (MMR). In this study we use human cells that differ only in their 06MeG DNA repair
methyltransferase (MGMT) or MMR status to study the 06MeG /MMR-dependent cell cycle and
cell death response after treatment with the methylating agent MNNG. We found that 06MeG
triggers MMR-dependent cell cycle perturbations in both the first and second cell cycle post
treatment. Both low and high levels of damage induce an intra-S phase arrest as cells proceed
into the second S-phase. At lower levels of damage, we show that this transient arrest precedes
survival and progression into subsequent cell cycles. However, at higher levels of damage arrest
coincides with a reduction in DNA replication followed by initiation of apoptotic cell death.
Further, we show that entry into apoptotic cell death is specifically from S-phase of the second
cell cycle.
44
Introduction
Our DNA is constantly under attack by DNA damaging agents that are found in our environment
as well as being present endogenously during normal cellular metabolism [1]. If not repaired,
DNA damage can lead to permanent genetic alterations such as mutations and chromosomal
aberrations that ultimately increase our risk of cancer and other diseases [2]. In order to maintain
genomic integrity, cells activate a DNA damage response that serves to slow down cell cycle
progression and to repair the DNA damage before mutations and aberrations are formed [3] [4].
In cases where damage is gauged as too severe or irreparable, cells activate a programmed cell
death response resulting in their elimination from the population. The accurate execution of the
DNA damage response is not only important in preventing cancer but also in treating cancer as
many commonly used chemotherapeutic agents function by generating DNA damage that
induces death in cancer cells [5].
Methylating agents are an important class of DNA damaging agents currently used as cancer
chemotherapeutic agents [6]. Here we investigate the cell cycle and cell death response to the
methylating agent N-methyl-N'-nitro-N-nitrosoguanidine (MNNG) to gain a better understanding
of how cells coordinate cell cycle progression and how cell death is triggered by the critical
DNA base lesion 0 6-methylguanine (0 6MeG). The monofunctional SNi type methylating agent
MNNG, like the chemotherapeutic agents temozolomide and procarbazine, produces a spectrum
of DNA damage that includes over a dozen different methylated base lesions [7]. The fact that
the specific repair of 0 6MeG by the MGMT DNA methyltransferase protein prevents many of
the detrimental effects of MNNG has pinpointed 0 6MeG as one of the major genotoxic,
carcinogenic, and cytotoxic lesions in cells treated with such agents [8]. MGMT directly repairs
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06MeG by transferring the methyl group from the 06 position of guanine to an internal cysteine
residue on the protein; such transfer causes a conformational change leading to MGMT's
ubiquitin-mediated degradation [9] [10] [11]. If left unrepaired, 06MeG preferentially mispairs
with T during DNA replication ultimately giving rise to G:C to A:T transition mutations [12]
[13]. Importantly, 06MeG-induced cytotoxicity is dependent on mismatch repair (MMR), as
cells deficient in this pathway are resistant to killing by SNI type methylating agents especially in
the absence of 06MeG repair by MGMT [14] [15]. With loss of MMR, cells become
'methylation tolerant', escaping cell death even though 06MeG remains unrepaired; however the
cost of such tolerance is increased sensitivity to the mutagenic and carcinogenic effects of
methylating agents that produce O6MeG lesions [16].
The methylating agent MNNG is known to induce apoptotic cell death in an 06MeG- and MMR-
dependent manner [17] [18] [19] [20] [21]. Two models have been proposed for the mechanism
of MMR-mediated sensitivity to this methylating agent (illustrated in Figure 1.2) and we should
point out that the models are not mutually exclusive. The first replication past an unrepaired
06 MeG lesion gives rise to an 06 MeG/T mismatch that can be recognized and bound by MutSa
(MSH2/MSH6) directing the recruitment of MutLa (MLH1/PMS2) to the mismatch [22] [23]
[24]. In the direct signaling model, MMR proteins bound to the 06MeG/T base pair are thought
to directly activate signaling that controls downstream events such as DNA repair, cell cycle
arrest, and apoptosis. In support of this hypothesis, recruitment of the ATR protein kinase to the
MutSa/MutLa-bound 06 MeG /T mismatch, accompanied by ATR kinase activation, was shown
to occur in vitro [23]. In addition, it was demonstrated that a particular missense mutation in
Msh2 or Msh6 uncouples the DNA repair function of MMR from its role in DNA damage-
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induced apoptosis suggesting that excision of DNA opposite the 06MeG lesion may not be
required for the DNA damage response function of MMR [25] [26]. Alternatively, it is thought
that the futile rounds of excision and resynthesis of DNA at 06MeG /T mismatches (on the T-
mismatch containing strand) provide the trigger for activation of the DNA damage response.
Following recognition of the mismatch by MutSa and MutLa, MMR initiates the removal and
reinsertion of the mispaired base in the newly-synthesized daughter strand (Figure 1.2). Given
that 06 MeG resides in the template strand, iterative repair attempts by MMR would lead to
secondary lesions in the DNA including nicks and single strand gaps [27]. It is hypothesized that
these gaps are encountered by replication forks in the next S-phase resulting in the blockage or
collapse of DNA replication forks with ensuing DNA double strand break formation. These
events in turn trigger a signaling response that activates the cell cycle checkpoint and the
apoptotic signaling pathways. Multiple lines of evidence support this model. In agreement with
the idea that a cell requires two rounds of replication to induce a DNA damage response,
06MeG/MMR-dependent apoptosis and G2 cell cycle arrest have been shown to only be
activated after the second S-phase following treatment with SN 1 type methylating agents [28]
[29] [30]. Indeed, it was shown that MMR-dependent single-stranded gaps accumulate and
persist in newly replicated DNA after MNNG treatment, providing in vivo evidence of iterative
excision by MMR, [31]. In addition, the importance of the excision step in inducing apoptosis
was demonstrated using a mouse model deficient in the MMR exonuclease, exonuclease 1
(Exo 1); the absence of Exo 1 conferred resistance to 06MeG-induced cell death, although the
extent of resistance was cell type dependent [32]. Finally, the futile repair model is thought to
lead to stalled replication forks at single strand regions in the second S-phase. The stalled forks
are ultimately rescued by recombination bypass or, in the event of fork collapse, give rise to
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DSBs that also require recombination in order to be resolved. Studies have demonstrated that
both sister chromatid exchanges (SCEs) and chromosomal aberrations, two results predicted by
the futile repair model, are induced by the O6MeG lesion in an MMR-dependent manner [33].
Importantly, the induction of SCEs and aberrations observed in these studies occurred almost
exclusively in the second post-treatment cell cycle. In addition, loss of homologous
recombination was shown to sensitize cells to MNNG in an 06MeG and MMR-dependent
manner suggesting that stalled replication forks and/or DSB lesions formed by collapsed
replication forks at MMR-induced strand breaks are responsible for the observed cell death [34]
[35] [36].
In this study we investigate the dynamics of the cell cycle checkpoint response and the cell death
response to MNNG in the human lymphoblastoid cell line TK6 and its derivatives
(TK6/MGMT+ and TK6/MMR-) to gain a deeper understanding of how MMR mediates these
cellular responses following induction of the O6MeG lesion. It was previously shown that the
06MeG DNA base lesion triggers a MMR-dependent apoptotic response in TK6 cells mediated
at least in part by the mitochondrial signaling pathway [37]. The expression of the MGMT
protein, which specifically repairs the O6MeG lesion, was able to suppress, in its entirety, the
apoptotic response of TK6 cells upon treatment with the methylating agent MNNG. In addition,
the MMR-deficient TK6-derivative cell line, TK6/MMR-, was used to demonstrate that this
06 MeG-induced apoptotic response is also entirely MMR dependent. The MMR-deficient
phenotype of TK6/MMR- cells is caused by a mutation in MSH6 that disables the MutSa sliding
clamp from translocating along the DNA, an important early event in the MMR process [38]
[39]. Due to this deficiency in the MutSa mismatch recognition complex, TK6/MMR- cells are
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resistant to MNNG despite their lack of MGMT expression and despite the persistence of
06MeG lesions in their DNA [15] [40]. Here, with detailed kinetic analysis, we demonstrate that
MNNG induces an intra-S-phase arrest in TK6 cells not only in the second cell cycle following
treatment, as expected, but also in the first cell cycle. Moreover, each response is dependent on
both 06 MeG and MMR. At lower levels of damage, we observe that transient arrest precedes
survival and progression into subsequent cell cycles. However, at higher levels of damage arrest
is followed by apoptotic cell death and entry into apoptotic cell death is specifically from S-
phase of the second cycle.
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Materials and Methods
Cell Culture and Treatment Conditions
The TK6 B-lymphoblastoid cell line and its derivatives, TK6/MGMT+ and MTl (here referred
to as TK6/MMR-) have been described previously [37]. Cells were maintained in RPMI
medium 1640 (Gibco #11875) supplemented with 10% equine serum, 2 mM L-glutamine, 100
units/ml penicillin, and 100 ptg/ml streptomycin. Due to the large number of cells needed,
timecourse experiments were performed in 1 L or 3L spinner flasks. For drug treatment,
logarithmically growing cells were split to a density of 3x10 5 cells/ml and MNNG, in 0.1 M
sodium acetate (pH 5.0) was added directly to the culture medium. Cells were collected at the
indicated time points and prepared as described for further analysis. Live and total cell
concentrations were monitored using a Vi-cell XR cell viability analyzer (Beckman-Coulter).
Percent control growth was quantified as the percent viable cell density of treated cells compared
to untreated control cells.
Annexin V and 7AAD Staining
Cells were washed once with annexin binding buffer (ABB: 10mM HEPES, 140mM NaCl,
2.5mM CaCl2, pH 7.4) and resuspended in 50pl ABB containing PE-conjugated annexin V (1:25
dilution) and 7AAD (15 tg/ml). Cells were incubated for 15 minutes at room temperature.
Following incubation, 250pl of ABB was added to the cell suspension and analyzed immediately
on a BD FACScan flow cytometer. 7-aminoactinomycin D (7AAD) (#A1310) and PE-
conjugated annexin V (#A351 11) were obtained from Molecular Probes.
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Cleaved (Active) Caspase-3 and Cleaved (Inactive) PARP Detection
Cells were washed once in cold PBS and resuspended in 500pl 4% paraformaldehyde in PBS
(Electron Microscopy Sciences #15700). Cells were fixed for 15 minutes at room temperature.
After fixation, cells were washed with PBS and resuspended in 500ptl 100% methanol. Methanol
suspensions were stored at -20'C. All antibody staining steps was performed in 96-well v-
bottom plates. Fixed cells were resuspended in 200pl PBS-B (1% BSA) and blocked at room
temperature for 30 minutes. Following incubation, cells were incubated in 100pl of primary
antibody diluted at 1:200 in PBS-TB (0.1% Tween 20 and 1% BSA) for 1 hour at room
temperature. Anti-cleaved (active) caspase-3 antibody (#559565) and anti-cleaved (inactive)
PARP antibody (#552597) were purchased from BD Biosciences. Following primary antibody
incubation, cells were washed twice with PBS-T (0.1% Tween 20). Cells were then resuspended
in 100pl PBS-TB containing secondary antibody diluted at 1:600 and incubated for 1 hour at
room temperature. The secondary antibodies used, PE-conjugated goat anti-rabbit IgG (#P2771)
and Alexa Fluor 647-conjugated goat anti-mouse IgG (#A21235), were purchased from
Molecular Probes. Finally, cells were washed twice with PBS-T, resuspended in 100plI PBS-TB,
and analyzed on a BD FACSCalibur flow cytometer.
Simultaneous Detection of DNA Content and Apoptotic Markers
For the simultaneous detection of DNA content and apoptosis, cells were fixed and stained for
cleaved (active) casapase-3 and cleaved (inactive) PARP as described above. Following
secondary antibody incubation, cells were washed once with PBS-T and resuspended in 200pl
Hoechst 33258 (10mg/ml stock solution, Invitrogen) at 1:10,000 dilution in PBS. Cells were
incubated in Hoechst 33258 for 10 minutes at room temperature in the dark. Finally, cells were
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washed with PBS-T and resuspended in 120pl PBS-TB for analysis on a FACS LSR II flow
cytometer.
Detection of Mitotic Cells - Phospho Histone H3 and DNA Content
Cells were washed once in cold PBS and resuspended in 500pl 4% paraformaldehyde in PBS
(Electron Microscopy Sciences #15700). Cells were fixed for 15 minutes at room temperature.
After fixation, cells were washed with PBS and resuspended in 500pl 100% methanol. Methanol
suspensions were stored at -20'C. Fixed cells were washed once with PBS followed by
permeabilization with Triton X-100. For permeabilization, cells were suspended in 400pl of
PBS + 0.25% Triton X-100 for 15 minutes at room temperature. Afterwards, cells were washed
with PBS-B (1% BSA) and resuspended in 100pl PBS-B containing primary antibody against
phosphorylated Histone H3 (0.75pg). Anti-phospho-Histone H3 (Ser 10) antibody was
purchased from Upstate (#06-570). Cells were incubated with primary antibody for three hours
at room temperature. Following antibody incubation, cells were washed twice with PBS-B and
incubated with Alexa Flour 647-conjugated goat anti-rabbit IgG antibody (Molecular Probes
#A21244) diluted in 100ptl PBS-B (1:30) for 30 minutes at room temperature. Finally, cells were
washed twice with PBS and resuspended in lml PBS containing 50pg propidium iodide
(Molecular Probes # P21493) and 500gg RNase A (Sigma #R6513). Cells were analyzed on a
BD FACSCalibur flow cytometer for phospho-Histone H3 detection and DNA content.
Detection of DNA Synthesis - BrdU Incorporation and DNA content
One hour before cell collection, BrdU was added to the culture medium at a concentration of
10p.M. At the corresponding time point, cells were collected, washed with cold PBS, and
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resuspended in 500pl cold PBS. Cells were fixed by adding 5ml ethanol (-20'C) while vortexing
to prevent clumping and stored at 4'C overnight. In order to provide access to the incorporated
BrdU, partial DNA denaturation was needed prior to staining with anti-BrdU antibody. Fixed
cells were washed with PBS-B (1% BSA) and incubated in lml 2M HCl + 0.5% Triton X-100
for 30 minutes at room temperature, followed by incubation in Iml 0.1M Na 2B40 7 for 2 minutes
at room temperature. Next, cells were washed in PBS-TB (0.5% Tween 20 and 1% BSA) and
resuspended with anti-BrdU antibody (BD Biosciences #555627) diluted in 60pl PBS-TB (5gg
antibody per approx 5x10 6 cells) and incubated at room temperature for 2 hours. Cells were
washed twice with PBS-T (0.5% Tween 20) and resuspended in 55pl PBS-T containing 5pl
Alexa Fluor 647-conjugated goat anti-mouse IgG antibody (1:11 dilution, 1 Opg of antibody per
approx 5x106 cells). Cells were incubated with secondary antibody for 1 hour at room
temperature (Molecular Probes #A21235). Cells were then washed twice with PBS-T and
resuspended in 1ml PBS containing 50pg propidium iodide (Molecular Probes # P21493) and
500pg RNase A (Sigma #R6513). Cells were analyzed on a BD FACSCalibur flow cytometer
for BrdU detection and DNA content.
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Results
In this study we used the TK6 human lymphoblastoid cell line and two of its derivatives
(TK6/MGMT+ and TK6/MMR-) to investigate the detailed kinetics of the cell cycle checkpoint
and apoptotic cell death responses after DNA damage by the methylating agent MNNG.
Quantitative and dynamic phenotype measurements were obtained for multiple treatment
conditions including untreated, low dose (0.01 pg/ml) MNNG, and high dose (0.1 tg/ml)
MNNG.
MNNG inhibits cell growth in an O6MeG/MMR-dependent manner.
Treatment of TK6 cells with MNNG resulted in a dose-dependent inhibition of cell growth. The
viable cell density of TK6 cells was monitored over time following exposure to MNNG (Figure
2. lA). We observed a significant decrease in the viable cell density compared with untreated
control (percent control growth) as early as 12 and 24 hours after treatment with high dose (0.1
ptg/ml) and low dose (0.01 pg/ml) MNNG, respectively, and this inhibition increased with time
(Figure 2.1B). At 48 hours, the percent control growth of TK6 cells was 60 percent and 19
percent for low dose and high dose conditions, respectively (Figure 2. 1B). This decrease in cell
growth was found to be dependent on the persistence of 06MeG lesions and on functional MMR
as this inhibition was not observed in TK6/MGMT+ or TK6/MMR- cell lines (Figures 2. lA and
2.1C). It is important to note that the viable cell density of untreated TK6 cells doubled within
the first 16 hours of the timecourse experiment and that this doubling was delayed following
treatment with low dose (0.01 ptg/ml) and high dose (0.1 pg/ml) MNNG (Figure 2.1A). This
would suggest that the growth inhibition we observed at 12 hours is due to events occurring
within the first cell cycle following treatment with MNNG. Although delayed, the cell density of
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TK6 cells treated with low dose (0.01 pg/ml) MNNG doubled twice within the 48 hour
timecourse, once by 20 hours and again at 40 hours, indicating cell division and progression into
subsequent cell cycles. In contrast, when treated with high dose (0.1 pig/ml) MINNG the cell
density doubled only once. To gain more insight into the source of this DNA damage-induced
growth inhibition we chose to look at the cellular responses of cell death and cell cycle
progression in more detail.
MNNG induces O6MeG/MMR-dependent apoptotic cell death in the second cell cycle.
A recent study by Quiros et al. [30] showed that activation of apoptosis is a late event occurring
only after cells pass through their second replication cell cycle post MNNG treatment. To more
precisely examine the timing of the cell death response in TK6 cells we monitored several
distinct markers of apoptosis including caspase-3 and PARP cleavage, phosphatidylserine
exposure, membrane permeability, and DNA fragmentation. An early event in apoptosis is the
flipping of the phospholipid phosphatidylserine (PS) to the outer surface of the cell membrane.
This translocation of phosphatidylserine was analyzed by flow cytometry using the
phospholipid-binding protein annexin V as a probe to detect PS exposure in cells undergoing
apoptosis. Staining with annexin V in combination with the vital dye 7AAD allowed us to
distinguish between cells that were early apoptotic (annexin+7AAD-), mid apoptotic or necrotic
(annexin+7AAD+), and late apoptotic or necrotic (annexin-7AAD+). Both mid to late apoptotic
and necrotic cells lose their membrane integrity and stain positive for 7AAD. We observed a
small but significant increase in the number of cells staining positive for annexin V and/or
7AAD (total cell death) as early as 24 hours after treatment with low dose (0.01 ptg/ml) MNNG
and 16 hours after treatment with high dose (0.1 ptg/ml) MNNG (Figure 2.2A). Cell death
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increased steadily with time in a dose-dependent manner, with approximately 11 percent, 30
percent, and 76 percent cell death at 48 hours for untreated, low dose MNNG, and high dose
MNNG respectively (Figure 2.2A). Representative flow cytometry plots of TK6 cells untreated
or treated with high dose MNNG are shown in Figure 2.2B. Although differentiation between
necrosis and mid- to late-apoptosis could not be determined directly, detection of PS by annexin
V preceded the loss of membrane integrity, providing evidence that the cell death observed in
these studies is apoptotic rather than necrotic (illustrated in Figure 2.2C).
Due to the central role of caspases in the execution of apoptotic cell death we chose to monitor
the active form of the effector caspase, caspase-3, and the cleavage of its substrate, PARP, by
flow cytometry. Caspases are intracellular cysteine proteases that are activated during the early
stages of apoptosis and are responsible for the execution phase of the apoptotic cell death
program [41]. We observed a small yet significant increase in apoptosis in TK6 cells at 16 hours
in response to both low (0.01 pg/ml) and high (0.1 [tg/ml) doses of MNNG that increased with
time in a dose-dependent manner (Figure 2.3A); in other words the increase in apoptosis with
time was steeper at the high dose versus the low dose of MNNG. At 48 hours, cleaved (active)
caspase-3 and/or cleaved (inactive) PARP levels (total apoptosis) was detected at 4 percent, 13
percent, and 68 percent for untreated, low dose MNNG, and high dose MNNG respectively
(Figure 2.3A). Figure 2.3B compares flow cytometry plots obtained for TK6 cells left untreated,
or treated with high dose MNING. Importantly, the induction of apoptosis observed in TK6 cells
was 06MeG- and MMR-dependent, as TK6/MGMT+ cells and TK6/MMR- cells did not display
any significant increase in apoptosis following treatment with high dose (0.1 ptg/ml) MNNG
(Figure 2.3C). Another commonly used marker and hallmark of apoptotic cell death is the
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fragmentation of DNA. In agreement with the caspase-3 and PARP results, flow cytometry
analysis of cells stained with propidium iodide (PI) showed a dose-dependent accumulation of
subG 1 DNA content beginning 16 hours after treatment with MNNG (Figure 2.6G); these results
are discussed later. In summary, using multiple methods of detection, we have demonstrated that
06MeG and MMR-dependent apoptosis was triggered as cells entered the second cell cycle post
treatment, supporting an indirect futile cycling model for mismatch repair-mediated signaling for
cytotoxicity. With that being said, we observed a significant reduction in viable cell density
compared to control as early as 12 hours after high dose treatment, prior to the induction of
apoptosis, leading us to hypothesize that additional behaviors besides cell death are influencing
cell growth after MNNG treatment (Figure 2.1 B). Cells exposed to DNA damage undergo cell
cycle arrest leading to a delay in cell cycle progression; to examine whether the growth
inhibition we observed was brought about by a delay in cell cycle progression we chose to
monitor the dynamics of the cell cycle response in cells exposed to MVNNG.
MNNG induces O6MeG and MMR-dependent cell cycle perturbations in both the first and
second cell cycle post treatment.
To characterize the cell cycle response to DNA alkylation damage we monitored DNA content in
combination with BrdU incorporation, a marker of active DNA replication, following MNNG
exposure. Cells were pulse labeled with BrdU for one hour prior to the indicated time point and
subsequently analyzed for incorporation of BrdU into replicating DNA, as well as for total DNA
content, by flow cytometry. Coupling a measure of active replication with DNA content allowed
us to visualize and quantitate cell cycle stage and the cellular events during S-phase in more
detail. Figure 2.4 depicts BrdU versus DNA content flow cytometry plots for a subset of time
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points analyzed in order to demonstrate the gating used to quantify the percent of cells in each
phase of the cell cycle. As shown, GI and G2/M cells have 2N and 4N DNA content
respectively. Using this method we could detect very early S-phase replicating cells even though
they stain as GI cells with PI. In addition, we could detect very late S-phase replicating cells
with apparent G2/M DNA content. Moreover, in mid S-phase it was possible to distinguish
replicating and non-replicating cells by whether or not they had incorporated BrdU during the
one hour pulse labeling time. As mentioned previously, subG1 DNA content was used as a
measure of apoptotic cell death.
The visualization and detailed quantitation of cell cycle stage with time following the treatment
of TK6 cells with low and high doses of MNNG revealed interesting cell cycle dynamics
(Figures 2.5 and 2.6A-H). As early as eight hours after MNNG treatment TK6 cells showed a
small but significant increase in the proportion of cells in mid S-phase (high dose) and G2/M-
phase (low and high dose) of the cell cycle with a simultaneous dose-dependent decrease in the
GI population (Figures 2.6A-C). These data indicate a delay in cell cycle progression within the
first cell cycle following treatment with MNNG and explains the observed delay in growth at
early timepoints (Figure 2. lA). This initial checkpoint response appeared to dissolve by 16
hours as cells were observed to progress from S to G2/M and from G2/M to G 1, indicated by a
drop in mid S-phase (total) cells in parallel with an increase in the G2/M and G 1 population at
this time (Figures 2.6A-C; high dose). At 24 hours post treatment we observed a distinct
accumulation of mid S-phase (total) cells under both low (0.01 pg/ml) and high (0.1 pg/ml) dose
conditions compared with untreated cells (Figure 2.6B). Notably, at this time the number of
viable cells under both treatment conditions had doubled suggesting that these cells are entering
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into the second S-phase post treatment (Figure 2.1A). Under low dose conditions this
accumulation was transient and was followed by an increase in the G2/M and G 1 fraction of cells
at 32 and 40 hours respectively, indicating resumed progression through the cell cycle (Figures
2.6A and 2.6C). In support of cell cycle progression, the density of these cells reached a second
doubling around 40 hours (Figure 2.1 A). Following treatment with the high dose, cells showed
an increased delay in S-phase compared to the low dose, with accumulation of total mid S-phase
cells peaking at 32 hours (Figure 2.6B). In contrast to the low dose, the subsequent decrease of
mid S-phase cells at late timepoints was not accompanied by an increase in the G2/M or GI
populations (Figures 2.6A and 2.6C). Rather we observed a corresponding increase in cells with
subG1 DNA content (Figure 2.6G). An increase in subG1 was also observed in cells treated with
the low dose of MNNG but to a lesser extent. It is important to note that the cell cycle
perturbations that we observed in TK6 cells were 06MeG- and MMR-dependent. Equivalent cell
cycle analysis was carried out using TK6/MGMT+ and TK6/MMR- cell lines following high
dose treatment with MNNG (Figures 2.7-2.10). Although a significant change (p-value<0.05)
was observed at eight hours in the G2/M- and early S-phase populations after high dose
treatment in TK6/MGMT+ cells, the perturbation was minimal and much smaller than that seen
for TK6 cells (Figure 2.8). At all the subsequent time points, no significant differences were
observed with high dose treatment compared to untreated cells in TK6/MGMT+ cells (Figure
2.8). TK6/MMR- cells showed no significant differences between the untreated and treated
conditions at any of the time points measured (Figure 2.10). From this analysis we have
demonstrated that MNNG induces dynamic changes in all phases of the cell cycle and that these
perturbations are 06MeG- and MMR-dependent. Delays in cell cycle progression in response to
DNA damage are brought about by the activation of cell cycle checkpoints that arrest cells in a
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particular cell cycle stage allowing time for DNA repair. Here we look more closely at several
of these cell cycle checkpoints.
MNNG induces an early G2/M arrest that delays but does not inhibit progression into the
next cell division.
Previous studies have demonstrated a G2 arrest in the second, but not the first, cell cycle
following MNNG treatment [28] [30]. To test whether the early cell cycle perturbations we
observed in TK6 cells involved a bonafide G2 arrest, cells were stained with an antibody against
the mitotic marker, phospho-histone H3, and mitotic cells were detected by flow cytometry
(Figure 2.61). As discussed previously, a small but significant increase in the percent of G2/M-
phase cells was seen at eight hours following treatment with both low and high doses of MNNG
(Figure 2.6C). At this time, we also detect a significant decrease in the proportion of mitotic
cells staining positive for phospho-histone H3 (Figure 2.61). This data suggests that shortly after
MNNG treatment TK6 cells activate a G2 checkpoint preventing G2 cells from entering mitosis.
However, this checkpoint appeared to be short-lived as the fraction of mitotic cells returned to
untreated levels at 16 hours, accompanied by a corresponding movement of cells into G 1
(compare high dose curves in Figures 2.6A and 2.61). Cell division and the entrance of cells into
G1 from G2 requires movement through mitosis; indeed the changes in phospho-histone H3
positive cells (mitotic cells) and G 1-phase cells mirror each other throughout the timecourse
experiment (compare Figures 2.6A and 2.61). Although a transient G2 arrest cannot be
eliminated in the second cell cycle, a strong delay in the progression of cells into GI from G2/M
at late time points was not evident following low dose treatment. Following the movement of
cells into G2/M-phase from S-phase, we detected an increase in the fraction of phospho-histone
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H3 positive cells between 32 and 40 hours in parallel with as an increase in the fraction of GI-
phase cells at this time (compare low dose curves in Figures 2.6A and 2.61). In addition, cell
division and cell cycle progression after low dose treatment was supported by a second cell
density doubling around 40 hours as discussed previously (Figure 2.1 A). Under high dose
conditions, cells did not appear to progress into G2/M from the second cell cycle S-phase but
rather we observed an increase in the fraction of cells with subG 1 DNA content at this time. In
agreement with this, phospho-histone H3 levels remained low at late timepoints (Figure 2.61).
The observation that TK6 cells do not arrest in G2 of the second cell cycle in response to MNNG
is in contrast to previous studies that show a dramatic accumulation of cells in this phase of the
cell cycle [28] [30]. In contrast, we observed that TK6 cells accumulate in mid S-phase of both
the first and second cell cycle, and under high doses do not appear to escape the second S-phase
indicating activation of an intra-S phase checkpoint that we chose to look into further.
MNNG induces an intra-S-phase arrest indicated by a reduction in S-phase DNA
replication.
In an effort to protect the genome, cells that encounter damage to their DNA during DNA
replication activate an intra-S-phase checkpoint. This checkpoint slows the progression of S-
phase, allowing time for repair, by suppressing the firing of late origins and by stabilizing stalled
replication forks. As discussed previously, we observed an 06MeG/MMR-dependent
accumulation of cells in mid S-phase in both the first and second cell cycle following treatment
with MNNG, suggesting activation of an intra-S-phase checkpoint (Figure 2.6B). To look more
closely at the replication status of these cells, we divided the mid S-phase population into
replicating and non-replicating populations defined by whether or not they incorporated BrdU
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during a one hour period prior to the time point indicated. Figures 2.6E and 2.6H break down
the data in Figure 2.6B into replicating (2.6E) and non-replicating (2.6H) cells; note that the data
look dramatically different in Figure 2.6E versus 2.6H, while 2.6B represents a composite. At
late time points, we observed an increase in mid S-phase cells with impaired DNA replication
following MNNG treatment (Figure 2.6H and Figure 2.11). To account for changes in the
number of mid S-phase cells specifically, loss of replication potential is more clearly represented
in Figure 2.11, which shows mid S BrdU- cells as the percent of total mid S-phase cells as
opposed to the percent of total cells (as displayed in Figure 2.6). Beginning 16 and 24 hours
after high dose and low dose treatment, respectively, we observed an increase in the fraction of
TK6 cells in mid S-phase with reduced BrdU incorporation; and the proportion of cells with low
replication activity increased with time in a dose-dependent manner (Figure 2.11). At 48 hours
the majority (80%) of cells remaining in mid-S phase following treatment with high dose MNNG
were not engaging in DNA replication (Figure 2.11). From this data it is clear that the DNA
lesion O6MeG provokes an intra-S phase checkpoint that, through either stalled replication forks
or a reduction in the firing of replication origins, or both, results in a dose-dependent decrease in
DNA replication, accompanied by the accumulation or trapping of cells in S-phase.
Apoptosis is specifically triggered out of the second cell cycle intra-S-phase arrest.
Cell cycle analysis of TK6 cells treated with MNNG indicated an intra-S-phase arrest in both the
first and second cell cycle post treatment. The second intra-S-phase arrest was marked by an
increase in the overall S-phase population as well as a decrease in the replication status of those
S-phase cells. Importantly, the second intra-S-phase arrest coincided with the induction of cell
death via apoptosis. We hypothesized that the MNNG-induced intra-S-phase arrest in the second
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cell cycle, is accompanied by an inability to recover, and that this prompts cells to trigger
apoptosis. To test the connection between triggering apoptosis and cell cycle stage we treated
TK6 cells with MNNG and measured cleaved (active) caspase-3 in combination with DNA
content. MNNG induced an increase in cleaved caspase-3 as cells entered the second cell cycle
post treatment (>16 hours) and the majority of cleaved caspase-3 positive cells had S-phase or
subG1 DNA content across all time points (Figure 2.12A, Figure 2.13). At 40 hours, 92 percent
of caspase-3 positive cells had either S phase or subG 1 DNA content following treatment with
high dose (0.1 ptg/ml) MNNG (Figure 2.12A). The specificity for cell death out of S phase is
evident in Figure 2.12B, which depicts the cell population 32 hours after treatment with MINNG
according to their cleaved caspase-3 and DNA content status. Under low dose conditions, a
fraction of cells in S-phase showed an induction of apoptosis, illustrated by their positive cleaved
caspase-3 status on the flow cytometry plot, while cells that had progressed through S into G2/M
were negative for cleaved caspase-3 and therefore not undergoing caspase-dependent apoptosis
(Figure 2.12B). Under high dose conditions, a similar but more pronounced S-phase-dependent
activation of caspase-3 was observed (Figures 2.12B). It is important to note that a fraction of
the subG 1 population is negative for cleaved caspase-3 indicating a caspase-independent mode
of apoptosis whose cell cycle origin cannot be accounted for using this assay (Figure 2.13, see 48
hour time point). Similar results were obtained for cleaved PARP (Figure 2.14). Overall, our
results suggest that following cell cycle arrest, cells that have repairable or tolerable amounts of
damage are able to avoid triggering apoptosis and are permitted to proceed through the cell cycle
whereas if severe damage is uncovered during the S-phase of the second cell cycle post treatment
with MNNG, cells are shunted directly into apoptosis without entering G2.
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Figure 2.1 0 6MeG/MMR-Dependent Growth Inhibition
(A) Viable cell density was monitored over time after treatment with 0 pg/ml (-0-), 0.01 pg/ml
(-), or 0.1 ptg/ml (-A-) MNNG for TK6, TK6/MGMT+, and TK6/MMR- cells. (B)
Percentage of control growth of TK6 cells at 12, 24, and 48 hours after treatment with 0 pg/ml
(black bars), 0.01 pg/ml (blue bars), and 0.1 ptg/ml (red bars) MNNG. (C) Percentage of control
growth of TK6, TK6/MGMT+, and TK6/MMR- cells at 48 hours following treatment with a 0
ptg/ml (black bars) or 0.1 pg/ml (red bars) of MNNG. *p<0.05, **p<0.01 (comparing treated
case to untreated control using two-sample t test)
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Figure 2.2 MNNG induces apoptotic cell death in TK6 cells
TK6 cell death was analyzed at specific time points following 0 pg/ml, 0.01 pg/ml (low dose), or
0.1 pg/ml (high dose) MNNG. Flow cytometry was used to simultaneous detect
phosphatidylserine (PS) exposure and membrane permeability by annexin V and 7AAD staining.
Four cell populations were observed: annexin-7AAD- (live cells), annexin+7AAD- (early
apoptotic), annexin+7AAD+ (mid apoptotic or necrotic), and annexin-7AAD+ (late apoptotic or
necrotic). (A) Shown is the percentage of cell death and the fraction of those cells which are
classified as early apoptotic (black bars), mid apoptotic/necrotic (gray bars), and late
apoptotic/necrotic (white bars). (B) Flow cytometry plots depicting the time-dependent
induction of cell death for TK6 cells treated with 0 pg/ml (untreated) or 0.1 pg/ml (high dose)
MNNG. (C) Illustration of apoptotic versus necrotic modes of cell death. Cells that undergo
apoptosis move in a counter-clockwise manner, with PS exposure occurring prior to loss of
membrane permeability. *p<0.05, **p<0.01 (comparing treated case to untreated control using
two-sample t test)
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Figure 2.3 O6MeG/MMR-Dependent Apoptosis
Cells undergoing apoptosis were detected by flow cytometry using antibodies against cleaved
(active) caspase-3 and cleaved (inactive) PARP. (A) TK6 cells were treated were 0 pig/ml, 0.01
pig/ml (low dose), or 0.1 pg/ml (high dose) MNNG and analyzed at the indicated timepoints.
The figure represents the percentage of apoptosis classified according to cleaved caspase-3 and
cleaved PARP levels: cleaved casp3+ cleaved parp- (black bars), cleaved casp3+ cleaved parp+
(gray bars), or cleaved casp3- cleaved parp+ (white bars). (B) Representative flow cytometry
plots of TK6 cells treated with 0 pg/ml (untreated) or 0.1 ptg/ml (high dose) MNNG. (C)
Percentage apoptosis of TK6/MGMT+ cells and TK6/MMR- cells after treatment with 0 pg/ml
and 0. 1 ptg/ml MNNG. *p<0.05, **p<0.01 (comparing treated case to untreated control using
two-sample t test)
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Figure 2.4 Cell Cycle Analysis
Cell cycle results for TK6 cells treated with 0 pg/ml (untreated), 0.01 pg/ml (low dose), or 0.1
pg/ml (high dose) MNNG are illustrated. One hour prior to the time point indicated BrdU was
added to the culture medium, allowing for its incorporation into actively replicating DNA. Flow
cytometry plots of BrdU intensity versus DNA content are shown along with a representation of
the gating used to quantitate the amount of cells in each cell cycle stage. G 1 and G2/M cells are
BrdU negative with 2N and 4N DNA content respectively. Mid S-phase cells have intermediate
DNA content and are either BrdU positive or BrdU negative depending on their replication
status. The transitions between these states are labeled early S-phase and late S-phase. Early S-
phase cells and late S-phase cells stain positive for BrdU but contain G1 and G2/M DNA content
respectively. In addition, apoptotic cells are identified by subG1 DNA content.
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Figure 2.5 TK6 cell cycle dynamics after exposure to MNNG
TK6 cells were exposed to 0 pg/ml (untreated), 0.01 pg/ml (low dose), or 0.1 pg/ml (high dose)
MNNG and the cell cycle was analyzed at the indicated times following treatment. Shown are
representative BrdU versus DNA content scatter plots alongside their corresponding DNA
content histograms.
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Figure 2.6 TK6 Cell Cycle Quantitation
(A-H) The percentage of TK6 cells in each phase of the cell cycle following treatment with 0
pg/mi (-0-), 0.01 pg/ml (-E-), or 0.1 pg/ml (-A-) MNNG. (I) The percentage of TK6 cells
staining positive for the mitotic marker, phospho-histone H3.
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Figure 2.7 TK6/MGMT+ cell cycle dynamics after exposure to MNNG
TK6/MGMT+ cells were exposed to 0 pg/ml (untreated) or 0.1 pig/ml (high dose) MNNG and
the cell cycle was analyzed at the indicated times following treatment. Shown are representative
BrdU versus DNA content scatter plots alongside their corresponding DNA content histograms.
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Figure 2.8 TK6/MGMT+ Cell Cycle Quantitation
The percentage of TK6/MGMT+ cells in each phase of the cell cycle following treatment with 0
pg/ml (-0-) or 0.1 pg/ml (-&r-) MNNG.
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Figure 2.9 TK6/MMR- cell cycle dyanimcs after exposure to MNNG
TK6/MMR- cells were exposed to 0 pg/ml (untreated) or 0.1 pg/ml (high dose) MNNG and the
cell cycle was analyzed at the indicated times following treatment. Shown are representative
BrdU versus DNA content scatter plots alongside their corresponding DNA content histograms.
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Figure 2.10 TK6/MMR- Cell Cycle Quantitation
The percentage of TK6/MMR- cells in each phase of the cell cycle following treatment with 0
pg/ml (-0-) or 0.1 tg/ml (-A-) MNNG.
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Figure 2.11 DNA synthesis is inhibited in the second S-phase following MNNG treatment
in a dose-dependent manner
The percentage of total mid S-phase cells that are negative for BrdU incorporation following
treatment with 0 pig/ml (-e-), 0.01 pg/ml (-E-), or 0.1 pg/ml (-A-) MNNG is shown. BrdU was
added to TK6 cells one hour prior to the indicated time point.
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Figure 2.12 Apoptosis is triggered in the second cell cycle S-phase
TK6 cells were treated with 0 ptg/ml (untreated), 0.01 Rg/ml (low MNNG), or 0.1 pg/ml (high
MNNG) and analyzed for cleaved (active) caspase-3 along with DNA content. (A) Percentage
of cleaved caspase-3 cells according to their cell cycle state; G 1 (blue), S phase (gray), G2/M
(red), and subG1 (white). (B) Representative flow cytometry plots of cleaved caspase-3 versus
DNA content and the corresponding DNA content histogram 32 hours after treatment with
MNNG.
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Figure 2.13 Cleaved Caspase-3/Cell Cycle Results
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Figure 2.14 Cleaved PARP/Cell Cycle Results
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Chapter 3
Measuring and Mining the DNA Damage Signaling Network
90
Abstract
In response to DNA damage, a cell activates a DNA damage signaling response that aims to
either delay cell cycle progression and promote DNA repair or, in the event of irreparable
damage, to trigger cell death. As described in Chapter 2, the SN1 type methylating agent N-
methyl-N'-nitro-N-nitrosoguanidine (MNNG) causes delayed cell cycle progression through both
the first and second cell cycle post treatment and, with high levels of damage, apoptotic cell
death out of the second S-phase. Moreover, such cellular outcomes are completely dependent on
the 0 MeG DNA base lesion and on a functional mismatch repair (MMR) pathway. Here we
demonstrate the O6MeG/MMR-dependent signaling events that accompany the observed
behavior. We find that the signaling response is made up of a modest but persistent early
response that includes phosphorylation of ATM, H2AX, CHKI and p53 and a more dramatic late
response that includes phosphorylation of the early response targets (ATM, H2AX, CHK1, and
p53) in addition to activation of CHK2 and the stress-activated protein kinase JNK. Notably, the
early and late signaling events occur in the first and second cell cycle post treatment,
respectively, with the transition taking place as cells progress into the second S-phase. From the
data we propose a model in which MMR acts both directly and indirectly to mediate cell cycle
arrest and cell death in response to the 06MeG DNA lesion. Further, we demonstrate the
extensive nature of the DDR network response through global transcriptional profiling of TK6
cells treated with the methylating agent MNNG. In addition to the regulation of genes involved
in DNA replication and repair, cell cycle, and apoptosis, we observe the regulation of genes
involved in a number of other biological processes including lipid metabolism, RNA processing,
translation, immune response, transcription, and cell signaling.
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Introduction
The DNA damage response (DDR) signaling network is responsible for the coordination of a
wide range of cellular events that are critical for maintaining genomic integrity and preventing
carcinogenesis in the face of DNA damage [1] [2]. Although other post-translational
modifications are emerging as invaluable components of the DDR network (e.g. ubiquitylation,
acetylation, sumoylation), protein phosphorylation plays a crucial role in amplifying and relaying
signal from the site of damage to effector proteins that regulate cell behavior [3]. Members of
the phosphatidylinositol-3 kinase (PI3K)-like protein kinase (PIKK) family, ATM and ATR,
play central roles in the DDR network [4]. In response to DNA damage, ATM and ATR
phosphorylate and activate numerous target proteins, most notably the checkpoint kinases CHK1
and CHK2 and the p53 tumor suppressor protein. These proteins in turn trigger, through
transcription-dependent and transcription-independent mechanisms, various cellular responses
including cell cycle arrest, DNA repair, and in the case of severe or irreparable damage,
programmed cell death. Ironically, DNA-damaging agents are commonly used to treat cancer;
therefore, an understanding of the DDR network players and their influence on cell behavior is
critical for the development of better chemotherapeutic strategies [5].
In this study we investigate the DDR network triggered by the DNA base lesion Q6O
methylguanine (06MeG). Although making up only a small fraction of the overall DNA
alkylation, this critical base lesion is responsible for most of the mutagenic, carcinogenic, and
cytotoxic properties of an important class of alkylating agents, the SN1 type methylating agents.
Such agents are found endogenously as normal metabolites, in our environment, and in the clinic
as chemotherapeutic agents [6]. In the absence of its repair by the 0 6-methylguanine DNA
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methyltransferase (MGMT) repair protein, 0 MeG alters cell cycle dynamics and under certain
circumstances induces apoptosis in a mismatch repair (MMR)-dependent manner (see Chapter
2). Although it is clear that MMR is required to trigger these events, the mechanism for
converting the damage into signal is still unclear with evidence pointing to both a direct and
indirect role for MMR in this process [7] [8]. In the direct signaling model, MMR acts as a
damage sensor that binds to O6MeG/T mispairs formed during replication and subsequently
signals directly to downstream effectors. Providing evidence for its function as a signaling
module, components of the MMR pathway, MutSa (MSH2/MSH6) and MutLa (MLH1/PMS2),
were shown to physically interact with signaling molecules that are activated in an MMR-
dependent manner following DNA damage [9] [10] [11]. In a recent study, MutSa and MutLa
were found to directly interact with multiple components of the ATR-CHK1 signaling pathway,
namely ATR, TOPBP 1, and CHK1, and moreover the recruitment of these proteins to chromatin
was enriched following treatment with MNNG [12]. In addition, it was demonstrated that the
ATR protein kinase is recruited in vitro to 06MeG/T mismatches in the presence of MMR
proteins, resulting in ATR's activation and phosphorylation of its downstream target kinase
CHK1 [13]. Alternatively, it is thought that the futile repair of 06MeG/T mismatches by MMR
generates gapped DNA that upon replication lead to fork collapse and double strand break
formation, both of which are well known activators of the DDR network. Indeed, an
accumulation of 06MeG- and MMR-dependent single-stranded DNA regions were observed in
newly replicated DNA after exposure to the methylating agent MNNG [14]. The need for two
rounds of replication to generate a DNA damage signal has been supported by studies showing
that 06MeG- and MMR-dependent G2 arrest and apoptotic cell death occur only after the second
S-phase following treatment with a SN1 type methylating agent [15] [16] [17]. In these studies,
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the events were accompanied by the activation of both the ATM-CHK2 and ATR-CHK1
signaling pathways. Importantly, the mismatch repair-dependent G2 arrest observed after
treatment with a low, barely-toxic dose of the methylating agent MNNG was shown to require
the ATR, but not ATM, protein kinase [15]. However, in a separate study, ATM, CHK1, and
CHK2 were required for a MMR-dependent G2 arrest induced by moderate doses of MNNG
[11]. Finally, loss of ATM was shown to sensitize cells to O6MeG-induced cell killing
indicating a protective role for ATM in the response to this lesion, possibly through its role in
double strand break repair [18].
It has become clear that signaling through ATM and ATR are important events downstream of
06 MeG and MMR in the response to SN1 type methylating agents. However, there exist
contradictory findings about signal initiation and the signals' influence on cell behavior,
presumably due to differences in experimental conditions across studies (e.g. cell type, dose,
time, etc.). In our lab, we have established through the use of the TK6 human lymphoblastoid
cell line and its isogenic derivatives (TK6/MGMT+ and TK6/MMR-) a range of MNNG doses
in which alkylation-induced apoptosis is completely dependent on a specific DNA base lesion,
namely 06MeG [19]. Under these conditions it was demonstrated that signaling downstream of
the O6MeG lesion and MMR leads to stabilization of the p53 tumor suppressor protein (although
this event is not ultimately required for apoptotic cell death) and activation of apoptosis via the
mitochondrial signaling pathway [20] [19]. In Chapter 2, we further demonstrate that the
06MeG lesion triggers a MMR-dependent cell cycle response that gives rise to an accumulation
of S-phase cells in both the first and second cell cycle post treatment and, under high doses of
MNNG, apoptotic cell death emanating out of the second S-phase. Here we aim to uncover the
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upstream signaling events that trigger these cellular responses by monitoring, with detailed
kinetic analysis, the activation or phosphorylation of known protein targets of ATM and ATR as
well as the activation of mitogen-activated protein kinase (MAPK) family members that have, in
various studies, also been implicated in the response to genotoxic stress [21]. As many of these
signal transduction events lead to the activation of transcription factors, like the ATM-
CHK2/ATR-CHK1 target p53, we investigate, in parallel, the temporal gene expression changes
induced by MNNG. Complementing the more focused protein signaling analysis, transcriptional
profiling provides insight into the genome-wide response to damage, highlighting the many
cellular processes that are regulated in response to MNNG.
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Materials and Methods
Cell Culture and Treatment Conditions
The TK6 B lymphoblastoid cell line and its derivatives, TK6/MGMT+ and MTl (referred to as
TK6[MMR-] have been described previously [19]. Cells were maintained in RPMI medium
1640 (Gibco #11875) supplemented with 10% equine serum, 2 mM L-glutamine, 100 units/ml
penicillin, and 100 pg/ml streptomycin. Due to the large number of cells needed, timecourse
experiments were performed in 1 L or 3L spinner flasks. For drug treatment, logarithmically
growing cells were split to a density of 3x 1 05 cells/ml and MNNG, in 0.1 M sodium acetate, pH
5.0, was added directly to the culture medium. For inhibitor studies, the JNK inhibitor
SP600125 (Calbiochem) was added to the cells one hour prior to drug treatment. Cells were
collected at the indicated time points and prepared as described for further analysis. Live and
total cell density was monitored using a Vi-cell XR cell viability analyzer (Beckman-Coulter).
Preparation of Cell Extracts
Cells were washed with cold PBS and lysed in 1% Triton X-100, 50mM Tris-HCl (pH 7.5),
150mM sodium chloride, 50mM p-glycerophosphate (pH 7.3), 10mM sodium pyrophosphate,
30mM sodium fluoride, 1 mM benzamidine, 2mM EGTA, 10pM sodium orthovanadate
(NaVO4), 1 mM dithiothreitol (DTT), ImM phenylmethylsulfonyl fluoride (PMSF), 1Opg/ml
aprotinin, 1 0ptg/ml leupeptin, 1p jg/ml pepstatin, 1 gg/ml microcystin-LR. Lysates were incubated
on ice for 30 minutes, and clarified by centrifugation at max speed (16110 x g) for 10 minutes at
4'C. Protein concentrations of clarified extracts were determined using the BCA protein assay
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(Pierce). Lysates prepared for western blotting were sonicated (Branson Model 450 Digital
Sonifier: Amplitude 20%, Pulse Time 2 seconds, Repeat 3x) prior to centrifugation.
Kinase Activity Assay
A microtiter-based assay was used in these studies to monitor protein kinase activity following
DNA damage. The assay was adapted from Janes et al. [22] who monitored various kinase
activities to identify critical nodes within the signaling network regulating cytokine-induced
apoptosis [23]. The assay is divided into three parts: immunoseparation of the kinase in
microtiter wells; in vitro kinase reaction; and measurement of 32 P incorporation into the
substrate. A detailed description of the experimental procedure was published previously [22]
and will be described here briefly along with any adjustments made to the original protocol.
Protein A or G coated microtiter wells were incubated overnight at 4"C with 10pig/ml antibody
against the kinase of interest. The following antibodies were used to perform the
immunoprecipitation step: Anti-MAP Kinase 1/2 (Erkl/2), CT (Upstate #06-182), Anti-JNK1
(C- 17) (Santa Cruz Biotechnology #sc-474), Anti-MAPKAPK-2 (Stressgen #KAP-MAO 15),
Anti-Chk2 (Bethyl Laboratories #BL1432). The next day, wells were washed and incubated
with cell lysate (150ptg for CHK2, 37.5pg for ERK, 150pg for JNK, and 150pg for MK2) for
three hours at 4'C. After being washed, the wells were filled with kinase buffer containing cold
ATP and [32 P]ATP along with the kinase-specific substrate. The substrate along with the
concentration of cold ATP and [3 2 P]ATP used in each kinase reaction can be found in Table 3.1.
The substrates include myelin basic protein (purchased from Sigma #M 1891), MK2tide
(described in [24]), and GST-ATF2 (1-109) (described in [25]). Following incubation at 37'C
for one hour, the reaction was quenched with 20mM EDTA or 75mM phosphoric acid depending
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on the kinase being tested (see Table 3.1). The contents were then applied to a 96-well
phosphocellulose filter to capture the phosphorylated substrate. After repeated washings, the
filter was punched into scintillation vials and the [3 2 P]substrate was measured by liquid
scintillation counting. The linearity and range of the assay, as well as its sensitivity to external
stimuli, was tested in our model system for each of the protein kinases monitored in this study.
To do so, positive control lysates were prepared from TK6 cells treated with known activators of
each protein kinase and kinase activities were measured over a range of lysate concentrations.
The following conditions were used for activation: 1 OOnM PMA for 10 minutes (ERK), 500 mM
NaCl for 30 minutes (MK2 and JNK), and 10 Gy IR for two hours (CHK2). Figure 3.1 depicts
the linearity and range of the kinase activity measurements as well as the level of activation
above untreated control activity for each kinase tested. Based on these results, we confirmed that
the assays were indeed sensitive and quantitative and proceeded to monitor the temporal
activation of each protein kinase following cellular treatment with MNNG. All measurements
were normalized to the positive control in order to control for day to day assay variability; results
are reported as fold activation above untreated background levels (activity at 0 hours).
Quantitative Western Blot
Regulatory phosphorylation events and total protein levels of several key DNA damage signaling
proteins were monitored by quantitative western blotting. Whole cell lysates were prepared at a
concentration of 2.5mg/ml in sample buffer, containing IX LDS (Lithium Dodecyl Sulfate)
Sample Buffer (NuPage, Invitrogen) and 2.5% p-mercaptoethanol, and heated at 80'C for 10
minutes. Protein samples were separated by SDS-PAGE using the NuPage Electrophoresis
System (Invitrogen), and transferred to a PVDF or nitrocellulose membrane in transfer buffer
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(49.1mM TrisBase, 38.6mM Glycine, 0.04% SDS, 20% Methanol) for one hour at 1OOV using a
Criterion Blotter (BioRad). After the transfer, membranes were blocked at room temperature for
one hour with Odyssey Blocking Buffer (OBB, Licor Biosciences) and then probed with primary
antibodies. Primary antibodies were diluted in a 1:1 mixture of OBB:PBS-T (PBS + 0.1%
Tween 20) and incubated with the membrane overnight at 4'C. Following repeated washes with
PBS-T, IRDye secondary antibodies (Licor Biosciences) were diluted in OBB:PBS-T (1:5000-
1:10000 dilution) and incubated with the membrane for one hour at room temperature covered
from light. The membrane was washed again in PBS-T and stored in PBS at 4'C in the dark
until detection using the Odyssey Infrared Imaging System (Licor Biosciences). Using the
Odyssey's two-color detection system we were able to detect both phopho- and total- antigen
targets simultaneously by probing with secondary antibodies that could be visualized in different
fluorescence channels. Following protein detection, membranes were stained with actin
antibody which was used as a loading control. The specific conditions for each of the proteins
detected are described in Table 3.2. Antibodies were tested for linearity and sensitivity using a
positive control (Figure 3.2). Positive controls were run on every gel and signal intensities were
normalized to the intensity of the reference sample to correct for differences in transfer and
probing efficiencies. Each timecourse is reported as fold change above untreated background
levels (signal at 0 hours).
RNA Isolation and Microarray Hybridization
TK6 cells were treated with 0 pig/ml, 0.01 ptg/ml, or 0.1 ptg/ml MNNG as described and collected
at various time points following exposure to the drug. Total RNA was extracted from cells with
TRIZOL reagent (Invitrogen) and purified using Qiagen's RNeasy Mini Kit. Evaluation of
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sample quality was performed on the Agilent 2100 BioAnalyzer (BioMicro Center, MIT).
Sample labeling, array hybridization, and data extraction were performed by the BioMicro
Center (MIT). RNA was hybridized to HGU133 Plus 2.0 full human genome arrays
(Affymetrix).
Microarray Data Analysis
Data normalization was performed in GenePattern [26]. Affymetrix CEL files were uploaded to
GenePattern (ExpressionFileCreator module) which was then used to carry out quantile
normalization using the Robust Multichip Average (RMA) algorithm and to compute
present/absent calls. Transcripts were included if they contained present calls in at least two (of
the 26) samples, i.e. expression in at least one of the 13 conditions tested in biological duplicate.
Data was additionally filtered using two-way ANOVA with respect to the variables treatment
and time. ANOVA analysis was performed using the anovan function in MATLAB. P-values
for each variable (treatment and time) and for the interaction of variables (treatment x time) were
obtained. Transcripts that displayed a p-value<0.0001 for treatment alone (i.e. genes that differ
across treatment, but similar across time) or for the interaction between treatment and time (i.e.
genes that have different time patterns across treatments) were selected for further analysis. This
resulted in a reduction of the dataset from the original 54,675 probe sets to 7,339 probe sets.
Hierarchical Cluster Analysis
Spotfire (TIBCO) was used to perform unsupervised hierarchical cluster analysis of the 7,339
differentially regulated probe sets selected by ANOVA. Expression levels were first normalized
by mean centering and variance scaling to force genes to cluster together based on their
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expression patterns rather than on their absolute values. Hierarchical clustering (complete-
linkage) was performed on both genes and samples using the Euclidean distance metric to assess
similarity.
K-means Cluster Analysis
To identify clusters of genes with similar expression patterns across dose and time, we
performed K-means cluster analysis on the 7,339 differentially regulated transcripts selected by
ANOVA. Prior to cluster analysis, biological replicates were averaged and data was normalized
relative to the log value (i.e. untreated cells in log phase) and expressed as log2 fold change. K-
means was performed using the program Cluster (available at http://rana.lbl.gov/) [27]. Clusters
were visualized in heat map form using Spotfire (TIBCO). Gene clusters were further analyzed
for functional enrichment as described below. A list of genes in each cluster (annotated with the
gene symbol, gene name, and Affymetrix probeset ID) is provided in the Appendix.
Functional Enrichment Analysis
Gene ontology biological process enrichment and KEGG pathway enrichment were performed
using the Database for Annotation, Visualization and Integrated Discovery (DAVID)
(http://david.abcc.ncifcrf.gov) [28] [29]. The GO-FAT enrichment terms within DAVID were
used for biological process analysis; GO-FAT terms filter out the broadest gene ontology
categories providing more focused biological functions. P-values were calculated based on a
modified Fisher's exact test (or EASE score) [30].
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Simultaneous Detection of DNA content and Apoptosis (Cleaved Caspase-3 and Cleaved
PARP) by Flow Cytometry
Cells were washed once in cold PBS and resuspended in 500pl 4% paraformaldehyde in PBS
(Electron Microscopy Sciences #15700). Cells were fixed for 15 minutes at room temperature.
After fixation, cells were washed with PBS and resuspended in 500pl 100% methanol. Methanol
suspensions were stored at -20'C. All antibody staining steps was performed in 96-well v-
bottom plates. Fixed cells were resuspended in 200pl PBS-B (1% BSA) and blocked at room
temperature for 30 minutes. After blocking, cells were incubated in 100pl of primary antibody
against cleaved caspase-3 and cleaved PARP diluted at 1:200 in PBS-TB (0.1% Tween 20 and
1% BSA) for 1 hour at room temperature. Primary antibody against the apoptotic markers,
cleaved (active) caspase-3 (#559565) and cleaved (inactive) PARP (#552597), were purchased
from BD Biosciences. Following primary antibody incubation, cells were washed twice with
PBS-T (0.1% Tween 20). Cells were then resuspended in 100pl PBS-TB containing secondary
antibody diluted at 1:600 and incubated for 1 hour at room temperature. The secondary
antibodies used, PE-conjugated goat anti-rabbit IgG (#P2771) and Alexa Fluor 647-conjugated
goat anti-mouse IgG (#A21235), were purchased from Molecular Probes. Following secondary
antibody incubation, cells were washed once with PBS-T and resuspended in 200pl Hoechst
33258 (1Omg/ml stock solution, Invitrogen) at 1:10,000 dilution in PBS to stain for DNA
content. Cells were incubated in Hoechst 33258 for 10 minutes at room temperature in the dark.
Finally, cells were washed with PBS-T and resuspended in 120pl PBS-TB for analysis on a
FACS LSR 1I flow cytometer.
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Results
Quantitative temporal measurements of key DDR network proteins reveal MMR-
dependent signaling dynamics triggered by the O6MeG DNA lesion.
As described in Chapter 2, the 06MeG base lesion triggers dynamic cell cycle changes and
apoptotic cell death in TK6 human lymphoblastoid cells treated with the methylating agent
MNNG. A complex network of signaling proteins, referred to as the DNA damage response
(DDR) network, is known to control such cellular outcomes in response to DNA damage and
replication stress in an effort to maintain genomic integrity [1] [2]. In the case of 06MeG, the
generation of a damage signal requires MMR; however, it is unclear whether this signal is
triggered by MMR directly or indirectly through the generation of repair intermediates.
Therefore, to shed light on the O6MeG-dependent cell cycle checkpoint and cell death signaling
response triggered by MMR, we monitored detailed kinetics of the activation or phosphorylation
of a number of key players in the DDR network, namely ATM, H2AX, CHK1, CHK2, and p53,
in TK6 cells and TK6 cell derivatives (TK6/MGMT+, TK6/MMR-) treated with MNNG.
ATM andATR
Central to the DDR are the ataxia telangiectasia mutated (ATM) and ATM-Rad3-related (ATR)
protein kinases [4]. Active ATM and ATR phosphorylate a large number of target proteins that
are involved in a variety of cellular processes including regulation of cell cycle, DNA replication
and repair, chromatin modification, transcription, cell signaling, and cell death [31]. Although
they share many common substrates, ATM responds primarily to double strand breaks (DSBs)
while ATR responds more broadly to damage that leads to replication protein A (RPA)-coated
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single-stranded DNA such as replication blocking lesions and double strand break resection
intermediates [32] [33]. In response to DNA damage, ATM and ATR are recruited to the
damage site through their accessory binding proteins, MRN (Mrel 1-Rad50-Nbsl) and ATRIP
respectively, promoting their activation and the efficient phosphorylation of downstream
signaling proteins [34] [35]. In this study, we monitored the phosphorylation of ATM at serine-
1981 following TK6 cell treatment with no MNNG, low dose (0.01 ptg/ml) MNNG, or high dose
(0.1 ptg/ml) MNNG (Figure 3.3). DNA damage results in the autophosphoryation of ATM at
serine-1981 triggering the dissociation of inactive ATM dimers into active monomers [36].
Following MNNG treatment, we observed a significant increase in the phosphorylation of ATM
at serine- 1981 above untreated levels beginning one hour and 16 hours post treatment for high
dose and low dose conditions respectively (Figure 3.3). After 16 hours, the phosphorylation of
ATM under low dose conditions, while minimal, remained upregulated up to 36 hours.
Interestingly, the phosphorylation kinetics under high dose conditions appeared biphasic with a
detectable early response (0-16 hours) and more dramatic late response (16-36 hours); transition
into the second phase occurred as cells began to enter their second cell cycle post treatment, at
which time we observed the accumulation of cells in S phase, loss of DNA replication in S phase
cells, and accumulation of apoptotic cells (see Chapter 2; Figure 2.6B, Figures 2.6H and 2.11,
and Figure 2.6G respectively). In contrast to ATM, the phosphorylation event marking ATR
activation is not well established; the steps leading to activation of ATR include its localization
to RPA-coated ssDNA through its partner protein ATRIP allowing for ATR's interaction with
the activator protein TOPBP 1 [33]. Lack of a reliable indicator for activation thus prevented us
from directly monitoring ATR activity following treatment with MNNG; instead, the analysis of
its activation relies on monitoring the phosphorylation of its substrates (discussed below).
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H2AX
An early event in the response to DNA damage is the phosphorylation of the histone H2A variant
H2AX at serine-139. Phosphorylated H2AX (yH2AX ) is important for the assembly and
retention of repair and signaling proteins to the site of damage, thereby facilitating DNA repair
and amplifying the DNA damage signal that mediates cell cycle checkpoints and other
downstream cellular events [37]. yH2AX foci were originally detected at sites of double strand
breaks and are often used as a surrogate to follow the formation and repair of DSBs in cells
treated with DNA damaging agents [38]. It is important to note that yH2AX is observed in
response to other types of damage, such has replication stress, in addition to double strand
breaks; H2AX can be phosporylated by the PIKKs ATM and ATR, with ATM and ATR
mediating the phosphorylation of H2AX in response to irradiation and UV or HU treatment
respectively [39] [40]. Here we observed a significant increase in the phosphorylation of H2AX
at serine-139 in TK6 cells treated with MNNG at both early (0-16 hours) and late (16-36 hours)
time points (Figure 3.4A). A significant increase in the phosphorylation of H2AX was observed
as early as four hours after treatment with 0.1 pg/ml MNNG (high dose) and 12 hours after
treatment with 0.01 pg/ml MNNG (low dose) suggesting active signaling by ATM and/or ATR
within the first cell cycle post treatment. After 16 hours, a second wave of H2AX
phosphorylation was observed with levels increasing up to 36 hours in a dose-dependent manner;
in other words, a greater increase in phosphorylation was observed under high dose conditions
compared to low dose conditions. Importantly, the induction of YH2AX at both early and late
timepoints in TK6 cells was completely dependent on O6MeG and MMR, as MNNG did not
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trigger H2AX phosphorylation in the TK6/MGMT+ or TK6/MMR- cell lines (Figures 3.44B
and 4C).
CHK1 and CHK2
Key transducers within the DDR network are the checkpoint kinases CHKl and CHK2. ATM
and ATR phosphorylate and activate the checkpoint kinases CHK2 and CHKl, respectively,
which in turn phosphorylate effector proteins (e.g. CDC25A/C, BRCA1, E2F1, p53) controlling
cell cycle progression, DNA repair, transcription, and apoptosis [41] [42]. Following MNNG
treatment, we observed CHK2 kinase activation; however, its induction was delayed compared
with ATM and H2AX phosphorylation. An increase in CHK2 activity above untreated levels
was not detected until 20 and 28 hours after exposure to high and low doses of MNNG,
respectively, after which time CHK2 activation continued to rise (Figure 3.5A). As CHK2 is
directly phosphorylated and activated by ATM, the lack of CHK2 activation at early timepoints
was unexpected. To confirm this result is not due to differences in assay sensitivity (western blot
versus kinase activity assay) we measured the phosphorylation of CHK2 at threonine-68 by
western blot. The phosphorylation of threonine-68 is often used as a marker of activation; CHK2
is phosporylated by ATM at threonine-68 in response to DNA damage, promoting CHK2
homodimerization and activation via trans-autophosphorylation at threonine-383 and threonine-
387 [43]. The phosphorylation of CHK2 at threonine-68 was detected in MNNG treated cells
with kinetics very similar to those seen with kinase activity measurements, confirming that
CHK2 is not activated until 20-24 hours post treatment (Figure 3.6). In contrast to CHK2,
CHK1 phosphorylation at serine-317 was evident in TK6 cells immediately after treatment with
a high dose of MNNG and remained modestly elevated up to 16 hours after which we observed
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an second, more pronounced, increase in phosphorylation levels (Figure 3.5D). A similar
phosphorylation pattern was observed under low dose conditions but at a decreased level relative
to the high dose treatment. The phosphorylation of CHK1 at serine-317 is used here as an
indicator of ATR-CHK1 pathway activation. Although the mechanism remains poorly
understood, CHK1 activation requires its recruitment to sites of damage via adaptor proteins
where it is subsequently phosphorylated by ATR at serine-317 and serine-345 [44]. Importantly,
MNNG-induced CHK1 phosphorylation (at both early and late times) and CHK2 activation (at
late times) were 06MeG- and MMR-dependent as demonstrated by the lack of signal in the
TK6/MGMT+ and TK6/MMR- cell lines across all time points (Figures 3.5B,C,E and F).
p53
The tumor suppressor protein p53 plays a critical role in protecting against genomic instability
and tumor progression (in response to cellular stress) by regulating the transcription of numerous
genes involved in DNA repair, cell-cycle arrest, senescence, and apoptosis [45]. In response to
DNA damage, the ATM/ATR protein kinases phosphorylate p53 at serine- 15 while
CHK1/CHK2 phosphorylate p53 and serine-20; these, along with other post-translational
modifications lead to stabilization of the p53 protein and the transactivation of p53 target genes
[46]. Cells exposed to the DNA methylating agent MNNG showed a modest but clear
upregulation of phosphorylated p53 at serine-15 and serine-20 within the first cell cycle (0-16
hours) post treatment (Figures 3.7A and 3.7D). After which time the level of phosphorylation at
both sites further increased, with a dramatic accumulation of phosphorylated p53 following high
dose treatment. The accumulation of phosphorylated p53 (S15 and S20), at both early and late
times, was absent in MNNG treated TK6/MGMT+ and TK6/MMR- cells, providing clear
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evidence that 06MeG and MMR are critical for both the early and the late signaling responses
observed (Figures 3.7B,C,E and F). Protein modifications enhance the stability of p53;
accordingly MNNG induced an O6MeG- and MMR-dependent accumulation of total p53 with
kinetics similar to its phosphorylation (Figures 3.8A-C). Importantly, to confirm activation of
the p53 transcriptional program we assessed the levels of several well studied p53-regulated
transcripts and found a similar pattern of induction between their expression and p53 protein
levels with MNNG treatment (Figure 3.8D).
A look at MAPK signaling: JNK activation after MNNG treatment is a late response that is
dependent on 06MeG and MMR.
An important group of signal transducers, the mitogen-activated protein kinases (MAPKs), are
well known for their ability to regulate a wide range of cellular processes in response to
extracellular stimuli, including gene expression, cell cycle progression/cell proliferation,
survival, apoptosis, inflammation, and differentiation [47]. The major classes of MAPKs include
extracellular signal-regulated kinases (ERKs), c-Jun amino (N)-terminal kinases (JNKs), and p38
MAPKs. Although they are not considered part of the canonical DNA damage response, it is
becoming increasingly clear that the MAPKs play important roles in the cellular response to
genotoxic stress [21]. The p38MAPK and its substrate MK2, for example, have been established
as integral components of the DDR network. In response to DNA damage, MK2 controls cell
cycle progression through the phosphorylation of the CDC25 family members to activate cell
cycle checkpoints [24] [48]. While TK6 cells showed no activation of ERK and minimal
activation of MK2 with MNNG treatment, we did observe a strong activation of JNK leading us
to focus on this response in greater detail (Figures 3.9A-C).
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0MeG- and MMR-dependent JNK activation
The JNK pathway is activated by cytokines and various environmental stresses such as heat
shock, radiation, oxidative stress, and DNA damaging agents; depending on the context, JNK
activation can lead to diverse cellular outcomes including cell proliferation, survival, death, or
differentiation [47]. Our results demonstrated an increase in JNK activity starting 12 hours and
20 hours after treatment with 0.1 tg/ml MNNG and 0.01 ptg/ml MNNG, respectively, in the late
phase after MNNG exposure (Figure 3.9C). Timecourse experiments in TK6/MGMT+ and
TK6/MMR- cells showed that this MNNG-induced activation of JNK was indeed triggered by
the 06MeG lesion in a MMR-dependent fashion (Figures 3.9D and 3.9E). Interestingly, the
timing and pattern of JNK activation coincided with the initiation of apoptosis (Chapter 2;
Figures 2.2A and 2.3A). We therefore hypothesized that, in TK6 cells, JNK may be involved in
mediating the apoptotic response to MNNG. It is well established that, for certain stimuli, JNK
plays a critical role in signaling apoptosis [49]. In response to UV, for example, it was shown
that JNK is required for the induction of apoptosis in primary murine embryonic fibroblasts [50].
To evaluate its role in MNNG-induced sensitivity we inhibited JNK activity using the JNK
inhibitor SP600125. To determine the optimal inhibitor concentration, TK6 cells were
stimulated with a JNK activator (500mM NaCl for 30 minutes) in the presence of various
concentrations of SP600125 and JNK activity was measured (Figure 3. 10A). At 50ptM
SP600125, we achieved almost complete inhibition of JNK activity; however, at this
concentration, inhibitor alone resulted in a severe reduction in cell growth and the appearance of
8N DNA content (Figures 3.10B and 3.10C). Due to the importance of active replication for
MNNG-induced sensitivity, we chose to work with SP600125 at lower concentrations. At 10pM
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SP600125, cell growth characteristics and cell cycle profiles were comparable to control cells
(i.e. no inhibitor) (Figures 3.10B and 3.10C). To test the effect of JNK inhibition on the DNA
damage response, TK6 cells were pretreated with JNK inhibitor one hour prior to MNNG
treatment. As expected, pretreatment with 10piM SP600125 resulted in a 50% reduction in JNK
activity, evaluated at 32 hours post MNNG treatment (Figure 3.1 IA). Survival was assessed
using a BrdU/Hoechst quenching proliferation assay (Valiathan et al., submitted). The inhibition
of JNK resulted in a modest increase in overall survival at higher doses of MNNG (Figure
3.11 B). In addition, we monitored subG1 DNA content and cleaved caspase-3/cleaved PARP
levels 48 hours after treatment with 0.1 pg/ml MNNG, +/- the SP600125 JNK inhibitor, to
determine the role of JNK in O6MeG-induced apoptosis. Pretreatment with 1 OpM SP600125
resulted in a reduction in the percentage of cells with subG 1 DNA content as well as cells
staining positive for cleaved caspase-3/cleaved PARP compared to cells without inhibitor
(Figures 3.1 iC-E). This decrease was even more dramatic with 30pM SP600125 (approximately
75% reduction in kinase activity; Figure 3.1 1A), however it is important to point out that this
reduction in apoptosis could stem from the cell cycle delay observed with inhibitor alone (Figure
3.1GB). Overall, while the JNK inhibitor effects are modest, these results are consistent with
JNK having a pro-apoptotic role in the response to MNNG.
Global transcriptional response of TK6 cells to the methylating agent MNNG
To study the global transcriptional response of TK6 cells to methylation damage, we used DNA
microarrays to monitor genome-wide changes in transcript levels after MNNG treatment as a
function of both time and dose. Conditions for treatment were classified as 'low' or 'high' based
on the level of apoptotic cell death induced at 48 hours. According to cleaved caspase-3 and
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cleaved PARP results, total apoptosis was detected at 4 percent, 13 percent, and 68 percent for
untreated, low dose (0.01 ptg/ml) MNNG, and high dose (0.1 [tg/ml) MNNG, respectively
(Chapter 2, Figure 2.3A). Importantly, as discussed in Chapter 2, both low and high doses
induced a cellular response (cell cycle arrest and apoptosis) that was completely dependent on
06MeG- and MMR. In this study, 13 conditions were analyzed in biological duplicate, including
log (i.e. untreated cells in log-phase), untreated (8, 24, 32, and 40 hours), low dose MNNG (8,
24, 32, and 40 hours), and high dose MNNG (8, 24, 32, and 40 hours). To identify genes that are
differentially regulated between treatment conditions, we used two-way ANOVA to select
transcripts that change significantly with treatment alone (irrespective of time) or with time and
treatment. The 7,339 probe sets selected by ANOVA are displayed in Figure 3.12. To assess the
quality of the data, hierarchical clustering was performed to group genes and samples with
similar expression patterns (Figure 3.12). Reassuringly, the majority of biological replicates
clustered together. Not surprisingly, the untreated samples (i.e. log, untreated 24 hours, and
untreated 32 hours) were grouped together indicating very similar expression patterns between
them. Also worth noting, low dose eight hours clustered together with untreated eight hours
suggesting minimal regulation of transcription by MNNG at this early time point. To obtain a
better understanding of the extent of transcription regulation with time we plotted the number of
transcripts induced or repressed by greater than 1.5 fold after MNNG treatment (Figure 3.13).
Here we observe that a small number of transcripts are up-regulated at 8 hours following high
dose treatment, but not low dose treatment, compared with untreated cells at this time point
(Figure 3.13A). As expected, the high dose induced a greater transcriptional response (in both
up- and down-regulated transcripts) than low dose at all time points measured (Figures 3.13A
and 3.13B). Interestingly, whereas the high dose resulted in the down-regulation of a substantial
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number of transcripts, we detected minimal down-regulation of gene expression under low dose
conditions (Figure 3.13B). It is also important to point out that cells grown in culture for 40
hours (without MNNG treatment) show substantial changes in transcript levels compared to
untreated cells at earlier time points (Figure 3.13); based on the hierarchical clustering results we
can see that the gene expression signature of the untreated 40 hours sample is distinct from the
gene expression signatures of the other treatment conditions measured (Figure 3.12).
K-means cluster analysis reveals distinct groups of genes that behave similarly across time and
dose
From the above analysis, it is clear that the methylating agent MNNG gives rise to significant
changes in gene expression, especially at late times, and that the set of transcriptionally
responsive genes changes with both time and level of damage. To study genes that behave
similarly across time and dose, we grouped transcripts with similar expression patterns into a
defined set of clusters using K-means. Figures 3.14 and 3.15 are graphical representations of the
ten clusters obtained. For this analysis, biological replicates were averaged and values were
normalized relative to the log value (i.e. untreated log-phase). In addition to uncovering gene
clusters that behave in a dose-dependent fashion (i.e. a more dramatic up- or down-regulation
with high dose than with low dose; e.g. Clusters 3 and 10), we found clusters that show equal
changes in gene expression under both treatment conditions (e.g. Cluster 2) as well as clusters
that are regulated exclusively following low dose treatment and not high dose treatment, or vise
versa (e.g. Clusters 5 and 7). Characterization of the genes in this manner gives an appreciation
for the complexity of the transcriptional response to MNNG; with a single drug, different levels
of damage produce very different gene expression patterns.
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As discussed previously, TK6 cells treated with MNNG undergo cell cycle arrest and, depending
on the level of damage, ultimately cell cycle progression and cell survival or cell death. To gain
insight into how cell behavior might be affected by gene expression, we analyzed each cluster for
enrichment of biological processes (gene ontology database) and pathways (KEGG pathway
database) using DAVID Bioinformatics [29] [28]. The top ten biological processes and top five
pathways for each cluster are listed in Tables 3.3-3.12. We might expect to see that genes
behaving similarly across time and treatment share common biological functions. Indeed, this
appears to be the case with respect to MNNG. Here we highlight some of the interesting
findings. Clusters 1 and 4 are enriched for the biological functions cell cycle, DNA repair, DNA
replication, and transcription (Tables 3.3 and 3.6). These clusters share very similar gene
expression patterns and therefore it is not surprising that they share overlapping functional
categories. However, with further inspection we are able to detect differences between the two.
For example, while they both contain genes involved in DNA repair, cluster 1 is enriched for
genes in the mismatch repair pathway (e.g. EXOl, LIG1, MSH2, RFC2, and RPA2) while
cluster 4 is enriched for genes in the homologous recombination pathway (e.g. RAD5 ILl,
RAD52, MRE I1, TOP3A). Taking a closer look at the cell cycle category, we find that these
clusters are highly enriched for genes involved in the initiation of replication and G 1/S transition
(e.g. Cyclin D, Cyclin E, CDC25A, Cdc45, cdc6, E2F etc.). As cells treated with MNNG
accumulate in early S-phase, these results are not necessarily surprising; however, they provide
confidence in our analysis. While clusters 1 and 4 provide information about several
'traditional' cellular responses to DNA damage stimuli (i.e. cell cycle regulation and DNA
repair) our study also points to a number of other important biological processes that mediate the
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cellular response to MNNG. Taking a look at cluster 2, we observe enrichment for genes that are
involved in the immune response (Table 3.4). Interestingly, these genes are induced by MNNG
treatment independently of dose (i.e. they are up-regulated equally under both low and high dose
conditions). While clusters 3 and 6 are both made up of genes that are down-regulated in
response to MNNG treatment, each cluster is enriched for distinct cellular processes. Cluster 3 is
highly enriched for lipid metabolism genes (Table 3.5). Cluster 6, on the other hand, is highly
enriched for genes involved in protein synthesis, RNA metabolism, ribosome biogenesis, and
protein degradation via the proteasome pathway (Table 3.8). Cluster 5 is an interesting cluster
due to the fact that it represents genes that are up-regulated in the low dose but not in the high
dose. We therefore speculate that these genes may be important for the survival of cells after
DNA damage. While the enrichment analysis of this set of genes is relatively uninformative, we
do note enrichment of the G-protein coupled receptor signaling pathway that contains the
endothelin- 1 protein (Table 3.7). Endothelin- 1 is known to induce signaling that promotes cell
proliferation and inhibits apoptosis in a variety of settings [51]. A more thorough look at the
individual genes in this set is needed. The prominent biological function of clusters 7, 9, and 10
are less clear. Cluster 7 is most highly enriched for genes involved in various aspects of
transcription (Table 3.9). Cluster 9 is enriched for genes involved in protein signaling/signal
transduction with the p53, MAPK, and apoptosis pathways at the forefront (Table 3.11). Finally,
cluster 10 is noted for its enrichment in genes involved in the induction of apoptosis as well as
for its highly significant enrichment score in the p53 signaling category (Table 3.12). While this
analysis provides us with a broad picture of the global transcriptional response to MNNG, further
studies are needed to obtain more specific information about the molecular pathways involved,
their regulation, and ultimately how they control cell behavior.
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Figure 3.1 Kinase Assay Validation
Individual kinase activity assays were tested for linearity and sensitivity to external stimuli.
Kinase activity in stimulated lysate (-e-) and untreated control lysate (X) is shown.
Positive control lysate was prepared from TK6 cells treated with a known kinase activator -
1OOnM PMA 10 minutes (ERK), 500mM NaCl 30 minutes (MK2 and JNK), or 1OGy IR 2 hours
(CHK2) - and kinase activity was quantified over a range of lysate concentrations.
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Figure 3.2 Quantitative Western Blot Validation
Western blot analysis was used to quantify the relative level of phosphorylated and total protein
in a given sample. Antibodies were tested for linearity and sensitivity using a positive control -
TK6 cells treated with lOGy IR 1 hour (H2AX), 5ptM HU 2 hours (CHK1), 1OGy IR 2hours
(p53), or lOGy IR 1 hour (CHK2). Shown are phospho and total intensity values with increasing
amounts of lysate. Phosphorylation levels of stimulated lysate (-0-) compared to untreated
control lysate (X) is shown.
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Figure 3.3 ATM
Quantitative western blot analysis of ATM phosphorylated at serine- 1981 following TK6 cell
treatment with 0 pg/ml (-0-), 0.01 pg/ml (-5-), or 0.1 pg/ml (-A-) MNNG. ATM(S1981) levels
are normalized to total ATM levels and plotted as fold change relative to 0 hours; error bars
represent standard deviation (error bars appear absent when they are smaller than the symbol).
Filled symbols represent a significant difference between treated and untreated values at the
indicated time point (p-value<0.05).
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Figure 3.4 H2AX
H2AX phosphorylation at serine- 139 was monitored in TK6, TK6/MGMT+, and TK6/MMR-
cells following treatment with 0 pg/ml (-e-), 0.01 gg/ml (-E3-), or 0.1 pg/ml (-A-) MINNG.
H2AX(S139) levels are normalized to total H2AX levels. Results are plotted as fold change
relative to 0 hours; error bars represent standard deviation (error bars appear absent when they
are smaller than the symbol). Filled symbols represent a significant difference between treated
and untreated values at the indicated time point (p-value<0.05).
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Figure 3.5 CHK1 and CHK2
(A-C) CHK2 kinase activity and (D-F) CHK1 phosphorylation at serine-317 were monitored in
TK6, TK6/MGMT+, and TK6/MMR- cells following treatment with 0 pg/ml (-0-), 0.01 pg/ml
(-2-), or 0.1 pg/ml (-A-) MNNG. CHI Kl(S317) levels are normalized to total CHIK1 levels.
Results are plotted as fold change relative to 0 hours; error bars represent standard deviation
(error bars appear absent when they are smaller than the symbol). Filled symbols represent a
significant difference between treated and untreated values at the indicated time point (p-
value<0.05).
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Figure 3.6 CHK2
Quantitative western blot analysis of CHK2 phosphorylated at threonine-68 following TK6 cell
treatment with 0 pg/ml (-0-), 0.01 pg/ml (-E-), or 0.1 ptg/ml (-A-) MNNG. CHK2(T68) levels
were normalized to total CHK2 levels and plotted as fold change relative to 0 hours; error bars
represent standard deviation (error bars appear absent when they are smaller than the symbol).
Filled symbols represent a significant difference between treated and untreated values at the
indicated time point (p-value<0.05).
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Figure 3.7 p53(S15) and p53(S20)
The phosphorylation of p53 at (A-C) serine- 15 and (D-F) serine-20 was monitored in TK6,
TK6/MGMT+, and TK6/MMR- cells following treatment with 0 pg/ml (-0-), 0.01 gg/ml (-5-),
or 0.1 pg/ml (-Ar-) MNNG. Results are plotted as fold change relative to 0 hours; error bars
represent standard deviation (error bars appear absent when they are smaller than the symbol).
Filled symbols represent a significant difference between treated and untreated values at the
indicated time point (p-value<0.05).
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Figure 3.8 p53
(A-C) Total p53 levels in TK6, TK6/MGMT+, and TK6/MMR- cells after treatment with 0
pg/ml (-0-), 0.01 pig/ml (-E-), or 0.1 gg/ml (--) MNNG. Results are plotted as fold change
relative to 0 hours. (D) Microarray expression values of known p53 target genes following TK6
cell treatment with 0 pg/ml (-0-), 0.01 pg/ml (-E-), or 0.1 pg/ml (-A-) MNNG. Error bars
represent standard deviation (error bars appear absent when they are smaller than the symbol).
Filled symbols represent a significant difference between treated and untreated values at the
indicated time point (p-value<0.05).
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Figure 3.9 MAPK
Kinase activation of (A) ERK (B) MK2 and (C) JNK after TK6 cell treatment with 0 pg/ml
(-0-), 0.01 pg/ml (-E-), or 0.1 pg/ml (-Ai-) MNNG. (D and E) JNK kinase activity in
TK6/MGMT+ and TK6/MMR- cells after treatment with 0 pg/ml (-0-) or 0.1 pig/ml (-A-)
MNNG. Results are plotted as fold change relative to 0 hours; error bars represent standard
deviation (error bars appear absent when they are smaller than the symbol).
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Figure 3.10 JNK Inhibitor Validation
(A) TK6 cells were treated with 500mM NaCl for 30 minutes in the presence of increasing
concentrations of JNK inhibitor (SP600125) and JNK kinase activity was measured. Values are
represented as percent of control (i.e. no inhibitor). (B) Live cell density of untreated TK6 cells
in the presence of OpM, 10pM, 20pM, or 50pM SP600125. (C) DNA content histograms of
untreated TK6 cells in the presence of OpM, 1OpM, 20pM, or 50pM SP600125.
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Figure 3.11 MNNG +/- SP600125
(A) TK6 cells were treated with 0.1 pig/ml MNNG for 32 hours in the presence of increasing
concentrations of JNK inhibitor (SP600125) and JNK kinase activity was measured. Values are
represented as percent of control (i.e. no inhibitor). (B) Survival of TK6 cells after MNNG
treatment +/- 1 OpM SP600125 as measured by the BrdU/Hoechst quenching assay. Proliferating
cells are displayed as percent of untreated control. (C) DNA content histograms (D) Percent
subG1 and (E) Percent cleaved caspase-3 and/or cleaved PARP 48 hours after TK6 cell treatment
with 0 pg/ml MNNG or 0.1 pg/ml MNNG in the presence of OpM, 1OpM, 30ptM, or 50pM
SP600125.
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Figure 3.12 Hierarchical Cluster Analysis
Hierarchical clustering was performed on the 7,339 differentially regulated probe sets selected
by ANOVA. The data was normalized by mean centering and variance scaling to group genes
based on the shape of their expression pattern rather than on their absolute values. Hierarchical
clustering (complete-linkage) was performed on both genes and samples using the Euclidean
distance metric to assess similarity (TIBCO Spotfire).
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Figure 3.13 Regulation of transcription after MNNG treatment
Number of transcripts (A) up-regulated or (B) down-regulated by 1.5 fold or greater after
MNNG treatment. Fold change is calculated relative to untreated log-phase cells.
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Figure 3.14 K-means Cluster Analysis (Heat Map Representation)
A total of 7339 transcripts were grouped into 10 clusters using K-means clustering. Prior to
cluster analysis data was normalized relative to log expression values (i.e. untreated log-phase
cells) and expressed as log2 fold change. K-means clustering was performed using the program
Cluster (available at http://rana.lbl.gov).
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Figure 3.15 K-means Cluster Analysis (Average Expression)
K-means cluster analysis was performed on the 7339 regulated transcripts as described in Figure
3.14. To more clearly visualize the expression patterns, average gene expression values within
each cluster are plotted.
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Table 3.1 Kinase Activity Assay Experimental Conditions
Kinase Antibody Substrate ATP (yM) [32P]ATP (pCi) Reaction Time (min) Termination
Chk2 Anti-Chk2 MK2tide 25 2 60 EDTA
ERK Anti-ERK1/2 Myelin basic protein 25 1 60 H3PO4
JNK Anti-JNK1 GST-ATF2 (1-109) 10 2 60 H3PO4
MK2 Anti-MAPKAPK2 MK2tide 25 2 60 EDTA
Table 3.2 Western Blot Experimental Conditions
Protein Cell Lysate (pg) Gel Buffer Membrane Antibody Dilution
ATM(S1981) 30ug 3-8% Tris-Acetate TA Nitrocellulose R&D Systems AF1655 1:750
ATM 30ug 3-8% Tris-Acetate TA Nitrocellulose Santa Cruz sc-23921 1:200
H2AX(S139) 25u 4-12% Bis-Tris MOPS PVDF Upstate 05-636 1:5000
H2AX 25ug 4-12% Bis-Tris MOPS PVDF Upstate 07-627 1:5000
Chk1 S317) 25ug 4-12% Bis-Tris MOPS PVDF Bethyl Laboratories BL229 1:1000
Chk1 25ua 4-12% Bis-Tris MOPS PVDF Santa Cruz sc-8408 1:400
Chk2(T68) 25ug 4-12% Bis-Tris MOPS Nitrocellulose Abcam ab3501 1:1000
Chk2 25ug 4-12% Bis-Tris MOPS Nitrocellulose Santa Cruz sc-8813 1:400
p53(S15) 25uq 10% Bis-Tris MOPS PVDF R&D Systems AF1043 1:1333
p53(S20) 25ug 10% Bis-Tris MOPS PVDF R&D Systems AF2286 1:2000
p53 25ug 10% Bis-Tris MOPS PVDF Santa Cruz sc-263 1:400
Actin Sigma A5441 1:6250
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Table 3.3 Enrichment Analysis: Cluster 1
Gene Ontology Gene Ontology
Category Number p-value
DNA metabolic process GO:0006259 1.70E-06
transcription GO:0006350 3.22E-05
cell cycle GO:0007049 4.32E-05
regulation of transcription GO:0045449 8.39E-05
DNA replication GO:0006260 1.02E-04
regulation of RNA metabolic process GO:0051252 1.47E-04
regulation of transcription, DNA-dependent GO:0006355 2.44E-04
response to DNA damage stimulus GO:0006974 1.04E-03
DNA repair GO:0006281 2.33E-03
cell cycle process GO:0022402 3.00E-03
KEGG Pathway p-value
Mismatch repair 1.20E-03
DNA replication 7.61 E-03
Pathways in cancer 1.14E-02
Pyrimidine metabolism 1.68E-02
Non-small cell lung cancer 3.03E-02
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Table 3.4 Enrichment Analysis: Cluster 2
Gene Ontology Gene Ontology
Category Number p-value
immune response GO:0006955 4.84E-09
regulation of apoptosis GO:0042981 3.15E-05
response to virus GO:0009615 3.73E-05
regulation of programmed cell death GO:0043067 3.92E-05
regulation of cell death GO:0010941 4.31E-05
regulation of cell proliferation GO:0042127 5.26E-05
defense response GO:0006952 7.07E-05
positive regulation of immune system process GO:0002684 1.59E-04
regulation of lymphocyte activation GO:0051249 2.1OE-04
induction of apoptosis GO:0006917 2.14E-04
KEGG Pathway p-value
Intestinal immune network for IgA production 1.65E-03
Cytokine-cytokine receptor interaction 4.01 E-03
Chemokine signaling pathway 4.03E-03
Cell adhesion molecules (CAMs) 2.40E-02
Viral myocarditis 3.43E-02
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Table 3.5 Enrichment Analysis: Cluster 3
Gene Ontology Gene Ontology
Category Number p-value
lipid biosynthetic process GO:0008610 2.84E-06
sterol biosynthetic process GO:0016126 1.16E-05
mast cell activation GO:0045576 6.62E-05
sterol metabolic process GO:0016125 9.21 E-05
cholesterol biosynthetic process GO:0006695 1.41 E-04
cholesterol metabolic process GO:0008203 1.70E-04
isoprenoid biosynthetic process GO:0008299 2.67E-04
carboxylic acid biosynthetic process GO:0046394 4.68E-04
organic acid biosynthetic process GO:0016053 4.68E-04
fatty acid biosynthetic process GO:0006633 7.05E-04
KEGG Pathway p-value
Terpenoid backbone biosynthesis 1.66E-03
Steroid biosynthesis 2.73E-03
Fc gamma R-mediated phagocytosis 6.55E-03
B cell receptor signaling pathway 1.69E-02
Valine, leucine and isoleucine degradation 2.04E-02
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Table 3.6 Enrichment Analysis: Cluster 4
Gene Ontology Gene Ontology
Category Number p-value
regulation of transcription GO:0045449 9.08E-07
cell cycle GO:0007049 2.33E-06
transcription GO:0006350 4.37E-06
DNA metabolic process GO:0006259 6.31 E-05
DNA replication GO:0006260 2.52E-04
DNA repair GO:0006281 5.43E-04
regulation of RNA metabolic process GO:0051252 1.29E-03
regulation of transcription, DNA-dependent GO:0006355 1.58E-03
regulation of DNA metabolic process GO:0051052 5.08E-03
response to DNA damage stimulus GO:0006974 5.52E-03
KEGG Pathway p-value
Prostate cancer 8.37E-04
Cell cycle 4.21 E-03
Homologous recombination 5.10E-03
p53 signaling pathway 1.05E-02
Spliceosome 1.99E-02
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Table 3.7 Enrichment Analysis: Cluster 5
Gene Ontology Gene Ontology
Category Number p-value
immune response GO:0006955 1.35E-04
defense response GO:0006952 1.01 E-03
lipid biosynthetic process GO:0008610 3.31 E-03
sterol metabolic process GO:0016125 3.64E-03
regulation of GPCR protein signaling pathway GO:0008277 3.94E-03
protein kinase cascade GO:0007243 7.81 E-03
intracellular signaling cascade GO:0007242 8.59E-03
fatty acid biosynthetic process GO:0006633 1.1 9E-02
inflammatory response GO:0006954 1.40E-02
leukocyte activation GO:0045321 1.74E-02
KEGG Pathway
Long-term potentiation 7.27E-02
B cell receptor signaling pathway 8.42E-02
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Table 3.8 Enrichment Analysis: Cluster 6
Gene Ontology Gene Ontology
Category Number p-value
translation GO:0006412 5.93E-19
RNA processing GO:0006396 4.96E-18
ncRNA metabolic process GO:0034660 1.21E-17
ncRNA processing GO:0034470 3.45E- 16
ribonucleoprotein complex biogenesis GO:0022613 4.75E-16
ribosome biogenesis GO:0042254 2.90E-15
rRNA metabolic process GO:0016072 3.96E-12
rRNA processing GO:0006364 7.51 E-12
positive regulation of ubiquitin-protein ligase activity GO:0051443 1.01 E-07
regulation of protein ubiquitination GO:0031396 1.32E-07
KEGG Pathway p-value
Parkinson's disease 2.19E-04
Purine metabolism 5.66E-04
Pyrimidine metabolism 1.58E-03
Proteasome 2.07E-03
Oocyte meiosis 2.25E-03
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Table 3.9 Enrichment Analysis: Cluster 7
Gene Ontology Gene Ontology
Category Number p-value
regulation of transcription GO:0045449 4.37E-06
transcription GO:0006350 4.70E-06
regulation of transcription, DNA-dependent GO:0006355 1.59E-04
regulation of RNA metabolic process GO:0051252 2.69E-04
enzyme linked receptor protein signaling pathway GO:0007167 1.38E-03
ossification GO:0001503 3.97E-03
regulation of cell-substrate adhesion GO:0010810 6.05E-03
bone development GO:0060348 7.05E-03
peptidyl-serine modification GO:0018209 1.OOE-02
transcription from RNA polymerase 11 promoter GO:0006366 1.08E-02
KEGG Pathway p-value
Pathways in cancer 1.23E-04
Renal cell carcinoma 3.98E-03
Focal adhesion 7.50E-03
Pancreatic cancer 1.54E-02
Insulin signaling pathway 1.76E-02
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Table 3.10 Enrichment Analysis: Cluster 8
Gene Ontology Gene Ontology
Category Number p-value
regulation of apoptosis GO:0042981 2.1OE-03
regulation of programmed cell death GO:0043067 2.35E-03
regulation of endothelial cell migration GO:0010594 2.35E-03
regulation of cell death GO:0010941 2.44E-03
small GTPase mediated signal transduction GO:0007264 4.68E-03
cell cycle arrest GO:0007050 5.05E-03
positive regulation of endothelial cell migration GO:0010595 8.29E-03
regulation of establishment of protein localization GO:0070201 9.51 E-03
enzyme linked receptor protein signaling pathway GO:0007167 1 .1OE-02
regulation of transcription GO:0045449 1 .13E-02
KEGG Pathway p-value
Selenoamino acid metabolism 2.50E-02
Alanine, aspartate and glutamate metabolism 3.47E-02
Glycine, serine and threonine metabolism 3.47E-02
Aminoacyl-tRNA biosynthesis 5.76E-02
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Table 3.11 Enrichment Analysis: Cluster 9
Gene Ontology Gene Ontology
Category Number p-value
positive regulation of nitrogen metabolic process GO:0051173 6.81 E-04
enzyme linked receptor protein signaling pathway GO:0007167 6.90E-04
PDGF receptor signaling pathway GO:0048008 1.35E-03
regulation of transcription GO:0045449 1.40E-03
positive regulation of signal transduction GO:0009967 1.89E-03
response to protein stimulus GO:0051789 1.95E-03
positive regulation of cell communication GO:0010647 2.37E-03
mesoderm development GO:0007498 2.85E-03
regulation of homeostatic process GO:0032844 3.02E-03
positive regulation of nucleobase, nucleoside, nucleotide
and nucleic acid metabolic process GO:0045935 3.42E-03
KEGG Pathway
p53 signaling pathway 4.65E-04
MAPK signaling pathway 5.52E-03
Cytokine-cytokine receptor interaction 4.46E-02
Pancreatic cancer 4.59E-02
Apoptosis 8.83E-02
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Table 3.12 Enrichment Analysis: Cluster 10
Gene Ontology Gene Ontology
Category Number p-value
leukocyte activation GO:0045321 4.51 E-04
regulation of cell proliferation GO:0042127 6.82E-04
regulation of cell motion GO:0051270 8.02E-04
positive regulation of protein transport GO:0051222 9.87E-04
lipid transport GO:0006869 1.35E-03
regulation of establishment of protein localization GO:0070201 1.55E-03
lipid localization GO:0010876 3.06E-03
transmembrane receptor protein tyrosine phosphatase
signaling pathway GO:0007185 3.18E-03
induction of apoptosis by intracellular signals GO:0008629 3.59E-03
coenzyme biosynthetic process GO:0009108 3.66E-03
KEGG Pathway p-value
p53 signaling pathway 1.39E-07
Pancreatic cancer 2.02E-04
Other glycan degradation 6.98E-03
Notch signaling pathway 8.27E-03
Small cell lung cancer 8.77E-03
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Chapter 4
Discussion
157
Overview
As SN 1 type methylating agents are commonly used in the treatment of cancer (e.g.
temozolomide, streptozotocin, procarbazine, dacarbazine) an understanding of how cells respond
to these agents will aid in the development of more personalized chemotherapeutic strategies.
Although SN1 type methylating agents cause damage to numerous sites within DNA, as well as
other macromolecules within the cell (e.g. RNA, lipids, proteins), it is well documented that the
06 methylguanine (O 6 MeG) lesion, in the presence of a functional mismatch repair (MMR)
pathway, is responsible for the toxic effects of these agents. Consequently, expression of the
MGMT repair protein, which directly repairs 06MeG lesions, and MMR proteins (i.e. MSH2 and
MLH 1) are known to modulate tumor resistance to chemotherapeutic alkylating agents [1]. In
this work, we take a systems-level approach towards achieving a more complete understanding
of the 0 MeG/MMR-dependent DNA damage response (DDR) induced by different doses of the
classical SN 1 type methylating agent MNNG. At the cellular level, we demonstrate through
detailed kinetic analysis that TK6 human lymphoblastoid cells delay progression through both
the first and second cell cycle post MNNG treatment and that, under lethal doses, cells initiate
apoptotic cell death out of the second S-phase; all of these responses are completely dependent
on the persistence of O6MeG lesions and on the presence of MMR. At the molecular level, we
find that these events coincide with the phosphorylation and/or activation of key DDR network
proteins including ATM, H2AX, CHKI, CHK2, and p53. In general, while the trend of network
activation is similar between low and high dose, the magnitude is much greater following high
dose treatment. In the following sections, we review our results with respect to the current
models for MMR-mediated cytotoxicity.
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The importance of 06MeG and MMR on MNNG-induced toxicity is well documented.
However, the precise mechanism by which the MMR pathway signals downstream events (i.e.
DNA repair, cell cycle arrest, apoptosis) is less clear. Two models have been proposed that link
the MMR pathway to MNNG sensitivity, a direct signaling model and an indirect futile repair
model (Figure 1.2). In the direct signaling model, the recognition of an O6MeG/T mismatch by
MMR proteins is thought to provoke a response through direct interaction between MMR
proteins and key DNA damage signaling kinases. If this were the case, we would expect to see a
signaling response directly following MNNG treatment due to misincorporation of T opposite
O6MeG in the first S-phase. The most likely signaling candidate in this scenario is the ATR
protein kinase. It has been shown in vitro that ATR is recruited to, as well as activated by,
06 MeG/T mismatches in a MMR-dependent manner [2]. Conversely, in the indirect futile repair
model the MMR-mediated futile excision and resynthesis of the T-mismatch opposite 06MeG
gives rise to the repeated generation of a single-stranded DNA region that interferes with
replication in the second S-phase triggering activation of DNA damage signaling. Under this
hypothesis, we would expect to observe induction of the DDR only after cells proceed into S-
phase of the second cell cycle. Our results, within this dissertation, indicate that both models
may be working together to mediate cell cycle arrest and cell death in response to the
methylating agent MNNG.
Evidence for direct signaling model
Replication past an O6MeG lesion gives rise to an O6MeG/T mismatch in the first S-phase that is
recognized by proteins in the MMR pathway. In the direct signaling model, binding of the MMR
components MutSa and MutLa to the mismatch is sufficient to trigger a DNA damage signal
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through direct interaction with signaling proteins. In support of this model, we observe MMR-
dependent inhibition of cell growth and dynamic cell cycle changes in TK6 cells within the first
cell cycle post MNNG treatment. More specifically, we detect an increase in the proportion of
cells in S- and G2-phase of the cell cycle alongside a decrease in the proportion of cells in
mitosis as early as eight hours following MNNG treatment, suggesting induction of an intra-S
and a G2-M cell cycle checkpoint response at this time. It is important to keep in mind that this
'early' checkpoint response is transient as cells are ultimately permitted to progress into
subsequent cell cycles. At this time, we also observe CHK1 phosphorylation, but not CHK2
phosphorylation or activation. While most likely an oversimplification, CHK1 is activated by
ATR following various forms of genotoxic stress whereas CHK2 is activated by ATM in
response to double strand breaks (DSBs). More specifically, the ATR-CHK1 pathway is
activated by DNA lesions that give rise to replication protein A (RPA)-coated single-stranded
DNA such as replication blocking lesions and DNA repair excision intermediates [3]. However,
with respect to the 06MeG lesion, ATR was shown to be directly activated by MMR, leading to
phosphorylation and activation of CHK1 [2]. Direct activation of the ATR-CHKl pathway by
MMR is therefore the most obvious mode of CHK1 phosphorylation within the first S-phase
following MNNG treatment. However, we cannot rule out the possibility that ATR activation
and subsequent CHK1 phosphorylation is due to single-stranded DNA (ssDNA) gaps formed
during MMR-mediated futile repair processing. In support of the latter, ssDNA gaps were
shown to accumulate in cellular DNA within the first S-phase following treatment with MNNG
in an MMR-dependent manner; but whether this is sufficient to invoke a signaling response is
not clear [4]. To note, this same study demonstrated that replication fork progression is not
effected in this first S-phase ruling out a replication block as the ultimate trigger for the early
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activation of ATR-CHK1 signaling. In line with the hypothesis that the ATR-CHK1 pathway is
central to the early MNNG response, we detect the phosphorylation of the ATR substrates H2AX
(S139) and p53 (S]5) and the CHK1 target p53 (S20) in the first cell cycle post treatment.
An unexpected result was the detection of phosphorylated ATM (S1981) within one hour after
treatment with MNNG. In response to double strand breaks (DSBs), ATM is
autophosphorylated at serine- 1981 leading to its activation [5]. The formation of DSBs, and the
subsequent phosphorylation of ATM, is not expected until cells progress into their second S-
phase post treatment. Therefore, it is important to point out that while ATM activation is often
associated with DSB formation, other forms of stress have been shown to activate ATM in a
DSB-independent manner, most recently in response to oxidative stress [6]. Additionally, ATM
phosphorylation at serine-1981 was shown to be mediated by ATR, and not by ATM
autophosphorylation, following UV treatment or replication fork stalling [7]. Moreover, ATM
has been shown to interact directly with the MMR protein MLH 1, providing a mechanism for
ATM localization to the site of damage indepenent of DSBs [8]. Normally, the phosphorylation
of ATM (S1981) is associated with ATM kinase activation and subsequent CHK2
phosphorylation. However, we did not detect either CHK2 phosphorylation at threonine-68 or
CHK2 kinase activation during this initial period of DDR signaling following MNNG treatment.
One explanation is that the observed phosphorylation of ATM at serine- 1981 is not sufficent to
trigger full kinase activation. Indeed, a number of post-translational modifications in addition to
the phosphorylation at serine- 1981 are required for the the complete activation of ATM [9].
Further, mediator proteins are required to stimulate the kinase activity of ATM towards its
substrates. For one, the Mre 11 -Rad50-Nbs 1 (MRN) complex is required for phosphorylation of
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ATM targets (including CHK2) in response to DSBs [10]. Although we do not know what
factors are present at the site of damage during this initial phase of signaling by MMR, we note
that lack of MRN recruitment would deter CHK2 activation by ATM.
Based on the available results, we propose that the ATR-CHKl pathway is the predominant
pathway governing cell behavior during the early response to MNNG. The ATR-CHKl pathway
is most recognized for its role in mediating cell cycle transitions in G 1 -S, intra-S, and G2-M and
therefore could potentially play a part in delaying cell cycle progression through S- and G2-
phase of the first cell cycle following MNNG treatment. Although the mechanism is yet to be
uncovered, cells are ultimately permitted to progress through the cell cycle with unresolved DNA
damage. We point out that the early signal detected in response to MNNG occurs at low
persistent levels. Based on previous studies showing that a permanent G2 arrest is only sustained
above a certain threshold of damage, we suggest that the MNNG damage signal may be too low
to induce a robust G2-M arrest in the first cell cycle post treatment [11]. Finally, we point out
that the signal trigger, whether it be MMR-bound 06MeG/T mismatches or MMR-mediated
ssDNA gaps, is not sufficient to invoke cell death in the first cell cycle post treatment.
Evidence for futile repair model
One of the main characteristics of the MMR futile repair model is the formation of secondary
damage (i.e. ssDNA gaps) that interferes with DNA replication in the second S-phase. Indeed,
TK6 cells treated with MNNG undergo an 06 MeG/MMR-dependent intra-S-phase arrest in the
second cell cycle that is distinct from the cell cycle effects observed at early time points. In
particular, the late intra-S-phase arrest is marked by a more dramatic accumulation of S-phase
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cells as well as a reduction in S-phase DNA replication. In addition, following a lethal dose of
MNNG, apoptotic cell death is triggered out of the second S-phase. It is hypothesized that the
source of O6MeG/MMR-dependent cell death following exposure to MNNG is the cytotoxic
DSB lesion. In the futile repair model, persistent single-strand gaps are encountered by
replicative polymerases leading to the collapse of replication forks and ultimately the formation
of DSBs. As stated previously, the ATM-CHK2 pathway is primarily activated in response to
DSB lesions whereas the ATR-CHK1 pathway is activated by various lesions that give rise to
ssDNA, like stalled replication forks and DSB repair intermediates. Based on the described
model, all of these events (i.e. fork stalling, DSB formation, DSB repair intermediates) are
presumed to take place in an MMR-dependent manner in the second S-phase following MNNG
exposure. In agreement with this, our data show 06MeG/MMR-dependent activation of both the
ATM-CHK2 pathway and the ATR-CHK1 pathway that coincides with the accumulation of cells
in the second S-phase. At this time, we detect the phosphorylation of ATM (S1981), CHK2
(T68), CHK1 (S317), H2AX (S139) and p53 (S15 and S20).
Proposed model
Figure 4.1 depicts our proposed model for O6MeG/MMR-dependent cell cycle arrest and cell
death according to the results discussed. Briefly, 06MeG lesions are converted to 06MeG/T
mispairs in the first replication cycle. Subsequently, members of the MMR pathway, MutSa and
MutLa, bind to the O6MeG/T mismatch leading to direct activation of the ATR-CHK1 pathway.
ATR-CHK1 signaling delays cell cycle progression through S- and G2- phase of the first cell
cycle. In parallel, ssDNA gaps arise due to futile repair attempts by the MMR pathway. These
gaps persist into the second cell cycle where they are encountered by replication forks in the
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second S-phase. Ultimately, this gives rise to stalled replication forks, fork collapse, and DSBs.
Such events in turn trigger activation of the ATR-CHKl and ATM-CHK2 signaling pathways
that together coordinate various cellular responses including an intra-S-phase arrest and,
depending on the dose, repair and survival or apoptotic cell death.
First versus second cell cycle post MNNG treatment
While many of the molecular players overlap between the first and second cell cycle response
there are several key differences. For one, the damage signal triggered in the second S-phase is
of a much greater magnitude than the damage signal triggered in the first cell cycle. Particularly
with regard to the p53 tumor suppressor protein, the extent of DNA damage is an important
factor in cellular outcome; low/transient stress induces a p53 transcriptional response that
promotes 'survival' (i.e. genes involved in cell cycle arrest, DNA repair, metabolic homeostasis,
etc.) while high/sustained levels of stress induces a p53 transcriptional response that promotes
cell death or senescence [12]. Another difference between the early and late signals is the
activation of CHK2, which occurs only in the second cell cycle. While both CHK1 and CHK2
have roles in regulating cell cycle checkpoints in response to DNA damage, CHK2 plays a
prominent role in the regulation of p53 and apoptosis in response to DSBs [13]. Therefore, we
might speculate that with regard to MNNG, CHK2 mediates cell death while CHK1 serves a
protective role by regulating cell cycle progression and DNA replication in the presence of
persistent damage. In regards to this, Bartek and Lukas [13] coined CHK1 as a "workhorse" and
CHK2 as an "amplifier" of the DDR. Indeed, this seems to be the case here. However,
inhibition studies are required to confirm the role for CHK1 and CHK2 in mediating the cellular
response to MNNG. In addition to the canonical DNA damage signaling proteins previously
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discussed, we detected activation of the stress-activated protein kinase JNK following MNNG
treatment. Further, this activation was dependent on the O6MeG DNA lesion and on a functional
MMR pathway. As with CHK2, JNK activation occurs only in the second cell cycle post
treatment, not in the first. As JNK has been implicated in the apoptotic response to a variety of
stresses, we hypothesized that it may be important for the induction of apoptosis following
exposure to MNNG [14]. Inhibition studies using the JNK inhibitor SP600125 showed a modest
increase in short-term survival after MNNG treatment. However, the inhibitor alone resulted in a
slower rate of cellular proliferation, limiting the conclusions of this study. To obtain a more
definitive answer to JNK's role in regulating apoptosis in response to MiNNG, we will need to
explore additional inhibitory approaches such as peptide inhibitors or RNAi knockdown
techniques. An understanding of how these signaling events influence cell behavior with respect
to the methylating agent MNNG could have important implications on cancer therapy [15].
Intra-S arrest in response to MNNG
Following DNA damage, a cell activates cell cycle checkpoints to delay cell cycle progression
until it has time to repair the damage. These include the G 1 and G2 checkpoints that prevent
progression into S- and M-phase, respectively, and the intra-S-phase checkpoint that delays but
does not completely block progression through S-phase [16]. In response to MNNG, we observe
a clear intra-S-phase arrest in the second cell cycle following both low and high dose treatments.
Further, we note that cells with low levels of damage, upon S-phase completion, continue
through the second G2 without any obvious delay. With that being said, previous reports have
demonstrated a dramatic accumulation of G2/M cells in the second cell cycle following
treatment with MNNG [17] [18]. We note that such differences could be contributed to
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differences in cell type and/or p53 status. While our experiments were performed with TK6
human lymphoblastoid cells, reports indicating a G2 arrest after MNNG treatment utilized
chinese hamster ovary CHO-9 and human embryonic kidney 293T cell lines, both having
defective p53 functions [17] [18]. A previous study from our lab demonstrated that loss of p53
in TK6 cells delays, but does not eliminate, MNNG-induced apoptosis [19]. It seems plausible
that without the timely induction of apoptosis by p53, cells complete S-phase ultimately arresting
with G2 DNA content and initiate apoptosis at late times through a p53-independent mechanism.
Global transcriptional response and ongoing studies
As the motivation of this thesis work was to uncover protein signaling events that control cell
behavior in response to 06MeG, our approach was focused on monitoring critical nodes in the
DDR protein network with detailed kinetics across various doses of the methylating agent
MNNG. While this provided valuable mechanistic insight into the MMR-mediated signaling
events that control cell cycle arrest and cell death in response to this agent, monitoring less
established components of the DDR proved difficult, either due to lack of knowledge of the
players involved or lack of available experimental techniques to measure those players. Global
transcriptional profiling of S.cerevisiae has proven a useful tool for uncovering the regulation of
a wide range of biological processes in addition to DNA repair, DNA replication, and cell cycle
progression in response to various DNA damaging agents [20] [21]. In this work, we used this
approach to investigate the gene expression changes occurring in the TK6 human lymphoblastoid
cell line following treatment with various doses of the methylating agent MNNG. In particular,
we were interested in understanding what, if any, differences could be observed with respect to
our 'low' and 'high' dose treatment conditions as these conditions have very different cellular
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outcomes (damage repair/tolerance and survival versus cell death). Based on our analysis of
protein signaling and cell behavior in response to MNNG we chose time points that we expected
to yield optimal differences (dynamic and absolute) between low and high dose treatment
conditions. This provided us with a rich dataset; a total of 7,339 probe sets were found to be
differentially regulated with respect to dose and time. Through an unsupervised K-means
clustering analysis we were able to identify sets of genes with similar behavior and, importantly,
with similar biological functions. In addition to the regulation of genes involved in DNA
replication and repair, cell cycle, and apoptosis, we observed the regulation of genes involved in
a number of other biological processes including lipid metabolism, RNA metabolism, translation,
immune response, transcription, and cell signaling.
This approach successfully highlighted a number of biological processes that had not been
previously associated with MNNG damage. While the described results provide us with a broad
understanding of the biology taking place, additional analysis (i.e. pathway analysis,
transcription factor analysis, etc.) is required to gain a deeper understanding of the specific
pathways involved and the regulation of those pathways. Importantly, the systems-level
approach taken in this thesis provides us with an opportunity to build a comprehensive model
incorporating transcriptional, post-translational, and phenotypic data that can be used for the
identification of transcription signatures and novel pathways that mediate specific cell behaviors
in response to DNA alkylation damage.
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Figure 4.1 Proposed model for 06MeG/MMR-dependent cell cycle arrest and cell death
06MeG lesions are converted to 06MeG/T mispairs in the first replication cycle. Subsequently,
members of the MMR pathway, MutSa and MutLa, bind to the O6MeG /T mismatch leading to
direct activation of various DDR network proteins and, consequently, the activation of a transient
cell cycle arrest in the first cell cycle. In parallel, single-strand DNA (ssDNA) gaps arise due to
futile repair attempts by the MMR pathway. The formation of these ssDNA gaps is an additional
source of (indirect) signal activation in the first cell cycle. These gaps persist into the second cell
cycle where they are encountered by replication forks in the second S-phase. Ultimately, this
gives rise to stalled replication forks, fork collapse, and DSB formation. Such events in turn
trigger activation of a second wave of DNA damage signaling. At this time we observe an intra-
S-phase arrest. Under low dose conditions, cells are able to repair/tolerate the damage and
proceed successfully through the cell cycle. Under high dose conditions, damage ultimately
leads to apoptotic cell death out of the second S-phase. Proteins that are regulated in the early-
and late-phase are indicated accordingly. While the majority of proteins are regulated in both the
first and second cell cycle following MNNG damage, CHK2 and JNK kinase activation occur
only after cells proceed into their second cell cycle post treatment. The regulation of ATR is not
monitored directly and therefore appears in parentheses.
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Appendix: Genes Associated with K-means Cluster 1
226146 at CDNA clone IMAGE:5294560
1561530 at Homo sapiens, clone IMAGE:5580856, mRNA
1559776 at CDNA FLJ36989 fis, clone BRACE2006753 -
225139_at Transcribed locus --
225494 at Transcribed locus
230750 at Transcribed locus
229926 at Transcribed locus
229821 at Transcribed locus -
235505 s at MRNA full length insert cDNAclone EUROIMAGE 2362292 -
235659 at Transcribed locus --
235058 at CDNA FLJ42803 fis, clone BRCAN2002826 -
235919 at Transcribed locus --
237122 at Transcribed locus
231827 at Full length insert cDNA clone ZE04G11 -
232447 at CDNA FLJ12161 fis, clone MAMMA1000576 -
231963 at CDNA FLJ13937 fis, clone Y79AA1000805 -
227437 at CDNA: FLJ23130 fis, clone LNG08419
236287 at Transcribed locus --
239907 at Transcribed locus
228209 at CDNA FLJ38931 fis, clone NT2NE2013189 -
228159 at CDNA FLJ38039 fis, clone CTONG2013934
239105 at Transcribed locus --
221861 at MRNA; cDNA DKFZp762M127 (from clone DKFZp762MI27) -
215128 at CDNA FLJ11682 fis, clone HEMBAI004880
215854 at CDNA FLJ11844 fis, clone HEMBAI 006665 -
242150 at Transcribed locus -
238854 at CDNA FLJ23130 fis, clone LNG08419
242258 at Transcribed locus -
49111 at MRNA; cDNA DKFZp762M127 (from clone DKFZp762M127)
243563 at Transcribed locus
239944 at Clone HLS IMAGE 755093 mRNA sequence
238775 at Transcribed locus ---
43511 s at MRNA; cDNA DKFZp762MI27 (from clone DKFZp762M127) -
41512 at Transcribed locus ---
242406 at Transcribed locus --.
236546_at Transcribed locus ---
1556937 at CDNA FLJ38433 fis, clone FEBRA2014578
242486 at Transcribed locus ---
Transcribed locus, strongly similar to XP_415008.1
237334 at PREDICTED: similar to Tubulin tyrosine ligase [Gallus gallus] -
216595 at MRNA; cDNA DKFZp564DO42 (from clone DKFZp564D042) -
203192 at ATP-binding cassette, sub-family B (MDR/TAP), melmber 6 ABCB6
209380 s at ATP-binding cassette, sub-family C (CFTR/MRP), member 5 ABCC5
228123 s at abhydrolase domain containing 12 ABHD12
228124_at abhydrolase domain containing 12 ABHD12
219384 s at adenosine deaminase, tRNA-specific 1 ADATI
217761_at acireductone dioxygenase 1 AD1
222400 s at acireductone dioxygenase 1 AQ1i
228445 at apoptosis-inducing factor, mitochondrion-associated, 2 AIFM2
224900_at ankyrin repeat and FYVE domain containing 1 ANKFYI
223024_at adaptor-related protein complex 1, mu 1 subunit AP M1
213454 at apoptosis-inducing, TAF9-like domain 1 APITDI
234001 s at ADP-ribosylation factor GTPase activating protein 1 ARFGAP1
ADP-ribosylation factor guanine nucleotide-exchange factor 2
215927 at (brefeldin A-inhibited) ARFGEF2
219431 at Rho GTPase activating protein 10 ARHGAP10
226055 at arrestin domain containing 2 ARRDC2
218115 at ASF1 anti-silencing function 1 homolog B (S. cerevisiae) ASF1 B
217987 at asparagine synthetase domain containing I ASNSD1
218782 s at ATPase family, AAA domain containing 2 ATAD2
226871 s at ATG4 autophagy related 4 homolog D (S. cerevisiae) ATG4D
219766 at B9 protein domain 2 B9D2
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209364 at BCL2-antaaonist of cell death BAD
225677 at B-cell receptor-associated protein 29 BCAP29
202518 _at B-cell CLUlymphoma 7B BCL78
207595_s at bone morphogenetic protein 1 BMP1
BRF2, subunit of RNA polymerase IlIl transcription initiation
218955 at factor, BRF1-like BRF2
225217_s at bromodomain and PHD finger containing, 3 BRPF3
Bernardinelli-Seip congenital lipodystrophy 2 (seipin) /
208906 at heterogeneous nuclear ribonudeoprotein U-lke 2 BSCL2 /// HNRNPUL2
203944_x at butyrophilin, subfamily 2, member Al BTN2A1
215493 x at butyrophilin, subfamily 2, member Al BTN2A1
211256 x at butyrophilin, subfamily 2, member Al BTN2A1
1209183 s at chromosome 10 open reading frame 10 C1Oorf10
228374 at chromosome 10 open reading frame 28 C1Oorf28
219953 s at chromosome 11 open reading frame 17 C11orf17
242847 at chromosome 11 open reading frame 30 C11orf3O
228281 at chromosome 11 open reading frame 82 C11orf82
222613 at chromosome 12 open reading frame 4 C12orf4
221821 s at chromosome 12 open reading frame 41 C12orf4l
226349 at chromosome 12 open reading frame 45 C12orf45
213346 _at chromosome 13 open reading frame 27 C13orf27
218108 at chromosome 14 open reading frame 130 C14orf130
1552400 a at chromosome 15 open reading frame 27 C15orf27
217957 at chromosome 16 open reading frame 80 C16orf8O
219879 s at chromosome 17 open reading frame 53 C17orf53
223351 at chromosome 17 open reading frame 80 C17orf8O
225967_s at chromosome 17 open reading frame 89 C17orf89
223526 at chromosome 18 open reading frame 21 C18orf21
223181 at chromosome 18 open reading frame 55 C18orf55
224468 s at chromosome 19 open reading frame 48 C19orf48
221512 at chromosome I open reading frame 160 Clorf160
52078 at chromosome 1 open reading frame 160 Clorf160
222720 x at chromosome 1 open reading frame 27 C1orf27
215691 x at chromosome I open reading frame 41 Clorf4l
236629 at chromosome 1 open reading frame 69 Clorf69
209020 at chromosome 20 open reading frame 111 C20orf111
226805 at chromosome 20 open reading frame 142 C20orf142
227160 s at chromosome 20 open reading frame 7 C20orf7
222894 x at chromosome 20 open reading frame 7 C20orf7
231303 at chromosome 21 open reading frame 42 C21orf42
220941 s at chromosome 21 open reading frame 91 C21orf9l
235396 at chromosome 22 open reading frame 25 C22orf25
213199_at C2 calcium-dependent domain containing 3' C2CD3
36552 at C2 calcium-dependent domain containing 3 C2CD3
203600 s at chromosome 4 open reading frame 8 C4orf8
230521 at chromosome 9 open reading frame 100 C9orf1OO
221946 at chromosome 9 open reading frame 116 C9orf116
226070 at chromosome 9 open reading frame 142 C9orf142
218998 at chromosome 9 open reading frame 6 C9orf6
220246 at calcium/calmodulin-dependent protein kinase ID CAMKID
46323 at calcium activated nucleotidase I CANT1
210944 s at calpain 3, (p94) CAPN3
231023 at cysteinyl-tRNA synthetase 2, mitochondrial (putative) CARS2
207842 s at cancer susceptibility candidate 3 CASC3
202763 at caspase 3, apoptosis-related cysteine peptidase CASP3
221822 at coiled-coil domain containing 101 CCDC101
48117 at coiled-coil domain containing 101 CCDC101
227818 at coiled-coil domain containing 21 CCDC21
221069 s at coiled-coil domain containing 44 CCDC44
223236 at coiled-coil domain containing 55 CCDC55
218175 at coiled-coil domain containing 92 CCDC92
219774 at coiled-coil domain containing 93 CCDC93
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209698 at coiled-coil alpha-helical rod protein I GUNGR TX
37425gat coiled-coil alpha-helical rod protein 1 CCHCR1
37424 at coiled-coil alpha-helical rod protein I CCHCRI
42361_gat coiled-coil alpha-helical rod protein 1 CCHCR1
201700 at cyclin D3 CCND3
203522_at copper chaperone for superoxide dismutase CCS
233647 s at cytidine and dCMP deaminase domain containing 1 CDADC1
223527 s at cytidine and dCMP deaminase domain containing 1 CDADC1
204695 at cell division cycle 25 homolog A(S. pombe) CDC25A
204126 s at CDC45 cell division cycle 45-like (S. cerevisiae) CDC45L
209056 s at CDC5 cell division cycle 5-like (S. pombe) CDC5L
203968 s at cell division cycle 6 homolog (S. cerevisiae) CDC6
224753 at cell division cycle associated 5 CDCA5
229468 at cyclin-dependent kinase 3 CDK3
218929 at CDKN2A interacting protein CDKN2AIP
214804 at centromere protein I CENPI
226118 at centromere protein 0 CENPO
212516 at centaurin, delta 2 CENTD2
204251 s at centrosomal protein 164kDa CEP164
219311_at centrosomal protein 76kDa CEP76
209668 x at carboxylesterase 2 (intestine, liver) CES2
218642_s at coiled-coil-helix-coiled-coil-helix domain containing 7 CHCHD7
222701 s at coiled-coil-helix-coiled-coil-helix domain containing 7 CHCHD7
242157 at Chromodomain helicase DNA binding protein 9 CHD9
cholinergic receptor, nicotinic, alpha 7 11 CHRNA7 (cholinergic
receptor, nicotinic, alpha 7, exons 5-10) and FAM7A (family with
sequence similarity 7A, exons A-E) fusion / similar to CHRNA7- CHRFAM7A /// CHRNA7 ///
210123 s at FAM7A fusion isoform I LOC732445
226314 at carbohydrate (N-acetylgalactosamine 4-0) sulfotransferase 14 CHST14
204085 s at ceroid-lipofuscinosis, neuronal 5 CLN5
CLP1, cleavage and polyadenylation factor I subunit, homolog
229496_at (S. cerevisiae) CLP1
CLPI, cleavage and polyadenylation factor I subunit, homolog
204370 at (S. cerevislae) CLPI
224998 at CKLF-like MARVEL transmembrane domain containing 4 CMTM4
203291 at CCR4-NOT transcription complex, subunIt 4 CNOT4
220095 at centlein, centrosomal protein CNTLN
1556499 s at collagen, type 1, alpha I COL1AI
202310 s at collagen, type 1, alpha 1 COL1A1
202311 s at collagen, type 1, alpha I COL1AI
COX15 homolog, cytochrome c oxidase assembly protein
235204 at (yeast) COX15
200621 at cysteine and glycine-rich protein 1 CSRP1
203915 at chemokine (C-X-C motif) ligand 9 CXCL9
220252 x at chromosome X open reading frame 21 CXorf21
213315 x at chromosome X open reading frame 40A CXorf4OA
chromosome X open reading frame 40A /// chromosome X open
214112 s at reading frame 40B CXorf4OA / CXorf4OB
chromosome X open reading frame 40A /// chromosome X open
212961 x at reading frame 40B CXorf4OA /// CXorf4OB
202263 at cytochrome b5 reductase I CY85RI
224735_at cytochrome b, ascorbate dependent 3 CYBASC3
209232 s at dynactin 5 (p25) DCTN5
209231 s at dynactin 5 (p25) DCTN5
DEAD/H (Asp-Glu-Ala-Asp/His) box polypeptide 11 (CHLI-like
208159 x at helicase homolog, S. cerevisiae) DDXII
DEAD/H (Asp-Glu-Ala-Asp/His) box polypeptide 11 (CHL1-like
208149 x at helicase homolog, S. cerevisiae) DDX11
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213378 s at
DEAD/H (Asp-Glu-Ala-Asp/His) box polypeptide 11 (CHL1-like
helicase homolog, S. cerevisiae) / DEAD/H (Asp-Glu-Ala-
Asp/His) box polypeptide 12 (CHLI1-like helicase homolog, S.
cerevisiae) /// DEAD/H (Asp-Giu-Ala-AspHis) box polypeptide 11
like DDX11 // DDX12 /// LOC642846
226540 at DEAD (Asp-Glu-Ala-Asp) box polypeptide 54 DDX54
226539 s at DEAD (Asp-Glu-Ala-Asp) box polypeptide 54 DDX54
219664 s at 2,4-dienoyl CoA reductase 2, peroxisomal DECR2
1554352 s at DENN/MADD domain containing 4A DENND4A
228184_at dispatched homolog 1 (Drosophila) DISP1
204687 at DKFZP56400823 protein DKFZP56400823
204522 at dom-3 homolog Z (C. elegans) DOM3Z
down-regulator of transcription 1, TBP-binding (negative cofactor
207654 x at 2) DRI
down-regulator of transcription 1, TBP-binding (negative cofactor
209188 x at 2) DR1
219000 s at defective in sister chromatid cohesion 1 homolog (S. cerevisiae) DSCC1
DSN1, MIND kinetochore complex component, homolog (S.
219512 at cerevisiae) DSN1
222680 s at denticleless homolog (Drosophila) DTL
2028 s at E2F transcription factor 1 E2F1
241725 at E2F transcription factor 7 E2F7
226042 at enhancer of mRNA decapping 3 homolog (S. cerevisiae) EDC3
209572 s at embryonic ectoderm development EED
216396 s at etoposide induced 2.4 mRNA E124
E74-like factor 3 (ets domain transcription factor, epithelial-
201510 at specific ) ELF3
E74-like factor 3 (ets domain transcription factor, epithelial-
229842 at specific) ELF3
203490 at E74-like factor 4 (ets domain transcription factor) ELF4
31845 at E74-like factor 4 (ets domain transcription factor) ELF4
234465 at essential melotic endonuclease I homolog 1 (S. pombe) EME1
1569868 s at essential meiotic endonuclease 1 homolog 2 (S. pombe) EME2
205521 at endonuclease G-like I ENDOGLI
220153 at ectonucleoside triphosphate diphosphohydrolase 7 ENTPD7
229974 at Ells van Creveld syndrome 2 (limbin) EVC2
204603 at exonuclease 1 EXO1
218248 at family with sequence similarity 111, member A FAM111A
222936_s at family with sequence similarity 152, member A FAM152A
family with sequence similarity 27, member A /l similar to
223791 at Protein FAM27A/B/C FAM27A / LOC 100132948
231880_at family with sequence similarity 40, member B FAM40B
213008 at Fanconi anemia, complementation group I FANCI
213007 at Fanconi anemia, complementation group I FANCI
227500 at F-box and leucine-rich repeat protein 18 FBXL18
221812_at F-box protein 42 FBXO42
221813 at F-box protein 42 FBX042
47773_at F-box protein 42 FBXO42
226451 at ferredoxin 1-like FDXIL
hypothetical gene supported by AK124342 /// hypothetical
230452 at protein LOC100131455 FLJ42351 I/ LOC100131455
218210 at fructosamine-3-kinase-related protein FN3KRP
225851 at famesyltransferase, CAAX box, beta FNTB
202723 s at forkhead box 01 FOXO1
222050 _at Fragile X mental retardation, autosomal homolog 2 FXR2
221245 s at frizzled homolog 5 (Drosophila) FZD5
202528_at UDP-galactose-4-epimerase GALE
UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-
230906 at acetylgalactosaminyltransferase 10 (GaINAc-T1O) GALNT10
UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-
212256 at acetylgalactosaminyltransferase 10 (GaINAc-T1O) GALNT10
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UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-
207357 s at acetylgalactosaminyftransferase 10 (GaINAc-TIO) GALNTIO
228286 at Gen homolog 1, endonuclease (Drosophila) GEN1
240778 at GINS complex subunit 4 (SId5 homolog) GINS4
sulfotransferase family, cytosolic, 1A, phenol-preferring, member
3 /// GIY-YIG domain containing 2 /// sulfotransferase family,
cytosolic, 1A, phenol-preferring, member 4 /// GIY-YIG domain GIYD1 // GIYD2 /// SULT1A3 ///
210580 x at containing 1 SULT1A4
sulfotransferase family, cytosolic, 1A, phenol-preferring, member
3 / GIY-YIG domain containing 2 // sulfotransferase family,
cytosolic, 1A, phenol-preferring, member 4 / GIY-YIG domain GIYD1 / GIYD2 /// SULT1A3 /
209607 x at containing 1 SULTIA4
239720 at GATA like protein-1 GLP-1
218147 s at glycosyltransferase 8 domain containing 1 GLT8D1
218146 at glycosyltransferase 8 domain containing 1 GLT8D1
235678 at GM2 ganglioside activator GM2A
203384 s at golgi autoantigen, golgin subfamily a, 1 GOLGA1
203383 s at golgi autoantigen, golgin subfamily a, 1 GOLGA1
204630 s at golgi SNAP receptor complex member 1 GOSRI
glucuronidase, beta-like 2 / similar to Beta-glucuronidase
226947 at precursor GUSBL2 /// LOC728411
228736_at DNA helicase HEL308 HEL308
222491 at heparan-alpha-glucosaminide N-acetyltransferase HGSNAT
212964 at hypermethylated in cancer 2 HIC2
218507 at hypoxia-inducible protein 2 HIG2
229697 at HIRA interacting protein 3 HIRIP3
major histocompatibility complex, class I, B // major
histocompatibility complex, class I, C /// MHC class I polypeptide
related sequence A / MHC class I polypeptide-related sequence HLA-B /// HLA-C /// MICA / MICB
205905 s at B /// XXbac-BPG181B23.1
major histocompatibility complex, class I, B /// major
histocompatibility complex, class I, C / MHC class I polypeptide
related sequence A/// MHC class I polypeptide-related sequence HLA-B /// HLA-C /// MICA /// MICB
209140 x at B /// XXbac-BPG181 823.1
212115 at hematological and neurological expressed 1-like HN1L
212983 at v-Ha-ras Harvey rat sarcoma viral oncogene homolog HRAS
201609 x at isoprenylcysteine carboxyl methyltransferase ICMT
228976 at inducible T-cell co-stimulator ligand ICOSLG
211197 s at inducible T-cell co-stimulator ligand ICOSLG
209721_s at intermediate filament family orphan IFFO
36030 at intermediate filament family orphan IFFO
219209_at interferon induced with helicase C domain 1 IFIH1
222062 at Interleukin 27 receptor, alpha IL27RA
205926_at interleukin 27 receptor, alpha IL27RA
222250 s at integrator complex subunit 7 INTS7
206650 at IQ motif containing C IQCC
204202 at IQ motif containing E IQCE
205469 s at interferon regulatory factor 5 IRF5
1553111_a at kelch repeat and BTB (POZ) domain containing 6 KBTBD6
206005 s at KIAA1 009 KIAA1 009
227479 at KIAA1244 KIAA1244
neuroblastoma breakpoint family, member 14 / neuroblastoma
breakpoint family, member 1 /// KIAA1 245 / neuroblastoma
breakpoint family, member 11 / neuroblastoma breakpoint
family, member 15 /1 neuroblastoma breakpoint family, member KIAA1245 /// LOC100132406 /
20 /// neuroblastoma breakpoint family, member 9 /// NBPF1 /// NBPF10 // NBPF11 ///
neuroblastoma breakpoint family, member 10 / neuroblastoma NBPF14 /// NBPF1 5 /// NBPF16 //
breakpoint family, member 8 / CG1 0522-PA-like /// CLIP-190- NBPF20 /// NBPF8 /// NBPF9 ///
like /// neuroblastoma breakpoint family, member 16 /// similar to RP3-377D14.1 / XXyac-
214693 x at NBPF9 YX155B6.1
225205 at kinesin family member 38 KIF3B
203943 at kinesin family member 3B KIF3B
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Ikelch-like 25 (Drosophila) / hypothetical protein LOC1001290821KLHL25 1/ LOC100129082
236275_at KRAB-A domain containing 1 KRBAI
227587 at KRI1 homolog (S. cerevisiae) KRIi
203451 at LIM domain binding 1 LDB1
35160 at LIM domain binding 1 LDB1
202726 at ligase 1, DNA, ATP-dependent LIG1
210582 s at LIM domain kinase 2 LIMK2
228348 at lines homolog 1 (Drosophila) LINSI
242207 at similar to hCG1985411 LOC100128361
1558447 at hypothetical protein LOC100128439 LOC100128439
227011 at hypothetical protein LOC100130262 LOC100130262
228117 at Hypothetical protein LOC100132273 LOC100132273
prostate collagen triple helix //X hypothetical protein
222277 at LOC100133696 LOC 100133696/// PCOTH
226796 at hypothetical protein LOC116236 LOC116236
229262 at hypothetical protein LOC284352 LOC284352
1556102 x at hypothetical protein LOC286434 LOC286434
239466 at hypothetical LOC344595 LOC344595
similar to Serine/threonine-protein kinase PRKX (Protein kinase
PKX1) / hypothetical protein LOC441528 /// similar to LOC389906 /// LOC441528 ///
1569629 x at hCG1981372 / similar to LOC389906 protein LOC728687 / LOC729162
1558046 x at hypothetical protein LOC441528 LOC441528
1558045 a at hypothetical protein LOC441528 LOC441528
221855 at hypothetical protein LOC644096 LOC644096
44669 at hypothetical protein LOC644096 LOC644096
1561759 at Hypothetical LOC645513 LOC645513
1561760 s at Hypothetical LOC645513 LOC645513
1561761 x at Hypothetical LOC645513 LOC645513
240436 at Similar to FRAS1 related extracellular matrix protein 2 LOC650794
meteorin, glial cell differentiation regulator-like 1/ similar to
225955 at meteorin, glial call differentiation regulator-like LOC653506 / METRNL
228859 at prematurely terminated mRNA decay factor-like LOC91431
232611 at hypothetical LOC92497 LOC92497
221834 at Lon peptidase 2, peroxisomal LONP2
low density lipoprotein receptor-related protein associated
201186 at protein 1 LRPAPI
221554 at protein kinase LYK5 LYK5
215566 x at lysophospholipase|| LYPLA2
204458_at lysophospholipase 3 (lysosomal phospholipase A2) LYPLA3
224689 at mannosidase, beta A, lysosomal-like MANBAL
203266 s at mitogen-activated protein kinase kinase 4 MAP2K4
203265 s at mitogen-activated protein kinase kinase 4 MAP2K4
226293_at mediator complex subunit 19 MED1 9
226300 at mediator complex subunit 19 MED19
225316_at major facilitator superfamily domain containing 2 MFSD2
mannosyt (beta-1,4-)-glycoprotein beta-1,4-N-
209764 at acetylglucosaminyltransferase MGAT3
Microtubule associated monoxygenase, calponin and LIM
231553 s at domain containing 3 MICAL3
1554450 s at mesoderm Induction early response 1, family member 3 MIER3
206495 s at MBD2-interacting zinc finger MIZF
222530_s at McKusick-Kaufman syndrome MKKS
Myeloid/lymphoid or mixed-lineage leukemia (trithorax homolog,
238257_at Drosophila); translocated to, 10 MLLT1 0
210752 s at MAX-like protein X MLX
224434 s at mitogen-activated protein kinase organizer 1 MORG1
1557455 s at motile sperm domain containing I MOSPD1
224330 s at mitochondrial ribosomal protein L27 MRPL27
209421 at mutS homolog 2, colon cancer, nonpolyposis type 1 (E. coli) MSH2
214303 x at mucin 5AC, oligomeric mucus/gel-forming MUC5AC
224206 x at myoneurin MYNN
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221867 at NEDD4 binding protein 1 N4BP1
204601 at NEDD4 binding protein I N4BP
48612 at NEDD4 binding protein 1 N4BP1
218231 at N-acetylglucosamine kinase NAGK
236273 at neuroblastoma breakpoint family, member 1 NBPF1
1557172 x at NIMA (never in mitosis gene a)- related kinase 8 NEK8
222774 s at neuropilin (NRP) and tolloid (TLL)-like 2 NETO2
nuclear factor of activated T-cells, cytoplasmic, calcineurin-
210555 s at dependent 3 NFATC3
nuclear factor of kappa light polypeptide gene enhancer in B-
209239 at cells 1 (p105) NFKB1
nuclear factor of kappa light polypeptide gene enhancer in B-
201502 s at cells inhibitor, alpha NFKBIA
202216 x at nuclear transcription factor Y, gamma NFYC
1559218 s at nuclear transcription factor Y, gamma NFYC
211251 x at nuclear transcription factor Y, gamma NFYC
207703 at neuroligin 4, Y-linked NLGN4Y
non-metastatic cells 1, protein (NM23A) expressed in /// non-
201577 at metastatic cells 2, protein (NM23B) expressed in NME1 /// NME2
221567 at nucleolar protein 3 (apoptosis repressor with CARD domain) NOL3
59625 at nucleolar protein 3 (apoptosis repressor with CARD domain) NOL3
226839 at nuclear receptor 2C2-associated protein NR2C2AP
225654 at nuclear receptor binding SET domain protein 1 NSD1
219084 at nuclear receptor binding SET domain protein I NSDI
229044 at nudix (nucleoside diphosphate linked moiety X)-type motif 17 NUDT17
2-oxoglutarate and iron-dependent oxygenase domain
225110 at containing I OGFOD1
219105 x at origin recognition complex, subunit 6 like (yeast) ORC6L
223920 s at p53-regulated apoptosis-inducing protein I P53AIP1
1554691 a at protein kinase C and casein kinase substrate in neurons 2 PACSIN2
219530 at partner and localizer of BRCA2 PALB2
227204 at par-6 partitioning defective 6 homolog gamma (C. elegans) PARD6G
206594 at PAS domain containing serine/threonine kinase PASK
216945 x at PAS domain containing serine/threonine kinase PASK
204210 s at phosphate cytldylyltransferase 1, choline, alpha PCYTIA
phosphodiesterase 4C, cAMP-specific (phosphodiesterase El
211818 s at dunce homolog, Drosophila) PDE4C
231065 at Phosphodiesterase 6D, cGMP-specific, rod, delta PDE6D
225075 at p53 and DNA damage regulated 1 PDRG1
222492 at pyridoxal (pyridoxine, vitamin B6) kinase PDXK
223037 at PDZ domain containing 11 PDZD11
200787 s at phosphoprotein enriched in astrocytes 15 PEA15
238004 at piggyBac transposable element derived 2 PGBD2
221816 s at PHD finger protein 11 PHF11
226942_at PHD finger protein 20-like 1 PHF20L1
212542 s at pleckstrin homology domain interacting protein PHIP
235062_at PIH1 domain containing 2 PlH1D2
203688 at polycystic kidney disease 2 (autosomal dominant) PKD2
204267_x_at protein kinase, membrane associated tyrosine/threonine 1 PKMYT1
219046 s at PBX/knotted I homeobox 2 PKNOX2
216551 x at phospholipase C, gamma 1 PLCG1
213309 at phospholipase C-like 2 PLCL2
216218 s at phospholipase C-like 2 PLCL2
pleckstrin homology domain containing, family M (with RUN
212146 at domain) member 2 PLEKHM2
1560069 at pleckstrin homology domain containing, family M, member 3 PLEKHM3
204441 s at polymerase (DNA directed), alpha 2 (70kD subunit) POLA2
225844 at polymerase (DNA-directed), epsilon 4 (p12 subunit) POLE4
polymerase (RNA) 1I (DNA directed) polypeptide J, 13.3kDa
224517 at pseudogene POLR2J4
polymerase (RNA) II (DNA directed) polypeptide J, 13.3kDa
60815_at pseudogene POLR2J4
I
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227872 at polymerase (RNA) Ill (DNA directed) polypeptide A, 155kDa POLR3A
POM121 membrane glycoprotein (rat) /// POM121 membrane
213360 s at glycoprotein C POM121 /// POM121C
POM121 membrane glycoprotein (rat) /// POM121 membrane
212178 s at glycoprotein C POM121 /// POM121C
zona pellucida glycoprotein 3 (sperm receptor) / POM
204148 s at (POM121 homolog, rat) and ZP3 fusion POMZP3 / ZP3
219483 s at porcupine homolog (Drosophila) PORCN
204353 s at POT1 protection of telomeres 1 homolog (S. pombe) POT1
211771 s at POU class 2 homeobox 2 POU2F2
219066 at phosphopantothenoylcysteine decarboxylase PPCDC
protein phosphatase 2 (formerly 2A), catalytic subunit, beta
201375 s at isoform PPP2CB
221772 s at protein phosphatase 2, regulatory subunit B, delta isoform PPP2R2D
218378 s at PRKR interacting protein 1 (IL11 inducible) PRKRIP1
217794 at proline rich 13 PRR13
218714 at proline rich 14 PRR14
45687 at proline rich 14 PRR14
205956 x at PSMC3 interacting protein PSMC31P
222405_at protein tyrosine phosphatase-like A domain containing 1 PTPLAD1
223463 at RAB23, member RAS oncogene family RAB23
204974_at RAB3A, member RAS oncogene family RAB3A
203573 s at Rab geranylgeranyltransferase, alpha subunit RABGGTA
204478 s at RAB interacting factor RABIF
RAB, member of RAS oncogene family-like 2B /// RAB, member
220500 s at of RAS oncogene family-like 2A RABL2A /// RABL2B
210630_s at RAD52 homolog (S. cerevisiae) RAD52
225738 at Rap guanine nucleotide exchange factor (GEF) 1 RAPGEFI
204346 s at Ras association (RaIGDS/AF-6) domain family member 1 RASSF1
226436 at Ras association (RalGDS/AF-6) domain family member 4 RASSF4
203344 s at retinoblastoma binding protein 8 RBBP8
226286 at RNA binding motif and ELMO/CED-12 domain I RBED1
219286 s at RNA binding motif protein 15 RBM15
218134 s at RNA binding motif protein 22 RBM22
224068 x at RNA binding motif protein 22 RBM22
222527 s at RNA binding motif protein 22 RBM22
212591 at RNA binding motif protein 34 RBM34
212430_at RNA binding motif protein 38 RBM38
209497 s at RNA binding motif protein 4B RBM4B
222666 s at RNA terminal phosphate cyclase-like 1 RCL1
v-rel reticuloendotheliosis viral oncogene homolog B, nuclear
factor of kappa light polypeptide gene enhancer in B-cells 3
205205 at (avian) RELB
203696 s at replication factor C (activator 1) 2, 4OkDa RFC2
210138 at regulator of G-protein signaling 20 RGS20
235742 at Ras homolog gene family, member C RHOC
226551 at receptor (TNFRSF)-interacting serine-threonine kinase 1 RIPK1
209941 at receptor (TNFRSF)-interacting serine-threonine kinase 1 RIPKI
1557545 s at ring finger protein 165 RNF165
205806 at retinal outer segment membrane protein I ROMI
201756 at replication protein A2, 32kDa RPA2
201477_s at ribonucleotide reductase M1 RRMI
206949 s at RUN and SH3 domain containing 1 RUSC1
205449 at SAC3 domain containing 1 SAC3D1
sorting and assembly machinery component 50 homolog (S.
201570 at cerevisiae) SAMM50
208740 at Sin3A-associated protein, 18kDa SAP18
1569594 a at serologically defined colon cancer antigen 1 SDCCAG1
223299 at SEC11 homolog C (S. cerevislae) SEC11C
210616 s at SEC31 homolog A (S. cerevisiae) SEC31A
217716 s at Sec6l alpha 1 subunit (S. cerevisiae) SEC61A1
222385 x at Sec61 alpha 1 subunit (S. cerevisiae) SEC61A1
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204978 at splicing factor, arginine/serine-rich 16 SFRS16
227560 at sideroflexin 2 SFXN2
228584 at sarcoglycan, beta (43kDa dystrophin-associated glycoprotein) SGCB
219083 at SHQ1 homolog (S. cerevisiae) SHQ1
203761 at Src-like-adaptor SLA
solute carrier family 12 (potassium/chloride transporters),
209401 s at member 4 SLC12A4
solute carrier family 25 (mitochondrial carrier; adenine nucleotide
202825 at translocator), member 4 SLC25A4
218985 at solute carrier family 2, (facilitated glucose transporter) member 8 SLC2A8
Solute carrier family 2, (facilitated glucose transporter) member
239426 at 8 SLC2A8
228181 at solute carrier family 30 (zinc transporter), member 1 SLC30A1
212907 at Solute carrier family 30 (zinc transporter), member I SLC3OA1
218988 at solute carrier family 35, member E3 SLC35E3
solute carrier family 36 (proton/amino acid symporter), member
213119 at 1 SLC36A1
solute carrier family 37 (glucose-6-phosphate transporter),
202830 s at member 4 SLC37A4
228696 at solute carrier family 45, member 3 SLC45A3
solute carrier family 7 (cationic amino acid transporter, y+
system), member 6 /// transient receptor potential cation
203578 s at channel, subfamily V, member 6 SLC7A6 /// TRPV6
229153 at solute carrier family 7, member 6 opposite strand SLC7A60S
207390 s at smoothelin SMTN
209427 at smoothelin SMTN
syntrophin, beta 2 (dystrophin-associated protein Al, 59kDa,
205315 s at basic component 2) SNTB2
214531 s at sorting nexin I SNX1
232739_at Spi-B transcription factor (Spi-1/PU.1 related) SPIB
38766 at Snf2-related CREBBP activator protein SRCAP
serum response factor (c-fos serum response element-binding
202401 s at transcription factor) SRF
224607 s at signal recognition particle 68kDa SRP68
202816 s at synovial sarcoma translocation, chromosome 18 SS18
234005 x at serine/threonine kinase 36, fused homolog (Drosophila) STK36
SYS1 Golgi-localized integral membrane protein homolog (S.
224669_at cerevisiae) SYSI
202307 s at transporter 1, ATP-binding cassette, sub-family B (MDR/TAP) TAP1
transcription elongation factor B (Sill), polypeptide 2 (18kDa,
213877 x at elongin B) TCEB2
223274 at transcription factor 19 (SCI) TCF19
203743 s at thymine-DNA glycosylase TDG
238346 s at trimethylguanosine synthase homolog (S. cerevisiae) TGS1
236371_s_at Trimethylguanosine synthase homolog (S. cerevisiae) TGS1
1554408 a at thymidine kinase 1, soluble TK1
227804 at TLC domain containing 1 TLCD1
201764 at transmembrane protein 106C TMEM106C
227393 at transmembrane protein 16J TMEM16J
219253 at transmembrane protein 185B (pseudogene) TMEM185B
1555790_a at zinc finger protein 320 /// transmembrane protein 192 TMEM192 /// ZNF320
227936 at transmembrane protein 68 TMEM68
223544_at transmembrane protein 79 TMEM79
212204 at transmembrane protein 87A TMEM87A
214948 s at TATA element modulatory factor 1 TMF1
226604 at transmembrane and tetratricopeptide repeat containing 3 TMTC3
tumor necrosis factor receptor superfamily, member 14
209354 at (herpesvirus entry mediator) TNFRSF14
202348 s at torsin family 1, member A (torsin A) TORA
202349 at torsin family 1, member A (torsin A) TOR1A
232546 at tumor protein p7 3 TP73
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202871_at TNF receptor-associated factor 4 TRAF4
235688 s at TNF receptor-associated factor 4 TRAF4
211899 s at TNF receptor-associated factor 4 TRAF4
205598 at TRAF interacting protein TRAIP
213301 x at tripartite motif-containing 24 TRIM24
202702 at tripartite motif-containing 26 TRIM26
236233 at tripartite motif-containing 32 TRIM32
240342 at tripartite motif-containing 61 TRIM61
222800 at tRNA selenocysteine associated protein 1 TRSPAP1
233999 s at tetratricopeptide repeat domain 26 TTC26
203272 s at tumor suppressor candidate 2 TUSC2
203273 s at tumor suppressor candidate 2 TUSC2
218794 s at thioredoxin-like 4B TXNL4B
222748 s at thioredoxin-like 4B TXNL4B
221839 s at ubiquitin associated protein 2 UBAP2
225209 s at ubiquitin-conjugating enzyme E2, J2 (UBC6 homolog yeast) UBE2J2
209103_s at ubiquitin fusion degradation 1 like (yeast) UFDI L
210681 s at ubiquitin specific peptidase 15 USP15
226063 at vav 2 guanine nucleotide exchange factor VAV2
205536_at vav 2 guanine nucleotide exchange factor VAV2
218415 at vacuolar protein sorting 33 homolog B (yeast) VPS33B
223022 s at Vps20-associated I homolog (S. cerevislae) VTA1
227490 at WD repeat and FYVE domain containing 2 WDFY2
211383_s at WD repeat domain 37 WDR37
230152_at WD repeat domain 52 WDR52
221103s at WD repeat domain 52 WDR52
219251 s at WD repeat domain 60 WDR60
213031_s at WD repeat domain 73 WDR73
236382 at WD repeat domain 8 WDR8
206213 at wingless-type MMTV integration site family, member 1OB WNTIOB
213445 at zinc finger CCCH-type containing 3 ZC3H3
223506 at zinc finger CCCH-type containing 8 ZC3H8
223212 at zinc finger, DHHC-type containing 16 ZDHHC16
226650 at zinc finger, ANI-type domain 2A ZFAND2A
1555982 at zinc finger, FYVE domain containing 16 ZFYVE16
232019 at zinc finger with KRAB and SCAN domains 2 ZKSCAN2
203731 s at zinc finger with KRAB and SCAN domains 5 ZKSCAN5
203730 s at zinc finger with KRAB and SCAN domains 5 ZKSCAN5
206240 s at zinc finger protein 136 ZNF136
219548 at zinc finger protein 16 ZNF16
207338 s at zinc finger protein 200 ZNF200
227689 at zinc finger protein 227 ZNF227
220350 at zinc finger protein 235 ZNF235
1555325 s at zinc finger protein 26 ZNF26
212892 at zinc finger protein 282 ZNF282
207753 at zinc finger protein 304 ZNF304
225296 at zinc finger protein 317 ZNF317
205182 s at zinc finger protein 324 ZNF324
214760 at zinc finger protein 337 ZNF337
37860 at zinc finger protein 337 ZNF337
227986 at zinc finger protein 343 ZNF343
1555015 a at zinc finger protein 398 ZNF398
219224 x at zinc finger protein 408 ZNF408
202010 s at zinc finger protein 410 ZNF410
213124 at zinc finger protein 473 ZNF473
230857 s at zinc finger protein 497 ZNF497
242621 at zinc finger protein 498 ZNF498
224518 s at zinc finger protein 559 ZNF559
230542 at zinc finger protein 597 ZNF597
226590 at zinc finger protein 618 ZNF618
218068 s at zinc finger protein 672 ZNF672
205089 at zinc finger protein 7 ZNF7
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ProbesetID Gene Name Gene Symbol
219627_at zinc finger family member 767 ZNF76
204453 at zinc finger protein 84 ZNF84
225076 s at zinc finger, NFX1-type containing 1 ZNFX1
zinc finger (CCCH type), RNA-binding motif and serine/arginine
213876 x at rich 2 ZRSR2
zinc finger (CCCH type), RNA-binding motif and serine/arginine
208174 x at rich 2 ZRSR2
1552499 a at zinc finger and SCAN domein containing 20 ZSCAN20
223424 s at zinc finger and SCAN domain containing 21 ZSCAN21
204026 s at ZW10 interactor WINT
1555853 at
225653 at
230476 at
222281 s at
238030 at
242139 s at
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1556294 at Transcribed locus
1557383 a at CDNA FLJ38112 fis, clone D30ST2002272 --
1559360 at Transcribed locus
1560523 at Homo sapiens, clone IMAGE:5166342, mRNA
1561044 at Homo sapiens, clone IMAGE:5548255, mRNA
1561045 a at Homo sapiens, clone IMAGE:5548255, mRNA ---
1561347 a at CDNA FLJ32691 fis, clone TEST12000221
1562921 at Homo sapiens, clone IMAGE:5580334, mRNA ---
1563244 at CDNA clone IMAGE:3881027
1567576 at Trapped 3' terminal exon, clone C2C4 ---
Transcribed locus, strongly similar to XP_001091338.1
PREDICTED: similar to solute carrier family 29 (nucleoside
222278 at transporters), member 1 [Macaca mulatta] --
225123 at CDNA FLJ33813 fis, clone CTONG2002744 --
225725 at CDNA clone IMAGE:5261213 -
226034 at Homo sapiens, clone IMAGE:3881549, mRNA ---
226546 at CDNA clone IMAGE:5268696
227221 at CDNA clone IMAGE:5261213 ---
228315 at CDNA clone IMAGE:5261213
228799_at Transcribed locus ---
228869 at Transcribed locus
229190 at CDNA FLJ90295 fis, clone NT2RP2000240
Transcribed locus, moderately similar to NP_919290.2 zinc
229465 s at finger and BTB domain containing 41 [Homo sapiens]
229592 at CDNA FLJ37509 fis, clone BRCAN1 000065
229659 s at Transcribed locus
230269 at Transcribed locus ---
230345 at Transcribed locus
231632 at Transcribed locus
232478 at CDNA clone IMAGE:4815026
233223 at CDNA FLJ20843 fis, clone ADKA01954
234250 at CDNA FLJ20410 fis, clone KATOI 922
234987 at Transcribed locus --
235242 at CDNA FLJ41375 fis, clone BRCAN2007700
235427 at Transcribed locus ---
235571 at MicroRNA 34a (MIRN34A) precursor RNA, complete sequence
235772 at Transcribed locus ---
235898 at Transcribed locus
236099 at CDNA FLJ41339 fis, clone BRASW1 000053 ---
Transcribed locus, moderately similar to XP_001102659.1
236398 s at PREDICTED: hypothetical protein [Macaca mulatta]
236982_at CDNA clone IMAGE:5270500 ---
238115 at Transcribed locus
238368_at Transcribed locus ---
238559 at CDNA clone IMAGE:5266242
238709 at CDNA FLJ38461 fis, clone FEBRA2020977
238733 at Transcribed locus
239278 at CDNA clone IMAGE:5301129 ---
239287 at Transcribed locus
239307 at Transcribed locus ---
239455 at Transcribed locus ___
239587_at Transcribed locus
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240458 at Transcribed locus
240708 at Transcribed locus -
241118 at Transcribed locus --
242525 at Transcribed locus ---
243383 at Transcribed locus
243754 at Transcribed locus ---
244040 at CDNA clone IMAGE:4796595
244457 at Transcribed locus -
204567 s at ATP-binding cassette, sub-family G (WHITE), member 1 ABCG1
200974 at actin, alpha 2, smooth muscle, aorta ACTA2
204639 at adenosine deaminase ADA
216705 s at adenosine deaminase ADA
209765 at ADAM metallopeptidase domain 19 (meltrin beta) ADAM19
209901 x at allograft inflammatory factor 1 AIF1
213095 x at allograft inflammatory factor 1 AIF1
215051 x at allograft inflammatory factor 1 AIF1
206513 at absent in melanoma 2 AIM2
230846 at A kinase (PRKA) anchor protein 5 AKAP5
aldehyde dehydrogenase 5 family, member Al (succinate-
203608 at semialdehyde dehydrogenase) ALDH5A1
204290 s at aldehyde dehydrogenase 6 family, member Al ALDH6A1
207992 s at adenosine monophosphate deaminase (isoform E) AMPD3
201302 at annexin A4 ANXA4
apolipoprotein B mRNA editing enzyme, catalytic polypeptide-
like 3G /// apolipoprotein B mRNA editing enzyme, catalytic
204205 at polypeptide-like 3F APOBEC3F /// APOBEC3G
apolipoprotein B mRNA editing enzyme, catalytic polypeptide-
like 3G /// apolipoprotein B mRNA editing enzyme, catalytic
214994 at polypeptide-like 3F APOBEC3F / APOBEC3G
apolipoprotein B mRNA editing enzyme, catalytic polypeptide-
like 3G I// apolipoprotein B rnRNA editing enzyme, catalytic
214995 s at polypeptide-like 3F APOBEC3F / APOBEC3G
amyloid beta precursor protein (cytoplasmic tail) binding protein
202630 at 2 APPBP2
205068 s at Rho GTPase activating protein 26 ARHGAP26
226576 at Rho GTPase activating protein 26 ARHGAP26
218501 at Rho guanine nucleotide exchange factor (GEF) 3 ARHGEF3
202641 at ADP-ribosylation factor-like 3 ARL3
212135 s at ATPase, Ca++ transporting, plasma membrane 4 ATP2B4
212136 at ATPase, Ca++ transporting, plasma membrane 4 ATP2B4
ATPase, Cu++ transporting, alpha polypeptide (Menkes
205198 s at syndrome) ATP7A
204624 at ATPase, Cu++ transporting, beta polypeptide ATP7B
alpha thalassemla/mental retardation syndrome X-linked
208861 s at (RAD54 homolog, S. cerevisiae) ATRX
UDP-GIcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase
1556134 a at 5 B3GNT5
202391 at brain abundant, membrane attached signal protein 1 BASP1
205681 at BCL2-related protein Al BCL2A1
219444 at BCL6 co-repressor-like 1 BCORL1
207399 at beaded filament structural protein 2, phakinin BFSP2
203773 x at biliverdin reductase A BLVRA
211729 x at biliverdin reductase A BLVRA
229109_s_at Biliverdin reductase A BLVRA
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Probeset ID Gene Name Gen Symbol
243445 at basonuclin 2 BNC2
201236 s at BTG family, member 2 BTG2
228372 at chromosome 10 open reading frame 128 Cl0orf128
212771 at chromosome 10 open reading frame 38 C1Oorf38
239093 at chromosome 10 open reading frame 65 ClOorf65
1556200 a at chromosome 10 open reading frame 90 COorf9O
227736_at chromosome 10 open reading frame 99 ClOorf99
224759 s at chromosome 12 open reading frame 23 C12orf23
224719 s at chromosome 12 open reading frame 57 C12orf57
220107 s at chromosome 14 open reading frame 140 C14orfI40
214696_at chromosome 17 open reading frame 91 C17orf91
209573 s at chromosome 18 open reading frame I C18off1
209574 s at chromosome 18 open reading frame 1 C18orf1
215734 at chromosome 19 open reading frame 36 CI9orf36
230033_at chromosome 19 open reading frame 51 C19orfl51
219670 at chromosome 1 open reading frame 165 C1orf165
207571 x at chromosome 1 open reading frame 38 Clorf38
210785 s at chromosome 1 open reading frame 38 Clor38
223272 s at chromosome 1 open reading frame 57 Clorf57
228100 at chromosome 1 open reading frame 88 Corf88
231514_at chromosome I open reading frame 94 C1orf94
218983 at complement component 1, r subcomponent-like C1 RL
232500 at chromosome 20 open reading frame 74 C20orf74
226688 at chromosome 3 open reading frame 23 C3orf23
219474 at chromosome 3 open reading frame 52 C3orf52
236984 at chromosome 4 open reading frame 26 C4orf26
205500 at complement component 5 C5
237016 at chromosome 6 open reading frame 128 C6orfI28
238504 at chromosome 6 open reading frame 57 C6orf57
219147_s at chromosome 9 open reading frame 95 C9orf95
206384 at calcium channel, voltage-dependent, gamma subunit 3 CACNG3
209002 s at calcium binding and coiled-coil domain 1 CALCOCO1
210244 at cathelicidin antimicrobial peptide CAMP
201850 at capping protein (actin filament), gelsolin-like CAPG
caspase 1, apoptosis-related cysteine peptidase (interleukin 1,
206011 at beta, convertase) CASP1
caspase 1, apoptosis-related cystelne peptidase (interleukin 1,
beta, convertase) /// caspase-1 dominant-negative inhibitor
1552703 s at pseudo-ICE CASPI /// COPI
1564757 a at coiled-coil domain containing 148 CCDC148
1568834 s at coiled-col domain containing 90B CCDC90B
207533 at chemokine (C-C motif) ligand 1 CCL1
210072 at chemokine (C-C motif) ligand 19 CCL19
207861 at chemokine (C-C motif) ligand 22 CCL22
206988 at chemokine (C-C motif) ligand 25 CCL25
206337 at chemokine (C-C motif) receptor 7 CCR7
205831 at CD2 molecule CD2
205456 at CD3e molecule, epsilon (CD3-TCR complex) CD3E
204661 at CD52 molecule CD52
34210 at CD52 molecule CD52
204440 at CD83 molecule CD83
205686_s_at CD86 molecule CD86
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.Probeset D Gene Name Gene Symbol
212899 at cell division cycle 2-like 6 (CDK8-like) CDC2L6
205852 at cyclin-dependent kinase 5, regulatory subunit 2 (p39) CDK5R2
202284 s at cyclin-dependent kinase inhibitor 1A (p21, Cip1) CDKN1A
213800 at complement factor H CFH
231221 at C-type lectin domain family 16, member A CLEC16A
203477 at collagen, type XV, alpha 1 COL15A1
1552701 a at caspase-1 dominant-negative inhibitor pseudo-ICE COP1
221676 s at coronin, actin binding protein, 1C CORO1C
226939 at cytoplasmic polyadenylation element binding protein 2 CPEB2
206100 at carboxypeptidase M CPM
221541 at cysteine-rich secretory protein LCCL domain containing 2 CRISPLD2
220445 s at CSAG family, member 3 /// CSAG family, member 2 CSAG2 l/ CSAG3
colony stimulating factor 2 receptor, beta, low-affinity
205159 at (granulocyte-macrophage) CSF2RB
219049 at chondroitin sulfate N-acetylgalactosaminyltransferase 1 CSGALNACT1
201201 at cystatin B (stefin B) CSTB
208407 s at catenin (cadherin-associated protein), delta 1 CTNND1
226000 at CTTNBP2 N-terminal like CTTNBP2NL
231822 at CTTNBP2 N-terminal like CTTNBP2NL
239525 at CTTNBP2 N-terminal like CTTNBP2NL
222453 at cytochrome b reductase 1 CYBRD1
220999 s at cytoplasmic FMR1 interacting protein 2 CYFIP2
213295 at cylindromatosis (turban tumor syndrome) CYLD
39582 at cylindromatosis (turban tumor syndrome) CYLD
222134 at D-aspartate oxidase DDO
218943 s at DEAD (Asp-Glu-Ala-Asp) box polypeptide 58 DDX58
202481 at dehydrogenase/reductase (SDR family) member 3 DHRS3
227094 at dehydrogenase El and transketolase domain containing 1 DHTKD1
205677 s at deleted in lymphocytic leukemia, 1 DLEU1
207147 at distal-tess homeobox 2 DLX2
203881 s at dystrophin (muscular dystrophy, Duchenne and Becker types) DMD
203811 s at DnaJ (Hsp4O) homolog, subfamily B, member 4 DNAJB4
218976 at DnaJ (Hsp40) homolog, subfamily C, member 12 DNAJC12
222640 at DNA (cytosine-5-)-methyltransferase 3 alpha DNMT3A
209691_s_at docking protein 4 DOK4
205248 at dopey family member 2 DOPEY2
238532 at D4, zinc and double PHD fingers, family 3 DPF3
1558868 a at Dermatan sulfate epimerase DSE
215565_at dystrobrevin, beta DTNB
204014_at dual specificity phosphatase 4 DUSP4
204015_s_at dual specificity phosphatase 4 DUSP4
209457 at dual specificity phosphatase 5 DUSP5
207231 at DAZ interacting protein 3, zinc finger DZIP3
222314 x at eosinophil granule ontogeny EGO
240475 at eosinophil granule ontogeny EGO
208112 x at EH-domain containing i EHD1
209037 s at EH-domain containing 1 EHDI
209039 x at EH-domain containing 1 EHD1
222221 x at EH-domain containing 1 EHD1
219190_s_at
eukaryotic translation initiation factor 2C, 3 /// eukaryotic
translation initiation factor 2C, 4 EIF2C3 /// EIF2C4
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227180 at
ELOVL family member 7, elongation of long chain fatty acids
(yeast) ELOVL7
207111 at egflike module containing, mucin-like, hormone receptor-like 1 EMR1
227609 at epithelial stromal interaction 1 (breast) EPST1
222354 at F11 receptor F1R
223000 s at F11 receptor F1IR
203989 x at coagulation factor II (thrombin) receptor F2R
210445_at fatty acid binding protein 6, ileal (gastrotropin) FABP6
202862 at fumarylacetoacetate hydrolase (fumarylacetoacetase) FAH
221601 s at Fas apoptotic inhibitory molecule 3 FAIM3
229739 s at family with sequence similarity 116, member B FAMi16B
221249_s at family with sequence similarity 117, member A FAM117A
226811 at family with sequence similarity 46, member C FAM46C
226215 s at F-box and leucine-rich repeat protein 10 FBXL10
225734 at F-box protein 22 FBXO22
231496 at Fc receptor, IgA, IgM, high affinity FCAMR
203561 at Fc fragment of IgG, low affinity Ila, receptor (CD32) FCGR2A
224404 s at Fc receptor-like 5 FCRL5
224405 at Fc receptor-like 5 FCRLS
224406 s at Fc receptor-like 5 FCRL5
231647 s at Fe receptor-like 5 FCRL5
235372 at Fc receptor-like A FCRLA
235400 at Fc receptorlike A FCRLA
235401 s at Fc receptor-like A FCRLA
203562 at fasciculation and elongation protein zeta 1 (zygin 1) FEZI
230231_at fibroblast growth factor 14 FGF14
208438 s at Gardner-Rasheed feline sarcoma viral (v-fgr) oncogene homolog FGR
220441 at hypothetical protein FLJ13236 FLJ13236
229559 at hypothetical protein FLJ40125 FLJ40125
xin actin-binding repeat containing 1/// hypothetical protein
235042 at LOC642987 FLJ43080 /// XIRP1
238823 at formin-like 3 FMNL3
224889 at forkhead box 03 FOXO3
224891 at forkhead box 03 FOXO3
231548_at Forkhead box 03 FOXO3
229763 at forkhead box P4 FOXP4
207178_s at fyn-related kinase FRK
216134 at FERM domain containing 4B FRMD4B
fascin homolog 1, actin-bundling protein (Strongylocentrotus
201564 s at purpuratus) FSCN1
209046_s_at GABA(A) receptor-associated protein-like 2 GABARAPL2
205890 s at gamma-aminobutyric acid (GABA) B receptor, 1 /// ubiquitin D GABBR1 /l UBD
202192 s at growth arrest-specific 7 GAS7
207704 s at growth arrest-specific 7 GAS7
211067 s at growth arrest-specific 7 GAS7
202269 x at guanylate binding protein 1, interferon-inducible, 67kDa GBP1
202270 at guanylate binding protein 1, interferon-inducible, 67kDa GBP1
231577 s at guanylate binding protein 1, interferon-inducible, 67kDa GBP1
219508 at glucosaminyl (N-acetyl) transferase 3, mucin type GCNT3
229367 s at GTPase, IMAP family member 6 GIMAP6
226142_at GLI pathogenesis-related 1 (glioma) GLIPR1
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224964 s at guanine nucleotide binding protein (G protein), gamma 2 GNG2
209469 at glycoprotein M6A GPM6A
209470 s at glycoprotein M6A GPM6A
205220 at G protein-coupled receptor 109B GPR 09B
204137 at G protein-coupled receptor 137B GPR1 37B
231166 at G protein-coupled receptor 155 GPR1 55
227970 at G protein-coupled receptor 157 GPR1 57
237559 at G protein-coupled receptor 55 GPR55
200736 s at glutathione peroxidase 1 GPX1
219313 at GRAM domain containing 1C GRAMDIC
205862 at GREB1 protein GREB1
hyperpolarization activated cyclic nucleotide-gated potassium
228741 s at channel 3 HCN3
206082 at HLA complex P5 HCP5
218839 at hairy/enhancer-of-split related with YRPW motif 1 HEYI
44783 s at hairy/enhancer-of-split related with YRPW motif 1 HEY1
220387 s at HERV-H LTR-associating 3 HHLA3
234665 x at HERV-H LTR-associating 3 HHLA3
234703 at HERV-H LTR-associating 3 HHLA3
205671 s at major histocompatibility complex, class I[, DO beta HLA-DOB
major histocompatibility complex, class lI, DP beta 2
239975 at (pseudogene) HLA-DPB2
214639 s at homeobox Al HOXA1
206858 s at homeobox C4 /// homeobox C6 HOXC4 /// HOXC6
221122 at HRAS-like suppressor 2 HRASLS2
215436 at Hydroxysteroid dehydrogenase like 2 HSDL2
211538 s at heat shock 70kDa protein 2 HSPA2
inhibitor of DNA binding 2, dominant negative helix-loop-helix
201565 s at protein ID2
210045 at isocitrate dehydrogenase 2 (NADP+), mitochondrial IDH2
218611 at immediate early response 5 IERS
214453 s at interferon-induced protein 44 IF144
203153 at interferon-induced protein with tetratricopeptide repeats 1 IFIT1
201887 at interleukin 13 receptor, alpha 1 IL13RA1
205992 s at interleukin 15 IL15
202948 at interleukin 1 receptor, type I IL1R1
205403 at interleukin 1 receptor, type Il IL1R2
211372 s at interleukin 1 receptor, type il IL1R2
1552912 a at interleukin 23 receptor IL23R
226333 at interleukin 6 receptor IL6R
202597 at interferon regulatory factor 6 IRF6
204698 at interferon stimulated exonuclease gene 20kDa ISG20
33304 at interferon stimulated exonuclease gene 2OkDa ISG20
207191 s at immunoglobulin superfamily containing leucine-rich repeat ISLR
202660 at inositol I,4,5-triphosphate receptor, type 2 ITPR2
202661 at inositol I 4,5-riphosphate receptor, type 2 ITPR2
202662 s at inositol 1,4,5-trphosphate receptor, type 2 ITPR2
214599 at involucrin IVL
213005 s at KN motif and ankyrin repeat domains 1 KANKI
205903_s_at
potassium intermediate/small conductance calcium-activated
channel, subfamily N, member 3 IKCNN3
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205902 at
potassium intermediate/small conductance calcium-activated
channel, subfamily N, member 3 /// similar to small conductance
calciur-activated potassium channel protein 3 KCNN3 ///1LOC100133958
1554438 at KIAA1217 KIAA1217
1562966 at KIAA1217 KIAA1217
231807 at KIAA1217 KIAA1217
232762 at KIAA1217 KIAA1217
230361_at hypothetical protein KIAA1833 KIAA1 833
227875 at keichlike 13 (Drosophila) KLHL13
216699 s at kallikrein 1 KLIK1
killer cell lectin-like receptor subfamily C, member 1 / killer cell
206785 s at lectin-like receptor subfamily C, member 2 KLRCI /// KLRC2
204385 at kynureninase (L-kynurenine hydrolase) KYNU
217388 s at kynureninase (L-kynurenine hydrolase) KYNU
207509_s at leukocyte-associated immunoglobulin-like receptor 2 LAIR2
205569 at lysosomal-associated membrane protein 3 LAMP3
201720 s at lysosomal associated multispanning membrane protein 5 LAPTM5
201721 s;at lysosomal associated multispanning membrane protein 5 LAPTM5
223380_s at LATS, large tumor suppressor, hornolog 2 (Drosophila) LATS2
207734 at lymphocyte transmembrane adaptor 1 LAXI
217892 s at LIM domain and actin binding 1 LIMA1
222457 s at LIM domain and actin binding I LIMAI
212086 x at lamin A/C LMNA
222197 s at Hypothetical protein LOC100128008 LOC100128008
243837 x at hypothetical protein LOC100128500 LOC100128500
241353 s at similar to hCG1821214 LOC100129105
1556409 a at hypothetical protein LOC1 00129932 LOC100129932
227840 at hypothetical protein LOCI 30355 LOC130355
1557049 at Hypothetical protein LOC149478 LOC149478
239691 at hypothetical protein LOC1 96415 LOC196415
1564150 a at hypothetical protein LOC256021 LOC256021
243601 at hypothetical protein LOC285957 LOC285957
221880 s at hypothetical gene supported by AK075564; BC060873 LOC400451
222085 at Hypothetical gene supported by AK075564; BC060873 LOC400451
51158 at hypothetical gene supported by AK075564; BC060873 LOC400451
1556639 at hypothetical gene supported by NM-175889 LOC439914
1558689 a at hypothetical gene supported by BC030123 LOC441461
225029 at hypothetical LOC550643 LOC550643
1557765 at hypothetical protein LOC643401 LOC643401
236835 at hypothetical LOC645431 LOC645431
237737_at similar to ankyrin repeat domain 20 family, member Al LOC727770
1558828 s at Hypothetical protein LOC728264 LOC728264
213248_at hypothetical LOC730101 LOC730101
234341 x at hypothetical protein LOC91548 LOC91548
212957 s at hypothetical LOC92249 LOC92249
214791 at hypothetical protein BC004921 LOC93349
216250 s at leupaxin LPXN
235126 at LQK1 hypothetical protein short isoform LQK1
205710 at low density lipoprotein-related protein 2 LRP2
230863 at low density lipoprotein-related protein 2 LRP2
210629 x at leukocyte specific transcript 1 LST1
211581_x at leukocyte specific transcript 1 LST1
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211582 x at leukocyte specific transcript 1 LST1
214181 x at leukocyte specific transcript 1 LST
214574 x at leukocyte specific transcript 1 LST1
215633 x at leukocyte specific transcript 1 LST1
221831 at leucine zipper protein 1 LUZP1
221832_s at leucine zipper protein 1 LUZPI
203518 at lysosomal trafficking regulator LYST
1552858 at melanoma antigen family B, 6 MAGEB6
222547 at mitogen-activated protein kinase kinase kinase kinase 4 MAP4K4
222548 s at mitogen-activated protein kinase kinase kinase kinase 4 MAP4K4
205819 at macrophage receptor with collagenous structure MARCO
220195 at methyl-CpG binding domain protein 5 MBD5
210605 s at milk fat globule-EGF factor 8 protein MFGE8
229254 at major facilitator superfamily domain containing 4 MFSD4
218205 s at MAP kinase interacting serine/threonine kinase 2 MKNK2
223199 at MAP kinase interacting serine/threonine kinase 2 MKNK2
matrix metallopeptidase 9 (gelatinase B, 92kDa gelatinase,
203936 s at 92kDa type IV collagenase) MMP9
212508 at modulator of apoptosis 1 MOAP1
229568 at MOB1, Mps One Binder kinase activator-like 2B (yeast) MOBKL2B
210280 at myelin protein zero (Charcot-Mare-Tooth neuropathy 1B) MPZ
224919_at mitochondrial ribosomal protein S6 MRPS6
223344 s at membrane-spanning 4-domains, subfamily A, member 7 MS4A7
224355 s at membrane-spanning 4-domains, subfamily A, member 8B MS4A8B
203347 s at metal response element binding transcription factor 2 MTF2
212096 s at mitochondrial tumor suppressor 1 MTUS1
204994 at myxovirus (influenza virus) resistance 2 (mouse) MX2
201960 s at MYC binding protein 2 MYCBP2
myeloma overexpressed gene (in a subset of t(1 1;14) positive
227342 s at multiple myelomas) MYEOV
212372 at myosin, heavy chain 10, non-muscle MYH10
227707 at Myosin regulatory light chain interacting protein MYLIP
1560788 at myosin Il1B MYO3B
203216 s at myosin VI MYO6
228608 at sodium leak channel, non-selective NALCN
211685 s at neurocalcin delta NCALD
neutrophil cytosolic factor 2 (65kDa, chronic granulomatous
209949 at disease, autosomal 2) NCF2
205147 x at neutrophil cytosolic factor 4, 4OkDa NCF4
207677 s at neutrophil cytosolic factor 4, 40kDa NCF4
209061 at nuclear receptor coactivator 3 NCOA3
neural precursor cell expressed, developmentally down-
1569020 at regulated 9 NEDD9
neural precursor cell expressed, developmentally down-
202149 at regulated 9 NEDD9
neural precursor cell expressed, developmentally down-
202150 s at regulated 9 NEDD9
243099 at NFAT activating protein with ITAM motif 1 NFAMI
237461 at NLR family, pyrin domain containing 7 NLRP7
1569631 at nicotinamide nucleotide adenylyltransferase 1 NMNAT1
205005 s at N-myristoyltransferase 2 NMT2
220106 at NPC1 (Niemann-Pick disease, type C1, gene)-like 1 NPCI LI
210174_at nuclear receptor subfamily 5, group A, member 2 NR5A2
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1553994 at 5'-nucleotidase, ecto (CD73) NT5E
1553995 a at 5'-nucleotidase, ecto (CD73) NT5E
203939 at '5'-nucleotidase, ecto (CD73) NT5E
209073 s at numb homolog (Drosophila) NUMB
219489 s at nucleoredoxin NXN
202869 at 2',5'-oligoadenylate synthetase 1, 40/46kDa OASI
205552 s at 2',5'-oligoadenylate synthetase 1, 40/46kDa OAS1
204972_at 2'-5'-oligoadenylate synthetase 2, 69/71kDa OAS2
20566 at 2'-5'-oligoadenylate synthetase-like OASL
210797 s at 2'-5'-oligoadenylate synthetase-like OASL
202074 s at optineurin OPTN
224701 at poly (ADP-ribose) polymerase family, member 14 PARP14
223220 s at poly (ADP-ribose) polymerase family, member 9 PARP9
230753 at protein associated with topoisomerase II homolog 2 (yeast) PATL2
212148 at Hypothetical LOCIO0131938 PBX1
204082 at pre-B-cell leukemia homeobox 3 PBX3
209361 s at poly(rC) binding protein 4 PCBP4
protocadherin gamma subfamily C, 3 /// protocadherin gamma
subfamily B, 4 /// protocadherin gamma subfamily A, 8 /
protocadherin gamma subfamily A, 12 /// protocadherin gamma
subfamily C, 5 /// protocadherin gamma subfamily C, 4 //
protocadherin gamma subfamily B, 7 /// protocadherin gamma PCDHGA1 /// PCDHGA10 ///
subfamily B, 6 /// protocadherin gamma subfamily B, 5 /// PCDHGA11 / PCDHGA12 /
protocadherin gamma subfamily B, 3 /// protocadherin gamma PCDHGA2 /// PCDHGA3 ///
subfamily B, 2 /// protocadherin gamma subfamily B, 1 /l PCDHGA4 /// PCDHGA5 /
protocadherin gamma subfamily A, 11 1/ protocadherin gamma PCDHGA6 /// PCDHGA7 /
subfamily A, 10 /// protocadherin gamma subfamily A, 9 / PCDHGA8 / PCDHGA9 /
protocadherin gamma subfamily A, 7 /// protocadherin gamma PCDHGB1 / PCDHGB2 /
subfamily A, 6 /// protocadherin gamma subfamily A, 5 / PCDHGB3 /// PCDHGB4 /
protocadherin gamma subfamily A, 4 /1/ protocadherin gamma PCDHGB5 / PCDHGB6 //
subfamily A, 3 /// protocadherin gamma subfamily A, 2 / PCDHGB7 / PCDHGC3 /
215836 s at protocadherin gamma subfamily A, 1 PCDHGC4 / PCDHGC5
1554256_a at pecanex-like 2 (Drosophila) PCNXL2
218953 s at prenylcysteine oxidase 1 like PCYOX1 L
208690 s at PDZ and LIM domain 1 (elfin) PDLIM1
208981 at platelet/endothelial cell adhesion molecule (CD31 antigen) PECAM1
208982 at platelet/endothelial cell adhesion molecule (CD31 antigen) PECAM1
208983 s at platelet/endothelial cell adhesion molecule (CD31 antigen) PECAM1
204866_at PHD finger protein 16 PHF16
205702 at putative homeodomain transcription factor I PHTF1
226147 s at polymeric immunoglobulin receptor PIGR
204269_at pim-2 oncogene PIM2
219584 at phospholipase Al member A PLAIA
219014 at placenta-specific 8 PLAC8
210845 s at plasminogen activator, urokinase receptor PLAUR
203895 at phospholipase C, beta 4 PLCB4
230120 s at plasminogen-like B2 PLGLB2
233177 s at paroxysmal nonkinesigenic dyskinesia PNKD
219756 s at premature ovarian failure, 1B POFIB
201494 at prolylcarboxypeptidase (angiotensinase C) PRCP
204061 at protein kinase, X-linked PRKX
213847 at peripherin PRPH
219938_s_at proline-serine-threonine phosphatase Interacting protein 2 PSTPIP2
193
Appendix: Genes Associated with K-means Cluster 2
210367 s at prostaglandin E synthase PTGES
prostaglandin-endoperoxide synthase 1 (prostaglandin G/H
205128 x at synthase and cyclooxygenase) PTGS1
prostaglandin-endoperoxide synthase 1 (prostaglandin G/H
215813 s at synthase and cyclooxygenase) PTGS1
prostaglandin-endoperoxide synthase I (prostaglandin G/H
238669 at synthase and cyclooxygenase) PTGS1
protein tyrosine phosphatase-like (proline instead of catalytic
219654 at arginine), member A PTPLA
208010 s at protein tyrosine phosphatase, non-receptor type 22 (lymphoid) PTPN22
221666 s at PYD and CARD domain containing PYCARD
200863 s at RAB11A, member RAS oncogene family RAB11A
228708 at RAB27B, member RAS oncogene family RAB27B
213982 s at RAB GTPase activating protein 1-like RABGAP1 L
ras-related C3 botulinum toxin substrate 2 (rho family, small GTP
213603 s at binding protein Rac2) RAC2
210255 at RAD51 -like 1 (S. cerevisiae) RAD51 LI
204070 at retinoic acid receptor responder (tazarotene induced) 3 RARRES3
1554992 at Ras protein-specific guanine nucleotide-releasing factor I RASGRF1
210550 s at Ras protein-specific guanine nucleotide-releasing factor 1 RASGRF1
203823 at regulator of G-protein signaling 3 RGS3
200885 at ras homolog gene family, member C RHOC
209684 at Ras and Rab interactor 2 RIN2
225929 s at ring finger protein 213 RNF213
225931 s at ring finger protein 213 RNF213
233880 at ring finger protein 213 RNF213
218007 s at ribosomal protein S27-like RPS27L
222487 s at ribosomal protein S27-like RPS27L
238935 at ribosomal protein S27-like RPS27L
204268 at S100 calcium binding protein A2 S100A2
227684 at sphingosine-1-phosphate receptor 2 S1PR2
206995 x at scavenger receptor class F, member 1 SCARF1
202898 at syndecan 3 SDC3
232894 at SEC14-like 2 (S. cerevisiae) SEC14L2
204563 at selectin L (lymphocyte adhesion molecule 1) SELL
232183 at serine active site containing 1 SERAC1
223538 at small EDRK-rich factor 1A (telomeric) SERFIA
serpin peptidase inhibitor, clade A (alpha-1 antiproteinase,
202833 s at antitrypsin), member 1 SERPINA1
serpin peptidase inhibitor, clade A (alpha-1 antiproteinase,
211429 s at antitrypsin), member 1 SERPINA1
33323 r at stratifin SFN
201811 x at SH3-domain binding protein 5 (BTK-associated) SH3BP5
219734 at SID1 transmembrane family, member 1 SIDT1
204362 at src kinase associated phosphoprotein 2 SKAP2
225639 at src kinase associated phosphoprotein 2 SKAP2
222838 at SLAM family member 7 SLAMF7
242274 x at solute carrier family 25, member 42 SLC25A42
1563498 s at solute carrier family 25, member 45 SLC25A45
1555500 s at SLC2A4 regulator SLC2A4RG
solute carrier family 2 (facilitated glucose/fructose transporter),
204430 s at member 5 SLC2A5
213164_at solute carrier family 5 (inositol transporters), member 3 SLC5A3
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sphingomyelin phosphodiesterase 3, neutral membrane (neutral
219695 at sphingomyelinase lI) SMPD3
230782_at sorbitol dehydrogenase SORD
212560 at sortilin-related receptor, L(DLR class) A repeats-containing SORLI
201416_at SRY (sex determining region Y)-box 4 SOX4
201417 at SRY (sex determining region Y)-box 4 SOX4
201418 s at SRY (sex determining region Y)-box 4 SOX4
213665_at SRY (sex determining region Y)-box 4 SOX4
213668 s at SRY (sex determining region Y)-box 4 SOX4
220217 x at SPANX family, member C SPANXC
200665 s at secreted protein, acidic, cysteine-rich (osteonectin) SPARC
244461 at sperm antigen with calponin homology and coiled-coll domains I SPECCI
sparclosteonectin, cwcv and kazal-like domains proteoglycan
202523 s at (testican) 2 SPOCK2
sparc/osteonectin, cwcv and kazal-Ilke domains proteoglycan
202524 s at (testican) 2 SPOCK2
217995_at sulfide quinone reductase-like (yeast) SQRDL
1554343 a at signal transducing adaptor family member I STAP1
220059 at signal transducing adaptor family member 1 STAP1
204597 x at stannlocalcin 1 STC1
230746 s at Stanniocalcin 1 STC1
231017 at seine/threonine kinase 11 STKII
231019 x at Serine/threonine kinase 11 STK11
212111 at syntaxin 12 STX12
210612 s at synaptojanin 2 SYNJ2
212828 at synaptojanin 2 SYNJ2
202796_at synaptopodin SYNPO
1553971 a at opposite strand transcription unit to STAG3 tcag7.1177
203054 s at T-cell leukemia translocation altered gene TCTA
203588 s at transcription factor Dp-2 (E2F dimerization partner 2) TFDP2
203589 s at transcription factor Dp-2 (E2F dimerization partner 2) TFDP2
226157 at Transcription factor Dp-2 (E2F dimerization partner 2) TFDP2
tissue factor pathway inhibitor (lipoprotein-associated
210664_s at coagulation inhibitor) TFPI
213135 at T-cell lymphoma invasion and metastasis I TIAM1
tyrosine kinase with immunoglobulin-like and EGF-like domains
204468 s at 1 TIE1
201666 at TIMP metallopeptidase inhibitor 1 TIMP1
TIMP metallopeptidase inhibitor 3 (Sorsby fundus dystrophy,
201147 s at pseudoinflammatory) TIMP3
TIMP metallopeptlidase inhibitor 3 (Sorsby fundus dystrophy,
201148 s at pseudoinflammatory) TIMP3
TIMP metallopeptidase inhibitor 3 (Sorsby fundus dystrophy,
201150 s at pseudoinflammatory) TIMP3
35148 at tight junction protein 3 (zona occludens 3) TJP3
207179 at T-cell leukemia homeobox 1 TLX1
210130 s at transmembrane 7 superfamily member 2 TM7SF2
217974 at transmembrane 7 superfamily member 3 TM7SF3
222477 s at transmembrane 7 superfamily member 3 TM7SF3
239824 s at transmembrane protein 107 TMEM107
222752 s at transmembrane protein 206 TMEM206
217743 s at transmembrane protein 30A TMEM30A
222391_at transmembrane protein 30A TMEM30A
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232591_s_at transmembrane protein 30A TMEM30A
1554485 s at transmembrane protein 37 TMEM37
227190_at transmembrane protein 37 TMEM37
235245 at transmembrane protein 92 TMEM92
235566 at TATA element modulatory factor 1 TMF1
206641 at tumor necrosis factor receptor superfamily, member 17 TNFRSF17
202687 s at tumor necrosis factor (ligand) superfamily, member 10 TNFSF10
202688 at tumor necrosis factor (ligand) superfamily, member 10 TNFSF10
214329 x at tumor necrosis factor (ligand) superfamily, member 10 TNFSF10
223501 at tumor necrosis factor (ligand) superfamily, member 13b TNFSF13B
223502 s at tumor necrosis factor (ligand) superfamily, member 13b TNFSF13B
227156 at trinucleotide repeat containing 8 TNRC8
202704 at transducer of ERBB2, 1 TOB1
226198 at target of myb1-like 2 (chicken) TOM1L2
209917 s at TP53 activated protein 1 TP53API
210241 s at TP53 activated protein 1 TP53AP1
225912 at tumor protein p53 inducible nuclear protein 1 TP531NP1
224836 at tumor protein p53 inducible nuclear protein 2 TP531NP2
1556876 s at TPTE pseudogene 1 TPTEps1
211902 x at T cell receptor alpha locus TRA@
209671 x at T cell receptor alpha locus /// T cell receptor alpha constant TRA@ /I TRAC
T cell receptor alpha locus /// T cell receptor alpha variable 20 /// TRA@ // TRAC / TRAJ17 /
210972 x at T cell receptor alpha joining 17 /// T cell receptor alpha constant TRAV20
202837 at TRAF-type zinc finger domain containing 1 TRAFD1
35254 at TRAF-type zinc finger domain containing 1 TRAFD1
213293 s at tripartite motif-containing 22 TRIM22
210705 s at tripartite motif-containing 5 TRIMS
209890 at tetraspanin 5 TSPAN5
225387 at tetraspanin 5 TSPAN5
229169 at tetratricopeptide repeat domain 18 TTC1 8
229170 s at tetratricopeptide repeat domain 18 TTC18
207392 x at UDP glucuronosyltransferase 2 family, polypeptide B15 UGT2B15
216687 x at UDP glucuronosyltransferase 2 family, polypeptide B15 UGT2B15
207245 at UDP glucuronosyltransferase 2 family, polypeptide B17 UGT2B17
236981 at GLPG464 UNQ464
220507 s at ureidopropionase, beta UPB1
224043 s at ureidopropionase, beta UPB1
228219 s at ureidopropionase, beta UPB1
219211 at ubiquitin specific peptidase 18 USPI8
229573 at ubiquitin specific peptidase 9, X-linked USP9X
225583_at UDP-glucuronate decarboxylase 1 UXS1
202546 at vesicle-associated membrane protein 8 (endobrevin) VAMP8
235343 at vasohibin 2 VASH2
203868 s at vascular cell adhesion molecule 1 VCAM1
233559 s at WD repeat and FYVE domain containing 1 WDFYI
1553425 at WD repeat domain 65 WDR65
230888 at WD repeat domain 91 WDR91
202908 at Wolfram syndrome 1 (wolframin) WFS1
202132 at WW domain containing transcription regulator 1 WWTR1
202133_at WW domain containing transcription regulator 1 WWTR1
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206133 at XIAP associated factor 1 XAF1
228617 at XIAP associated factor 1 XAF1
206366 x at chemokine (C motif) ligand 1 XCL1
214567 s at chemokine (C motif) ligand 1 /// chemokine (C motif) ligand 2 XCL1 / XCL2
227329 at zinc finger and BTB domain containing 46 ZBTB46
227358 at zinc finger and BTB domain containing 46 ZBTB46
219628 at zinc finger, matrin type 3 ZMAT3
206059 at zinc finger protein 91 ZNF91
225959 s at zinc and ring finger I ZNRF1
231188_at zinc finger and SCAN domain containing 2 ZSCAN2
222271_at
227985 at
231302 at
236682 at
23732i at
242878_at
242907 at
244456_at
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225553 at CDNA FLJ12874 fis, clone NT2RP2003769
239797 at Transcribed locus -
243671 at Transcribed locus ---
226458 at CDNA FLJ30340 fis, clone BRACE2007411 -
1559922 at Full length insert cDNA clone ZD86A03
226525 at Transcribed locus -
1560739 a at CDNA clone IMAGE:5300703
1562777 at CDNA FLJ40180 fis, clone TESTI2018035 -
1562473 at CDNA clone IMAGE:5285657
239086 at Transcribed locus -
234088 at CDNA FLJ12087 fis, clone HEMBB1002522 -
1569713 at CDNA clone IMAGE:4049873 -
222378 at Transcribed locus
226438 at CDNA: FLJ21447 fis, clone COL04468
1569052 at CDNA clone IMAGE:3840062 -
1568817 at Transcribed locus -
226397 s at CDNA: FLJ21028 fis, clone CAE07155
1559026 at CDNA clone IMAGE:5295490 -
230662 at Transcribed locus -
1555976 s at CDNA FLJ33153 fis, clone UTERU2000332
1556033 at CDNA FLJ38785 fis, clone LIVER2001329 ---
Transcribed locus, strongly similar to XP_001478456.1
230586 s at PREDICTED: ES neuronal differentiation 2 [Mus musculus] -
1554964 x at CDNA clone IMAGE:5310797
226855 at CDNA FLJ40954 fis, clone UTERU2010525 ---
243366 s at Transcribed locus
241833 at Full length insert cDNA clone YY86C01 --
243543 at Transcribed locus ---
230791 at CDNA FLJ12033 fis, clone HEMBB1001899 ---
1558938 at Homo sapiens, clone IMAGE:5222953, mRNA ---
238887 at Transcribed locus
232319 at CDNA FLJ12360 fis, clone MAMMA1 002356
1556261 a at CDNA FLJ40252 fis, clone TEST12024299 ---
226773 at CDNA FLJ35131 fis, clone PLACE6008824
230672 at CDNA clone IMAGE:4841343
1556121_at CDNA FLJ11689 fis, clone HEMBA1004977
1556301 at CDNA clone IMAGE:5288145 -
230733 at Transcribed locus
1556713 at CDNA FLJ11969 fis, clone HEMBB1001142 ---
240327 at Transcribed locus
244599 at Transcribed locus --
240233_at Homo sapiens, clone IMAGE:5228959, mRNA
240309 at Transcribed locus ---
CDNA: FLJ22515 fis, clone HRC12122, highly similar to
211976 at AF052101 Homo sapiens clone 23872 mRNA sequence -
239358 at Transcribed locus -
236503 at Transcribed locus ---
244532 x at Clone HLS IMAGE 1699118 mRNA sequence -
239516 at Transcribed locus
244114 x at Clone HLS IMAGE 1699118 mRNA sequence --
222170 at Familial Mediterranean fever locus region, mRNA sequence
244596 at Transcribed locus -
243947 s at Transcribed locus
231142 at Transcribed locus ---
241093 at Transcribed locus
226280 at CDNA FLJ43545 fis, clone PROST2011631
Transcribed locus, strongly similar to XP_001140852.1
239280_at PREDICTED: hypothetical protein [Pan troglodytes]
225750 at CDNA FLJ14162 fis, clone NT2RM4002504
243780 at CDNA FLJ46553 fis, clone THYMU3038879
236452 at Transcribed locus ---
222350 at Transcribed locus -
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225193_at CDNA FLJ32881 fis, clone TEST2004153
239331 at Transcribed locus -
225199 at MRNA; cDNA DKFZp45101818 (from clone DKFZp45101818) --
239294 at Transcribed locus
231406 at MRNA; cDNA DKFZp667G1412 (from clone DKFZp667G1412) --
227952 at Full length insert cDNA clone Y146G04 -
243013 at Transcribed locus ---
229969 at Transcribed locus
235502 at Transcribed locus
238243 at Full length insert cDNA clone Y143B12
242363 at Transcribed locus
228084 at Transcribed locus
215322 at MRNA; cDNA DKFZp434A202 (from clone DKFZp434A202) -
229370 at Transcribed locus
229934 at Mir-223 transcript variant 1 mRNA, complete sequence --
240090 at Transcribed locus
238456 at CDNA FLJ36202 fis, clone TEST12028296 --
227476 at Transcribed locus
Transcribed locus, strongly similar to XP_001125843.1
235422 at PREDICTED: hypothetical protein [Homo sapiens] ---
214848 at Clone 23548 mRNA sequence ---
CDNA FLJ90571 fis, clone OVARCI001725, highly similar to
227745 at Homo sapiens patched related protein TRC8 (TRC8) gene
214871 x at CDNA clone IMAGE:3347954
Transcribed locus, strongly similar to XP_001717314.1
227724 at PREDICTED: hypothetical protein [Homo sapiens] -
244728 at CDNA clone IMAGE:7501601
230020_at Transcribed locus
1557450 s_at I.M.A.G.E. clone 241447, mRNA sequence
1557099_at CDNA FLJ35092 fis, clone PLACE6006077
232555 at CDNA FLJ11431 fis, clone HEMBAI 001094
233137 at Clone IMAGE:121687 mRNA sequence -
217529_at MRNA; cDNADKFZp667G14l2 (from clone DKFZp667G1412) -
236994_at CDNA FLJ30658 fis, clone DFNES2000432
242740_at Transcribed locus
Transcribed locus, moderately similar to XP_001111392.1
PREDICTED: similar to CHK1 checkpoint homolog isoform 2
229423 at [Macaca mulatta]
242834 at Transcribed locus
236164 at Transcribed locus
229048rat Full length insert cDNA clone ZD86A03
237328 at Transcribed locus
236174 at Transcribed locus
Transcribed locus, strongly similar to XP_001164900.1
237034_at PREDICTED: hypothetical protein [Pan troglodytes] ---
236168 at Transcribed locus
235971_at Transcribed locus
243467 at CDNA FLJ46553 fis, clone THYMU3038879 
--
242993 at Transcribed locus
242568 s at CDNA FLJ38922 fis, clone NT2NE2011691
228273 at Transcribed locus
235740 at Transcribed locus
242523_at Transcribed locus
236364 at Transcribed locus
229629 at Transcribed locus
244887_at Transcribed locus
235875 at Transcribed locus
242637 at Transcribed locus
230675 at Transcribed locus
244359 s at Clone HLS IMAGE 1699118 mRNA sequence
230346 x at Transcribed locus
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237464 at
Transcribed locus, strongly similar to XP_001478376.1
PREDICTED: similar to Solute carrier family 7 (cationic amino
acid transporter. y+ system). member 5 [Mus usus
235217 at CDNA clone IMAGE:5302680 --
230300 at CDNA FLJ42315 fis, clone TRACH2019661 -
224601 at CDNA clone IMAGE:3831740 -
236582 at Transcribed locus -
227116 at Transcribed locus -
227117 at CDNA FLJ40762 fis, clone TRACH2002847
242104 at Transcribed locus --
Transcribed locus, moderately similar to XP_001091208.1
227368 at PREDICTED: hypothetical protein [Macaca mulatta] -
214373 at CDNA clone IMAGE:3613219 -
243092 at CDNA clone IMAGE:4817413 --
201000_at alanyl-tRNA synthetase AARS
224821 at abhydrolase domain containing 14B ABHD14B
45288_at abhydrolase domain containing 6 ABHD6
210461_s_at actin binding LIM protein I ABLIM1
212186 at acetyl-Coenzyme A carboxylase alpha ACACA
214358 at acetyl-Coenzyme A carboxylase alpha ACACA
205355 at acyl-Coenzyme A dehydrogenase, short/branched chain ACADSB
206465 at acyl-CoA synthetase bubblegum family member 1 ACSBG1
206466 at acyl-CoA synthetase bubblegum family member 1 ACSBG1
201662 s at acyl-CoA synthetase long-chain family member 3 ACSL3
201661 s at acyl-CoA synthetase long-chain family member 3 ACSL3
201660 at acyl-CoA synthetase long-chain family member 3 ACSL3
210377 at acyl-CoA synthetase medium-chain family member 3 ACSM _3
205942 s at acyl-CoA synthetase medium-chain family member 3 ACSM3
218395 at ARP6 actin-related protein 6 homolog (yeast) ACTR6
226814 at ADAM metallopeptidase with thrombospondin type I motif, 9 ADAMTS9
201752 s at adducin 3 (gamma) ADD3
205882_x at adducin 3 (gamma) ADD3
205013 s at adenosine A2a receptor ADORA2A
1-acylglycerol-3-phosphate 0-acyltransferase 5
232007 at (lysophosphatidic acid acyltransferase, epsilon) AGPAT5
224480 s at 1-acylglycerol-3-phosphate O-acyltransferase 9 AGPAT9
225113 at alkylglycerone phosphate synthase AGPS
204174 at arachidonate 5-lipoxygenase-activating protein ALOX5AP
227438 at alpha-kinase 1 ALPKI
226258 at antagonist of mitotic exit network 1 homolog (S. cerevisiae) AMN1
228023 x at amylase, alpha 2B (pancreatic) AMY2B
226012 at ankyrin repeat domain 11 ANKRD11
212747 at ankyrin repeat and sterile alpha motif domain containing 1A ANKSIA
acidic (leucine-rich) nuclear phosphoprotein 32 family, member
201306 s at B ANP32B
201012_at annexin Al ANXA1
203410 at adaptor-related protein complex 3, mu 2 subunit AP3M2
adaptor protein, phosphotyrosine interaction, PH domain and
218158 s at leucine zipper containing I APPL1
225166 at Rho GTPase activating protein 18 ARHGAP1 8
225171 at Rho GTPase activating protein 18 ARHGAP18
209435_s at rho/rac guanine nucleotide exchange factor (GEF) 2 ARHGEF2
211935 at ADP-ribosylation factor-like 6 interacting protein 1 ARL6IPi
1554480 a at armadillo repeat containing 10 ARMC10
201954 at actin related protein 2/3 complex, subunit I B, 41kDa ARPCIB
226914 at actin related protein 2/3 complex, subunit 5-like ARPCSL
213902 at N-acylsphingosine amidohydrolase (acid ceramidase) 1 ASAH1
ATP synthase, H+ transporting, mitochondrial FO complex,
206992 s at subunit s (factor B) ATP5S
ATP synthase, H+ transporting, mitochondrial FO complex,
213995 at subunits (factor B) ATP5S
203232 s at ataxin 1 ATXN1
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2U50052 at AU RNA blndlng protein/enoyl-Coenzyme A hvrte
UDP-Gal:betaGlcNAc beta 1,4- galactosyltransferase,
210243 s at polypeptide 3 B4GALT3
220358 at basic leucine zipper transcription factor, ATF-like 3 BATF3
226517 at branched chain aminotransferase 1, cytosolic BCAT1
225285 at branched chain aminotransferase 1, cytosolic BCAT1
214452 at branched chain aminotransferase 1, cytosolic BCAT1
214390 s at branched chain aminotransferase-1, cytosolic BCATI
205433 at butyrylcholinesterase BCHE
221320 at BCL2-lke 10 (apoptosis facilitator) BCL2LIO
236491 at BCL2-like 10 (apoptosis facilitator) BCL2L10
212645 x at brain and reproductive organ-expressed (TNFRSF1A modulator) BRE
205550 s at brain and reproductive organ-expressed (TNFRSF1A modulator) BRE
218792 s at B-box and SPRY domain containing BSPRY
209770 at butyrophilin, subfamily 3, member Al BTN3A1
butyrophilin, subfamily 3, memberA3 /// butyrophilin, subfamily
204820 s at 3, member A2 BTN3A2 /// BTN3A3
204821 at butyrophilin, subfamily 3, memberA3 BTN3A3
230259 at chromosome 10 open reading frame 125 C1Oorf125
226398 s at chromosome 10 open reading frame 4 C1Oorf4
218789 s at chromosome 11 open reading frame 71 C11orf71
204521 at chromosome 12 open reading frame 24 C12orf24
223477 s at chromosome 12 open reading frame 65 C12orf65
220084 at chromosome 14 open reading frame 105 C14orfl105
226630 at chromosome 14 open reading frame 106 C14orfiO6
229054 at chromosome 14 open reading frame 181 C14orf181
217915 s at chromosome 15 open reading frame 15 C15orf15
203173 s at chromosome 16 open reading frame 62 C16orf62
239754 at Chromosome 17 open reading frame 45 C17orf45
219435 at chromosome 17 open reading frame 68 C17orf68
221621 at chromosome 17 open reading frame 86 C17orf86
221797 at chromosome 17 open reading frame 90 C17orf9O
210157 at chromosome 19 open reading frame 2 C19orf2
219010 at chromosome 1 open reading frame 106 Clorf106
228517 at chromosome I open reading frame 149 Clorfi49
229973 at chromosome 1 open reading frame 173 C1orf173
230257 s at chromosome 1 open reading frame 19 C1orfI9
202217 at chromosome 21 open reading frame 33 C21orf33
223360_at chromosome 21 open reading frame 56 C21 of56
1556072 at chromosome 22 open reading frame 37 C22orf37
1553974_at chromosome 22 open reading frame 39 C22orf39
227144 at chromosome 22 open reading frame 9 C22orf9
225410_at chromosome 2 open reading frame 64 C2orf64
225409 at chromosome 2 open reading frame 64 C2orf64
219029 at chromosome 5 open reading frame 28 C~orf28
222682 s at chromosome 5 open reading frame 3 C5orf3
229299 at chromosome 5 open reading frame 33 C5orf33
228594 at chromosome 5 open reading frame 33 C5orf33
39817 s at chromosome 6 open reading frame 108 C6orf108
213871 s at Chromosome 6 open reading frame 108 C6orf108
210409 at chromosome 6 open reading frame 124 // similar to HGC6.4 C6orf124 /// LOC729439
226301_at chromosome 6 open reading frame 192 C6orf 192
chromosome 7 open reading frame 28A / chromosome 7 open
reading frame 28B / similar to Chromosome 7 open reading C7orf28A / C7orf28B //
201973 s at frame 28B LOC100133775
228728 at chromosome 7 open reading frame 58 C7orf58
1555241 at chromosome 8 open reading frame 59 C8orf59
1555168 a at calneuron 1 CALN1
209682 at Cas-Br-M (murine) ecotropic retroviral transforming sequence b CBLB
227900 at Cas-Br-M (murine) ecotropic retroviral transforming sequence b CBLB
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244052 at carbonyl reductase 4 CBR4
1553693 s at carbonyl reductase 4 CBR4
209472 at cysteine conjugate-beta lyase 2 CCBL2
218125 s at coiled-coil domain containing 25 CCDC25
1553102 a at coiled-col domain containing 69 CCDC69
224521 s at coiled-coil domain containing 77 CCDC77
233543 s at coiled-coil domain containing 98 CCDC98
202705 at cyclin B2 CCNB2
205098 at chemokine (C-C motif) receptor 1 CCRI
204581 at CD22 molecule CD22
217422 s at CD22 molecule CD22
38521 at CD22 molecule CD22
220674 at CD22 molecule CD22
209933 s at CD300a molecule CD300A
217072 at CD300a molecule CD300A
203799 at CD302 molecule CD302
213857 s at CD47 molecule CD47
204118 at CD48 molecule CD48
203416 at CD53 molecule CD53
CD55 molecule, decay accelerating factor for complement
1555950 a at (Cromer blood group) CD55
CD55 molecule, decay accelerating factor for complement
201926 s at (Cromer blood group) CD55
1555779_a at CD79a molecule, immunoglobulin-associated alpha CD79A
205049 s at CD79a molecule, immunoglobulin-associated alpha CD79A
211347 at CDC14 cell division cycle 14 homolog B (S. cerevisiae) CDC14B
235226 at cell division cycle 2-like 6 (CDK8-like) CDC2L6
224428 s at cell division cycle associated 7 CDCA7
204996 s at cyclin-dependent kinase 5, regulatory subunit 1 (p35) CDK5R1
204995_at cyclin-dependent kinase 5, regulatory subunit 1 (p35) CDK5R1
224848 at cyclin-dependent kinase 6 CDK6
224847 at cyclin-dependent kinase 6 CDK6
204962 s at centromere protein A CENPA
212677 s at centrosomal protein 68kDa CEP68
219036 at centrosomal protein 70kDa CEP70
209662 at centrin, EF-hand protein, 3 (CDC31 homolog, yeast) CETN3
228999 at chromodomain helicase DNA binding protein 2 CHD2
cell adhesion molecule with homology to L1CAM (close homolog
204591 at of Li) CHL1
201897 s at CDC28 protein kinase regulatory subunit 1 B CKS1B
203950 s at chloride channel 6 CLCN6
209732 _at C-type lectin domain family 2, member B CLEC2B
1556209 at C-type lectin domain family 2, member B CLEC2B
233500 x at C-type lectin domain family 2, member D CLEC2D
228426 at C-type lectin domain family 2, member D CLEC2D
220132 s at C-type lectin domain family 2, member D CLEC2D
209143 s at chloride channel, nucleotide-sensitive, 1A CLNS1A
1562460 at CNDP dipeptidase 2 (metallopeptidase M20 family) CNDP2
226277 at collagen, type IV, alpha 3 (Goodpasture antigen) binding protein COL4A3BP
223465 at collagen, type IV, alpha 3 (Goodpasture antigen) binding protein COL4A3BP
201359 at coatomer protein complex, subunit beta 1 COPB1
205931 s at cAMP responsive element binding protein 5 CREBS
229228 at cAMP responsive element binding protein 5 CREB5
205474 at cytokine receptor-like factor 3 CRLF3
222015 at Casein kinase 1, epsilon CSNK1E
220768 s at casein kinase 1, gamma 3 CSNK1G3
similar to CTAGE6 /// CTAGE family, member 4 /// CTAGE family CTAGE4 // LOC100142659 /
214355 x at member LOC441294
201059 at cortactin CTTN
214074~s at cortactin CTTN
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232746 at Chemokine (C-X-C motif) receptor 7
238554_at cytochrome b5 type B (outer mitochondrial membrane) CYB5B
227109 at cytochrome P450, family 2, subfamily R, polypeptide 1 CYP2R1
235719 at Cytochrome P450, family 4, subfamily V, polypeptide 2 CYP4V2
229959 at Cytochrome P450, family 4, subfamily V, polypeptide 2 CYP4V2
216607_s at cytochrome P450, family 51, subfamily A, polypeptide 1 CYP51A1
DCN1, defective in cullin neddylation 1, domain containing 4 (S.
212855 at cerevisiae) DCUN1D4
DCN1, defective in cullin neddylation 1, domain containing 5 (S.
223151_at cerevisiae) DCUN1D5
222958 s at DEP domain containing 1 DEPDC1
235545 at DEP domain containing 1 DEPDC1
201791 s at 7-dehydrocholesterol reductase DHCR7
201790 s at 7-dehydrocholesterol reductase DHCR7
230426 at dihydrollpoamide dehydrogenase DLD
212728 at discs, large homolog 3 (neuroendocrine-dlg, Drosophila) DLG3
212729 at discs, large homolog 3 (neuroendocrine-dlg, Drosophila) DLG3
207732 s at discs, large homolog 3 (neuroendocrine-dig, Drosophila) DLG3
226926 at dermokine DMKN
221782 at DnaJ (Hsp40) homolog, subfamily C, member 10 DNAJC1O
225174 at DnaJ (Hsp4O) homolog, subfamily C, member 10 DNAJC10
1561336 at deoxyribonuclease I-like 3 DNASEIL3
209831 x at deoxyribonuclease I1, lysosomal DNASE2
226154 at dynamin 1-like DNM1L
203635 at Down syndrome critical region gene 3 DSCR3
204455_at dystonin DST
234107 s at D-tyrosyl-tRNA deacylase i homolog (S. cerevislae) DTD1
224832 at dual specificity phosphatase 16 DUSP16
227708 at eukaryotic translation elongation factor I alpha I EEFIAi
212225 at eukaryotic translation initiation factor 1 EIF1
204409 s at eukaryotic translation initiation factor 1A, Y-linked EIF1AY
217736 s at eukaryotic translation initiation factor 2-alpha kinase 1 EIF2AK1
extracellular leucine-rich repeat and fibronectin type IlIl domain
229581 at containing I ELFN1
ELOVL family member 6, elongation of long chain fatty acids
204256 at (FEN1/Elo2, SUR4/Elo3-like, yeast) ELOVL6
ELOVL family member 6, elongation of long chain fatty acids
210868 s at (FENI/Elo2, SUR4/EIo3-llke, yeast) ELOVL6
ELOVL family member 6, elongation of long chain fatty acids
227491 at (FEN1/Elo2, SUR4/Elo3-like, yeast) ELOVL6
221094 s at elongation protein 3 homolog (S. cerevisiae) ELP3
212573_at endonuclease domain containing 1 ENDOD1
209473 at ectonucleoside triphosphate diphosphohydrolase 1 ENTPD1
396 f at erythropoietin receptor EPOR
excision repair cross-complementing rodent repair deficiency,
complementation group 1 (includes overlapping antisense
228131 at sequence) ERCCI
endoplasmic reticulum-golgi intermediate compartment (ERGIC)
224576_at 1 ERGIC1
endoplasmic reticulum-golgi Intermediate compartment (ERGIC)
224577 at I ERGICI
221543 s at ER lipid raft associated 2 ERLIN2
218342.s at endoplasmic reticulum metallopeptidase 1 ERMPI
222603 at endoplasmic reticulum metallopeptidase 1 ERMP1
218498 s at ERO1-like (S. cerevislae) ERO1L
201328 at v-ets erythroblastosis virus E26 oncogene homolog 2 (avian) ETS2
ecotropic viral integration site 2A /// ecotropic viral integration
204774,at site 2B EV12A /// EV12B
209537 at exostoses (multiple)-like 2 EXTL2
202218 s at fatty acid desaturase 2 FADS2
213861 s at family with sequence similarity 119, member B FAM119B
212527 at family with sequence similarity 152, member B FAM152B
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225226 at family with sequence similarity 40, member A FAM40A
gastric cancer up-regulated-2 / family with sequence similarity
72, member B / family with sequence similarity 72, member D FAM72A /// FAM72B /// FAM72D ///
225834_at / family with sequence similarity 72, member A GCUD2
222001 x at family with sequence similarity 91, memberA2 FAM91A2
229429 x at family with sequence similarity 91, member A2 FAM9IA2
family with sequence similarity 91, member A2 /// hypothetical
1568609 s at FLJ39739 FAM91A2 /// FLJ39739
212218 s at fatty acid synthase FASN
202766 s at fibrillin I FBN1
209943 at F-box and leucine-rich repeat protein 4 FBXL4
235450 at F-box and leucine-rich repeat protein 4 FBXL4
209004 s at F-box and leucine-rich repeat protein 5 FBXL5
241954 at Farnesyl-diphosphate farnesyltransferase 1 FDFT1
210950 s at famesyl-diphosphate famesyltransferase 1 FDFTI
famesyl diphosphate synthase (farnesyl pyrophosphate
synthetase, dimethylallyltranstransferase,
201275 at geranyltranstransferase) FDPS
221345 at free fatty acid receptor 2 FFAR2
205510 s at hypothetical protein FLJ10038 FLJ10038
64438 at hypothetical protein FLJ22222 FLJ22222
53071 s at hypothetical protein FLJ22222 FLJ22222
220399 at hypothetical protein FLJ22639 FLJ22639
203245 s at FLJ35348 FLJ35348
1563369_at FLJ42957 protein FLJ42957
237591 at FLJ42957 protein FLJ42957
215245 x at fragile X mental retardation 1 FMR1
230086 at formin binding protein 1 FNBP1
214094 at far upstream element (FUSE) binding protein 1 FUBP1
210506 at fucosyltransferase 7 (alpha (1,3) fucosyltransferase) FUT7
UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-
218885 s at acetylgalactosaminyltransferase 12 (GaINAc-T12) GALNT12
Phosphoribosylglycinamide formyltransferase,
phosphoribosylglycinamide synthetase,
244822 at phosphoribosylaminoimidazole synthetase GART
phosphoribosylglycinamide formyltransferase,
phosphoribosylglycinamide synthetase,
212378 at phosphoribosylaminoimidazole synthetase GART
205848 at growth arrest-specific 2 GAS2
220587 s at G protein beta subunit-like GBL
206589 at growth factor independent 1 transcription repressor GF11
225392 at G elongation factor, mitochondrial 2 GFM2
1554345 a at gypsy retrotransposon integrase 1 GIN1
206646 at glioma-associated oncogene homolog 1 (zinc finger protein) GL1
210279 at G protein-coupled receptor 18 GPR18
214467 at G protein-coupled receptor 65 GPR65
203817 at guanylate cyclase 1, soluble, beta 3 GUCY1 B3
209818 s at hyaluronan binding protein 4 HABP4
232341 x at hyaluronan binding protein 4 HABP4
233919 s at hyaluronan binding protein 4 HABP4
211569 s at hydroxyacyl-Coenzyme A dehydrogenase HADH
216063 at hemoglobin, beta pseudogene 1 HBBP1
209316 s at HBS1-like (S. cerevisiae) HBS1L
226482 s at KAT protein / hypothetical protein LOC100134860 hCG_20857// RP11-544M22.4
232026 at hect domain and RLD 4 HERC4
204689 at hematopoletically expressed homeobox HHEX
220812 s at HERV-H LTR-associating 2 HHLA2
234673 at HERV-H LTR-associating 2 HHLA2
210719 s at high-mobility group 20B HMG20B
202539 s at 3-hydroxy-3-methylglutaryl-CoenzymeA reductase HMGCR
202540_s at 3-hydroxy-3-methylglutaryl-Coenzyme A reductase HMGCR
221750_at 3-hydroxy-3-methylglutaryl-Coenzyme A synthase I (soluble) HMGCSI
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205822_s at 3-hydroxy-3-methylglutaryl-Coenzyme A synthase 1 (soluble)
209787 s, at high mobility group nucleosoal binding domain 4 HMGN4
209786 at high mobility group nucleosomal binding domain 4 HMGN4
202579 x at high mobility group nucleosomal binding domain 4 HMGN4
209709 s at hyaluronan-mediated motility receptor (RHAMM) HMMR
205292 s at heterogeneous nuclear ribonucleoprotein A2/13 HNRNPA21
211929 at heterogeneous nuclear ribonucleoprotein A3 HNRNPA3
208599 at HECT, UBA and WWE domain containing 1 HUWE1
225908 at isoamyl acetate-hydrolyzing esterase 1 homolog (S. cerevisiae) IAH1
1555037 a at isocitrate dehydrogenase I (NADP+), soluble IDH1
201193 at isocitrate dehydrogenase 1 (NADP+), soluble IDH1
242065 x at isopentenyl-diphosphate delta isomerase I IDII
206342 x at iduronate 2-sulfatase (Hunter syndrome) IDS
201601 x at interferon induced transmembrane protein 1 (9-27) IFITMI
214022 s at interferon induced transmembrane protein 1 (9-27) IFITM1
202727 s at interferon gamma receptor I IFNGRI
218100 s at intraflagellar transport 57 homolog (Chlamydomonas) IFT57
203819 s at insulin-like growth factor 2 mRNA binding protein 3 1GF2BP3
203820_s at insulin-like growth factor 2 mRNA binding protein 3 IGF2BP3
213674 x at immunoglobulin heavy constant delta IGHD
223165 s_at inositol hexaphosphate kinase 2 IHPK2
227346Tat IKAROS family zinc finger I (Ikaros) IKZF1
201625 s_at insulin induced gene 1 INSIG1
201626_at insulin induced gene I INSIGI
226216 at insulin receptor INSR
225528 at importin 8 IPO0
203474 at IQ motif containing GTPase activating protein 2 IQGAP2
1555476_at iron-responsive element binding protein 2 IREB2
224572 s at interferon regulatory factor 2 binding protein 2 IRF2BP2
integrin, alpha 4 (antigen CD49D, alpha 4 subunit of VLA-4
205885 s at receptor) ITGA4
205718 at integrin, beta 7 ITGB7
213146 at umoni domain containing 3, histone lysine demethylase JMJD3
41387 r at jumonji domain containing 3, histone lysine demethylase JMJD3
235863 at Junctional sarcoplasmic reticulum protein 1 JSRPI
218418_s at KN motif and ankyrin repeat domains 2 KANK2
KDEL (Lys-Asp-Glu-Leu) endoplasmic reticulum protein
1555575 a at retention receptor 1 KDELR1
38892 at KIAA0240 KIAA0240
223162 s at KIAA1147 KIAA1147
223256 at KIAA1 333 KIAA1 333
230569 at KIAA1430 KIAA1430
236641 at kinesin family member 14 KIF14
1554261 at kelch-like 29 (Drosophila) KLHL29
229310 at kelch-like 29 (Drosophila) KLHL29
202020 s at LanC lantibiotic synthetase component C-like I (bacterial) LANCL1
217810 x at leucyl-tRNA synthetase LARS
221581 s at linker for activation of T cells family, member 2 LAT2
Lymphocyte cytosolic protein 2 (SH2 domain containing
244251 at leukocyte protein of 76kDa) LCP2
lymphocyte cytosolic protein 2 (SH2 domain containing
205269 at leukocyte protein of 76kDa) LCP2
lymphocyte cytosolic protein 2 (SH2 domain containing
205270 s_at leukocyte protein of 76kDa) LCP2
202068 s at low density lipoprotein receptor (familial hypercholesterolemia) LDLR
224673 at leukocyte receptor cluster (LRC) member 8 LENG8
202595 s at leptin receptor overlapping transcript-like 1 LEPROTLI
225793 at LixI homolog (mouse)-like LIX L
228647 at hypothetical protein LOC100049716 LOC100049716
1564691 at similar to hCG1791139 LOC100128594
235174 s at hypothetical protein LOC100128822 LOC100128822
243757 at hypothetical protein LOC100129006 LOC100129006
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'[560163 at hypothetical protenLC 00191 LOC100129510
243179 at Hypothetical protein LOC100130360 LOC100130360
230198 at Hypothetical protein LOC100130837 LOC1 00130837
1562738_a_at hypothetical protein LOC100130855 LOC100130855
201398 s at translocation associated membrane protein 1 /// PRO1292 LOC100130862 /// TRAM1
1569496 s at hypothetical protein LOC100130872 LOC100130872
protein tyrosine phosphatase type IVA, member 3 // similar to
209695 at protein tyrosine phosphatase type IVA, member 3 LOCI00131062 / PTP4A3
229872 s at hypothetical protein LOC1 00132999 LOC100132999
213826 s at similar to histone LOC100133109
TRAF3 interacting protein 3 /// hypothetical protein
213888 s at LOC100133233 LOC100133233 /// TRAF31P3
mature T-cell proliferation 1 /// similar to mature T-cell
216862 s at proliferations 1 LOC1O0133946 /// MTCP1
232281 at Hypothetical protein LOC148189 LOC148189
242663 at Hypothetical protein LOC148189 LOC148189
229090 at hypothetical protein LOC220930 LOC220930
1555865 at hypothetical protein LOC255512 LOC255512
1559488 at hypothetical protein LOC257358 LOC257358
1559489 a at hypothetical protein LOC257358 LOC257358
225457 s at hypothetical LOC25845 LOC25845
1556064 at hypothetical protein LOC284926 LOC284926
230179 at hypothetical protein LOC285812 LOC285812
232420 x at hypothetical protein LOC286260 LOC286260
213556 at similar to R28379 1 LOC390940
226413 at hypothetical gene supported by BC047417 LOC400027
224723_x at hypothetical LOC401397 LOC401397
215090 x at hypothetical protein FLJ11822 LOC440434
214107 x at hypothetical protein FLJ11822 LOC440434
MRNA; cDNA DKFZp686D1025O (from clone
DKFZp686D10250) /// Hypothetical gene supported by
1560128 x at AK128882 LOC441108
230405 at hypothetical gene supported by AK128882 LOC441108
243432 at hypothetical LOC642891 LOC642891
212274_at lipin 1 LPIN1
212276 at lipin 1 LPINI
211596_s at leucine-rich repeats and immunoglobulin-like domains 1 LRIG1
218684 at leucine rich repeat containing 8 family, member D LRRC8D
223492_s at leucine rich repeat (in FLII) interacting protein 1 LRRFIP1
207339 s at lymphotoxin beta (TNF superfamily, member 3) LTB
202625_at v-yes-1 Yamaguchi sarcoma viral related oncogene homolog LYN
219188 s at MACRO domain containing 1 MACROD1
206853_s at Mitogen-activated protein kinase kinase kinase 7 MAP3K7
243 g at microtubule-associated protein 4 MAP4
200836 s at microtubule-associated protein 4 MAP4
207121 s at mitogen-activated protein kinase 6 MAPK6
213672_at methionyl-tRNA synthetase MARS
201475 x at methionyl-tRNA synthetase MARS
226797_at mbt domain containing 1 MBTD1
220603 s at multiple C2 domains, transmembrane 2 MCTP2
243109_at multiple C2 domains, transmembrane 2 MCTP2
209397 at malic enzyme 2, NAD(+)-dependent, mitochondrial ME2
209363 s at mediator complex subunit 21 MED21
203003 at myocyte enhancer factor 2D MEF2D
1565898 at Methyltransferase 5 domain containing 1 METT5D1
222447 at methyltransferase like 9 MET TL9
227296 at major facilitator superfamily domain containing 3 MFSD3
240814 at hypothetical gene supported by BC029568 MGC39584
224918 x at microsomal glutathione S-transferase 1 MGST1
231727 s at MIF4G domain containing MIF4GD
220990 s at transmembrane protein 49 /// microRNA 21 MIRN21 /// TMEM49
204206 at MAX binding protein MNT
I
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233557_s at |MON1 homolog B (yeast)
64883 at motile sperm domain containing 2 MOSPD2
202472 at mannose phosphate isomerase MPI
222948 s at mitochondrial ribosomal protein S18C MRPS18C
220103 s at mitochondrial ribosomal protein S18C MRPS18C
212145 at mitochondrial ribosomal protein S27 MRPS27
236165 at male-specific lethal 3-like I (Drosophila) MSL3L1
204956 at methylthioadenosine phosphorylase MTAP
203207 s at mitochondrial fission regulator 1 MTFRI
203208 s at mitochondrial fission regulator 1 MTFRI
methylenetetrahydrofolate dehydrogenase (NADP+ dependent)
225520 at 1-like MTHFD1L
methylenetetrahydrofolate dehydrogenase (NADP+ dependent)
231094 s at 1-ike MTHFDIL
methylenetetrahydrofolate dehydrogenase (NADP+ dependent)
233083 at 2-like MTHFD2L
225232 at myotubularin related protein 12 MTMR12
212462_at MYST histone acetyltransferase (monocytic leukemia) 4 MYST4
212414 s at septin 6 /// cytokine-like nuclear factor n-pac N-PAC /// SEPT6
229718 at NEDD4 binding protein 2-like 1 N4BP2L1
202259_s at NEDD4 binding protein 2-like 2 N4BP2L2
207738_s at NCK-associated protein 1 NCKAP1
203916 at N-deacetylase/N-sulfotransferase (heparan glucosaminyt) 2 NDST2
NADH dehydrogenase (ubiquinone) 1, subcomplex unknown, 2,
218101 s at 14.5kDa NDUFC2
232881 at GNAS1 antisense NESPAS
226103 at nexilin (F actin binding protein) NEXN
212129at non imprinted in Prader-Willi/Angelman syndrome 2 NIPA2
1570342 at natural killer-tumor recognition sequence NKTR
205581 s at nitric oxide synthase 3 (endothelial cell) NOS3
215073 s at nuclear receptor subfamily 2, group F, member 2 NR2F2
209121 x at nuclear receptor subfamily 2, group F, member 2 NR2F2
209120 at nuclear receptor subfamily 2, group F, member 2 NR2F2
229092 at nuclear receptor subfamily 2, group F, member 2 NR2F2
218625 at neuritin 1 NRN1
226643 s at NudC domain containing 2 NUDCD2
230329 s at nudix (nucleoside diphosphate linked moiety X)-type motif 6 NUDT6
228855 at nudix (nucleoside diphosphate linked moiety X)-type motif 7 NUDT7
NUF2, NDC80 kinetochore complex component, homolog (S.
223381 at cerevisiae) NUF2
O-linked N-acetylglucosamine (GIcNAc) transferase (UDP-N-
acetylglucosamine:polypeptide-N-acetylglucosaminy
212307_s at transferase) OGT
O-linked N-acetylglucosamine (GIcNAc) transferase (UDP-N-
acetylglucosamine:polypeptide-N-acetylglucosaminy
207564 x at transferase) OGT
O-flinked N-acetylglucosamine (GlcNAc) transferase (UDP-N-
acetylglucosamine:polypeplde-N-acetylglucosaminy
207563 s at transferase) OGT
O-linked N-acetylglucosamine (GlcNAc) transferase (UDP-N-
acetylglucosamine:polypeptide-N-acetylglucosaminy
209240 at transferase) OGT
212213 x at optic atrophy 1 (autosomal dominant) OPA1
214306 at optic atrophy 1 (autosomal dominant) OPA1
olfactory receptor, family 7, subfamily E, member 37
217499 x at pseudogene OR7E37P
228566 at Cyclin-dependent kinase 2B-inhibitor-related protein P15RS
210448 s at purinergic receptor P2X, ligand-gated ion channel, 5 P2RX5
244268 x at p21 (CDKN1A)-activated kinase 2 PAK2
228569 at poly(A) polymerase alpha PAPOLA
226423 at progestin and adipoQ receptor family member VIII PAQR8
227626 at progestin and adipoQ receptor family member Vill PAQR8
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218271 s at presenilin associated, rhomboid-like PARL
PCF11, cleavage and polyadenylation factor subunit, homolog
227622 at (S. cerevisiae) PCF11
202847 at phosphoenolpyruvate carboxykinase 2 (mitochondrial) PCK2
Protein-L-isoaspartate (D-aspartate) 0-methyltransferase
238114 at domain containing I PCMTDI
209577 at phosphate cytidylyltransferase 2, ethanolamine PCYT2
227751 at Programmed cell death 5 PDCD5
218025_s_at peroxisomal D3,D2-enoyl-CoA isomerase PECI
203244 at peroxisomal biogenesis factor 5 PEX5
222910 s at peroxisomal biogenesis factor 5-like PEX5L
201397 at phosphoglycerate dehydrogenase PHGDH
213889 at phosphatidylinositol glycan anchor biosynthesis, class L PIGL
204369 at phosphoinositide-3-kinase, catalytic, alpha polypeptide PIK3CA
213222 at phospholipase C, beta 1 (phosphoinositide-specific) PLCB1
214745 at phospholipase C, eta 1 PLCH1
177 at phospholipase D1, phosphatidylcholine-specific PLD1
226636 at phospholipase D1, phosphatidylcholine-specific PLD1
232530 at phospholipase D1, phosphatidylcholine-specific PLD1
205203 at phospholipase D1, phosphatidylcholine-specific PLD1
202620_s at procollagen-lysine, 2-oxoglutarate 5-dioxygenase 2 PLOD2
225194 at pleiotropic regulator 1 (PRL1 homolog, Arabidopsis) PLRG1
239699 s at postmeiotic segregation increased 2-like 1 PMS2L1
226384 at phosphatidic acid phosphatase type 2 domain containing IB PPAPDC1B
protein tyrosine phosphatase, receptor type, f polypeptide
210236 at (PTPRF), interacting protein (liprin), alpha I PPFIA1
223999 at peptidylprolyl isomerase (cyclophilin)-like 2 PPIL2
protein phosphatase 1 B (formerly 2C), magnesium-dependent,
209296 at beta isoform PPM1B
200726_at protein phosphatase 1, catalytic subunit, gamma isoform PPP1CC
213305 s at protein phosphatase 2, regulatory subunit B', gamma isoform PPP2R5C
201877 s at protein phosphatase 2, regulatory subunit B', gamma isoform PPP2R5C
1554365 a at protein phosphatase 2, regulatory subunit B', gamma isoform PPP2R5C
protein phosphatase 3 (formerly 2B), catalytic subunit, alpha
202429 s at isoform PPP3CA
230708 at Prickle homolog 1 (Drosophila) PRICKLE1
207957 s at protein kinase C, beta 1 PRKCBI
223839 s at PRO1933 PRO1933
pleckstrin homology, Sec7 and coiled-coil domains, binding
209606 at protein PSCDBP
202244 at proteasome (prosome, macropain) subunit, beta type, 4 PSMB4
219485 s at proteasome (prosome, macropain) 26$ subunit, non-ATPase, 10 PSMD10
218467_at proteasome (prosome, macropain) assembly chaperone 2 PSMG2
1561304 a at proteasome (prosome, macropain) assembly chaperone 4 PSMG4
1555910 at pentatricopeptide repeat domain 2 PTCD2
208820 at PTK2 protein tyrosine kinase 2 PTK2
208617 s at protein tyrosine phosphatase type IVA, member 2 PTP4A2
212587 s at protein tyrosine phosphatase, receptor type, C PTPRC
207238 s at protein tyrosine phosphatase, receptor type, C PTPRC
212636_at quaking homolog, KH domain RNA binding (mouse) QKI
225177 at RAB11 family interacting protein I (class 1) RAB11FIP1
206039 at RAB33A, member RAS oncogene family RAB33A
225001 at RAB3D, member RAS oncogene family RAB3D
228521 s at RAB4B, member RAS oncogene family RAB4B
203136 at Rab acceptor 1 (prenylated) RABAC1
226090 x at RAB, member of RAS oncogene family-like 3 RABL3
213970 at RAB, member of RAS oncogene family-like 3 RABL3
201223 sat RAD23 homolog B (S. cerevisiae) RAD238
1554745 at Ral GEF with PH domain and SH3 binding motif 1 RALGPS1
237856 at RAP1, GTP-GDP dissociation stimulator 1 RAP1GDSI
202677 at RAS p21 protein activator (GTPase activating protein) 1 RASA1
I
208
Appendix: Genes Associated with K-means Cluster 3
210621 s at RAS p21 protein activator (GTPase activating protein) 1 RASA1
225562 at RAS p21 protein activator 3 RASA3
232044 at retinoblastoma binding protein 6 RBBP6
1552329 at retinoblastoma binding protein 6 RBBP6
221827 at RanBP-type and C3HC4-type zinc finger containing 1 RBCKI
236613 at RNA binding motif protein 25 RBM25
208873 s at receptor accessory protein 5 REEPS
219045_at ras homolog gene family, member F (in filopodia) RHOF
222148 s at ras homolog gene family, member T1 RHOTI
212478 at required for meiotic nuclear division 5 homolog A (S. cerevisiae) RMND5A
226077 at ring finger protein 145 RNF145
1569775 at ring finger protein 157 RNF157
202683 s at RNA (guanine-7-) methyltransferase RNMT
211057 at receptor tyrosine kinase-like orphan receptor 1 ROR1
221614 s at rabphilin 3A-like (without C2 domains) RPH3AL
1555878 at Ribosomal protein S24 RPS24
226335 at ribosomal protein S6 kinase, 90kDa, polypeptide 3 RPS6KA3
226660 at ribosomal protein S6 kinase, 70kDa, polypeptide 1 RPS6KB1
228531 at sterile alpha motif domain containing 9 SAMD9
218737 at strawberry notch homolog 1 (Drosophila) SBNO1
212425 at secretory carrier membrane protein 1 SCAMP1
235206 at SCAN domain containing 1 SCAND1
211708 s at stearoyl-CoA desaturase (delts-9-desaturase) SCD
211162_x at stearoy-CoA desaturase (delta-9-desaturase) SCD
200832 s at stearoyl-CoA desaturase (delta-9-desaturase) SCD
200831 s at stearoyl-CoA desaturase (delta-9-desaturase) SCD
201915_ at SEC63 homolog (S. cerevisiae) SEC63
221931 s at SEH1-like (S. cerevisiae) SEHIL
225561 at selenoprotein T SEL.
200961 at selenophosphate synthetase 2 SEPHS2
213666 at septin 6 SEPT6
212413_at septin 6 SEPT6
212415 at septin 6 SEPT6
214298 x at septin 6 SEPT6
220482 s at secretion regulating guanine nucleotide exchange factor SERGEF
200969 at stress-associated endoplasmic reticulum protein 1 SERPI
233753 at splicing factor, arginine/serine-rich 15 SFRS15
235692 at SH3-domain kinase binding protein 1 SH3KBP1
209339 at seven in absentia homolog 2 (Drosophila) SIAH2
1554624 a at signal-regulatory protein beta 1 SIRPB1
225057 at solute carrierfamily 15, member 4 SLC15A4
solute carrier family 16, member 1 (monocarboxylic acid
209900 s at transporter 1) SLC16A1
solute carrier family 16, member I (monocarboxylic acid
202234 s at transporter 1) SLC16A1
solute carrier family 1 (neutral amino acid transporter), member
208916 at 5 SLC1AS
solute carrier family 25 (mitochondrial carrier; phosphate carrier),
226010 at member 23 SLC25A23
223698_at solute carrier family 25, member 36 SLC25A36
solute carrier family 2 (facilitated glucose transporter), member
244353 s at 12 SLC2A12
solute carrier family 37 (glycerol-3-phosphate transporter),
223304 at member 3 SLC37A3
218237 s at solute carrier family 38, member 1 SLC38A1
225295 at solute carrier family 39 (zinc transporter), member 10 SLC39A1O
229677 at solute carrier family 39 (zinc transporter), member 3 SLC39A3
225175_s at solute carrier family 44, member 2 SLC44A2
solute carrier family 7 (cationic amino acid transporter, y+
201195 s at system), member 5 SLC7A5
203021 at secretory leukocyte peptidase inhibitor SLPI
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227719 at SMAD family member 9 SMAD9
SWI/SNF related, matrix associated, actin dependent regulator
202303 x at of chromatin, subfamily a, member 5 SMARCA5
SWI/SNF related, matrix associated, actin dependent regulator
213859 x at of chromatin, subfamily a, member 5 SMARCA5
SWI/SNF related, matrix associated, actin dependent regulator
201827 at of chromatin, subfamily d, member 2 SMARCD2
1568627 at SMEK homolog 2, suppressor of mek1 (Dictyostelium) SMEK2
202043 s at spermine synthase SMS
225101 s at sorting nexin 14 SNX14
218638 s at spondin 2, extracellular matrix protein SPON2
204011 at sprouty homolog 2 (Drosophila) SPRY2
209218 at squalene epoxidase SQLE
212061 at U2-associated SR140 protein SR140
202308 at sterol regulatory element binding transcription factor 1 SREBF1
208920 at sorcin SRI
208322 s at ST3 beta-galactoside alpha-2,3-sialyltransferase 1 ST3GAL1
201998 at ST6 beta-galactosamide alpha-2,6-sialyltranferase 1 ST6GAL1
230836 at ST8 alpha-N-acetyl-neuraminide alpha-2,8-sialyltransferase 4 ST8SIA4
230261 at ST8 alpha-N-acetyl-neuraminide alpha-2,8-sialyltransferase 4 ST8SIA4
205542 at six transmembrane epithelial antigen of the prostate 1 STEAP1
225871 at six transmembrane epithelial antigen of the prostate 2 STEAP2
230934 at serine/threonine kinase 32C STK32C
216451 at Serine/threonine kinase 38 STK38
233252_s at spermatid perinuclear RNA binding protein STRBP
229513 at Chromosome 9 open reading frame 45 STRBP
235670 at syntaxin 11 STXI 1
203457 at syntaxin 7 STX7
212632 at syntaxin 7 STX7
212631 at syntaxin 7 STX7
221727 at SUB1 homolog (S. cerevisiae) SUB1
214512 s at SUBI homolog (S. cerevisiae) SUB1
227182 at sushi domain containing 3 SUSD3
217833 at synaptotagmin binding, cytoplasmic RNA interacting protein SYNCRIP
1561882 at synaptotagmin-like 3 SYTL3
TAF5 RNA polymerase 11, TATA box binding protein (TBP)-
1553528 a at associated factor, 1OOkDa TAF5
TAF8 RNA polymerase 11, TATA box binding protein (TBP)-
229412 at associated factor, 43kDa TAF8
220761 s at TAO kinase 3 TAOK3
1554701 a at TBC1 domain family, member 16 TBC1D16
222116 s at TBC1 domain family, member 16 TBC1D16
218466 at TBC1 domain family, member 17 TBC1D17
226664 at TBCI domain family, member 20 TBC1D20
213401 s at Transducin (beta)-like 1X-linked TBL1X
213400 s at transducin (beta)-like 1X-linked TBL1X
203919 at transcription elongation factor A (S1l), 2 TCEA2
212385_at transcription factor 4 TCF4
212386 at transcription factor 4 TCF4
212387 at transcription factor 4 TCF4
228837 at transcription factor 4 TCF4
213891 s at transcription factor 4 TCF4
219169_s at transcription factor -1, mitochondrial TFBM
228075 x at transcription factor B1, mltochonddal TFBIM
219950 s at T-cell lymphoma invasion and metastasis 2 TIAM2
238858 at RAF-interacting protein Ath forkhead-associated domain TIFA
223750_s at toll-like receptor 10 TLR1O
'207446 at toll-like receptor 6 TLR6
223892_s at transmembrane BAX inhibitor motif containing 4 TMBIM4
204328 at transmembrane channel-like 6 TMC6
214958 s at transmembrane channel-like 6 TMC6
221096 s at transmembrane and coiled-coil domains 6 ITMC06
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218910_at transmembrane protein 16K TMEM16K
225666 at transmembrane and tetratricopeptide repeat containing 4 TMTC4
1554101_a at transmembrane and tetratricopeptide repeat containing 4 TMTC4
207113 s at tumor necrosis factor (TNF superfamily, member 2) TNF
207641 at tumor necrosis factor receptor superfamily, member 13B TNFRSF13B
1552892 at tumor necrosis factor receptor superfamily, member 13C TNFRSF13C
213109 at TRAF2 and NCK interacting kinase TNIK
211987 at topoisomerase (DNA) It beta 180kDa TOP2B
201691 s at tumor protein D52 TPD52
202080 s at trafficking protein, kinesin binding 1 TRAKI
238520 at transcriptional regulating factor 1 TRERF1
202241 at tribbles homolog 1 (Drosophila) TRIBI
202478_at tribbles homolog 2 (Drosophila) TRIB2
1568596 a at trophinin associated protein (tastin) TROAP
213027 at TROVE domain family, member 2 TROVE2
201515 s at translin TSN
201513_at translin TSN
225178 at tetratricopeptide repeat domain 14 TTC14
225180 at tetratricopeptide repeat domain 14 TTC14
1554086 at tubulin, gamma complex associated protein 3 TUBGCP3
223017 at thioredoxin domain containing 12 (endoplasmic reticulum) TXNDC12
201581 at thioredoxin domain containing 13 TXNDC13
201580 s at thioredoxin domain containing 13 TXNDC13
209142.s_at ubiquitin-conjugating enzyme E2G 1 (UBC7 homolog, yeast) UBE2Gi
217825 s at ubiquitin-conjugating enzyme E2, J1 (UBC6 homolog, yeast) UBE2J1
208997 s at uncoupling protein 2 (mitochondrial, proton carrier) UCP2
214169 at unc-84 homolog A (C. elegans) UNC84A
201832 s at US01 homolog, vesicle docking protein (yeast) USOI
1552678 a at ubiquitin specific peptidase 28 USP28
221654 s at ubiquitin specific peptidase 3 USP3
226652 at ubiquitin specific peptidase 3 USP3
202681 at ubiguitin specific peptidase 4 (proto-oncogene) USP4
222734 at tryptophanyl tRNA synthetase 2, mitochondrial WARS2
221531 at WD repeat domain 61 WDR61
221532 s at WD repeat domain 61 WDR61
1556429 a at WD repeat domain 67 WDR67
224748 at WD repeat domain 68 WDR68
227174 at WD repeat domain 72 WDR72
222777 s at Wolf-Hirschhom syndrome candidate 1 WHSC1
231182 at WAS/WASL interacting protein family, member 1 WIPFI
230847 at Werner helicase interacting protein 1 WRNIP1
212160 at exportin, tRNA (nuclear export receptor for tRNAs) XPOT
X-ray repair complementing defective repair in Chinese hamster
205072 s at cells 4 XRCC4
234977_at zinc binding alcohol dehydrogenase, domain containing 2 ZADH2
227049_at zinc binding alcohol dehydrogenase, domain containing 2 ZADH2
1554239 s at zinc binding alcohol dehydrogenase, domain containIng 2 ZADH2
226496_at zinc finger, CCHC domain containing 7 ZCCHC7
222731 at zinc finger, DHHC-type containing 2 ZDHHC2
203556 at zinc fingers and homeoboxes 2 ZHX2
1556035 s at zinc finger protein 207 ZNF207
228157 at zinc finger protein 207 ZNF207
239898 x at zinc finger protein 286A ZNF286A
222760_at zinc finger protein 703 ZNF703
1558762aat zinc finger protein 789 ZNF789
1564656 at
239801 at
222033 s at
244757 at
242264 at
219880 at
229681 at
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Probeset ID Gene Name Gene Symbol
1206874 s at I
216565 x at
212
Appendix: Genes Associated with K-means Cluster 4
1556347 at Full length insert cDNA clone ZD70GO4
1557149 at Full length insert cDNA clone ZB55F04
1557174 a at CDNA FLJ39542 fis, clone PUAEN2008815
1557667_at CDNA FLJ36588 fis, clone TRACH2013991 ---
1559086 at CDNA FLJ35769 fis, clone TEST12005040 ---
1559154 at CDNA FLJ40682 fis, clone THYMU2023264 ---
1566633 at CDNA clone IMAGE:3950788
1570264_at Transcribed locus
214949 at CDNA FLJ31919 fis, clone NT2RP7004964 -
215612_at CDNA FLJ12349 fis, clone MAMMA1002308 ---
225141 at Transcribed locus
225740_x at Transcribed locus ---
226375 at CDNA clone IMAGE:6584326
227107 at Transcribed locus
227431 at CDNA clone IMAGE:4791585
229226 at MRNA; cDNA DKFZp547MO59 (from clone DKFZp547MO59) -
229504 at Transcribed locus
229919 at CDNA FLJ36926 fis, clone BRACE2005196
233237 at CDNA FLJ10720 fis, clone NT2RP3001116
233935 at CDNA: FLJ23051 fis, clone LNG02642 ---
234111 at CDNA: FLJ23063 fis, clone LNG04745
235882 at CDNA clone IMAGE:5303499
235912 at Transcribed locus
236458 at Transcribed locus
236537 at CDNA FLJ23896 fis, clone LNG15157
236580 at Transcribed locus
237332 at Transcribed locus
238477 at CDNA clone IMAGE:4830091 ---
238495 at CDNA FLJ41444 fis, clone BRSTN2001801
238576 at Homo sapiens, clone IMAGE:4414697, mRNA
239054 at Transcribed locus
239567 at Transcribed locus
239731 at Transcribed locus
239800 at Transcribed locus
240190 at Transcribed locus
240201 at Transcribed locus
Transcribed locus, moderately similar to NP_001030112.1 zinc
241608 at finger CCHC-type and RNA binding motif 1 [Rattus norvegicus]
241689 at Transcribed locus
241790 at Transcribed locus
242965 at Transcribed locus
221569 at Abelson helper Integration site 1 AHII
asparagine-linked glycosylation 9 homolog (S. cerevisiae, alpha-
219374 s at 1,2-mannosyltransferase) ALG9
223542_at ankyrin repeat domain 32 ANKRD32
Rho GTPase activating protein 8 /// proline rich 5 (renal) ///
205980 s at PRR5-ARHGAP8 fusion ARHGAP8 / LOC553158 /// PRR5
Rho GTPase activating protein 8 /// proline rich 5 (renal) /
37117 at PRR5-ARHGAP8 fusion ARHGAP8 /I LOC553158 /I PRR5
201229 s at ariadne homolog 2 (Drosophila) ARIH2
216008 s at ariadne homolog 2 (Drosophila) ARIH2
227932 at ariadne homolog 2 (Drosophila) ARIH2
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1555964 at
ADP-ribosylation factor-like 17 pseudogene 1 /ADP-
ribosylation factor-like 17 ARLI7 /// ARL17P1
232908 at ATPase family, AAA domain containing 2B ATAD2B
207712 at B melanoma antigen BAGE
B melanoma antigen family, member 4 /// B melanoma antigen
1555408 at family, member 2 BAGE2 /// BAGE4
205084 at B-cell receptor-associated protein 29 BCAP29
B double prime 1, subunit of RNA polymerase Il transcription
226290 at initiation factor IlB BDP1
213154 s at bicaudal D homolog 2 (Drosophila) BICD2
bone morphogenetic protein receptor, type II (serine/threonine
225144 at kinase) BMPR2
1553227 s at bromodomain and WD repeat domain containing 1 BRWDI
214820 at bromodomain and WD repeat domain containing 1 BRWD1
204586 at bassoon (presynaptic cytomatrix protein) BSN
222852 at chromosome 10 open reading frame 88 C1Oorf88
214772 at chromosome 11 open reading frame 41 C1lorf4l
213701 at chromosome 12 open reading frame 29 C12orf29
219563 at chromosome 14 open reading frame 139 C14orf139
1561985 at chromosome 14 open reading frame 39 C14orf39
229660 at chromosome 16 open reading frame 55 C16orf55
223352 s at chromosome 17 open reading frame 80 C17orf8O
220840 s at chromosome I open reading frame 112 C1orf112
203960 s at chromosome 1 open reading frame 41 Clorf4l
223773 s at chromosome 1 open reading frame 79 CIorf79
223774 at chromosome 1 open reading frame 79 Clorf79
217835_x_at chromosome 20 open reading frame 24 C20orf24
223880 x at chromosome 20 open reading frame 24 C20orf24
224376 s at chromosome 20 open reading frame 24 C20orf24
235181 at chromosome 2 open reading frame 60 C2orf6O
230506 at chromosome 6 open reading frame 164 C6orf 164
1552299 at chromosome 6 open reading frame 199 C6orf 199
225699 at chromosome 7 open reading frame 40 C7orf4O
227672_at chromosome 8 open reading frame 73 C8orf73
222195_s_at chromosome 9 open reading frame 156 C9orf156
47530 at chromosome 9 open reading frame 156 C9orf 156
218904 s at chromosome 9 open reading frame 40 C9orf4O
223007 s at chromosome 9 open reading frame 5 C9orf5
226004 at Cdk5 and AbI enzyme substrate 2 CABLES2
224910 at calcium regulated heat stable protein 1, 24kDa CARHSP1
222201 s at CASP8 associated protein 2 CASP8AP2
1554513 s at coiled-coil domain containing 123 CCDC123
219644 at coiled-coil domain containing 41 CCDC41
225705 at coiled-coil domain containing 45 CCDC45
228122 at coiled-coil domain containing 66 CCDCO66
239233 at coiled-coil domain containing 88A CCDC88A
207955 at chemokine (o7C motif) ligand 27 CCL27
213523 at cyclin El CCNE1
211814 s at cyclin E2 CCNE2
233564 s at cytidine and dCMP deaminase domain containing 1 CDADC1
220885 s at centromere protein J CENPJ
223513 at centromere protein J CENPJ
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234023 s at centromere protein J CENPJ
229208_at centrosomal protein 27kDa CEP27
206861 s at CGG triplet repeat binding protein 1 CGGBP1
204775_at chromatin assembly factor 1, subunit B (p60) CHAF1B
204233 s at choline kinase alpha CHKA
204266 s at choline kinase alpha CHKA
210221jat cholinergic receptor, nicotinic, alpha 3 CHRNA3
211587 x at cholinergic receptor, nicotinic, alpha 3 CHRNA3
219161 s at chemokine-Ilke factor CKLF
210346_s at CDC-like kinase 4 CLK4
ceroid-lipofuscinosis, neuronal 8 (epilepsy, progressive with
229958 at mental retardation) CLN8
212489 at collagen, type V, alpha 1 COL5A1
COP9 constitutive photomorphogenic homolog subunit 3
202078_at (Arabidopsis) COPS3
COP9 constitutive photomorphogenic homolog subunit 7B
225696 at (Arabidopsis) COPS7B
COP9 constitutive photomorphogenic homolog subunit 7B
243628 at (Arabidopsis) COPS7B
222533 at cereblon CRBN
228177 at CREB binding protein (Rubinstein-Taybi syndrome) CREBBP
220640 at casein kinase 1, gamma 1 CSNK1G1
202613 at CTP synthase CTPS
222234 s at dysbindin (dystrobrevin binding protein 1) domain containing 1 DBNDD1
206414 s at development and differentiation enhancing factor 2 DDEF2
219111_s at DEAD (Asp-Glu-Ala-Asp) box polypeptide 54 DDX54
220939 s at dipeptidyl-peptidase 8 DPP8
down-regulator of transcription 1, TBP-binding (negative cofactor
216652 s at 2) DR1
1558867 at Dermatan sulfate epimerase DSE
218576 s at dual specificity phosphatase 12 DUSP12
228361 at E2F transcription factor 2 E2F2
203692 s at E2F transcription factor 3 E2F3
219990 at E2F transcription factor 8 E2F8
210656 at embryonic ectoderm development EED
224189 x at ets homologous factor EHF
213310_at Eukaryotic translation initiation factor 2C, 2 EIF2C2
208290 s at eukaryotic translation initiation factor 5 EIF5
208705_s_at eukaryotic translation initiation factor 5 EIF5
208706 s at eukaryotic translation initiation factor 5 EIF5
208708 x at eukaryotic translation initiation factor 5 EIF5
201313 at enolese 2 (gamma, neuronal) ENO2
235588_at establishment of cohesion 1 homolog 2 (S. cerevisiae) ESCO2
205061 s at exosome component 9 EXOSC9
218080_x at Fas (TNFRSF6) associated factor 1 FAF1
1557128 at family with sequence similarity 111, member B FAM111B
1557129 a at family with sequence similarity 111, member B FAM111B
230009 at family with sequence similarity 118, member B FAM118B
239391_at Family with sequence similarity 120A opposite strand FAM120AOS
228069 at family with sequence similarity 54, member A FAM54A
1553244 at Fanconi anemia, complementation group B FANCB
1557218 s at Fanconi anemia, complementation group B FANCB
237428 at FLJ27505 protein FLJ27505
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204764 at farnesyltransferase, CAAX box, beta FNTB
203734 at forkhead box J2 FOXJ2
202488 s at FXYD domain containing ion transport regulator 3 FXYD3
206670 s at glutamate decarboxylase 1 (brain, 67kDa) GADI
214524 at growth hormone releasing hormone GHRH
206102 at GINS complex subunit 1 (Psfl homolog) GINS1
229311 at G kinase anchoring protein 1 GKAP1
234192 s at G kinase anchoring protein 1 GKAPI
222251 s at glucocorticoid modulatory element binding protein 2 GMEB2
44146 at glucocorticoid modulatory element binding protein 2 GMEB2
218350 s at geminin, DNA replication inhibitor GMNN
200696 s at gelsolin (amyloidosis, Finnish type) GSN
203674 at helicase with zinc finger HELZ
238003 at hepatocyte cell adhesion molecule HEPACAM
237407 at HCLSI binding protein 3 HS1BP3
217618 x at HUS1 checkpoint homolog (S. pombe) HUS1
201611 s at isoprenylcysteine carboxyl methyltransferase ICMT
225330 at insulin-like growth factor 1 receptor IGF1R
216491 x at immunoglobulin heavy constant mu IGHM
inhibitor of kappa light polypeptide gene enhancer in B-cells,
209341 s at kinase beta IKBKB
inhibitor of kappa light polypeptide gene enhancer in B-cells,
209342 s at kinase beta IKBKB
212196 at interleukin 6 signal transducer (gp1 30, oncostatin M receptor) IL6ST
239044 at Integrin alpha FG-GAP repeat containing 1 ITFGI
227297 at integrin, alpha 9 ITGA9
integrin, alpha E (antigen CD103, human mucosal lymphocyte
205055 at antigen 1; alpha polypeptide) ITGAE
226479 at kelch repeat and BTB (POZ) domain containing 6 KBTBD6
209256 s at KIAA0265 protein KIAA0265
1556060 a at KIAA1702 protein KIAAI 702
232139_s_at KIAA1919 KIAA1919
238828 at KIAA1919 KIAA1919
219306 at kinesin family member 15 KIF15
220652_at kinesin family member 24 KlF24
209212 s at Kruppel-like factor 5 (intestinal) KLF5
202058 s at karyopherin alpha 1 (importin alpha 5) KPNA1
218587 s at KTEL (Lys-Tyr-Glu-Leu) containing 1 KTELCI
213728 at lysosomal-associated membrane protein 1 LAMP1
1552362 a at liver expressed antimicrobial peptide 2 LEAP2
219399_at lin-7 homolog C (C. elegans) LIN7C
220121 at lines homolog 1 (Drosophila) LINS1
231976 at lines homolog 1 (Drosophila) LINS1
ST3 beta-galactoside alpha-2,3-sialyltransferase 4 ///
203759 at hypothetical protein LOC100129068 LOCI 00129068/ ST3GAL4
236075_s at similar to hCG2042915 LOCI 00129673
228591 at Hypothetical protein LOC100131096 LOC100131096
227604 at hypothetical protein LOC151146 LOC151146
227037 at similar to CG12314 gene product LOC201164
236363 at hypothetical protein LOC285378 LOC285378
1564282 a at hypothetical protein LOC285708 LOC285708
217480 x at similar to hCG1 742442 LOC339562
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235606 at hypothetical LOC344595 LOC344595
RRN3 RNA polymerase I transcription factor homolog (S.
cerevisiae) /// RRN3 RNA polymerase I transcription factor LOC653390 // LOC730092 ///
216902 s at homolog (S. cerevisiae) pseudogene RRN3
226908 at leucine-rich repeats and immunoglobulin-like domains 3 LRIG3
220220 at leucine rich repeat containing 37, rnember A4 (pseudogene) LRRC37A4
LSM2 homolog, U6 small nuclear RNAassociated (S.
209449 at cerevisiae) LSM2
LSM3 homolog, U6 small nuclear RNA associated (S.
202209_at cerevisiae) LSM3
223295 s at LUC7-like (S. cerevisiae) LUC7L
217842_at LUC7-like 2 (S. cerevisiae) LUC7L2
226758 at LUC7-like 2 (S. cerevislae) LUC7L2
243852 at LUC7-like 2 (S. cerevisiae) LUC7L2
207457 s at lymphocyte antigen 6 complex, locus G6D LY6G6D
mitogen-activated protein kinase kinase kinase 7 interacting
1552927_at protein 3 MAP3K71P3
224320 s at minichromosome maintenance complex component 8 MCM8
213123 at Microfibrillar-associated protein 3 MFAP3
225478 at malignant fibrous histiocytoma amplified sequence 1 MFHAS1
208384 s at midline 2 MID2
212023 s at antigen identified by monoclonal antibody Ki-67 MK167
217910 x at MAX-like protein X MLX
M-phase phosphoprotein 10 (U3 small nucleolar
212885 at ribonucleoprotein) MPHOSPH10
205395 s at MRE11 meiotic recombination 11 homolog A (S. cerevisiae) MRE11A
239289 x at myotubularin related protein 15 MTMR15
204837_at myotubularin related protein 9 MTMR9
219378 at NMDA receptor regulated 1-like NARGIL
218662_s at non-SMC condensin I complex, subunit G NCAPG
218663 at non-SMC condensin I complex, subunit G NCAPG
241395 at nitrilase 1 NIT1
230916 at nodal homolog (mouse) NODAL
235760 at nuclear receptor binding SET domain protein 1 NSD1
218786 at 5'-nucleotidase domain containing 3 NT5DC3
228379 at nuclear transport factor 2 NUTF2
229230 at organic solute transporter alpha OSTalpha
203660 s at pericentrin PCNT
204209 at phosphate cytidylyltransferase 1, choline, alpha PCYTIA
212522_at phosphodiesterase 8A PDE8A
218517 at PHD finger protein 17 PHF17
209625 at phosphatidylinositol glycan anchor biosynthesis, class H PIGH
209302 at polymerase (RNA) II (DNA directed) polypeptide H POLR2H
236142_at Peptidylprolyl isomerase H (cyclophilin H) PPIH
protein phosphatase 2 (formerly 2A), regulatory subunit B",
218852.at gamma PPP2R3C
207805_s at proteasome (prosome, macropain) 26S subunit, non-ATPase, 9 PSMD9
222612 at Paraspeckle component 1 PSPC1
226110_at protein prenyltransferase alpha subunit repeat containing 1 PTAR1
233978_at Protein tyrosine phosphatase, receptor type, E PTPRE
209694 at 6-pyruvoyltetrahydropterin synthase PTS
203883 s at RAB11 family interacting protein 2 (class I) RAB11FIP2
216880 at RAD51-like 1 (S. cerevisiae) RAD51L1
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205647 at RAD52 homolog (S. cerevisiae) RAD52
205296 at retinoblastoma-like 1 (p107) RBL1
224780 at RNA binding motif protein 17 RBM17
226732 at RNA binding motif protein 33 RBM33
recombination signal binding protein for immunoglobulin kappa J
211974 x at region RBPJ
212749 s at ring finger and CHY zinc finger domain containing 1 RCHY1
218344 s at REST corepressor 3 RCOR3
222605 at REST corepressor 3 RCOR3
218428 s at REV1 homolog (S. cerevisiae) REV1
204023 at replication factor C (activator 1) 4, 37kDa RFC4
203225 s at riboflavin kinase RFK
233065 at ring finger protein 207 RNF207
227852 at retinitis pigmentosa 9 (autosomal dominant) RP9
209773 s at ribonucleotide reductase M2 polypeptide RRM2
1557950 at serologically defined colon cancer antigen 1 SDCCAG1
244287 at splicing factor, arginine/serine-rich 12 SFRS12
213649 at splicing factor, arginine/serine-rich 7, 35kDa SFRS7
1558703 at solute carrier family 46 (folate transporter), member 1 SLC46A1
232057 at solute carrier family 7, member 6 opposite strand SLC7A6OS
212947 at solute carrier family 9 (sodium/hydrogen exchanger), member 8 SLC9A8
227791 at solute carrier family 9 (sodium/hydrogen exchanger), member 9 SLC9A9
1553423 a at schlafen family member 13 SLFN13
220368 s at SMEK homolog 1, suppressor of mek1 (Dictyostelium) SMEKI
223160 s at SMEK homolog 1, suppressor of mek1 (Dictyostelium) SMEK1
212666 at SMAD specific E3 ubiquitin protein ligase 1 SMURF1
Syntrophin, beta 2 (dystrophin-associated protein Al, 59kDa,
213814 s at basic component 2) SNTB2
syntrophin, beta 2 (dystrophin-associated protein Al, 59kDa,
238925 at basic component 2) SNTB2
209647 s at suppressor of cytokine signaling 5 SOCS5
209648 x at suppressor of cytokine signaling 5 SOCS5
226342 at spectrin, beta, non-erythrocytic 1 SPTBN1
serum response factor (c-fos serum response element-binding
202400 s at transcription factor) SRF
213329 at SLIT-ROBO Rho GTPase activating protein 2 SRGAP2
202293 at stromal antigen 1 STAG1
202294 at stromal antigen 1 STAG1
243719 at serine/threonine kinase 19 STK19
225840 at thyrotrophic embryonic factor TEF
219248 at THUMP domain containing 2 THUMPD2
228671 at transmembrane protein 201 TMEM201
212202 s at transmembrane protein 87A TMEM87A
214299 at topoisomerase (DNA) Ill alpha TOP3A
214195 at tripeptidyl peptidase I TPP1
214458 at TNF receptor-associated factor 3 interacting protein 1 TRAF3IP1
225485 at testis specific, 14 TSGA14
202266 at TRAF and TNF receptor associated protein TTRAP
220746 s at ubiquitin interaction motif containing 1 UIMC1
227256 at ubiquitin specific peptidase 31 USP31
212980 at ubiquitin specific peptidase 34 USP34
215013 s at ubiquitin specific peptidase 34 USP34
I
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202172 at vascular endothelial zinc finger 1 VEZFI
232386 at vacuolar protein sorting 13 hornolog C (S. cerevisiae) VPS13C
209054 s at Wolf-Hirschhom syndrome candidate 1 WHSCi
227309 at YOD1 OTU deubiquinating enzyme 1 homolog (S. cerevisiae) YOD1
217836 s at YYi associated protein 1 YYiAPi
212860_at zinc finger, DHHC-type containing 18 ZDHHC18
214741 at zinc finger protein 131 ZNF131
205181_at zinc finger protein 193 ZNF193
214706 at zinc finger protein 200 ZNF200
205791 x at zinc finger protein 230 ZNF230
218490 s at zinc finger protein 302 ZNF302
226202_at zinc finger protein 398 ZNF398
228145 s at zinc finger protein 398 ZNF398
238937_at zinc finger protein 420 ZNF420
213130 at zinc finger protein 473 ZNF473
220444 at zinc finger protein 557 ZNF557
230164jat zinc finger protein 621 ZNF621
1554958 at zinc finger protein 641 ZNF641
232028 at Zinc finger protein 678 ZNF678
227294_at zinc finger protein 689 ZNF689
227445 at zinc finger prote 689 ZNF689
232076 at zinc finger protein 707 ZNF707
225964 at ZXD family zinc finger C ZXDC
222179_at
228178 s at
236238 at
238192 at
241341_at
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241386 at Transcribed locus
236400 at Transcribed locus
229898 at Transcribed locus ---
244667 at CDNA FLJ35683 fis, clone SPLEN2019131 ---
238386 x at Transcribed locus
239452 at Transcribed locus ---
5.5 kb mRNA upregulated in retinoic acid treated HL-60
229670 at neutrophilic cells
229121 at CDNA FLJ44441 fis, clone UTERU2020242 --
227452 at CDNA FL26252 fis, clone DMC03335
226498 at CONA FLJ35153 fis, clone PLACE6010765 ---
226497 s at CDNA FLJ35153 fis, clone PLACE6010765
231310 at Transcribed locus ---
239744 at Transcribed locus
201128_s at ATP citrate lyase ACLY
234799 at Adenosine deaminase, RNA-specific, BI (REDi honolog rat) ADARB1
237282 s at A kinase (PRKA) anchor protein 14 AKAP14
207328 at arachidonate 15-lipoxygenase ALOXI 5
209546 s at apolipoprotein L, I APOL1
221653 x at apolipoprotein L, 2 APOL2
221087 s at apolipoprotein L, 3 APOL3
205673 s at ankyrin repeat and SOCS box-containing 9 ASB9
UDP-GlcNAc:betaGal beta-I ,3-N-acetylglucosarninyltransferase
225612 s at 5 B3GNT5
218285 s at 3-hydroxybutyrate dehydrogenase, type 2 BDH2
212993 at BTB (POZ) domain containing 14A BTBD14A
38241 at butyrophilin, subfamily 3, member A3 BTN3A3
232230_at Chromosome 10 open reading frame 75 C1 orf75
231538 at Chromosome 11 open reading frame 1 CIorfi
202562 s at chromosome 14 open reading frame I C14orfl
1569434 at chromosome 14 open reading frame 105 Cl4orfl05
chromosome 16 open reading frame 54 /// similar to
1559584 a at chromosome 16 open reading frame 54 C16orf54 /// hCG 1644884
218060 s at chromosome 16 open reading frame 57 016orf57
217513 at chromosome 17 open reading frame 60 C17orf60
212925 at chromosome 19 open reading frame 21 Cl9orf2l
219506 at chromosome I open reading frame 54 C1orf54
chromosome 2 open reading frame 59/N/hypothetical
225799 at LOC541471 C2orf59 /// LOC541471
calcium/calmodulin-dependent protein kinase (CaM kinase) 11
225019 at delta CAMK2D
228087 at coiled-coil domain containing 126 CCDC126
206983 at chemokine (C-C motif) receptor 6 CCR6
220446 s at carbohydrate (N-acetylglucosarnine 6-0) sulfotransferase 4 CHST4
208792 s at clustern CLU
208791 at clusterin CLU
225312 at COMM domain containing 6 COMMD6
204920 at carbamoyl-phosphate synthetase 1, mitochondrial CPS1
227178 at CUG triplet repeat, RNA binding protein 2 CUGBP2
dehydrogenaselreductase (SDR family) member 4/1
218021 at dehydrogenase/reductase (SDR family) member 4 like 2 DHRS4 I// DHRS4L2
1222802 at endothelin I EDN 1
218995 s at lendothelin I EDNI
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212336 at erythrocyte membrane protein band 4.1-like 1
228298 at family with sequence similarity 113, member B FAM113B
210992 x at Fc fragment of IgG, low affinity lIc, receptor for (CD32) FCGR2C
211395 x at Fc fragment of igG, low affinity lic, receptor for (CD32) FCGR2C
221239_s at Fc receptor-like 2 FCRL2
1563674 at Fc receptor-like 2 FCRL2
RAS p21 protein activator 4 /// hypothetical protein FLJ21767 /// FLJ21767 /// LOC100132214 //
similar to HSPC047 protein /// similar to RAS p21 protein LOC100133005 /// LOC100134722
212706 at activator 4 /// RASA4
232024 at GTPase, IMAP family member 2 GIMAP2
219243_at GTPase, IMAP family member 4 GIMAP4
225706_at glucocorticold Induced transcript 1 GLCCII
209276_s at glutaredoxin (thioltransferase) GLRX
206662 at glutaredoxin (thioltransferase) GLRX
1554712_a at glycine-N-acyltransferase-like 2 GLYATL2
207651 at G protein-coupled receptor 171 GPR171
219327 s at G protein-coupled receptor, family C, group 5, member C GPRC5C
205919 at hemoglobin, epsilon 1 HBEI
226879_at hydrogen voltage-gated channel 1 HVCN1
208881 x at isopentenyl-diphosphate delta isomerase 1 ID1I
204615_x at isopentenyl-diphosphate delta isomerase 1 ID11
ISYI splicing factor homolog (S. cerevisiae) /// RAB43, member
225632 s at RAS oncogene family ISY1 /// RAB43
201015 s at junction plakoglobin JUP
211433 x at KIAA1539 KIAA1539
208949 s at lectin, galactoside-binding, soluble, 3 LGALS3
leukocyte immunoglobulin-like receptor, subfamily A (with TM
211100 x at domain), member 2 LILRA2
leukocyte immunoglobulin-like receptor, subfamily A (with TM
207857_at domain), member 2 LILRA2
leukocyte immunoglobulin-like receptor, subfamily A (with TM
211101 x at domain), member 2 LILRA2
leukocyte immunoglobulin-like receptor, subfamily B (with TM
207104_x at and ITIM domains), member 1 LILRB1
leukocyte immunoglobulin-flike receptor, subfamily B (with TM
211336 x at and ITIM domains), member 1 LILRB1
leukocyte immunoglobulin-like receptor, subfamily B (with TM
210152 at and ITIM domains), member 4 LILRB4
229930 at similar to hCG1811002 LOCI 00134361
228058_at similar to common salivary protein 1 LOC124220
212098 at hypothetical LOC151162 LOC151162
1558685 a at hypothetical protein BC009467 LOC158960
1569454 a at hypothetical protein LOC283352 LOC283352
1561757 a at hypothetical protein LOC283352 LOC283352
hypothetical gene supported by BC022385; BC035868;
229599 at 048326 LOC440335
1564276 at hypothetical gene supported by AK128882 LOC441108
227901 at hypothetical LOC648987 LOC648987
210102 at loss of heterozygosity, 11, chromosomal region 2, gene A LOH11CR2A
230252 at lysophosphatidic acid receptor 5 LPAR5
212046 x at mitogen-activated protein kinase 3 MAPK3
207761 s at methyltransferase like 7A METTL7A
238366 at Hypothetical LOC339541 MGC33556
238367 s at Hypothetical LOC339541 MGC33556
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211071 s at
myeloid/lymphoid or mixed-lineage leukemia (trithorax homolog,
Drosophila); translocated to, 11 MLLT11
228592 at membrane-spanning 4-domains, subfamily A, member I MS4A
228599 at membrane-spanning 4-domains, subfamily A, member 1 MS4A1
218687_s at mucin 13, cell surface associated MUC13
224920 x at myeloid-associated differentiation marker MYADM
225673 at myeloid-associated differentiation marker MYADM
223442 at nicolin 1 NICNI
219594 at ninjurin 2 NINJ2
201708 s at nipsnap homolog I (C. elegans) NIPSNAP1
234469 at olfactory receptor, family 51, subfamily B, member 4 OR51 B4
223619 x at peroxisomal trans-2-enoyl-CoA reductase PECR
204484 at phosphoinositide-3-kinase, class 2, beta polypeptide PIK3C2B
235802 at phospholipase D family, member 4 PLD4
205901 at prepronociceptin PNOC
202996 at polymerase (DNA-directed), delta 4 POLD4
protein phosphatase 3 (formerly 2B), catalytic subunit, alpha
202457 s at isoform PPP3CA
phosphatidylinositol 3,4,5-trisphosphate-dependent RAC
224925 at exchanger 1 PREX1
201276 at RAB5B, member RAS oncogene family RAB5B
218699 at RAB7, member RAS oncogene family-like 1 RAB7L1
223820 at retinol binding protein 5, cellular RBP5
202388 at regulator of G-protein signaling 2, 24kDa RGS2
220300 at regulator of G-protein signaling 3 RGS3
214538 x at regulator of G-protein signaling 6 RGS6
213566 at ribonuclease, RNase A family, k6 RNASE6
206027 at S100 calcium binding protein A3 S100A3
203186 s at S100 calcium binding protein A4 S10OA4
213283_s at sal-like 2 (Drosophila) SALL2
226603_at sterile alpha motif domain containing 9-like SAMD9L
230036 at sterile alpha motif domain containing 9-like SAMD9L
209146 at sterol-C4-methyl oxidase-like SC4MOL
1556471 at sex comb on midleg-like 4 (Drosophila) SCML4
1556472 s at sex comb on midleg-like 4 (Drosophila) SCML4
228730 s at secemin 2 SCRN2
1555851 s at selenoprotein W, 1 SEPW1
220485 s at signal-regulatory protein gamna SIRPG
219885 at schlafen family member 12 SLFN12
207777 s at SP140 nuclear body protein SP140
205406 s at sperm autoantigenic protein 17 SPA1 7
212565 at serine/threonine kinase 38 like STK38L
226264 at sushi domain containing I SUSD1
227274_at synaptojanin 2 binding protein SYNJ2BP
235914 at synaptopodin SYNPO
240480 at tubulointerstitial nephritis antigen TINAG
231154 x at tubulointerstitial nephritis antigen TINAG
210176 at toll-like receptor 1 TLR1
224341 x at toll-like receptor 4 TLR4
236420 s at transmembrane protein 16D TMEM16D
236655 at tumor protein D52 TPD52
I
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Probeset D Gene Name Gene Symbol
tripartite motif-containing 34/// tripartite motif-containing 6/// TRIM34 /// TRIM6 // TRIM6-
221044_s at TRIM6-TRIM34 TRIM34
223830 s_at tripartite motif-containing 5 TFRIMS
1568592 at tripartite motif-containing 69 TRIM69
208073 x at tetralricopeptide Meat domain 3 TTC3
209118_s_at tubulinalpha 1a TUBA1A
201649 at ubiguJtin-conjugating enzyme E2L 6 UBE2L6
227020_at yippee-like 2 (Drosophila) YPEL2
229060 at yippeeVike 2 Drosophila) YPEL2
226912 at zinc finger, DHHC-type containing 23 ZDHHC23
214311_at zinc finger protein-like I ZFPLI
242714_at I 
_
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243176 at CDNA FLJ30090 fis, clone BNGH41000015
243112 at Transcribed locus ---
243023 at Transcribed locus
243030 at Transcribed locus
243246 at Transcribed locus
213705 at CDNA FLJ30007 fis, clone 3NB692000012
243331 at Transcribed locus
213964 x at CDNA FLJ37852 fis, clone BRSSN2014513
217498 at Transcribed locus
217721 at Transcribed locus -
214857 at CDNA FLJ37852 fis, clone BRSSN2014513
217922 at CDNA FLJ40810 fis, clone TRACH2009743 --
217647 at CDNA FLJ40920 fis, clone UTERU2005905 -
222090 at CDNA FLJ26073 fis, clone RCT01314 --
243888 at Transcribed locus
Transcribed locus, strongly similar to NP_057211.4
222352 at transmembrane protein 66 [Homo sapiens] --
211444 at CDNA clone IMAGE:3636371
222275 at MRNA; cDNA DKFZp686K0394 (from clone DKFZp686K0394) --
222280 at CDNA FLJ34713 fis, clone MESAN2004138
81811 at CDNA FLJ37304 fis, clone BRAMY2016070
243417 at Transcribed locus -
213574_s at Transcribed locus ---
243478 at CDNA FLJ40061 fis, clone TESOP2000083 --
243808 at Transcribed locus ---
212528 at CDNA clone IMAGE:3878236
244647 at Transcribed locus
243745 at Transcribed locus
226848 at CDNA FLJ39306 fis, clone OCBBF2013123
238822 at Transcribed locus -
1554597 at MRNA; cDNA DKFZp547KI89 (from clone DKFZp547K189) --
1554599 x at MRNA; cDNA DKFZp547K189 (from clone DKFZp547K1 89) -
1556008 a at MRNA full length insert cDNA clone EUROIMAGE 146729 -
1557487 at CDNA clone IMAGE;4797099 -
1558250 s at CDNA FLJ40891 fis, clone UTERU2001110
1558381 a at CDNA FLJ34713 fis, clone MESAN2004138
1556989 at Full length insert cDNA clone YZ35C05 -
1556048 at Homo sapiens, clone IMAGE:4753714, mRNA
1556103 at CDNA FLJ30565 fis, clone BRAWH2005008
1556110 at CDNA FLJ39819 fis, clone SPLEN20I0534
1556111 s at CDNA FLJ39819 fis, clone SPLEN2010534 -
1556346 at Partial mRNA; ID YG39-IA
238896 at Transcribed locus ---
1556584.at CDNA clone IMAGE:5310697
1556586_x at CDNA clone IMAGE:5310697 ---
238694 at Transcribed locus
227293 at CDNA FLJ34052 fis, clone FCBBF3000175 --
238565 at CDNA FLJ40891 fis, clone UTERU2001110
235530 at CDNA FLJ38922 fis, clone NT2NE2011691 ---
227505 at CDNA FLJ42497 fis, clone BRACE2035278
227504 s at CDNA FLJ42497 fis, clone BRACE2035278 ---
227010 at CDNA clone IMAGE:4453251
227044 at Transcribed locus
Transcribed locus, strongly similar to XP_001140852.1
243707 at PREDICTED: hypothetical protein [Pan troglodytes]
244524 at Transcribed locus
238666 at Transcribed locus -
1558525 at Homo sapiens, clone IMAGE:3459334, mRNA --
226234 at CDNA FLJ33772 fis, clone BRSSN2000175
226232 at CDNA FLJ33772 fis, clone BRSSN2000175 --
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226138 s at
Transcribed locus, strongly similar to NP_032915.2 protein
phosphatase 1, regulatory (inhibitor) subunit 148 [Mus
musculusi
238953 at CDNA clone IMAGE:5206119 ---
226444 at CDNA FLJ31108 fis, clone IMR322000164 -
1564220 a at CDNA FLJ39613 fis, clone SKNSH2009357
239124 at Transcribed locus
1565567 at Full length insert cDNAYN68A11
1562275 at Transcribed locus
1562612 at CDNA FLJ30250 fis, clone BRACE2002304 ---
1559822 s at CDNA FLJ33330 fis, clone BRACE2000441
1562067 at CDNA clone IMAGE:5312957 -
1560724 at CDNA FLJ33564 fis, clone BRAMY2010135
1561604 at CDNA clone IMAGE:4796102 ---
1568795 at CDNA clone IMAGE:5193442
1569127 at CDNA FLJ36537 fis, clone TRACH2004950 ---
239199 at Transcrbed locus
230651 at Transcribed locus
230535 s at Transcribed locus
Transcribed locus, strongly similar to NP_001028866.1 sterol
230805 at regulatory element binding factor 2 [Rattus norvegicus] -
236791 at Transcribed locus
229815 at CDNA clone IMAGE:4814828
236795 at Transcribed locus
236387 at CDNA FLJ36857 fis, clone ASTR02014961 ---
230408 at Transcribed locus
231311 at CDNA FLJ11417 fis, clone HEMBA1000960
231039 at Transcribed locus -
Transcribed locus, strongly similar to NP_001028866.1 sterol
231038 s at regulatory element binding factor 2 [Rattus norvegicus] -
230967 s at Transcribed locus
230401 at Transcribed locus
230407 at Transcribed locus
229757_at Transcribed locus
236958 at CDNA FLJ25271 fis, clone STM05584
229822 at Transcribed locus
236974 at CDNA clone IMAGE:5265193
229640 x at CDNA FLJ26856 fis, clone PRS08123
236952 at Transcribed locus
229907 at Homo sapiens, clone IMAGE:6176018, mRNA -
230321 at Transcribed locus
230304_at CDNA clone IMAGE:30332316
230234 at Transcribed locus
236830 at Transcribed locus
230053 at Transcribed locus
238591 at Transcribed locus ---
236528 at Transcribed locus
235268 at CDNA FLJ41128 fis, clone BRACE2018448
235211 at Transcribed locus
Transcribed locus, strongly similar to XP_001101634.1
PREDICTED: similar to tripartite motif-containing 25 [Macaca
236898 at mulatta]
236411 at Transcribed locus
235324_at Transcribed locus ---
235423_at Transcribed locus
236322_at Transcribed locus ---
Transcribed locus, weakly similar to XP_854764.1 PREDICTED:
similar to LINE-1 reverse transcriptase homolog [Canis
236194 at familiaris]
236139 at Transcribed locus ---
236106 at Transcribed locus ---
236090 at Transcribed locus ---
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235954 at Transcribed locus
MRNA; cDNA DKFZp564E202 (from clone DKFZp564E202) ///
235826 at CDNA FLJ44257 fis, clone TKIDN2015263
236384_ at CDNA FLJ32162 fis, clone PLACE6000325
232150 at CDNA clone IMAGE:4792085 -
231651 at CDNA FLJ36110 fis, clone TEST12021939
232118 at CDNA: FLJ22446 fis, clone HRC09457 -
231952 at CDNA FLJ1161 fis, clone PLACE1007021
232601 at CDNA FLJ12007 fis, clone HEMBB1001588 --
232589 at CDNA FLJ11489 fis, clone HEMBAI001915
233005 at CDNA FLJ 12602 fis, clone NT2RM4001437 --
232975 at Homo sapiens, clone IMAGE:6152133, mRNA
232790 at Homo sapiens, clone IMAGE:6058191, mRNA ---
232758 s at CDNA FLJ1 3024 fis, clone NT2RP3000865 -
229549 at Transcribed locus --
228120 at CDNA: FLJ22073 fis, clone HEP11868
229214 at CDNA FLJ 10505 fis, clone NT2RP2000503 -
229874 x at CDNA clone IMAGE:3960708
Transcribed locus, strongly similar to XP_001083198.1
228066_at PREDICTED: hypothetical protein [Macaca mulatta] --
228314 at CDNA FLJ37485 fis, clone BRAWH2014379
232700_at MRNA; cDNA DKFZp667C1 31 (from clone DKFZp667C1 31) -
Transcribed locus, strongly similar to XP_001154344.1
235487 at PREDICTED: hypothetical protein [Pan troglodytes] -
239502 at Transcribed locus -
Transcribed locus, moderately similar to XP_415798.2
PREDICTED: similar to CDNA sequence BC046404 [Gallus
236913 at gallus] --
238082 at Transcribed locus -
243831 at Transcribed locus
233174 at CDNA clone IMAGE:5288145 -
231443 at Transcribed locus
Transcribed locus, strongly similar to XP_001172939.1
228049 x at PREDICTED: hypothetical protein [Pan troglodytes] --
238156 at Transcribed locus -
227963 at Transcribed locus --
MRNA; cDNA DKFZp434N2116 (from clone DKFZp434N2116)
/// CDNA FLJ37098 fis, clone BRACE2019004 /// CDNA clone
227917 at IMAGE:5285282
Transcribed locus, strongly similar to NP_001028866.1 sterol
230980 x at regulatory element binding factor 2 [Rattus norvegicus] -
238172_at Transcribed locus
227805_at Transcribed locus
229544 at CDNA clone IMAGE:4791887 /// Transcribed locus
229129 at Transcribed locus ---
239551 at Transcribed locus
237115 at Transcribed locus
238895 at Transcribed locus
229455 at Full length insert cDNA clone YZ04E02
229366_at Transcribed locus
228944_at Transcribed locus
228955 at Transcribed locus
228539_at Transcribed locus -
237419 at Transcribed locus
228797 at Transcribed locus
228930_at MRNA full length insert cDNA clone EUROIMAGE 898037 -
239643 at CDNA FLJ37128 fis, clone BRACE2022928
228710 at Transcribed locus
217656 at Transcribed locus
228661 s at CDNA FLJ11489 fis, clone HEMBA1I0019 15
228626 at Transcribed locus -
241503_at Transcribed locus
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225008_at CDNA FLJ39064 fis, clone NT2RP7014583
241373_at Transcribed locus
241369 at CDNA FLJ32283 fis, clone PROST2000212 ---
241687 at Transcribed locus
Transcribed locus, moderately similar to NP_001099826.1 zinc
241904 at finger, ANI-type domain 5 [Rattus norvegicus] --
241892 at Transcribed locus --
224996 at CDNA FLJ39064 fis, clone NT2RP7014583 --
241792 x at CDNA FLJ33355 fis, clone BRACE2005151 --
240372_at Transcribed locus --
CDNA FLJ39067 fis, clone NT2RP7014910 /// CDNA FLJ38048
225276 at fis, clone CTONG2014264
225227 at CDNA clone IMAGE:5299642 -
236280 at Transcribed locus 
-
240908 at CDNA FLJ37304 fis, clone BRAMY2016070 --
242521 at CDNA clone IMAGE:4342162 -
242839 at Transcribed locus ---
242798 at Transcribed locus --
224755 at Transcribed locus --
242052 at CDNA FLJ31445 fis, clone NT2NE2000864 --
239973 at Transcribed locus --
225543 at MRNA full length insert cDNA clone EUROIMAGE 1674211 -
239912 at Transcribed locus --
240023at Transcribed locus -
225886 at MRNA; cDNA DKFZp434E109 (from clone DKFZp434E1O9) --
239361at Transcribed locus
240124 at Transcribed locus --
240121 x at CDNA clone IMAGE:3867353 ---
achalasia, adrenocortical insufficiency, alacrimia (Allgrove, triple-
218075_at A) AAAS
209620 s at ATP-binding cassette, sub-family B (MDR/TAP), member 7 ABCB7
201872 s at ATP-binding cassette, sub-family E (OABP), member 1 ABCEI
209246 at ATP-binding cassette, sub-family F (GCN20), member 2 ABCF2
209247 s at ATP-binding cassette, sub-family F (GCN20), member 2 ABCF2
221552 at abhydrolase domain containing 6 ABHD6
221679 s at abhydrolase domain containing 6 ABHD6
200965 s at actin binding LIM protein I ABLIMI
218405 at activator of basal transcription 1 ABT1
236514 at Acyl-CoA thioesterase 8 ACOT8
238825 at acidic repeat containing ACRC
212363 x at actin, gamma 1 ACTG1
211995 x at actin, gamma 1 ACTG1
214957 at actin-like 8 ACTL8
219623 at ARP5 actin-related protein 5 homolog (yeast) ACTR5
222147 s at ARP5 actin-related protein 5 homolog (yeast) ACTR5
222707 s at ARP8 actin-related protein 8 homolog (yeast) ACTR8
220287 at ADAM metallopeptidase with thrombospondin type I motif, 9 ADAMTS9
adenosine deaminase, tRNA-specific 2, TAD2 homolog (S.
227213 at cerevisiae) ADAT2
adenosine deaminase, tRNA-specific 2, TAD2 homolog (S.
236817 at cerevisiae) ADAT2
209320 at adenylate cyclase 3 ADCY3
210250 x at adenylosuccinate lyase ADSL
202144 s at adenylosuccinate lyase ADSL
240318 at aryformamidase AFMID
225440 at 1-acylglycerol-3-phosphate O-acyltransferase 3 AGPAT3
226783 at alanine-glyoxylate aminotransferase 2-like 2 AGXT2L2
AHA1, activator of heat shock 90kDa protein ATPase homolog 1
201491 at (yeast) AHSA1
212174 at adenylate kinase 2 AK2
201675 at A kinase (PRKA) anchor protein 1 AKAP1
201674 s at A kinase (PRKA) anchor protein 1 AKAP1
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225701 at AT-hook transcription factor AKNA
222416 at aldehyde dehydrogenase 18 family, member Al ALDH18A1
asparagine-linked glycosylation 3 homolog (S. cerevisiae, alpha-
207396 s at 1,3-mannosyltransferase) ALG3
asparagine-linked glycosylation 5 homolog (S. cerevisiae,
218203 at dolichyl-phosphate beta-glucosyltransferase) ALG5
201196_s at adenosylmethionine decarboxylase 1 AMD1
208722 s at anaphase promoting complex subunit 5 ANAPC5
211036 x at anaphase promoting complex subunit 5 ANAPC5
200098 s at anaphase promoting complex subunit 5 ANAPC5
225521 at anaphase promoting complex subunit 7 ANAPC7
eukaryotic translation initiation factor 4E binding protein 3///
219081 at ankyrin repeat and KH domain containing 1 ANKHDI / EIF4EBP3
211717 at ankyrin repeat domain 40 ANKRD40
228257_ at ankyrin repeat domain 52 /// CVWG5837 ANKRD52 /// UNQ5837
acidic (leucine-rich) nuclear phosphoprotein 32 family, member
208103 s at E ANP32E
210427 x at annexin A2 ANXA2
213503 x at annexin A2 ANXA2
201590 x at annexin A2 ANXA2
200612 s at adaptor-related protein complex 2, beta 1 subunit AP2B1
231714 s at adaptor-related protein complex 4, beta 1 subunit AP4BI
210027 s at APEX nuclease (multifunctional DNA repair enzyme) 1 APEX1
214960 at apoptosis inhibitor 5 APIS
214959 s at apoptosis inhibitor 5 API5
201687 s at apoptosis inhibitor 5 API5
201686 x at apoptosis inhibitor 5 AP15
213892 s at adenine phosphoribosyltransferase APRT
203219 s at adenine phosphoribosyltransferase APRT
1565651_at ADP-ribosylation factor I ARFI
200065 s at ADP-ribosylation factor 1 ARF1
232175 at ADP-ribosylation factor 1 ARFI
204492 at Rho GTPase activating protein 11A ARHGAP11A
218870 at Rho GTPase activating protein 15 ARHGAP15
224764 at Rho GTPase activating protein 21 ARHGAP21
203756 at Rho guanine nucleotide exchange factor (GEF) 17 ARHGEF17
225486_at AT rich interactive domain 2 (ARID, RFX-like) ARID2
201659 s at ADP-ribosylation factor-like I ARL1
201658 at ADP-ribosylation factor-like 1 ARLI
202564 x at ADP-ribosylation factor-like 2 / sorting nexin 15 ARL2 /// SNX15
223328 at armadillo repeat containing 10 ARMC10
223101 s at actin related protein 2/3 complex, subunit 5-like ARPC5L
220966 x at actin related protein 2/3 complex, subunit 5-like ARPC5L
226915 s at actin related protein 2/3 complex, subunit 5-like ARPCSL
1569132 s at Arylsulfatase family, member K ARSK
218862 at ankyrin repeat and SOCS box-containing 13 ASB13
233807 at ankyrin repeat and SOCS box-containing 7 ASB7
227015 at aspartate beta-hydroxylase domain containing 2 ASPHD2
227014 at aspartate beta-hydroxylase domain containing 2 ASPHD2
asp (abnormal spindle) homolog, microcephaly associated
219918 s at (Drosophila) ASPM
212234 at additional sex combs like 1 (Drosophila) ASXL1
234584 s at arginyltransferase 1 ATEI
221492 s at ATG3 autophagy related 3 homolog (S. cerevisiae) ATG3
1569827 at ATG7 autophagy related 7 homolog (S. cerevisiae) ATG7
201855 s at ATM interactor ATMIN
212361 s at ATPase, Ca++ transporting, cardiac muscle, slow twitch 2 ATP2A2
ATP synthase, H+ transporting, mitochondrial F1 complex,
208870 x at gamma polypeptide 1 ATP5C1
ATP synthase, H+ transporting, mitochondrial F1 complex, delta
213041 s at subunit ATPSD
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203926_x at
ATP synthase, H+ transporting, mitochondrial F1 complex, delta
subunit ATP5D
ATP synthase, H+ transporting, mitochondrial FO complex,
208972 s at subunit C1 (subunit 9) ATPSGI
ATP synthase, H+ transporting, mitochondrial FO complex,
228168_at subunit C3 (subunit 9) ATP5G3
Homo sapiens, clone IMAGE:4698842, mRNA //ATPase, class
238055 at I, type 8B, member 1 ATP8B1
238662 at ATP binding domain 4 ATPBD4
224969 at ataxin 7-like 3 ATXN7L3
208080 at aurora kinase A AURKA
218580 x at aurora kinase A interacting protein 1 AURKAIPI
225552 x at aurora kinase A interacting protein 1 AURKAIPI
225555 x at aurora kinase A interacting protein 1 AURKAIPI
227100 at beta 1,3-galactosyltransferase-like B3GALTL
209406 at BCL2-associated athanogene 2 BAG2
219667 s at B-cell scaffold protein with ankyrin repeats 1 BANK1
1558662 s at B-cell scaffold protein with ankyrin repeats 1 BANK1
218264 at BRCA2 and CDKN1A interacting protein BCCIP
227896 at BRCA2 and CDKN1A interacting protein BCCIP
202030 at branched chain ketoacid dehydrogenase kinase BCKDK
236979 at BCL2-like 15 BCL2L15
229454 at BCL2-associated transcription factor 1 BCLAF1
211715 s at 3-hydroxybutyrate dehydrogenase, type 1 BDH1
228636_at basic helix-loop-helix domain containing, class B, 5 BHLHB5
214806 at bicaudal D homolog 1 (Drosophila) BICD1
227291 s at bolA homolog 3 (E. coli) BOLA3
211566 x at brain and reproductive organ-expressed (TNFRSFIA modulator) BRE
227651 at BTB (POZ) domain containing 14B BTBD14B
205504 at Bruton agammaglobulinemia tyrosine kinase BTK
209642 at BUB1 budding uninhibited by benzimidazoles 1 homolog (yeast) BUB1
218462 at brix domain containing 5 BXDC5
217809 at basic leucine zipper and W2 domains 2 BZW2
217905 at chromosome 10 open reading frame 119 C1Oorf1I9
218590 at chromosome 10 open reading frame 2 C1Oorf2
220152 at chromosome 10 open reading frame 95 C1Oorf95
221637 s at chromosome 11 open reading frame 48 CI1orf48
221652 s at chromosome 12 open reading frame 11 C12orf11
225888 at chromosome 12 open reading frame 30 C12orf3O
219817 at chromosome 12 open reading frame 47 C12orf47
229888 at chromosome 12 open reading frame 60 C12orf6O
218420 s at chromosome 13 open reading frame 23 C13orf23
223215 s at chromosome 14 open reading frame 100 C14orf1OO
206500 s at chromosome 14 open reading frame 106 C14orf106
213398 s at chromosome 14 open reading frame 124 C14orfl24
225300 at chromosome 15 open reading frame 23 C15orf23
222745 s at chromosome 15 open reading frame 29 C15orf29
227378 x at chromosome 16 open reading frame 13 C16orf13
227380 x at Chromosome 16 open reading frame 13 C16orf13
230851 x at Chromosome 16 open reading frame 13 C16orf13
228118 x at Chromosome 16 open reading frame 13 C16orf13
228114 x at chromosome 16 open reading frame 13 C16orf13
225861 at chromosome 16 open reading frame 14 C16orf14
219709 x at chromosome 16 open reading frame 24 C16orf24
226410 at chromosome 16 open reading frame 84 C16orf84
226901 at chromosome 17 open reading frame 58 C17orf58
203830 at chromosome 17 open reading frame 75 C17orf75
223286 at chromosome 17 open reading frame 81 C17orf81
230739 at chromosome 18 open reading frame 19 C18orf19
242149 at chromosome 18 open reading frame 19 C18orf19
229
Appendix: Genes Associated with K-means Cluster 6
223977 s at chromosome 18 open reading frame 2 C18orf2
221739 at chromosome 19 open reading frame 10 C9orf1
214173 x at chromosome 19 open reading frame 2 Cl9orf2
222266 at Chromosome 19 open reading frame 2 C19orf2
211563 s at chromosome 19 open reading frame 2 C19orf2
221587 s at chromosome 19 open reading frame 24 C19orf24
227352 at chromosome 19 open reading frame 39 C19orf39
218958 at chromosome 19 open reading frame 60 C19or9
219283 at C1GALT1-specific chaperone 1 C1GALT1C1
204700 x at chromosome 1 open reading frame 107 ClorfiC7
204699 s at chromosome 1 open reading frame 107 Clorfl107
219988 s at chromosome 1 open reading frame 164 CIorfl64
203550 s at chromosome 1 open reading frame 2 C1orf2
225404 at chromosome 1 open reading frame 212 Clorf212
1555225 at chromosome 1 open reading frame 43 C1orf43
228990 at chromosome 1 open reading frame 79 CIorf79
214214 s at complement component 1, q subcomponent binding protein C1QBP
208910 s at complement component 1, q subcomponent binding protein CIQBP
232619 at chromosome 20 open reading frame 134 C20orfl34
229899 s at chromosome 20 open reading frame 199 C20orf199
218586 at chromosome 20 open reading frame 20 C20orf2O
50314 i at chromosome 20 open reading frame 27 C20orf27
218081 at chromosome 20 open reading frame 27 C20orf27
219559 at chromosome 20 open reading frame 59 C20orf59
224932 at chromosome 22 open reading frame 16 C22orf 16
219176 at chromosome 2 open reading frame 47 C2orf47
223560 s at chromosome 2 open reading frame 56 C2orf56
226891 at chromosome 3 open reading frame 21 C3orf2l
224523 s at chromosome 3 open reading frame 26 C3orf26
223193 x at chromosome 3 open reading frame 28 C3orf28
209177 at chromosome 3 open reading frame 60 C3orf6O
232066 x at chromosome 4 open reading frame 42 C4orf42
201310 s at chromosome 5 open reading frame 13 C5orf 13
221823 at chromosome 5 open reading frame 30 C5orf3O
226946 at chromosome 5 open reading frame 33 C5orf33
204238 s at chromosome 6 open reading frame 108 Ceorf108
221787 at chromosome 6 open reading frame 120 C6orf 120
221786 at chromosome 6 open reading frame 120 C6orf120
227456 s at chromosome 6 open reading frame 136 C6orf 136
227455 at chromosome 6 open reading frame 136 C6orfl36
219006 at chromosome 6 open reading frame 66 C6orf66
226386 at chromosome 7 open reading frame 30 C7orf3O
226385 s at chromosome 7 open reading frame 30 C7orf3O
226434 at chromosome 7 open reading frame 47 C7orf47
240147 at chromosome 7 open reading frame 50 C7orf5O
218565 at chromosome 9 open reading frame 114 C9orf114
224879 at chromosome 9 open reading frame 123 C9orf 123
225777 at chromosome 9 open reading frame 140 C9orf140
225403 at chromosome 9 open reading frame 23 C9orf23
225532 at Cdk5 and Abi enzyme substrate 1 CABLESI
225531 at Cdk5 and Ab enzyme substrate 1 CABLES1
210967 x at calcium channel, voltage-dependent, beta 1 subunit CACNBI
206996 x at calcium channel, voltage-dependent, beta 1 subunit CACNB1
210691 s at calcyclin binding protein CACYBP
211761 s at calcyclin binding protein CACYBP
201381 x at calcyclin binding protein CACYBP
201382 at calcyclin binding protein CACYBP
221879 at calmodulin-like 4 CALML4
230698 at calneuron 1 CALNI
200756 x at calumenin CALU
calcium/calmodulin-dependent protein kinase (CaM kinase) 11
228555 at delta CAMK2D
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230706 s at calclum/calmodulin-dependent protein kinase 11 inhibitor 2 CAMK2N2
212252 at calcium/calmodulin-dependent protein kinase kinase 2, beta CAMKK2
212512 s at coactivator-associated arginine methyltransferase 1 CARMI
212097 at caveolin 1, caveolae protein, 22kDa CAV1
chromobox homolog 3 (HP1 gamma homolog, Drosophila) ///
201091 s at similar to chromobox homolog 3 CBX3 /// LOC653972
202047 s at chromobox homolog 6 CBX6
202048 s at chromobox homolog 6 /// neuronal pentraxin receptor CBX6 / NPTXR
207006 s at coiled-coil domain containing 106 CCDC106
'229063 s at coiled-coil domain containing 107 CCDC107
1560354 at Coiled-coil domain containing 127 CCDC127
!222525 s at coiled-coil domain containing 25 CCDC25
218936 s at coiled-coil domain containing 59 CCDC59
222792 s at coiled-coil domain containing 59 CCDC59
228472 at hypothetical BC282485_1 /// coiled-coil domain containing 61 CCDC61 /// LOC388554
212886 at coiled-coil domain containing 69 CCDC69
213250 at Coiled-coil domain containing 85B CCDC85B
204610 s at coiled-coil domain containing 85B CCDC85B
226521 s at coiled-coil domain containing 98 CCDC98
214710 s at cyclin B1 CCNB1
204093 at cyclin H CCNH
224647 at cyclin Y CCNY
200877 at chaperonin containing TCP1, subunit 4 (delta) CCT4
208696 at chaperonin containing TCPI, subunit 5 (epsilon) CCT5
201326 at chaperonin containing TCP1, subunit 6A (zeta 1) CCT6A
201327 sat chaperonin containing TCPI, subunit 6A (zeta 1) CCT6A
218529 at CD320 molecule CD320
211075 s at CD47 molecule CD47
200663 at CD63 molecule CD63
201725 at cell division cycle 123 homolog (S. cerevisiae) CDC123
209659 s at cell division cycle 16 homolog (S. cerevisiae) CDC16
202870 s at ceil division cycle 20 homolog (S. cerevisiae) CDC20
201853 s at cell division cycle 25 homolog B (S. pombe) CDC25B
cell division cycle 26 homolog (S. cerevisiae) /// similar to CDC26 /// LOC729948 //
225422 at CDC26 subunit of anaphase promoting complex LOC730314
217879 at cell division cycle 27 homolog (S. cerevisiae) CDC27
209501 at cerebellar degeneration-related protein 2, 62kDa CDR2
212010 s at CDV3 homolog (mouse) CDV3
213554 s at CDV3 homolog (mouse) CDV3
204039 at CCAAT/enhancer binding protein (C/EBP), alpha CEBPA
203341 at CCAAT/enhancer binding protein zeta CEBPZ
205046 at centromere protein E, 312kDa CENPE
207828 s at centromere protein F, 350/400ka (mitosin) CENPF
214102_at centaurin, delta 1 CENTD1
224462 s at coiled-coil-helix-coiled-coil-helix domain containing 6 CHCHD6
220647 s at coiled-coil-helix-coiled-coil-helix domain containing 8 CHCHD8
204258 at chromodomain helicase DNA binding protein 1 CHD1
223061 at chitinase domain containing 1 CHIDI
1565951 s at choroideremia-like (Rab escort protein 2) CHML
226350 at choroideremia-like (Rab escort protein 2) CHML
202121 s at chromatin modifying protein 2A CHMP2A
212313 at CHMP family, member 7 CHMP7
1559739 at Choline phosphotransferase I CHPT1
203921 at carbohydrate (N-acetylglucosamine-6-0) sulfotransferase 2 CHST2
226727 at CDGSH Iron sulfur domain 3 CISD3
200999 s at cytoskeleton-associated protein 4 CKAP4
203229_ sat CDC-like kinase 2 CLK2
214252 s at ceroid-lipofuscinosis, neuronal 5 CLN5
226935 s at CLPTMI-like / hypothetical protein LOC100133849 CLPTML /// LOC100133849
227481 at CNKSR family member 3 CNKSR3
223431 at cappuccino homolog (mouse) CNO
228369 at canopy 3 homolog (zebrafish) CNPY3
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227313 at canopy 4 homolog (zeb ) sh CNPY4
201913 s at Coenzyme A synthase COASY
203073 at component of oligomeric golgi complex 2 COG2
1555953 at collagen, type XVIIl, alpha 1 COL18A1
219625 s at collagen, type IV, alpha 3 (Goodpasture antigen) binding protein COL4A3BP
223466 x at collagen, type IV, alpha 3 (Goodpasture antigen) binding protein COL4A3BP
223819 x at COMM domain containing 5 COMMD5
208818 s at catechol-O-methyltransferase COMT
208817 at catechol-O-methyltransferase COMT
COP9 constitutive photomorphogenic homolog subunit 2
209838 at (Arabidopsis) COPS2
COP9 constitutive photomorphogenic homolog subunit 4
218042 at (Arabidopsis) COPS4
221227 x at coenzyme Q3 homolog, methyltransferase (S. cerevisiae) COQ3
228931 at coenzyme Q4 homolog (S. cerevisiae) COQ4
210820 x at coenzyme Q7 homolog, ubiquinone (yeast) COQ7
221059 s at coactosin-like I (Dictyostelium) COTL1
224583 at coactosin-like 1 (Dictyostelium) COTLI
230909_at COX18 cytochrome c oxidase assembly homolog (S. cerevisiae) COX18
213735 s at cytochrome c oxidase subunit Vb COX5B
211025 x at cytochrome c oxidase subunit Vb COX5B
202470 s at cleavage and polyadenylation specific factor 6, 68kDa CPSF6
203368 at cysteine-rich with EGF-like domains 1 CRELDI
227942 s at cysteine-rich PDZ-binding protein CRIPT
225690 at Cdc2-related kinase, arginine/serine-rich CRKRS
225694 at Cdc2-related kinase, arginine/serine-rich CRKRS
226937 at Cardiolipin synthase 1 CRLS1
241741 at cardiolipin synthase 1 CRLS1
223978 s_at cardiolipin synthase 1 CRLS1
219939 s at cold shock domain containing El, RNA-binding CSDE1
222975 s at cold shock domain containing El, RNA-bindlng CSDEI
212075 s at casein kinase 2, alpha 1 polypeptide CSNK2A1
202937 x at CGI-96 protein CTA-12684.3
202521 at CCCTC-binding factor (zinc finger protein) CTCF
CTD (carboxy-terminal domain, RNA polymerase 11, polypeptide
217844 at A) small phosphatase 1 CTDSPI
222819 at CTP synthase I CTPS2
225646 at cathepsin C CTSC
201423 s at cullin 4A CUL4A
242194 at Cullin 4A CUL4A
221488 s at cutA divalent cation tolerance homolog (E. coli) CUTA
218970 s at cutC copper transporter homolog (E. coli) CUTC
217119_s at chemokine (C-X-C motif) receptor 3 CXCR3
207681_at chemokine (C-X-C motif) receptor 3 CXCR3
228752 at chromosome X open reading frame 10 CXorfl0
227520 at chromosome X open reading frame 15 CXorfi5
232463 at chromosome X and Y open reading frame 10 CXYorf10
212133 at Cytoplasmic FMR1 interacting protein I CYFIP1
223421 at cysteine/histidine-rich 1 CYHR1
231747 at cysteinyl leukotriene receptor 1 CYSLTR1
230866 at cysteinyl leukotriene receptor 1 CYSLTR1
disabled homolog 1 (Drosophila) /// OMA1 homolog, zinc
226020 s at metallopeptidase (S. cerevislae) DABI / OMA1
216038 x at death-associated protein 6 DAXX
218443 s at DAZ associated protein 1 DAZAPI
202806 at drebrin 1 DBN1
201571 s at dCMP deaminase DCTD
225971 at DDHD domain containing 1 DDHDI
214788 x at dendrin DDN
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204977 at DEAD (Asp-Glu-Ala-Asp) box polypeptide 10 DDXIO
208897s at DEAD (Asp-Glu-Ala-Asp) box polypeptide 18 DDX18
40255at DEAD (Asp-Glu-Ala-Asp) box polypeptide 28 DDX28
219641 at de-etiolated homolog 1 (Arabidopsis) DET1
203733 at dexamethasone-induced transcript DEXI
1554623 x at diacylglycerol kinase, epsilon 64kDa DGKE
1554621 at diacylglycerol kinase, epsilon 64kDa DGKE
224064 s at dehydrodolichyl diphosphate synthase DHDDS
213632 at dihydroorotate dehydrogenase DHODH
213631 x at dihydroorotate dehydrogenase DHODH
1556144 at DEAH (Asp-Glu-Ala-His) box polypeptide 30 DHX30
227335 at death inducer-obliterator 1 DIDOI
235005 at DIS3 mitotic control homolog (S. cerevisiae)-like DIS3L
201478 s at dyskeratosis congenita 1, dyskerin DKC1
201479 at dyskeratosis congenita 1, dyskerin DKC1
231954 at hypothetical protein DKFZP43410714 DKFZP43410714
214030 at hypothetical protein DKFZp667G2110 DKFZp667G2110
211150 s at dihydrolipoamide S-acetyltransferase DLAT
213149 at dihydrolipoamide S-acetyltransferase DLAT
203764 at discs, large homolog 7 (Drosophila) DLG7
200881 s at DnaJ (Hsp40) homolog, subfamily A, member 1 DNAJA1
200880 at DnaJ (Hsp4O) homolog, subfamily A, member I DNAJA1
200666 s at DnaJ (Hsp40) homolog, subfamily B, member 1 DNAJB1
223054 at DnaJ (Hsp40) homolog, subfamily B, member 11 DNAJB11
221781 s at DnaJ (Hsp40) homolog, subfamily C, member 10 DNAJCIO
229588 at DnaJ (Hsp40) homolog, subfamily C, member 10 DNAJC10
225358 at DnaJ (Hsp4O) homolog, subfamily C, member 19 DNAJC19
225359 at DnaJ (Hsp4O) homolog, subfamily C, member 19 DNAJC19
203105 s at dynamin 1-like DNM1L
38703 at aspartyl aminopeptidase DNPEP
202776 at deoxynucleotidyltransferase, terminal, interacting protein 2 DNTTIP2
225384 at dedicator of cytokinesis 7 DOCK7
dolichyl-phosphate (UDP-N-acetylglucosamine) N-
acetylglucosaminephosphotransferase 1 (GlcNAc-1-P
209509 s at transferase) DPAGT1
204514 at DPR2 homolog (S. cerevisiae) DPH2
219590 x at DPH5 homolog (S. cerevisiae) DPH5
223671 x at DPH5 homolog (S. cerevisiae) DPHS
224060 s at DPH5 homolog (S. cerevisiae) DPH5
224196 x at DPH5 homolog (S. cerevisiae) DPH5
dipeptidyl-peptidase 4 (CD26, adenosine deaminase complexing
203716 s at protein 2) DPP4
dipeptidyl-peptidase 4 (CD26, adenosine deaminase complexing
203717 at protein 2) DPP4
238012 at Dipeptidyl-peptidase 7 DPP7
1560916_aat dpy-19-like 1 (C. elegans) DPY19L1
225633 at dpy-19-like 3 (C. elegans) DPY19L3
201537 saat dual specificity phosphatase 3 DUSP3
dishevelled, dsh homolog 1 (Drosophila) // hypothetical
203230 at LOC642469 DVL1 /// LOC642469
222479 s at dynein, cytoplasmic 1, light intermediate chain I DYNC11
202969 at dual-specificity tyrosine-(Y)-phosphorylation regulated kinase 2 DYRK2
221586s_ at E2F transcription factor 5, p130-binding E2F5
225993 at glutamyl-tRNA synthetase 2, mitochondrial (putative) EARS2
204274 at estrogen receptor binding site associated, antigen, 9 EBAG9
204278_s at estrogen receptor binding site associated, antigen, 9 EBAG9
Epstein-Barr virus Induced gene 2 (lymphocyte-specific G
205419 at protein-coupled receptor) EB12
201323 at EBNA1 binding protein 2 EBNA1BP2
223306 at emopamil binding protein-like EBPL
227103 s at endothelin converting enzyme 2 ECE2
223088 x at enoyl Coenzyme A hydratase domain containing 1 ECHDC1
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219974 xat enoyl Coenzyme A hydratase domain containing 1 ECHDC1
233124 s at enoyl Coenzyme A hydratase domain containing 1 ECHDC1
213907 at Eukaryotic translation elongation factor 1 epsilon 1 EEF1E1
204905 s at eukaryotic translation elongation factor I epsilon 1 EEFIE1
225545 at eukaryotic elongation factor-2 kinase EEF2K
210132 at ephrin-A3 EFNA3
223015 at eukaryotic translation initiation factor 2A, 65kDa EIF2A
201144 s at eukaryotic translation initiation factor 2, subunit 1 alpha, 35kDa ElF2S1
208725 at eukaryotic translation initiation factor 2, subunit 2 beta, 38kDa EIF2S2
242550 at eukaryotic translation initiation factor 3, subunit B EIF38
208264_s_at eukaryotic translation initiation factor 3, subunit J EIF3J
208985 s at eukaryotic translation initiation factor 3, subunit J E_F3J
214805 at Eukaryotic translation initiation factor 4A, isoform 1 EF4A1
211787 s at eukaryotic translation initiation factor 4A, isoform 1 EIF4A1
201530 x at eukaryotic translation initiation factor 4A, isoform 1 EF4A1
eukaryotic translation initiation factor 4E / similar to Eukaryotic EIF4E /// LOCI 00131565 //
201436 at translation initiation factor 4E /// similar to hCG1 777996 LOC100132918
208625 s at eukaryotic translation initiation factor 4 gamma, 1 ElF4G1
208707 at eukaryotic translation initiation factor 5 EIF5
213753 x at eukaryotic translation initiation factor 5A EIF5A
201122 x at eukaryotic translation initiation factor 5A EIF5A
201027_s at eukaryotic translation initiation factor 5B EIF5B
201024 x at eukaryotic translation initiation factor 5B EIF5B
201025 at eukaryotic translation initiation factor 5B EIF5B
201026 at eukaryotic translation initiation factor 58 EIF5B
219517 at elongation factor RNA polymerase ll-like 3 ELL3
219518 s at elongation factor RNA polymerase lI-like 3 ELL3
209233_at EMG1 nucleolar protein homolog (S. cerevisiae) EMG1
203729 at epithelial membrane protein 3 EMP3
212570 at endonuclease domain containing 1 ENDOD1
204142 at enolase superfamily member I ENOSFI
204143 s at enolase superfamily member 1 ENOSF1
209474 s at ectonucleoside triphosphate diphosphohydrolase I ENTPD1
228585 at ectonucleoside triphosphate diphosphohydrolase I ENTPDI
207691 x at ectonucleoside triphosphate diphosphohydrolase I ENTPD1
1555358 a at ectonucleoside triphosphate diphosphohydrolase 4 ENTPD4
228259 s at erythrocyte membrane protein band 4.1 like 4A EPB4IL4A
epilepsy, progressive myoclonus type 2A, Lafora disease
205231 s at (laforin) EPM2A
209962_at erythropoietin receptor EPOR
excision repair cross-complementing rodent repair deficiency,
complementation group 1 (includes overlapping antisense
203720_s at sequence) ERCC1
218135 at ERGIC and golgi 2 ERGIC2
240172 at ERGIC and golgi 2 ERGIC2
221542 s at ER lipid raft associated 2 ERLIN2
222646 s at ERO1-like (S. cerevisiae) ERO1 L
228162 at esterase D/formylglutathione hydrolase ESD
201573 s at eukaryotic translation termination factor 1 ETF1
201574 at eukaryotic translation termination factor I ETF1
211742 s at ecotropic viral integration site 2B EV12B
218695 at exosome component 4 EXOSC4
212627 s at exosome component 7 EXOSC7
215136 s at exosome component 8 EXOSC8
1554844_at eyes absent homolog 3 (Drosophila) EYA3
202535 at Fas (TNFRSF6)-associated via death domain FADD
220643_s at Fas apoptotic inhibitory molecule FAIM
1553743_at family with sequence similarity 119, member A FAM119A
235177 at family with sequence similarity 119, member A FAM119A
221983_at family with sequence similarity 134, member A FAM134A
202973_x at family with sequence similarity 13, memberAl FAM13A1
202916 s at family with sequence similarity 20, member B FAM20B
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[220547_s at family with sequence similarity 35, member A FAM35A
233048 at family with sequence similarity 35, member A FAM35A
243011 at family with sequence similarity 55, member C FAM55C
218898 at family with sequence similarity 57, member A FAM57A
226466 s at family with sequence similarity 58, member A FAM58A
45749 at family with sequence similarity 65, member A FAM65A
218029 at family with sequence similarity 65, member A FAM65A
213689 x at family with sequence similarity 69, member A FAM69A
216044 x at family with sequence similarity 69, member A FAM69A
227002 at family with sequence similarity 78, member A FAM78A
227756_at family with sequence similarity 81, member A FAM81A
family with sequence similarity 86, member C /// family with
sequence similarity 86, member 61 /// family with sequence
similarity 86, member A // hypothetical protein LOC348926 /
similar to CG7889-PA // hypothetical protein LOC645332 /// FAM86A /// FAM86B1 / FAM86C
family with sequence similarity 86, member D /// similar to family /// FAM86D / LOC1 00125556 /
with sequence similarity 86, member C /// hypothetical LOC348926 / LOC387745 //
222013 x at LOC100125556 LOC645332 /// LOC729375
65585 at family with sequence similarity 86, member B1 FAM86B1
212333 at family with sequence similarity 98, member A FAM98A
218689 at Fanconi anemia, complementation group F FANCF
222713 s at Fanconi anemia, complementation group F FANCF
223785 at Fanconi anemia, complementation group I FANCI
219002 at FAST kinase domains 1 FASTKDI
219200 at FAST kinase domains 3 FASTKD3
44040 at F-box protein 41 FBXO41
221945 at F-box protein 41 FBXO41
235195 at F-box and WD repeat domain containing 2 FBXW2
FCF1 small subunit (SSU) processome component homolog (S.
240928 at cerevisiae) FCF1
210889_s at Fc fragment of IgG, low affinity lIb, receptor (CD32) FCGR2B
238452 at Fc receptor-like B FCRLB
1556283 s at FGFR1 oncogene partner 2 FGFRIOP2
202041 s at fibroblast growth factor (acidic) intracellular binding protein FIBP
219522 at four jointed box 1 (Drosophila) FJXI
222485 at FK506 binding protein 3, 25kDa FKBP3
200894 s at FK506 binding protein 4, 59kDa FKBP4
200895 s at FK506 binding protein 4, 59kDa FKBP4
1560305 x at FK506 binding protein 4, 59kDa FKBP4
218610 s at hypothetical protein FLJ11151 FLJ11151
222686 s at hypothetical protein FLJ11151 FLJ11115
239135 at hypothetical protein FLJ11151 FLJI1151
228433_at hypothetical protein FLJ11236 FLJ11236
220465 at hypothetical protein FLJ12355 FLJ12355
226171 at hypothetical LOC57245 FLJ20209
211724 x at hypothetical protein FLJ20323 FLJ20323
206860s at hypothetical protein FLJ20323 FLJ20323
241367 at FLJ35767 protein FLJ35767
230999 at Hypothetical gene supported by AK096370 FLJ39051
transmembrane protein 106A / similar to transmembrane
1552302 at protein 106A FLJ77644 /// TMEM1 06A
208749 x at flotillin 1 FLOT1
210142 x at flotillin 1 FLOT1
212288 at fomin binding protein 1 FNBP1
213937 s at FtsJ homolog 1 (E. coli) FTSJI
205324 s at FtsJ homolog 1 (E. coil) FTSJ
223042 s at FUN14 domain containing 2 FUNDC2
fucosyltransferase 4 (alpha (1,3) fucosyltransferase, myeloid-
209893 s at specific) FUT4
fucosyltransferase 4 (alpha (1,3) fucosyltransferase, myeloid-
209892 at specific) FUT4
218204_s at FYVE and coiled-coil domain containing 1 FYCO1
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225007 at GTPase activating protein (SH3 domain) binding protein G3BP1
226900 at GA binding protein transcription factor, beta subunit 2 GABPB2
UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-
218313 s at acetylgalactosaminyltransferase 7 (GaINAc-T7) GALNT7
phosphoribosylglycinamide forrnyltransferase,
phosphoribosylglycinamide synthetase,
210005 at phosphoribosylaminoimidazole synthetase GART
227517 s at growth arrest-specific 5 GAS5
1560402 at growth arrest-specific 5 GASS
228238 at growth arrest-specific 5 GASS
201816 s at glioblastoma amplified sequence GBAS
208369 s at glutaryl-Coenzyme A dehydrogenase GCDH
203500 at glutaryl-Coenzyme A dehydrogenase GCDH
202923 s at glutamate-cysteine ligase, catalytic subunit GCLC
glucosaminyl (N-acetyi) transferase 2, I-branching enzyme (I
230788 at blood group) GCNT2
210627 s at glucosidase I GCS1
glycine cleavage system protein H (aminomethyl carrier) ///
213133 s at similar to Glycine cleavage system H protein, mitochondrial GCSH /// LOC730107
glycine cleavage system protein H (aminomethyl carrier) ///
213129_s at similar to Glycine cleavage system H protein, mitochondrial GCSH /// LOC730107
217099 s at gem (nuclear organelle) associated protein 4 GEMIN4
205527 s at gem (nuclear organelle) associated protein 4 GEMIN4
225712 at gem (nuclear organelle) associated protein 5 GEMIN5
219539 at gem (nuclear organelle) associated protein 6 GEMIN6
222821 s at gem (nuclear organelle) associated protein 7 GEMIN7
225161 at G elongation factor, mitochondrial 1 GFM1
219467 at gypsy retrotransposon integrase 1 GIN1
207525 s at GIPC PDZ domain containing family, member 1 GIPC1
214205 x at glutaredoxin 3 GLRX3
221932 s at glutaredoxin 5 GLRX5
228395 at Glycosyltransferase 8 domain containing I GLT8DI
guanine nucleotide binding protein (G protein), alpha z
204993 at polypeptide GNAZ
guanine nucleotide binding protein (G protein), beta polypeptide
220762 s at 1-like GNB1L
Guanine nucleotide binding protein (G protein), beta polypeptide
222034 at 2-like 1 GNB2L1
217850_at guanine nucleotide binding protein-like 3 (nucleolar) GNL3
225853_at glucosamine-phosphate N-acetyltransferase 1 GNPNAT1
217771 at golgi membrane protein 1 GOLMI
208842 s at golgi reassembly stacking protein 2, 55kDa GORASP2
glucose phosphate isomerase / similar to Glucose phosphate
208308 s at isomerase GPI /// LOC100133951
220993 s at G protein-coupled receptor 63 GPR63
206204 at growth factor receptor-bound protein 14 GRB14
212432_at GrpE-like 1, mitochondrial (E. coli) GRPEL1
212434 at GrpE-like 1, mitochondrial (E. coli) GRPEL1
201520_s at G-rich RNA sequence binding factor 1 GRSF1
215438 x at GI to S phase transition 1 GSPT1
201912_s at G1 to S phase transition 1 GSPT1
213357 at general transcription factor IIH, polypeptide 5 GTF2H5
210620 s at general transcription factor IIIC, polypeptide 2, beta 110kDa GTF3C2
218238 at GTP binding protein 4 GTPBP4
203314 at GTP binding protein 6 (putative) GTPBP6
221942_s at guanylate cyclase 1, soluble, alpha 3 GUCY1A3
211555 s at guanylate cyclase 1, soluble, beta 3 GUCY1B3
213621 s at Guanylate kinase I GUK1
200075^s at guanylate kinase 1 GUK1
211998 at H3 histone, family 3A /// H3 histone, family 38 (H13.3B) H3F3A /// H3F3B
217232 x at hemoglobin, beta HBB
206834 at hemoglobin, beta /// hemoglobin, delta HBB /// HBD
I
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20230s0th t Bn viru xen irn onH202300 at hepatitis B virus x interacting protein HBXIP
202299 s at hepatitis B virus x interacting protein HBXIP
45714 at host cell factor C1 regulator 1 (XPO1 dependent) HCFC1R1
major histocompatibility complex, class 11, DQ beta 1 / major
histocompatibility complex, class 11, DQ beta 2 /// major
histocompatibility complex, class 11, DR beta I / major
histocompatibility complex, class lI, DR beta 2 (pseudogene) ///
major histocompatibility complex, class 11, DR beta 31// major
histocompatibility complex, class 11, DR beta 4 //major
histocompatibility complex, class 11, DR beta 51// ribonuclease, hCG-1998957 / HLA-DQB1 ///
RNase A family, 2 (liver, eosinophil-derived neurotoxin) /// zinc HLA-DQB2 / HLA-DRB1 /// HLA-
finger protein 749 /// hypothetical protein LOC730415 / similar DRB2 /// HLA-DRB3 /// HLA-DRB4
to Major histocompatibility complex, class 11, DR beta 4 /// similar /// HLA-DRB5 / LOCI 00133484 /
to major histocompatibility complex, class 11, DQ beta 1 /// similar LOC100133583 / LOC100133661
to HLA class Il histocompatibility antigen, DR-W53 beta chain /// /// LOC100133811 / LOC730415
212998 x at similar to hCG1992647 /// RNASE2 // ZNF749
hCG_2004593 / LOC100129657
ribosomal protein L17 /// similar to hCG24487 / similar to /// LOCI 00132742 /// LOC442232
hCG39912 /// ribosomal protein Li 7-like / similar to /// LOC643863 / LOC727984 ///
hCG1641837 /// hypothetical protein LOC100129657 / LOC729340 / LOC729349 /
214291_at hypothetical protein LOC100132742 RPL17
229989 at hypothetical protein BC006136 hCG 2033039
203259_s_at HD domain containing 2 HDDC2
hepatoma-derived growth factor (high-mobility group protein 1-
200896 x at like) HDGF
223155_at haloacid dehalogenase-like hydrolase domain containing 2 HDHD2
218594 at HEAT repeat containing 1 HEATR1
218595 s at HEAT repeat containing 1 HEATR1
228351 at HEAT repeat containing 1 HEATRI
203430 at heme binding protein 2 HEBP2
202815 s at hexamethylene bis-acetamide Inducible I HEXIM1
histone cluster 1, H2bg /// histone cluster 1, H2bf / histone HIST1H2BC /// HIST1H2BE /
cluster 1, H2be /// histone cluster 1, H2bi /// histone cluster 1, HIST1 H2BF / HIST1 H2BG //
208527_x at H2bc HIST1 H2BI
208546 x at histone cluster 1, H2bh HIST1H2BH
222305 at hexokinase 2 HK2
202934 at hexokinase 2 HK2
213537 at major histocompatibility complex, class 11, DP alpha 1 HLA-DPAI
211656 x at major histocompatibility complex, class 11, DO beta I HLA-DQB1
211654 x at major histocompatibility complex, class 11, DQ beta 1 HLA-DQB1
209823 x at major histocompatibility complex, class 11, DO beta 1 HLA-DQBi
216548 x at high-mobility group (nonhistone chromosomal) protein 4-like HMG4L
208025 s at high mobility group AT-hook 2 HMGA2
217755 at hematological and neurological expressed 1 HNI
222396 at hematological and neurological expressed 1 HNI
201054 at heterogeneous nuclear ribonucleoproteinAO HNRNPAO
201055 s at heterogeneous nuclear ribonucleoprotein AO HNRNPAO
229083 at heterogeneous nuclear ribonucleoprotein AO HNRNPAO
225107 at heterogeneous nuclear ribonucleoproteln A2/B1 HNRNPA2BI
NDRG family member 3 / heterogeneous nuclear
221082_s at ribonucleoprotein A3 pseudogene 2 HNRNPA3P2 /// NDRG3
heterogeneous nuclear ribonucleoprotein D (AU-rich element
221480 at RNA binding protein 1, 37kDa) HNRNPD
208990 s at heterogeneous nuclear ribonucleoprotein H3 (2H9) HNRNPH3
210588 x at heterogeneous nuclear ribonucleoprotein H3 (2H9) HNRNPH3
207127 s at heterogeneous nuclear ribonucleoprotein H3 (2H9) HNRNPH3
232004 at heterogeneous nuclear ribonucleoprotein R HNRNPR
heterogeneous nuclear ribonucleoprotein U (scaffold attachment
235603 at factor A) HNRNPU
heterogeneous nuclear ribonucleoprotein U (scaffold attachment
225805_at factor A) HNRNPU
209068 at heterogeneous nuclear ribonucleoprotein D-like HNRPDL
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212454 x at Heterogeneous nucla rbncorten D-like r1IMrruL
226651 at homer homolog 1 (Drosophila) HOMER1
229332 at 4-hydroxyphenylpyruvate dioxygenase-like HPDL
218091 at HIV-1 Rev binding protein HRB
200942 s at heat shock factor binding protein 1 HSBPI
213540 at hydroxysteroid (17-beta) dehydrogenase 8 HSD17B8
223248 at hydroxysterold dehydrogenase like 1 HSDLI
200064 at heat shock protein 90kDa alpha (cytosolic), class B member 1 HSP90AB1
219212 at heat shock 70kDa protein 14 HSPA14
230031 at heat shock 70kDa protein 5 (glucose-regulated protein, 78kDa) HSPA5
208687 x at heat shock 70kDa protein 8 HSPA8
224187 x at heat shock 70kDa protein 8 HSPA8
202415 s at hsp70-interactlng protein HSPBP1
209327 s at hypothetical protein HSPC111 HSPC111
214011 s at hypothetical protein HSPC111 HSPCI11
203023 at hypothetical protein HSPC111 HSPC111
217774 s at hypothetical protein HSPC152 HSPC152
200806 s at heat shock 60kDa protein 1 (chaperonin) HSPD1
heat shock 6OkDa protein I (chaperonin) / similar to 60 kDa
heat shock protein, mitochondrial precursor (Hsp6O) (60 kDa
chaperonin) (CPN60) (Heat shock protein 60) (HSP-60)
(Mitochondrial matrix protein P1) (P60 lymphocyte protein)
243372 at (HuCHA60) HSPD1 /// LOC644745
205133_s at heat shock 1OkDa protein 1 (chaperonin 10) HSPE1
206944 at 5-hydroxytryptamine (serotonin) receptor 6 HTR6
218680_x_at Huntingtin interacting protein K HYPK
233746 x at Huntingtin interacting protein K HYPK
242956 at Isocitrate dehydrogenase 1 (NADP+), soluble IDH1
209100 at interferon-related developmental regulator 2 IFRD2
231929 at IKAROS family zinc finger 2 (Helios) IKZF2
217805 at interleukin enhancer binding factor 3, 90kDa ILF3
212411_at IMP4, U3 small nucleolar ribonucleoprotein, homolog (yeast) IMP4
224743 at inositol monophosphatase domain containing 1 IMPAD1
241447 at Inhibitor of growth family, member 5 INGS
228287 at inhibitor of growth family, member 5 /// similar to p28 ING5 ING5 /// LOC727773
229356 x at IN080 complex homolog 1 (S. cerevisiae) INOC1
229632 s at integrator complex subunit 10 INTSIO
237504 at integrator complex subunit 10 INTS10
218305 at importin 4 IP04
203906_at IQ motif and Sec7 domain 1 IQSECI
203907 s at IQ motif and Sec7 domain 1 IQSEC1
204562_at interferon regulatory factor 4 IRF4
212766 s at interferon stimulated exonuclease gene 20kDa-like 2 ISG2OL2
integrin, alpha 4 (antigen CD49D, alpha 4 subunit of VLA-4
213416 at receptor) ITGA4
216958 s at isovaleryl Coenzyme A dehydrogenase IVD
225311 at isovaleryl Coenzyme A dehydrogenase IVD
218750 at Josephin domain containing 3 JOSD3
214692_s at jerky homolog (mouse) JRK
216309 x at jerky homolog (mouse) JRK
37872 at jerky homolog (mouse) JRK
1554916 a at jerky homolog (mouse) JRK
1568605 at erky homolog (mouse) JRK
210434 x at umping translocation breakpoint JTB
210927 xat jumping translocation breakpoint JTB
200048 s at umping translocation breakpoint JTB
209971 x at JTV1 gene JTV1
202138 x at JTVI gene JTV1
217511 at Kazal-type serine peptidase inhibitor domain 1 KAZALD1
1568598 at Kazal-type serine peptidase inhibitor domain I KAZALD1
222471_s at potassium channel modulatory factor 1 KCMF1
242887 at potassium channel modulatory factor 1 KCMF1
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210471 s at
potassium voltage-gated channel, shaker-related subfamily, beta
member 1
223727 at Kv channel interacting protein 2 KCNIP2
244623 at potassium voltage-gated channel, KQT-like subfamily, member 5 KCNQ5
218553 s at potassium channel tetramerisation domain containing 15 KCTD15
222668 at potassium channel tetramerisation domain containing 15 KCTD15
222664 at potassium channel tetramerisation domain containing 15 KCTD15
214849 at potassium channel tetramerisation domain containing 20 KCTD20
228299 at potassium channel tetramerisation domain containing 20 KCTD20
203712 at KIAA0020 KIAA0020
224870 at KIAA0114 KIAA0114
200617 at KIAA0152 KIAA0152
212056 at KIAA0182 KIAA0182
214356 s at KIAA0368 KIAA0368
212943 at KIAA0528 KIAA0528
214231 s at KIAA0564 KIAA0564
203955 at KIAA0649 KIAA0649
215081 at KIAA1 024 KIAA1024
224502 s at KIAA1191 KIAA1191
243927 x at KIAA1429 KIAA1429
227920 at K1AA1553 KIAA1553
226588 at KIAA1 604 protein KIAA1604
236518 at KIAA1 984 KIAA1984
204709 s at kinesin family member 23 KIF23
228429 x at kinesin family member 9 KIF9
228377 at kelch-like 14 (Drosophila) KLHL14
213233 s at kelch-like 9 (Drosophila) KLHL9
karyopherin alpha 2 (RAG cohort 1, importin alpha 1)///
211762 s at karyopherin alpha-2 subunit like KPNA2 / LOC728860
221503 s at karyopherin alpha 3 (importin alpha 4) KPNA3
229570 at Laminin, alpha 5 LAMA5
212193 s at La ribonucleoprotein domain family, member 1 LARPI
210966 x at La ribonucleoprotein domain family, member 1 LARP1
208954 s at La ribonucleoprotein domain family, member 5 LARP5
222427 s at leucyl-tRNA synthetase LARS
217183 at low density lipoprotein receptor (familial hypercholesterolemia) LDLR
202067_s at low density lipoprotein receptor (familial hypercholesterolemia) LDLR
221790 s at low density lipoprotein receptor adaptor protein 1 LDLRAP1
57082 at low density lipoprotein receptor adaptor protein 1 LDLRAP1
1554589 at leukocyte receptor cluster (LRC) member 9 LENG9
Leol, Pafl/RNA polymerase il complex component, homolog (S.
235096 at cerevisiae) LEO1
208936 x at lectin, galactside-binding, soluble, 8 (galectin 8) LGALS8
208935 s at lectin, galactoside-binding, soluble, 8 (galectin 8) LGALS8
208934 s at lectin, galactoside-binding, soluble, 8 (galectin 8) LGALS8
204123 at ligase Ill, DNA, ATP-dependent LIG3
229349 at lin-28 homolog B (C. elegans) LIN28B
221264 s at TAR DNA binding protein /// hypothetical protein LOC100128223 LOCI 00128223 / TARDBP
235829 at Hypothetical protein LOC100128405 LOC100128405
1562783_at hypothetical protein LOC100128840 LOC100128840
244730 x at hypothetical protein LOC100129195 LOC100129195
1557062 at hypothetical protein LOC100129195 LOC100129195
230507 at hypothetical protein LOC100130360 LOC100130360
236059 at Similar to IGYY565 LOC100130428
239214 at Hypothetical protein LOC100130458 LOCI 00130458
226006 at similar to hCG2036585 LOC100131801
228438 at Hypothetical protein LOC100132891 LOCIO0132891
solute carrier organic anion transporter family, member 4A1 //
similar to Solute carrier organic anion transporter family, member
219911 s at 4A1 LOC1 00134295/// SLCO4A1
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225670 at hypothetical protein LOC134145 LOG134145
229742 at hypothetical LOC145853 LOC145853
225934 at hypothetical LOC148413 LOC148413
227590 at similar to RIKEN cDNA 2210021 J22 LOC150383
225657 at hypothetical LOC152217 LOC152217
232154 at hypothetical protein LOC199800 LOC199800
1558641 at hypothetical protein LOC202051 LOC202051
235587 at hypothetical protein LOC202781 LOC202781
1564651 at hypothetical protein LOC221710 LOC221710
225458 at hypothetical LOC25845 LOC25845
215617 at viral DNA polymerase-transactivated protein 6 LOC26010
229528 at hypothetical protein LOC283378 LOC283378
225749 at hypothetical protein LOC283951 LOC283951
225786 at hypothetical protein LOC284702 LOC284702
1560089 at hypothetical protein LOC286208 LOC286208
226235 at hypothetical protein LOC339290 LOC339290
231088 at Hypothetical protein LOC340544 LOC340544
225329 at hypothetical protein LOC348262 LOC348262
226236 at hypothetical LOC388789 LOC388789
ribosomal protein L5 / similar to MSTP030 /// similar to LOC388907 /// LOC647436 /
210034 s at ribosomal protein L5 RPL5
ribosomal protein L5 / small nucleolar RNA, H/ACA box 66 /// LOC388907 /// LOC647436 /
210035 s at similar to MSTP030 / similar to ribosomal protein L5 RPL5 / SNORA66
65472 at hypothetical LOC388969 LOC388969
221878 at hypothetical LOC388969 LOC388969
224602 at HCV F-transactivated protein 1 LOC401152
239247 at Hypothetical protein LOC401577 LOC401577
232052 at Hypothetical gene supported by AK128398 LOC440944
238207 at similar to CG32736-PA LOC440957
ribosomal protein S16 /// similar to Rpsl6 protein /// similar to LOC441876 /// LOC729903 ///
226130 at 40S ribosomal protein S16 RPS16
232878 at hypothetical LOC644192 LOC644192
229870 at Hypothetical protein LOC644656 LOC644656
226927 at hypothetical LOC728568 LOC728568
THAP domain containing 4 / similar to THAP domain-containing
220417 s at protein 4 LOC728944 /// THAP4
THAP domain containing 4 1/ similar to THAP domain-containing
224057 s at protein 4 LOC728944 /// THAP4
238043 at hypothetical LOC729446 LOC729446
228977 at hypothetical protein LOC729680 LOC729680
229200_at hypothetical protein LOC729810 LOC729810
230591 at hypothetical protein LOC729887 LOC729887
229099 at hypothetical protein LOC790955 LOC790955
213367 at hypothetical LOC791120 LOC791120
209017_s at Ion peptidase 1, mitochondrial LONP1
226038 at LON peptidase N-terminal domain and ring finger 1 LONRF1
201818 at lysophosphatidylcholine acyltransferase 1 LPCATI
low density lipoprotein receptor-related protein 8, apolipoprotein
208433 s at e receptor LRP8
low density lipoprotein receptor-related protein 8, apolipoprotein
205282 at e receptor LRP8
201932 at leucine rich repeat containing 41 LRRC41
1570007_at leucine rich repeat containing 8 family, member C LRRC8C
223533 at leucine rich repeat containing 8 family, member C LRRC8C
209841_s at leucine rich repeat neuronal 3 LRRN3
224512 s_ at LSM domain containing 1 LSMD1
225441 x at LSM domain containing I LSMD1
225748 at LTV1 homolog (S. cerevisiae) LTV1
218729 at latexin LXN
205859 at lymphocyte antigen 86 LY86
223414 s at Lyl antibody reactive homolog (mouse) LYAR
202626 s at v-yes-1 Yamaguchi sarcoma viral related oncogene homolog LYN
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218561 s at LYR motif containing 4 LYRM4
200901's at mannose-6-phosphate receptor (cation dependent) M6PR
226132 s at mannosidase, endo-alpha-like MANEAL
231564 at Mannosidase, endo-alpha-like MANEAL
219626 at MAP7 domain containing 3 MAP7D3
1556340 at mitogen-activated protein kinase 12 MAPK12
1556341 s at mitogen-activated protein kinase 12 MAPK12
225781 at Mitogen-activated protein kinase 9 MAPK9
202787 s at mitogen-activated protein kinase-activated protein kinase 3 MAPKAPK3
200768 S at methionine adenosyltransferase 11, alpha MAT2A
200769_s at methionine adenosyltransferase 11, alpha MAT2A
minichromosome maintenance complex component 3
220459 at associated protein antisense MCMSAPAS
minichromosome maintenance complex component 3
232740 at associated protein antisense MCM3APAS
1553759_.at minichromosome maintenance complex component 9 MCM9
212693_at MDN1, midasin homolog (yeast) MDN1
206593 s at mediator complex subunit 22 MED22
231272 at mediator complex subunit 7 MED7
209200 at myocyte enhancer factor 2C MEF2C
209199_s at myocyte enhancer factor 2C MEF2C
207480 s at Meis homeobox 2 MEIS2
209861_s at methionyl aminopeptidase 2 METAP2
227993 at methionyl aminopeptidase 2 METAP2
226744 at methyltransferase 10 domain containing METT1 OD
226631 at methyltransferase like 10 MFLNG
213783 at MFNG 0-fucosylpeptide 3-beta-N-acetylglucosaminyltransferase MFNG
204153 s at MFNG 0-fucosylpeptide 3-beta-N-acetylglucosaminyltransferase WING
mannosyl (alpha-1,6-)-glycoprotein beta-1,2-N-
211061_s at acetylglucosaminyltransferase MGAT2
224456 sat hypothetical protein MGC12982 MGC12982
224457 at hypothetical protein MGC12982 MGC12982
|231844 at hypothetical protein MGC27345 MGC27345
221286 s at hypothetical protein MGC29506 MGC29506
223565 at hypothetical protein MGC29506 MGC29506
220934 s at hypothetical protein MGC3196 MGC3196
230664 at thymosin betal5b MGC39900
211026_s at monoglyceride lipase MGLL
239001 at Microsomal glutathione S-transferase 1 MGST1
225954 s at midnolin MIDN
223411 at MIF4G domain containing MIF4GD
213188_s at MYC induced nuclear antigen MINA
213189 at MYC induced nuclear antigen MINA
1554774 at MYC induced nuclear antigen MINA
229675 at MYC induced nuclear antigen MINA
229132 at MYC induced nuclear antigen MINA
232291 at microRNA host gene (non-protein coding) I MIRHG1
224714_at MK167 (FHA domain) interacting nucleolar phosphoprotein MK1671P
220615 sat male sterility domain containing 1 MLSTD1
239108_at Male sterility domain containing 1 MLSTD1
236347_at methylmalonic acidurla (cobalamin deficiency) cbIA type MMAA
methylmalonic aciduria (cobalamin deficiency) cblC type, with
211774 s at homocystinuria MMACHC
221381 s at mortality factor 4 like 1 /// mortality factor 4 MORF4 /// MORF4Li
224561 s at mortality factor 4 like I MORF4L1
201994 at mortality factor 4 like 2 MORF4L2
230524 at mannose phosphate isomerase MPI
membrane protein, palmitoylated 6 (MAGUK p55 subfamily
205429 s at member 6) MPP6
203524 s at mercaptopyruvate sulfurtransferase MPST
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21059!at myelin protein zr-ie1 MPZL1
_r i
223154 at mitochondrial ribosomal protein L1 MRPL1
229165 at Mitochondrial ribosomal protein L12 MRPL12
203931 s at mitochondrial ribosomal protein L12 MRPL12
217980 s at mitochondrial ribosomal protein L16 MRPL16
222216s at mitochondrial ribosomal protein L17 MRPL17
203465 at mitochondrial ribosomal protein 19 MRPL19
218270 at mitochondrial ribosomal protein L24 MRPL24
208787 at mitochondrial ribosomal protein L3 MRPL3
223996 s at mitochondrial ribosomal protein L30 MRPL30
221692s at mitochondrial ribosomal protein L34 MRPL34
225255 at mitochondrial ribosomal protein L35 MRPL35
218105 s at mitochondrial ribosomal protein L4 MRPL4
230027s at mitochondrial ribosomal protein L43 MRPL43
230026 at mitochondrial ribosomal protein L43 MRPL43
224332 s at mitochondrial ribosomal protein L43 MRPL43
222555 s at mitochondrial ribosomal protein L44 MRPL44
223480_s at mitochondrial ribosomal protein L47 MRPL47
243219xat Mitochondrial ribosomal protein L50 MRPL50
225580 at mitochondrial ribosomal protein L50 MRPL50
225797 at mitochondrial ribosomal protein L54 MRPL54
227024 s at Mitochondrial ribosomal protein L55 MRPL55
225719 s at mitochondrial ribosomal protein L55 MRPL55
213840sat Mitochondrial ribosomal protein S12 MRPS12
203801 at mitochondrial ribosomal protein S14 MRPS14
226296 s at mitochondrial ribosomal protein S15 MRPS15
218982 s at mitochondrial ribosomal protein S17 MRPS17
219220 x at mitochondrial ribosomal protein S22 MRPS22
226257 x at mitochondrial ribosomal protein S22 MRPS22
228059 x at mitochondrial ribosomal protein S22 MRPS22
223448_x at mitochondrial ribosomal protein S22 MRPS22
224869 s at mitochondrial ribosomal protein S25 MRPS25
224873 s at mitochondrial ribosomal protein S25 MRPS2
218112 at mitochondrial ribosomal protein S34 MRPS34
224302 s at mitochondrial ribosomal protein S36 MRPS36
224333 s at rnitochondrial ribosomal protein S5 MRPSS
220688 s at mRNA turnover 4 homolog (S. cerevisiae) MRTO4
209928 s at musculin (activated B-cell factor-1) MSC
212708 at male-specific lethal-1 homolog MSL-1
212185 x at metallothionein 2A MT2A
Mdm2, transformed 3T3 cell double minute 2, p53 binding
1563614 at protein (mouse) binding protein, 104kDa MTBP
212248_at CDNA FLJ41088 fis, clone ASTR02002459 /// Metadherin MTDH
212250 at metadherin MTDH
219363_s at MTERF domain containing 1 MTERFD1
225346 at MTERF domain containing 3 MTERFD3
methylenetetrahydrofolate dehydrogenase (NADP+ dependent)
220346_at 2-like MTHFD2L
methylenetetrahydrofolate dehydrogenase (NADP+ dependent)
239562 at 2-like MTHFD2L
203095 at mitochondrial translational initiation factor 2 MTIF2
223356 s at mitochondrial translational initiation factor 3 MTIF3
220953 s at myotubularin related protein 12 MTMR12
214268 s at myotubularin related protein 4 MTMR4
226969 at 5-methyltetrahydrofolate-homocysteine methyltransferase MTR
242996 at mitochondrial translational release factor 1 MTRF1
223348 x at melanoma associated antigen (mutated) 1 MUMI
221290 s at melanoma associated antigen (mutated) 1 MUMI
221253 s at muted homolog (mouse) /// thioredoxin domain containing 5 MUTED /// TXNDCS
219098 at MYB binding protein (P160) la MYBBP1A
myosin, light chain 6, alkali, smooth muscle and non-muscle /
212082 s at myosin, light chain 6B, alkali, smooth muscle and non-muscle MYL6 /// MYL6B
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221826 s at MYST histone acetyltransferase 1 MYST1
234698 at N-6 adenine-specific DNA methyltransferase 1 (putative) N6AMT1
227054_at N-6 adenine-specific DNA methyltransferase 2 (putative) N6AMT2
nascent polypeptide-associated complex alpha subunit ///
nascent-polypeptide-associated complex alpha polypeptide
pseudogene 1 /// nascent polypeptide-associated complex alpha
222018 at subunit 2 NACA /// NACA2 /// NACAP1
1555041 a at N-acetylgalactosaminidase, alpha- NAGA
204360 s at N-acetylglucosaminidase, alpha- (Sanfilippo disease IllB) NAGLU
226998_at NMDA receptor regulated I NARGI
219217 at asparaginyl-tRNA synthetase 2, mitochondrial (putative) NARS2
223284_at N-acetyltransferase 14 NAT14
200610 s at nucleolin NCL
NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 3,
218563 at 9kDa NOUFA3
NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 7,
202785 at 14.5kDa NDUFA7
NADH dehydrogenase (ubiquinone) 1, alpha/beta subcomplex,
202077 at 1, 8kDa NDUFABI
NADH dehydrogenase (ubiquinone) 1 alpha subcomplex,
204125 at assembly factor 1 NDUFAF1
NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 10,
223112 s at 22kDa NDUF810
NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 10,
228301 x at 22kDa NDUFB10
NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 6,
203613 s at 17kDa NDUFB6
NADH dehydrogenase (ubiquinone) 1, subcomplex unknown, 1,
203478 at 6kDa NDUFC1
NADH dehydrogenase (ubiquinone) Fe-S protein 2, 49kDa
201966 at (NADH-coenzyme Q reductase) NDUFS2
202941 at NADH dehydrogenase (ubiquinone) flavoprotein 2, 24kDa NDUFV2
204702 s at nuclear factor (erythroid-derived 2)-like 3 NFE2L3
209289 at nuclear factor 1/B NFIB
209290 s at nuclear factor I/B NFIB
213032 at nuclear factor I/B NFIB
213029 at nuclear factor I/B NFIB
233394 at Nuclear factor I/B NFIB
201076 at NHP2 non-histone chromosome protein 2-like 1 (S. cerevisiae) NHP2L1
201077 s at NHP2 non-histone chromosome protein 2-like 1 (S. cerevisiae) NHP2L1
218133 s at NIF3 NGG1 interacting factor 3-like 1 (S. pombe) NIF3L1
219031 s at nuclear import 7 homolog (S. cerevisiae) NIP7
223397 s at nuclear import 7 homolog (S. cerevisiae) NIP7
225930 at NFKB inhibitor interacting Ras-like I NKIRAS1
203867 s at notchless homolog 1 (Drosophila) NLE1
225943 at neurolysin (metallopeptidase M3 family) NLN
225944 at neurolysin (metallopeptidase M3 family) NLN
204862 s at non-metastatic cells 3, protein expressed in NME3
212739 s at non-metastatic cells 4, protein expressed In NME4
non-metastatic cells 6, protein expressed in (nucleoside-
205851 at diphosphate kinase) NME6
223018 at NINI/RPN12 binding protein 1 homolog (S. cerevisiae) NOB1
221970 s at nucleolar protein 11 NOL11
218199 s at nucleolar protein family 6 (RNA-associated) NOL6
213838 at nucleolar protein 7, 27kDa NOL7
210097 s at nucleolar protein 7, 27kDa NOL7
202882 x at nucleolar protein 7, 27kDa NOL7
21824 at nucleolar protein 8 NOL8
nucleolar protein family A, member 1 (H/ACA small nucleolar
219110_at RNPs) NOLA1
nucleolar protein family A, member 2 (H/ACA small nucleolar
209104 s at RNPs) NOLA2
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216583 x at
nucleolar protein family A, member 2 (H/ACA small nucleolar
RNPs) NOLA2
nucleolar protein family A, member 3 (H/ACA small nucleolar
217962 at RNPs) NOLA3
211951 at nucleolar and coiled-body phosphoprotein I NOLC1
205895 s at nucleolar and coiled-body phosphoprotein 1 NOLCI
205129_at nucleophosmin/nucleoplasmin, 3 NPM3
201468 s at NAD(P)H dehydrogenase, quinone I NQO1
210531 at nuclear receptor subfamily 2, group C, member 1 NR2C1
226499 at Notch-regulated ankyrin repeat protein NRARP
211279 at nuclear respiratory factor 1 NRF1
204651 at nuclear respiratory factor 1 NRF1
204652 s at nuclear respiratory factor 1 NRF1
225592 at nurin (nuclear envelope membrane protein) NRM
215093_at NAD(P) dependent steroid dehydrogenase-like NSDHL
220248 x at NSFL1 (p97) cofactor (p47) NSFL1C
217831 s at NSFL1 (p97) cofactor (p47) NSFL1C
217830_s at NSFL1 (p97) cofactor (p47) NSFL1C
232520_s at NSFL1 (p97) cofactor (p47) NSFLIC
211376 s at non-SMC element 4 homolog A (S. cerevisiae) NSMCE4A
retinol dehydrogenase 14 (all-trans/9-cis/1 1-cis) /// 5'-
222203 s at nucleotidase, cytosolic IB NT5C1B /// RDH14
225044 at 5-nucleotidase, cytosolic Ill-like NT5C3L
209731 at nth endonuclease Ill-like 1 (E. coli) NTHL1
225439 at NudC domain containing I NUDCD1
226642 s at NudC domain containing 2 NUDCD2
223535 at nudix (nucleoside diphosphate linked moiety X)-type motif 12 NUDT12
205135 s at nuclear fragile X mental retardation protein interacting protein 1 NUFIP1
224958 at nuclear fragile X mental retardation protein interacting protein 2 NUFIP2
218622 at nucleoporin 37kDa NUP37
202153 s at nucleoporin 62kDa NUP62
202900 s at nucleoporin 88kDa NUP88
nuclear undecaprenyl pyrophosphate synthase 1 homolog (S.
225071 at cerevisiae) NUSI
nuclear undecaprenyl pyrophosphate synthase 1 homolog (S.
225070 at cerevisiae) NUSI
1554151 at oxoglutarate (alpha-ketoglutarate) dehydrogenase (lipoamide) OGDH
1554152_a_at oxoglutarate (alpha-ketoglutarate) dehydrogenase (lipoamide) OGDH
226019 at OMAI homolog, zinc metalopeptidase (S. cerevisiae) OMA1
optic atrophy 3 (autosomal recessive, with chorea and spastic
238630 at paraplegia) OPA3
219032 x at opsin3 OPN3
224392 s at opsin 3 OPN3
204853 at origin recognition complex, subunit 2-like (yeast) ORC2L
201799 s at oxysterol binding protein OSBP
219133_at 3-oxoacyl-ACP synthase, mitochondrial OXSM
1555202 a at cyclin-dependent kinase 2B-inhibitor-related protein P1 5RS
214615 at purinergic receptor P2Y, G-protein coupled, 10 P2RYIO
201064 s at poly(A) binding protein, cytoplasmic 4 (inducible form) PABPC4
platelet-activating factor acetyihydrolase, isoform Ib, gamma
203228 at subunit 29kDa PAFAH1B3
phosphoribosylaminoimidazole carboxylase,
201013 s at phosphoribosylaminoimidazole succinocarboxamide synthetase PAICS
phosphorbosylaminoimidazole carboxylase,
201014 s at phosphoribosylaminoimidazole succinocarboxamide synthetase PAICS
209063 x at poly(A) binding protein interacting protein 1 PAIP1
209064 x at poly(A) binding protein interacting protein 1 PAIP1
208875_s at p21 (CDKNIA)-activated kinase 2 PAK2
233873 x at PAP associated domain containing I PAPD1
209388 at poly(A) polymerase alpha PAPOLA
222035 s at poly(A) polymerase alpha PAPOLA
229515 at PRKC, apoptosis, WTI, regulator PAWR
I
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212825 at PAX interacting (with transcription-activation domain) protein 1 PAXIP1
pterin-4 alpha-carbinolamine dehydratase/dimerization cofactor
203557 s at of hepatocyte nuclear factor 1 alpha PCBD1
pterin-4 alpha-carbinolamine dehydratase/dimerzation cofactor
1554894 a at of hepatocyte nuclear factor 1 alpha (TCFI) 2 PCBD2
214239 x at polycomb group ring finger 2 PCGF2
213551 x at polycomb group ring finger 2 PCGF2
203793 x at polycomb group ring finger 2 PCGF2
219940 s at PCI domain containing 2 PCD2
225149 at PCI domain containing 2 PCID2
213585 s at Programmed cell death 2 PDCD2
213581 at programmed cell death 2 PDCD2
243773 at Programmed cell death 2 PDCD2
228420 at programmed cell death 2 PDCD2
204025 s at programmed cell death 2 PDCD2
224467 s at programmed cell death 2-like PDCD2L
222380 s at Aryl-hydrocarbon receptor repressor PDCD6
200980 s at pyruvate dehydrogenase (lipoamide) alpha 1 PDHA1
208911 s at pyruvate dehydrogenase (lipoamide) beta PDHB
211023 at pyruvate dehydrogenase (lipoamide) beta PDHB
208612 at protein disulfide isomerase family A, member 3 PDIA3
227033 at protein disulfide isomerase family A, member 3 PDIA3
229453 at Protein disulfide isomerase family A, member 3 PDIA3
216640 s at protein disulfide isomerase family A, member 6 PDIA6
208638 at protein disulfide isomerase family A, member 6 PDIA6
PDS5, regulator of cohesion maintenance, homolog A (S.
213983 s at cerevisiae) PDS5A
219307 at prenyl (decaprenyl) diphosphate synthase, subunit 2 PDSS2
225829_at PDZ domain containing 8 PDZD8
210825 s at phosphaidylethanolamine binding protein I PEBP1
205353 s at phosphatidylethanolamine binding protein 1 PEBP1
207621 soat phosphatidylethanolamine N-methyltransferase PEMT
203972_s at peroxisomal biogenesis factor 3 PEX3
phosphoribosylformylglycinamidine synthase (FGAR
213302 at amidotransferase) PFAS
222029 x at prefoldin subunit 6 PFDN6
210976 s at phosphofructokinase, muscle PFKM
217383 at Phosphoglycerate kinase 1 PGK1
217356 s at phosphoglycerate kinase 1 PGK1
200737 at phosphoglycerate kinase 1 PGK1
201968 s at phosphoglucomutase 1 PGMI
213227 at progesterone receptor membrane component 2 PGRMC2
200658 s at prohibitin PHB
235024 at PHD finger protein 17 PHF17
225533 at PHD finger protein 19 PHF19
223081 at PHD finger protein 23 PHF23
1555789 s at PHD finger protein 23 PHF23
228252 at PIF1 5'-to-3' DNA helicase homolog (S. cerevisiae) PIF1
209998 at phosphatidylinositol glycan anchor biosynthesis, class 0 PIGO
221689 s at phosphatidylinositol glycan anchor biosynthesis, class P PIGP
207469 s at pirin (iron-binding nuclear protein) PIR
202240 at polo-like kinase 1 (Drosophila) PLK1
204887 s at polo-like kinase 4 (Drosophila) PLK4
210183 x at pinin, desmosome associated protein PNN
203622 s at partner of NOB1 homolog (S. cerevisiae) PNOI
218229 s at pogo transposable element with KRAB domain POGK
222564 at pogo transposable element with KRAB domain POGK
205811 at polymerase (DNA directed), gamma 2, accessory subunit POLG2
223403_s at polymerase (RNA) I polypeptide B, 128kDa POLR1 B
1555837 s at polymerase (RNA) II (DNA directed) polypeptide B, 140kDa POLR2B
201803 at polymerase (RNA) II (DNA directed) polypeptide B, 140kDa POLR2B
209511 at polymerase (RNA) II (DNA directed) polypeptide F POLR2F
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219459 at polymerase (RNA) Ill (DNA directed) polypeptide B PULR3
218016 s at polymerase (RNA) III (DNA directed) polypeptide E (8OkD) POLR3E
222490 at polymerase (RNA) Ill (DNA directed) polypeptide E (80kD) POLR3E
206653 at polymerase (RNA) Ill (DNA directed) polypeptide G (32kD) POLR3G
225682 s at polymerase (RNA) IlIl (DNA directed) polypeptide H (22.9kD) POLR3H
processing of precursor 5, ribonuclease P/MRP subunit (S.
204839_at cerevisiae) POPS
220741 s at pyrophosphatase (inorganic) 2 PPA2
221649 s at peter pan homolog (Drosophila) PPAN
223568 s at phosphatidic acid phosphatase type 2 domain containing 1 B PPAPDC1B
223569 at phosphatidic acid phosphatase type 2 domain containing 1 B PPAPDC1B
200968 s at peptidylprolyl isomerase B (cyclophilin B) PPIB
200967_at peptidylprolyl isomerase B (cyclophilin B) PPIB
228469 at Peptidy prolyl isomerase D (cyclophilin D) PPID
204186_s at peptidylprolyl isomerase D (cyclophilin D) PPID
227412 at protein phosphatase 1, regulatory (inhibitor) subunit 3E PPP1 R3E
protein phosphatase 3 (formerly 2B), catalytic subunit, beta
202432 at isoform PPP3CB
protein phosphatase 3 (formerly 2B), catalytic subunit, gamma
32541 at isoform PPP3CC
peroxisome proliferator-activated receptor gamma, coactivator-
203737 s at related 1 PPRC1
paimitoyl-protein thioesterase I (ceroid-lipofuscinosis, neuronal
200975 at 1, infantile) PPTI
218009 s at protein regulator of cytokinesis 1 PRC1
37950 at prolyl endopeptidase PREP
226069 at prickle homolog 1 (Drosophila) PRICKLE1
226065 at prickle homolog 1 (Drosophila) PRICKLE1
223516 s at prickle homolog 4 (Drosophila) PRICKLE4
202741 at protein kinase, cAMP-dependent, catalytic, beta PRKACB
protein-kinase, interferon-inducible double stranded RNA
209323 at dependent inhibitor, repressor of (P58 repressor) PRKRIR
206445 s at protein arginine methyltransferase 1 PRMT1
213320 at protein arginine methyltransferase 3 PRMT3
226611 s at proline rich 6 PRR6
226610 at proline rich 6 PRR6
230436 s at Proline rich 6 PRR6
226695 at paired related homeobox 1 PRRX1
215923 s at pleckstrin and Sec7 domain containing 4 PSD4
201316 at proteasome (prosome, macropain) subunit, alpha type, 2 PSMA2
201274 at proteasome (rosome, macropain) subunit, alpha type, 5 PSMA5
200039 s at proteasome (prosome, macropain) subunit, beta type, 2 PSMB2
201400 at proteasome (prosome, macropain) subunit, beta type, 3 PSMS3
204219_s at proteasome (prosome, macropain) 26S subunit, ATPase, 1 PSMC1
201699 at proteasome (prosome, macropain) 268 subunit, ATPase, 6 PSMC6
202352_s at proteasome (prosome, macropain) 26S subunit, non-ATPase, 12 PSMD12
232284 at Proteasome (prosome, macropain) 268 subunit, non-ATPase, 6 R'SMD6
202753 at proteasome (prosome, macropain) 26S subunit, non-ATPase, 6 PSMD6
proteasome (prosome, macropain) activator subunit 3 (PA28
209853 s at gamma; KI) PSME3
proteasome (prosome, macropain) activator subunit 3 (PA28
200988 s at gamma; Ki) PSME3
233443_at proteasome (prosome, macropain) assembly chaperone 4 PSMG4
228217 s at proteasome (prosome, macropain) assembly chaperone 4 PSMG4
201896 s at proline/serine-rich coiled-coil 1 PSRCI
228020 at Pentatricopeptide repeat domain 3 PTCD3
228590 at Pentatricopeptide repeat domain 3 PTCD3
218083 at prostaglandin E synthase 2 PTGES2
224937 at prostaglandin F2 receptor negative regulator PTGFRN
223808_s_at protein tyrosine phosphatase, mitochondrial 1 PTPMT1
I
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213521 at
protein tyrosine phosphatase, non-receptor type 18 (brain-
derived)
protein tyrosine phosphatase, receptor type, C-associated
204960 at protein PTPRCAP
227718 at purine-rich element binding protein B PURB
225120 at purine-rich element binding protein B PURB
218670 at pseudouridylate synthase 1 PUSI
221277 s at pseudouridylate synthase 3 PUS3
229751 s at pseudouridylate synthase 7 homolog (S. cerevisiae)like PU$7L
219812 at poliovirus receptor related immunoglobulin domain containing PVRIG
201608 s at PWP1 homolog (S. cerevisiae) PWPi
201607 at PWP1 homolog (S. cerevisiae) PWP1
209336 at PWP2 periodic tryptophan protein hornolog (yeast) PWP2
210296 s at peroxisomal membrane protein 3, 35kDa (Zellweger syndrome) PXMP3
202148 s at pyrroline-5-carboxylate reductase 1 PYCR1
218944 at pyrroline-5-carboxylate reductase-like PYCRL
241938 at Quaking homolog, KH domain RNA binding (mouse) QKI
233089 at glutaminyl-tRNA synthase (glutamine-hydrolyzing)-like 1 QRSL1
231002 s at Rabaptin, RAB GTPase binding effector protein 1 RABEPI
225064 at rabaptin, RAB GTPase binding effector protein 1 RABEP1
1558021 at Rab9 effector protein with kelch motifs RABEPK
203150 at Rab9 effector protein with kelch motifs RABEPK
226089 at RAB, member of RAS oncogene family-like 3 RABL3
228535 at RAD1 homolog (S. pombe) RAD1
210826 x at RAD17 homolog (S. pombe) RAD17
201046 s at RAD23 homolog A (S. cerevisiae) RAD23A
223598 at RAD23 homolog B (S. cerevislae) RAD23B
218526 s at RAN guanine nucleotide release factor RANGRF
201330 at arginyl-tRNA synthetase RARS
212170 at RNA binding motif protein 12 RBM12
211686 s at RNA binding motif protein 13 RBM13
228455 at RNA binding motif protein 15 RBM15
226987 at RNA binding motif protein 15B RBM15B
218593 at RNA binding motif protein 28 RBM28
222443 s at RNA binding motif protein 8A RBM8A
215747 s at regulator of chromosome condensation 1 /I SNHG3-RCC1 RCC1 /// SNHG3-RCC1
206499 s at regulator of chromosome condensation 1 / SNHG3-RCCI RCC1 /l SNHG3-RCC1
208872_s at receptor accessory protein 5 REEP5
RER1 retention in endoplasmic reticulum 1 homolog (S.
202296 saat cerevisiae) RER1
202964 s at regulatory factor X, 5 (influences HLA class Il expression) RFX5
223267 at RNA (guanine-9-) methyltransferase domain containing 1 RG9MTD1
226989 at RGM domain family, member B RGMB
204336 s at regulator of G-protein signaling 19 RGS19
213297 at required for meiotic nuclear division 5 homolog B (S. cerevisiae) RMND5B
218497 s at ribonuclease HI RNASEHI
217984 at ribonuclease T2 RNASET2
217983 s at ribonuclease T2 RNASET2
205748 s at ring finger protein 126 RNF126
209510 at ring finger protein 139 RNF139
235536 at Ring finger protein 149 RNF149
224947 at ring finger protein 26 RNF26
205805 s at receptor tyrosine kinase-like orphan receptor 1 ROR1
216403 at Sp3 transcription factor pseudogene RPI1-114G1 .1
216962 at RPA interacting protein RPAIN
216961 s at RPA interacting protein RPAIN
221989 at ribosomal protein L10 RPL1O
214976 at ribosomal protein L13 RPL13
1565759 at Ribosomal protein Li 3 RPL1 3
229590 at ribosomal protein L13 RPL13
225541 at ribosomal protein L22-like 1 RPL22L1
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235314 at rnbosomal protein L32 pseudogene 3 RPL32P3
207585 s at ribosomal protein L36a-like RPL36AL
213459 at rbosomal protein L37a RPL37A
224738 x at ribosomal protein L7-like 1 RPL7L1
205562 at ribonuclease P/MRP 38kDa subunit RPP38
213427_at ribonuclease P/MRP 4OkDa subunit RPP40
235309 at Ribosomal protein S1Sa RPS 5A
214097 at ribosomal protein S21 RPS21
208903 at ribosomal protein S28 RPS28
221940 at RNA pseudouridylate synthase domain containing 2 RPUSD2
242297 at ras responsive element binding protein 1
214764 at ribosomal RNA processing 15 homolog (S. cerevisiae) _ _ _ __5
218307 at radical S-adenosyl methionine domain containing 1
212018 s at ribosomal Li domain containing 1 R _ _ _ _ _
Rtf1, Pafl /RNA polymerase I I complex component, homolog (S.
212302 at cerevisae)RTF
225150 s at rhotekin
211509 s at retlculon 4
1555679 a at reticulon 4 interacting protein 1 RTN4IPI
224509_s"at reticulon 4 interacting protein 1 RTN4I
219957_at RUN and EWE domain containing 2 RUFY2
225614 at serum amylold A-like 1 SAAL1
213259 s at sterile alpha and TIR motif containing 1 SARM1
226923 at seci family domain containing 2 SCFD2
236834 at seci family domain containing 2 SCFD2
218793 s at sex comb on midleg-like 1 (Drosophila) SCMLI
223221 at SCO cytochrome oxidase deficient homolog 1 (yeast) SCOl
202675 at succinate dehydrogenase complex, subunit B, iron sulfur (1p) SDHB
207707 s at SECL3 homolog (S. cerevisiae) SEC1 3
1552790 a at LEC62 homolog (S. cerevisiae) 1EC62
225352_at SEC62 homolog (S. cerevisiae) SEC62
208940 at selenophosphate synthetase 1 SEPHSI
208941 s at selenophosphate synthetase 1 SEPHSI
217977 at selenoprotein X, I SEPXI
217725 x at SERPINE1 mRNA binding protein 1 SERBP1
227369 at SERPINEI mRNA binding protein I S§ERBPI
228129 at SERPINE1 mRNA binding protein 1 SERBPI
232983 s at secretion regulating guanine nucleotide exchange factor SERGEF
214243 s at serine hydrolase-like /// serine hydrolase-like 2 SERHL IIISERHL2
209722 s at serpin peptidase inhibitor, dlade B (ovalbumnin), member 9 SERPINB9
213153 at SET domain containing l B SETD1B3
214197 s at SET domain, bifurcated I SETOBI
221263 s at splicing factor 3b, subunit 5, 1lOkDa SF3B35
splicing factor, argininelserine-rich 1 (splicing factor 2, alternate
227164 at splicing factor) ________________
212179 at splicing factor, arginine/serine-rich 18 SFRS18 ___________
200754_x at splicing factor, argininelserine-rich 2 ________________
203380 x at splicing factor, arginine/serine-rich 5 _________________
230637 at sideroflexln 4 FN
231505 s at Sideroflexin 4 SFX_____________
229236 s at sideroflexin 4 FN
225143 at sideroflexin 4 FN
224817 at 5113 and PX domains 2A S3X2
206934 at signal-regulatory protein beta 1IIRB
232891 at signal-regulatory protein delta lP
212896 at superkiller viralicidic activity 2-like 2 (S. cerevisiae) _K2_____________
210567 s at S-phase kinase-associated protein 2 (p45) SP
solute carrier family 11 (proton-coupled divalent metal ion
203123 s at transporters), member 2 C1A
solute carrier family 11 (proton-coupled divalent metal ion
203124 s at transporters), member 2 _________________
224752 at ISolute carrier family 13 (sodium/sulfate symporters), member 4 SLC13A4
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225043_at solute carrier family 15, member 4 SLC15A4
solute carrier family 16, member 1 (monocarboxylic acid
202235 at transporter 1) SLC16A1
solute carrier family 16, member 14 (monocarboxylic acid
238029 s at transporter 14) SLC16A14
solute carrier family 16, member 9 (monocarboxylic acid
227506 at transporter 9) SLC16A9
211576 s at solute carrier family 19 (folate transporter), member I SLC19A1
1555952 at Solute carrier family 19 (folate transporter), member 1 SLC19A1
202744 at solute carrier family 20 (phosphate transporter), member 2 SLC20A2
222529 at solute carrier family 25, member 37 SLC25A37
221920 s at solute carrier family 25, member 37 SLC25A37
226928_x at Solute carrier family 25, member 37 SLC25A37
226179 at solute carrier family 25, member 37 SLC25A37
242335 at solute carrier family 25, member 37 SLC25A37
219733 s at solute carrier family 27 (fatty acid transporter), member 5 SLC27A5
1553540 a at solute carrier family 29 (nucleoside transporters), member 2 SLC29A2
204717 s at solute carrier family 29 (nucleoside trans rters), member 2 SLC29A2
229065 at solute carrier family 35, member F3 SLC35F3
solute carrier family 37 (glycerol-3-phosphate transporter),
238638 at member 2 SLC37A2
224579 at solute carrier family 38, member 1 SLC38A1
227046 at solute carrier family 39 (metal ion transporter), member 11 SLC39A1I
223917 s at solute carrier family 39 (zinc transporter), member 3 SLC39A3
220984 s at solute carrier organic anion transporter family, member SA1 SLCO5A1
209259 s at structural maintenance of chromosomes 3 SMC3
204594 s'at Smith-Magenis syndrome chromosome region, candidate 7-like SMCR7L
204593 s at Smith-Magenis syndrome chromosome region, candidate 7-like SMCR7L
222270_at SMEK homolog 2, suppressor of mek1 (Dictyostellum) SMEK2
212922 s at SET and MYND domain containing 2 SMYD2
210465 s at small nuclear RNA activating complex, polypeptide 3, 50kDa SNAPC3
242790 at SNF8, ESCRT-l1 complex subunit, homolog (S. cerevisiae) SNF8
215011 at small nucleolar RNA host gene (non-protein coding) 3 SNHG3
229050 s at small nucleolar RNA host gene (non-protein coding) 7 SNHG7
228645_at small nucleolar RNA host gene (non-protein coding) 9 SNHG9
228879 at small nucleolar RNA, C/D box 104 SNORD1 04
202691 at small nuclear ribonucleoprotein D1 polypeptide 16kDa SNRPDI
207438 s at snurportin 1 SNUPN
221498 at sorting nexin family member 27 SNX27
218974 at sine oculis binding protein homolog (Drosophila) SOBP
203373 at suppressor of cytokine signaling 2 SOCS2
220129_at spermatogenesis and oogenesis specific basic helix-loop-helix 2 SOHLH2
155401_at spermatogenesis and oogenesis specific basic helix-loop-helix 2 SOHLH2
214988 s at SON DNA binding protein SON
213538 at SON DNA binding protein SON
201086 x at SON DNA binding protein SON
204432 at SRY (sex determining region Y)-box 12 SOX12
225134 at SPRY domain containing 3 SPRYD3
225095 at Serine palmitoyltransferase, long chain base subunit 2 SPTLC2
227752 at serine palmitoyltransferase, long chain base subunit 3 SPTLC3
239004 at Sequestosome 1 SQSTMI
212058 at U2-associated SR140 protein SR140
236431 at U2-associated SR1 40 protein SR140
201516 at spermidine synthase SRM
208801 at signal recognition particle 72kDa SRP72
219204_s at serine racemase SRR
225252,at sulfiredoxin 1 homolog (S. cerevisiae) SRXNI
218283 at synovial sarcoma translocation gene on chromosome 18-like 2 SS18L2
201138 s at Slogren syndrome antigen B (autoantigen La) SSB
201139 s at Sjogren syndrome antigen B (autoantigen La) SSB
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202591 s at single-stranded DNA binding Drotein 1 SSBP1
signal sequence receptor, gamma (translocon-associated protein
217790 s at gamma) SSR3
signal sequence receptor, gamma (translocon-associated protein
222411 s at gamma) SSR3
Signal sequence receptor, gamma (translocon-associated
237817 at protein gamma) SSR3
203114 at Sjogren syndrome/scleroderma autoantigen I SSSCA1
SSU72 RNA polymerase Il CTD phosphatase homolog (S.
227244 s at cerevisiae) SSU72
229336 at ST3 beta-galactoside alpha-2,3-sialyltransferase 2 ST3GAL2
205346 at ST3 beta-galactoside alpha-2,3-sialyltransferase 2 ST3GAL2
ST6 (alpha-N-acetyl-neuraminyl-2,3-beta-galactosyl-1,3)-N-
220937 s at acetylgalactosaminide alpha-2,6-sialyltransferase 4 ST6GALNAC4
ST6 (alpha-N-acetyl-neuraminyl-2,3-beta-galactosyl-1,3)-N-
228163 at acetylgalactosaminide alpha-2,6-sialyltransferase 4 ST6GALNAC4
242943 at ST8 alpha-N-acetyl-neuraminide alpha-2,8-sialyltransferase 4 ST8SIA4
227607 at STAM binding protein-like 1 STAMBPL1
227606 s at STAM binding protein-like 1 STAMBPLI
220803 at STAM binding protein-like 1 STAMBPL1
signal transducer and activator of transcription 6, interleukin-4
201331 s at induced STAT6
227179 at staufen, RNA binding protein, homolog 2 (Drosophila) STAU2
stress-induced-phosphoprotein 1 (Hsp70/Hsp9O-organizing
213330 s at protein) STIP1
205214 at serine/threonine kinase 17b STK17B
STT3, subunit of the oligosaccharyltransferase complex,
238303 at homolog B (S. cerevisiae) STT3B
1553030 a at sulfite oxidase SUOX
204067 at sulfite oxidase SUOX
201483 s at suppressor of Ty 4 homolog 1 (S. cerevisiae) SUPT4H1
201484 at suppressor of Ty 4 homolog 1 (S. cerevisiae) SUPT4H1
222979 s at surfeit 4 SURF4
222978 at surfeit 4 SURF4
226068 at spleen tyrosine kinase SYK
217834 s at synaptotagmin binding, cytoplasmic RNA interacting protein SYNCRIP
213854 at synaptogyrin 1 SYNGRI
210613 s at synaptogyrin 1 SYNGRI
244307 s at Synaptotagmin XV SYT15
225455 at transcriptional adaptor 1 (HFII homolog, yeast)-like TADAI L
229723_at T-cell activation RhoGTPase activating protein TAGAP
243376 at TRAF family member-associated NFKB activator TANK
225973 at transporter 2, ATP-binding cassette, sub-family B (MDR/TAP) TAP2
201263 at threonyl-tRNA synthetase TARS
226173 at TBC1 domain family, member 25 TBC1 D25
216194 s t tubulin folding cofactor B TBCB
211759 x at tubulin folding cofactor B TBCB
201804 x at tubulin folding cofactor B TBCB
203714 s at tubulin folding cofactor E TBCE
212685 s at transducin (beta)-like 2 TBL2
209820_s_at transducin (beta)-like 3 TBL3
transcription factor 3 (E2A immunoglobulin enhancer binding
209153 s at factors E12/E47) TCF3
transcription factor 3 (E2A immunoglobulin enhancer binding
209151 x at factors E12/E47) TCF3
transcription factor 3 (E2A immunoglobulin enhancer binding
213730 x at factors E12/E47) TCF3
transcription factor 3 (E2A immunoglobulin enhancer binding
210776 x at factors E12/E47) TCF3
222146 s at transcription factor 4 TCF4
203753 at transcription factor 4 TCF4
208778 s at t-complex 1 TCP1
I
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1557945 at T-complex-associated-testis-expressed 3 TUTE3
219715 s at tyrosyi-DNA phosphodiesterase 1 TDP1
214028 x at tudor domain containing 3 TDRD3
208089 s at tudor domain containing 3 TDRD3
218104 at testis expressed 10 TEX10
1558702 at Testis expressed 10 TEX10
218605 at transcription factor B2, mitochondrial TFB2M
1554493 s at thyroid adenoma associated THADA
230380 at THAP domain containing, apoptosis associated protein 2 THAP2
229253 at thioesterase superfamily member 4 THEM4
219800 s at threonine synthase-like 1 (S. cerevisiae) THNSL1
222931 s at threonine synthase-like 1 (S. cerevisiae) THNSL1
209418 s at THO complex 5 THOC5
218540 at thiamine triphosphatase THTPA
218491 s at thymocyte nuclear protein 1 THYN1
1553099 at tigger transposable element derived I TIGDI
translocase of inner mitochondrial membrane 13 homolog
218188_s at (yeast) TIMM13
translocase of inner mitochondrial membrane 17 homolog A
201821 s at (yeast) TIMM17A
translocase of inner mitochondrial membrane 17 homolog B
203342 at (yeast) TIMM17B
223751 x at toll-like receptor 10 TLR10
201078 at transmembrane 9 superfamily member 2 TM9SF2
222845 x at transmembrane BAX inhibitor motif containing 4 TMBIM4
227353_at transmembrane channel-like 8 TMC8
226467at transmembrane and coiled-coil domains 7 TMC07
242263 at Transmembrane emp24 protein transport domain containing 5 TMED5
223334 at transmembrane protein 126A TMEM126A
221622 s at transmembrane protein 126B TMEM126B
202475 at transmembrane protein 147 TMEM147
43977_at transmembrane protein 161A TMEM161A
218897 at transmembrane protein 177 TMEM177
204676 at transmembrane protein 186 TMEM186
225052 at transmembrane protein 203 TMEM203
222642 s at transmembrane protein 33 TMEM33
218465 at transmembrane protein 33 TMEM33
222896 at transmembrane protein 38A TMEM38A
218073 s at transmembrane protein 48 TMEM48
234672 s at transmembrane protein 48 TMEM48
225182_at transmembrane protein 50B TMEM50B
219448 at transmembrane protein 70 TMEM70
223043 at transmembrane protein 85 TMEM85
226322 at transmembrane and tetratricopeptide repeat containing 1 TMTC1
translocase of outer mitochondrial membrane 20 homolog
200662 s at (yeast) TOMM20
translocase of outer mitochondrial membrane 22 homolog
217960 s at (yeast) TOMM22
translocase of outer mitochondrial membrane 40 homolog
202264 s at (yeast) TOMM40
238065 at tropomyosin 3 TPM3
225360 at TraB domain containing TRABD
204352 at TNF receptor-associated factor 5 TRAF5
225870 s at trafficking protein particle complex 5 TRAPPCS
206308 at tRNA aspartic acid methyltransferase 1 TRDMT1
202479 s at tribbles homolog 2 (Drosophila) TRIB2
203148 s at tripartite motif-containing 14 TRIM14
204341 at tripartite motif-containing 16 TRIM16
212118 at tripartite motif-containing 27 TRIM27
204033,at thyroid hormone receptor interactor 13 TRIP13
219299 at tRNA methyltransferase 12 homolog (S. cerevisiae) TRMT12
222754 at tRNA nucleotidyl transferase, CCA-adding, 1 TRNT1
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2289J97 at tRNA selenocystein asoitd 1rt I TRSPAP1
215111 s at TSC22 domain family, member i TSC22D1
219581 at tRNA splicing endonuclease 2 homolog (S. cerevisiae) TSEN2
244391 at tRNA splicing endonuclease 2 homolog (S. cerevisiae) TSEN2
214332 s at Ts translation elongation factor, mitochondrial TSFM
212656 at Ts translation elongation factor, mitochondrial TSFM
223282 at teashirt zinc finger homeobox 1 TSHZ1
201504 s at translin TSN
218156 s at TSR1, 20S rRNA accumulation, homolog (S. cerevisiae) TSR1
221987 s at TSRI, 20$ rRNA accumulation, homolog (S. cerevisiae) TSRI
36936 at tissue specific transplantation antigen P35B TSTA3
201644 at tissue specific transplantation antigen P35B TSTA3
217964 at tetratricopeptide repeat domain 19 TTC19
218710 at tetratricopeptide repeat domain 27 TTC27
203584 at tetratricopeptide repeat domain 35 TTC35
216251 s at tubulin tyrosine ligase-like family, member 12 TTLL12
1552257 a at tubulin tyrosine ligase-like family, member 12 TTLL12
213646_ x at tubulin, alpha 1b TUBAIB
211058 x at tubulin, alpha lb TUBA1B
201090 x at tubulin, alpha lb TUBAIB
209251_x_at tubulin, alpha 1c TUBA1C
211750 x at tubulin, alpha 1c TUBA1C
209026_x at tubulin, beta TUBB
211714 x at tubulin, beta TUBB
230690 at tubulin, beta I TUBB1
226784 at TWIST neighbor TWISTNB
220495 s at thioredoxin domain containing 15 TXNDC15
238802 at trypsin domain containing 1 TYSNDI
214695_at ubiquitin associated protein 2-like UBAP2L
202954 at ubiquitin-conjugating enzyme E2C UBE2C
210024 s at ubiquitin-conjugating enzyme E2E 3 (UBC4/5 homolog, yeast) UBE2E3
217823 s at ubiquitin-conjugating enzyme E2, J1 (UBC6 homolog, yeast) UBE2J1
217824 at ubiquitin-conjugating enzyme E2, J1 (UBC6 homolog, yeast) UBE2J1
222435 s at ubiquitin-conjugating enzyme E2, J1 (UBC6 homolog, yeast) UBE2JI
225179 at ubiquitin-conjugating enzyme E2K (UBC1 homolog, yeast) UBE2K
200684 s at ubiquitin-conjugating enzyme E2L 3 UBE2L3
201524_x at ubiquitin-conjugating enzyme E2N (UBC13 homolog, yeast) UBE2N
201523_x_at ubiquitin-conjugating enzyme E2N (UBC13 homolog, yeast) UBE2N
1554794 a at ubiquitin protein ligase E3C UBE3C
201535_at ubiguitin-like 3 UBL3
221746_at ubiquitin-like 4A UBL4A
218011 at ubiquitin-like 5 UBL5
222989 s at ubiquilin 1 UBQLN1
222991 s at ubiquilin i UBQLN1
224513 s at ubiquilin 4 UBQLN4
223012_ at UBX domain containing 1 UBXDi
220757 s at UBX domain containing 1 UBXD1
212008 at UBX domain containing 2 UBXD2
215983 s at UBX domain containing 6 UBXD6
220083 x at ubiquitin carboxyl-terminal hydrolase L5 UCHL5
219960 s at ubiquitin carboxyl-terminal hydrolase L5 UCHL5
209825_s at uridine-cytidine kinase 2 UCK2
240280 at UFM1-specific peptidase 1 (non-functional) UFSP1
205480 s at UDP-glucose pyrophosphoryase 2 UGP2
230210 at unc-84 homolog A (C. elegans) _UNC84A
214879 x at upstream transcription factor 2, c-fos interacting USF2
212381 at ubiquitin specific peptidase 24 USP24
226669 at ubiquitin specific peptidase 42 USP42
222032 s at ubiquitin specific peptidase 7 (herpes virus-associated) USP7
201498 at ubiquitin specific peptidase 7 (herpes virus-associated) USP7
201499 s at ubiquitin specific peptidase 7 (herpes virus-associated) USP7
205138 s at uronyl-2-sulfotransferase UST
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205139 s at uronvl-2-sulfotransferase
UTP15, U3 small nucleolar ribonucleoprotein, homolog (S.
228050 at cerevisiae) UTP15
UTP6, small subunit (SSU) processome component, homolog
218715_at (yeast) UTP6
229492 at vang-like 1 (van gogh, Drosophila) VANGL1
208649 s at valosin-containing protein VCP
217949 s at vitamin K epoxide reductase complex, subunit I VKORC1
1553679 s at vitamin K epoxide reductase complex, subunit 1-like 1 VKORC1 Li
224881 at vitamin K epoxide reductase complex, subunit 1-like I VKORC1LI
204376 at Vpr (HIV-1) binding protein VPRBP
220068 at pre-B lymphocye gene 3 VPREB3
218679 s at vacuolar protein sorting 28 homolog (S. cerevisiae) VPS28
222478 at vacuolar protein sorting 36 homolog (S. cerevisiae) VPS36
218423 x at vacuolar protein sorting 54 homolog (S. cerevisiae) VPS54
233656 s at vacuolar protein sorting 54 homolog (S. cerevisiae) VPS54
Vesicle transport through interaction with t-SNAREs homolog 1A
242356 at (yeast) VT11A
212264 s at wings apart-like homolog (Drosophila) WAPAL
218766 s at tryptophanyl tRNA synthetase 2, mitochondrial WARS2
222093 s at WW domain binding protein I /// zinc finger HIT type 4 WBP1 /// ZNHIT4
221247 s at Williams-Beuren syndrome chromosome region 16 WBSCR16
218512 at WD repeat domain 12 WDR12
209461 x at WD repeat domain 18 WDR18
226938 at WD repeat domain 21A WDR21A
214758 at WD repeat domain 21A WDR21A
201886 at WD repeat domain 23 WDR23
218882 s at WD repeat domain 3 WDR3
241937 s at Dpeat domain 4 WDR4
209592 s at WD repeat domain 68 WDR68
2217 44at WD repeat domain 68 WDR68
218278 at WD repeat domain 74 WDR74
221712 s at WD repeat domain 74 WDR74
224721 at WD repeat domain 75 WDR75
201421 s at WD repeat domain 77 WDR77
201420 s at WD repeat domain 77 WDR77
225676 s at WD repeats and SOF1 domain containing WDSOFI
242304 at within bgcn homolog (Drosophila) WIBG
213085 s at WW and C2 domain containing 1 WWC1
228820 at X-prolyl aminopeptidase (aminopeptidase P) 3, putative XPNPEP3
223055 s at exportin 5 XPO5
212166_at exportin 7 XPO7
X-ray repair complementing defective repair in Chinese hamster
200792 at cells 6 (Ku autoantigen, 70kDa) XROC6
218470 at tyrosyl-tRNA synthetase 2, mitochondrial YARS2
227042 at YdjC homolog (bacterial) YDJC
65086 at Yipl domain family, member 2 YIPF2
221939 at Yipi domain family, member 2 YIPF2
224711 at YY1 transcription factor YY1
226284 at zinc finger and BTB domain containing 2 ZBTB2
1553858 at zinc finger and BTB domain containing 3 ZBTB3
220118 at zinc finger and BTB domain containing 32 ZSTB32
226500 at zinc finger and BTB domain containing 47 ZBTB47
227430 at zinc finger CCCH-type containing 10 ZC3 H 10
227536 at zinc finger CCCH-type containing 13 ZC3HI3
201595s at zinc finger CCCH-type containing 15 ZC3HI5
225634 at zinc finger CCCH-type, antiviral 1 ZC3HAV1
219062s at zinc finger, CCHC domain containing 2 ZCCHC2
222730 s at zinc finger, DHHC-type containing 2 ZDHHC2
1563502 at Zinc finger, DHHC-type containing 2 ZDHHC2
210291 s at zinc finger protein 174 ZNF174
210290 at zinc finger protein 174 ZNF174
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Probeset ID Gene Name Gene Symbol
218005 -at zinc finger protein 22 (KOX 15) ZNF22
218149 s at zinc finger protein 395 ZNF395
1557616 at zinc finger protein 496 ZNF496
55872 at zinc finger protein 512B ZNF512B
220748 s at zinc finger protein 580 ZNF580
223389 s at zinc finger protein 581 ZNF581
204175 at zinc finger protein 593 ZNF593
222623 s at zinc finger protein 639 ZNF639
225266 at Zinc finger protein 652 ZNF652
232780 s at zinc finger protein 691 ZNF69I
39891 at zinc finger protein 710 ZNF710
213659 at zinc finger protein 75 (D8C6) ZNF75
239204 at zinc finger protein 75a ZNF75A
78495 at zinc finger protein 783 ZNF783
221876 at zinc finger protein 783 ZNF783
226323 at zinc finger protein 830 ZNF830
227734_s at zinc finger, HIT type 2 ZNHIT2
214232 at
220450 at
217503 at
216142 at
219881 s at
244425 at
210098 s at
1554766 s at
1555852 at
238920_at
1565689 at
226348 at
230714 s at
231401 s at
237618 at
227793 at
231085 s at
229131 at
225108 at
240247 at
240552 at
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zz s at Transcribed locus
230728 at Transcribed locus --
229885 at Transcribed locus
230403 at CDNA FLJ45905 fis, clone OCBBF3026576
226297 at CDNA clone IMAGE:4799578
230248 x at Transcribed locus
242233 at Transcribed locus
225923 at CDNA FLJ41394 fis, clone BRCAN2026197 -
235162 at Transcribed locus
Transcribed locus, strongly similar to XP_001157267.1
244600 at PREDICTED: hypothetical protein [Pan troglodytes] -
Transcribed locus, strongly similar to XP_001102524.1
235229_at PREDICTED: similar to Olfactory receptor 211 [Macaca mulatta] -
242705 x at Full length insert cDNA clone YT86EO1 --
233729 at CDNA FLJ11677 fis, clone HEMBA1004778
236160 at Transcribed locus
236117 at Transcribed locus
235975 at Transcribed locus
235363 at Transcribed locus
236385 at Transcribed locus -
235609 at Transcribed locus
242881 x at Clone HLS_ IMAGE_626842 mRNA sequence --
244811 at MRNA; cDNA DKFZp779F0411 (from clone DKFZp9F0411 -
231431 s at CDNA clone IMAGE:4798730
244663 at Transcribed locus
239476_at CDNA FLJ36491 fis, clone THYMU2018197 ---
226191 at MRNA; cDNA DKFZp686L15210 (from clone DKFZp686LI5210)
232257 s at CDNA FLJ12583 fis, clone NT2RM4001160
226183 at MRNA; cDNA DKFZp686tLi210 (from clone DKFZp686LI5210) -
221625 at CDNA FLJ46609 fis, clone TKIDN2010200 -
227579 at CDNA FLJ35001 fis, clone OCBBF2011887
227462 at Transcribed locus ---
241202 at Transcribed locus
238548 at Transcribed locus ---
241407 at CDNA FU11682 fis, clone HEMBA1004880
227955_s at CDNA: FLJ22256 fis, clone HRC02860 ---
227897 at Transcribed locus
241371 at Transcribed locus ---
227031 at Transcribed locus
240232 at Transcribed locus ---
243260 x at CDNA FLJ31557 fis, clone NT2R12001307
224769 at CDNA clone IMAGE:5263531 ---
226391 at CDNA FLJ36704 fis, clone UTERU2009335 -
229498 at Transcribed locus ---
229460 at CDNA FLJ37917 fis, clone CTONG1 000137 -
229380 at Transcribed locus
239178 at CDNA FLJ38252 Ifs, clone FCBBF3000269
243491 at Transcribed locus
243489_at Transcribed locus
238963 at MRNA full length insert cDNA clone EUROIMAGE 1652049 -
225567 at CDNA clone IMAGE:4798730
243514 at Transcribed locus
239760 at CDNA FLJ30257 fis, clone BRACE2002467 -
228471 at CDNA FLJ 11570 fis, clone HEMBA1 003309 ---
230208 at Transcribed locus
233591 at CDNA: FLJ23098 fis, clone LNG07440 -
Transcribed locus, strongly similar to NP_742120.1 ciliary rootlet
235947 at coiled-coil, rootletin [Mus musculus] ---
237311 at Transcribed locus 
_ _---
1562996 at CDNA clone IMAGE:5303317 
-
255
Appendix: Genes Associated with K-means Cluster 7
244147 at Transcribed locus
242909 at Transcribed locus
230772 at Transcribed locus --
1565549 at CDNA FLJ10978 fis, clone PLACE1001484 -
239509 at Transcribed locus
227498 at CDNA FLJ11723 fis, clone HEMBA1005314
224811 at CDNA FLJ30652 fis, clone DFNES2000011 -
237582 at Transcribed locus
232538 at CDNA: FLJ23573 fis, clone LNG12520 ---
231924 at CDNA FLJ10570 fis, clone NT2RP2003117 -
230017 at Transcribed locus -
231095 at CDNA FLJ42857 fis, clone BRHIP2009340
1557315 a at CDNA FLJ39920 fis, clone SPLEN2020166 --
238044 at Transcribed locus --
1561754 at Full length insert cDNA clone ZA88B06 --
1565801 at CDNA clone IMAGE:4796818 -
1560973 a at Full length insert cDNA clone ZD78G02 -
243515 at Transcribed locus -
1558801 at CDNA FLJ31207 fis, clone KIDNE2003357 --
1559788 at CDNA: FLJ23388 fis, clone HEP17008 -
1555848 at MRNA full length insert cDNA clone EUROIMAGE 1652049 --
1561762 s at Full length insert cDNA clone ZD67D03
237083 at Transcribed locus ---
234352 x at Mutant DNA polymerase beta -
1566144 at CDNA FLJ41018 fis, clone UTERU2018881 --
242681 at Transcribed locus -
240038 at Transcribed locus -
1566146 x at CDNA FLJ41018 fis, clone UTERU2018881
239306 at Transcribed locus
Transcribed locus, strongly similar to XP_001168873.1
241074 at PREDICTED: hypothetical protein [Pan troglodytes]
205316 at CDNA FLJ33407 fis, clone BRACE2010535 --
244371 at Transcribed locus
1559867 at CDNA FLJ32420 fis, clone SKMUS2000898
233908 x at CDNA FLJ12050 fis, clone HEMBB1 002002 -
232429 at MRNA; cDNA DKFZp434G1972 (from clone DKFZp434G1 972) --
243200 at Transcribed locus
242873 at Transcribed locus --
216782 at CDNA: FLJ23492 fis, clone LNGOI731
228214 at Transcribed locus ---
227497 at CDNA FLJ 11723 fis, clone HEMBA1 005314 -
228807 at Transcribed locus ---
231557 at Transcribed locus
215476_at Clone 23726 mRNA sequence ---
240457 at Transcribed locus
240095 at Transcribed locus ---
1560891 a at Full length insert cDNA clone YY75G10
1561612_at CDNA clone IMAGE:5275628 ---
216002 at CDNA FLJ12105 fis, clone HEMBB1002699
1561476_at CDNA clone IMAGE:5284581 ---
235144 at CDNA FLJ32320 fis, clone PROST2003537
238632 at Full length insert cDNA clone ZD51 F08
237421 at Full length insert cDNA clone ZD48A05
1560480_at Homo sapiens, clone IMAGE:5223521, mRNA ---
1556747 a at CDNA FLJ39784 fis, clone SPLEN2002314
240747 at Transcribed locus
244136 at CDNA clone IMAGE:5272580 -
242613 at Transcribed locus
1556194 a at CDNA FLJ33585 fis, clone BRAMY2012163
Transcribed locus, weakly similar to XP_001105455.1
1569459 a at PREDICTED: zinc finger protein 451 [Macaca mulatta] -
244874 at Transcribed locus
I
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229823 at Transcribed locus
212534 at CDNA FLJ11904 fis, clone HEMBB1000048
212812 at CDNA: FLJ22642 fis, clone HS106970 --
1553605 a at ATP-binding cassette, sub-family A (ABCI), member 13 ABCAI3
236205_at ATP-binding cassette, sub-family C, member 6 pseudogene 1 ABCC6P1
225337 at abhydrolase domain containing 2 ABHD2
228490 at abhydrolase domain containing 2 ABHD2
213805 at abhydrolase domain containing 5 ABHD5
1567623 at Actin binding LIM protein family, member 2 ABLIM2
1567622_at Actin binding LIM protein family, member 2 ABLIM2
acylphosphatase 1, erythrocyte (common) type /// chromosome
205260_s at 17 open reading frame 13 ACYP1 // C17orfl13
adenylate cyclase activating polypeptide 1 (pituitary) receptor
226690 at type I ADCYAPIR1
226325_at adenylosuccinate synthase like 1 ADSSL1
225229 at AF4/FMR2 family, member 4 AFF4
243487 at AF4/FMR2 family, member 4 AFF4
238135 at Angiotensin i receptor-associated protein AGTRAP
AHA1, activator of heat shock 90kDa protein ATPase homolog 2
230148 at (yeast) AHSA2
AHA1, activator of heat shock 90kDa protein ATPase homolog 2
226334 s at (yeast) AHSA2
210929 s at alpha-2-HS-glycoprotein /// PRO1454 AHSG /// LOC100131613
210962 s at A kinase (PRKA) anchor protein (yotlao) 9 AKAP9
215483 at A kinase (PRKA) anchor protein (yotiao) 9 AKAP9
aldo-keto reductase family 1, member C2 (dihydrodiol
dehydrogenase 2; bile acid binding protein; 3-alpha
209699 x at hydroxysteroid dehydrogenase, type Ill) AKR1C2
aldo-keto reductase family 1, member D1 (delta 4-3-ketosteroid-
207102_at 5-beta-reductase) AKR1D1
203180 at adehyde dehydrogenase I family, member A3 ALDH1A3
208950 s at aldehyde dehydrogenase 7 family, member Al ALDH7A1
208951 at aldehyde dehydrogenase 7 family, member Al ALDH7AI
asparagine-linked glycosylation 9 homolog (S. cerevisiae, alpha-
228817 at 1,2-mannosyltransferase) ALG9
225450 at angiomotin like I AMOTL1
225459 at angiomotin like 1 AMOTL1
eukaryotic translation initiation factor 4E binding protein 3 /
ankyrin repeat and KH domain containing I /// ANKHD1- ANKHDI // ANKHDI-EIF4EBP3 N
208773 s at EIF4EBP3 EIF4EBP3
212286 at ankyrin repeat domain 12 ANKRD12
227720 at ankyrin repeat domain 138 ANKRD13B
1558076 at ankyrin repeat domain 32 ANKRD32
224694 at anthrax toxin receptor I ANTXR1
203074 at annexin A8-like 2 /// annexin A8 /l annexin A8-like 1 ANXA8 /// ANXA8L1 /// ANXA8L2
222516 at adaptor-related protein complex 3, mu I subunit AP3M1
228164 at adaptor-related protein complex 4, epsilon 1 subunit AP4EI
211553 x at apoptotic peptidase activating factor 1 APAFI
apolipoprotein B mRNA editing enzyme, catalytic polypeptide-
206160_at like 2 APOBEC2
201525 at apolipoprotein D APOD
amyloid beta precursor protein (cytoplasmic tail) binding protein
202631 s at 2 APPBP2
amyloid beta precursor protein (cytoplasmic tail) binding protein
202629 at 2 APPBP2
39248 at aquaporin 3 (Gill blood group) AQP3
205568 at aquaporin 9 AQP9
ADP-ribosylation factor guanine nucleotide-exchange factor 2
222518 at (brefeldin A-inhibited) ARFGEF2
ADP-ribosylation factor guanine nucleotide-exchange factor 2
218098 at (brefeldin A-inhibited) ARFGEF2
213039 at rho/rac guanine nucleotide exchange factor (GEF) 18 ARHGEF18
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1558000 at AT rich interactive domain 58 (MRF1 -like) ARID5B
238068 at Ariadne homolog 2 (Drosophila) ARIH2
201228 s at ariadne homolog 2 (Drosophila) ARIH2
217852 s at ADP-ribosylation factor-like 8B ARL8B
210971 s at aryl hydrocarbon receptor nuclear translocator-lke ARNTL
210147 at ADP-ribosyltransferase 3 ART3
224524 s at ankyrin repeat and SOCS box-containing 3 ASB3
206743 s at asialoglycoprotein receptor 1 ASGR1
226447 at ashi (absent, small, or homeotic)-like (Drosophila) ASHIL
206030 at aspartoacylase (Canavan disease) ASPA
235266 at ATPase family, AAA domain containing 2 ATAD2
222740 at ATPase family, AAA domain containing 2 ATAD2
213387 at ATPase family, AAA domain containing 2B ATAD2B
219870 at activating transcription factor 7 interacting protein 2 ATF7lP2
213026_at ATG12 autophagy related 12 homolog (S. cerevisiae) ATG12
201243 s at ATPase, Na+/K+ transporting, beta 1 polypeptide ATP1B1
205444 at ATPase, Ca++ transporting, cardiac muscle, fast twitch 1 ATP2A1
216120 s at ATPase, Ca++ transporting, plasma membrane 2 ATP2_2
204685 s at ATPase, Ca++ transporting, plasma membrane 2 ATP2B2
220197_at ATPase, H+ transporting, lysosomal VO subunit a4 ATP6VOA4
ATPase, Cu++ transporting, alpha polypeptide (Menkes
205197 s at syndrome) ATP7A
226771 at ATPase, class I, type 8B, member 2 ATP8B2
220416 at ATPase, class I, type 8B, member 4 ATP8B4
235240 at Ataxin 3 ATXN3
218631 at arginine vasopressin-induced I AVPlI
202685 s at AXL receptor tyrosine kinase AXL
222446 s at beta-site APP-cleaving enzyme 2 BACE2
217867 x at beta-site APP-cleaving enzyme 2 BACE2
235007 at Bardet-Biedl syndrome 7 BBS7
219688 at Bardet-Biedl syndrome 7 BBS7
37549_g_at Bardet-Biedl syndrome 9 BBS9
209958 s at Bardet-Biedl syndrome 9 BBS9
37547 at Bardet-Biedl syndrome 9 BBS9
225674 at B-cell receptor-associated protein 29 BCAP29
221241 s at BCL2-like 14 (apoptosis facilitator) BCL2L14
203140 at B-cell CLL/lymphoma 6 (zinc finger protein 51) BCL6
1560684 x at B-cell CLLilymphoma 8 BCL8
1560683 at B-cell CLLlymphoma 8 BCL8
206746_at beaded filament structural protein 1, filensin BFSP1
210538 s at baculoviral IAP repeat-containing 3 BIRC3
201032 at bladder cancer associated protein BLCAP
205290 s at bone morphogenetic protein 2 BMP2
205548_s at BTG family, member 3 BTG3
213134 x at BTG family, member 3 BTG3
205690 s at BUD31 homolog (S. cerevisiae) BUD31
209182 s at chromosome 10 open reading frame 10 C1Oorf1O
226892 at chromosome 10 open reading frame 12 ClOorf12
224435 at chromosome 10 open reading frame 58 C1Oorf58
219240 s at chromosome 10 open reading frame 88 C1Oorf88
1554509 a at chromosome 10 open reading frame 97 C1Oorf97
218297 at chromosome 10 open reading frame 97 ClOorf97
226383 at chromosome 11 open reading frame 46 CI1orf46
230151 at chromosome 13 open reading frame 1 CI3orfl
226196 s at chromosome 14 open reading frame 179 C14orf179
226195 at chromosome 14 open reading frame 179 C14orf179
239470 at chromosome 15 open reading frame 56 C15orf56
218447 at chromosome 16 open reading frame 61 C16orf61
226406 at chromosome 18 open reading frame 25 C18orf25
1553686 at chromosome 18 open reading frame 25 C18orf25
244324 at chromosome 18 open reading frame 54 C18orf54
229442 at chromosome 18 open reading frame 54 C18orf54
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223511 at chromosome I open reading frame 124
_Clorl2&231549 at chromosome 1 open reading frame 158 Clorfl58
238625 at chromosome I open reading frame 168 Clorfl168
155838 s at chromosome I open reading frame 187 C1orf187
1554340 a at chromosome 1 open reading frame 187 Clorf187
210652 s at chromosome 1 open reading frame 34 Corf34
208747 s at complement component 1, s subcomponent CiS
1555229 a at complement component 1, s subcomponent CS1
1554818 s at chromosome 20 open reading frame 12 C20orfI2
232186 at chromosome 20 open reading frame 142 C200rf142
220172 at chromosome 2 open reading frame 37 C2orf37
241430 at chromosome 2 open reading frame 51 C2orf51
241825 at chromosome 2 open reading frame 60 C2orf60
223787 at chromosome 3 open reading frame 19 C3orfi9
225559 at chromosome 3 open reading frame 19 C3orfl9
1558094s at chromosome 3 open reading frame 19 C3orf19
206741_at chromosome 3 open reading frame 32 C3orf32
1559429 at chromosome 3 open reading frame 43 C3orf43
241817 at chromosome 3 open reading frame 62 C3orf62
227267 at chromosome 5 open reading frame 37 C5orf37
48031_r at chromosome 5 open reading frame 4 C5orf4
220751 s at chromosome 5 open reading frame 4 C5orff4
226263 at chromosome 6 open reading frame 151 C6orf151
232444 at chromosome 6 open reading frame 204 C6orf204
244829at Chromosome 6 open reading frame 218 C6orf218
243943. xat chromosome 6 open reading frame 52 C6orf52
238385 at Chromosome 6 open reading frame 58 C6orf58
238383 at chromosome 6 open reading frame 58 C6orf58
223006_s at chromosome 9 open reading frame 5 C9orf5
238912 at chromosome 9 open reading frame 85 C9orf85
213161 at chromosome 9 open reading frame 97 C9orf97
212077 at caldesmon I CALD1
201617_x at m/cdesmon 1 CALD1
calcium/calmodulin-dependent protein kinase (CaM kinase) C
211483 s at beta CAMK2B
225693_s at calmodulin binding transcription activator I CAMTA1
caspase 2, apoptosis-related cysteine peptidase (neural
226032 at precursor cell expressed, developmentally down-regulated 2) CASP2
core-binding factor, runt domain, alpha subunit 2; translocated
209144 s at to, 2 CBFA2T2
core-binding factor, runt domain, alpha subunit 2; translocated
208056 s at to, 3 CBFA2T3
239282 at coiled-coil domain containing 41 CCDC41
228320 x at coiled-coil domain containing 64 CCDC64
1552320 a at coiled-coil domain containing 65 CCDC65
1552321 a at coiled-coil domain containing 65 CCDC65
221167 s at coiled-coil domain containing 70 CCDC70
209688 s at coiled-coli domain containing 93 CCDC93
chemokine (C-C motif) ligand 14 /// chemokine (C-C motif) ligand
210390_s at 15 CCL14 // CCL15
chaperonin containing TCP1, subunit 6A (zeta 1) pseudogene 1
227301 at /// similar to chaperonin containing TCP1, subunit 6A CCT6API /// LOC649553
209583 s at CD200 molecule CD200
233317 at CD9 molecule CD9
209286 at CDC42 effector protein (Rho GTPase binding) 3 CDC42EP3
203967 at cell division cycle 6 homolog (S. cerevisiae) CDC6
204510 at cell division cycle 7 homolog (S. cerevisiae) CDC7
218399 s at cell division cycle associated 4 CDCA4
220115 s at cadherin 10, type 2 (T2-cadherin) CDH10
209847 at cadherin 17, LI cadherin (liver-intestine) CDH17
228868 x at Chromatin licensing and DNA replication factor 1 CDT1
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41660 at
cadherin, EGF LAG seven-pass G-type receptor 1 (flamingo
homolog, Drosophila) CELSR1
cadherin, EGF LAG seven-pass G-type receptor 2 (flamingo
36499 at homolog, Drosophila) CELSR2
206003_at centrosomal protein 135kDa CEP135
1556850_at Centrosomal protein 290kDa CEP290
52285 f at centrosomal protein 76kDa CEP76
cystic fibrosis transmembrane conductance regulator (ATP-
205043 at binding cassette sub-family C, member 7) CFTR
244848_at Chromodomain helicase DNA binding protein 1-like CHD1L
217250_s_at chromodomain helicase DNA binding protein 5 CHD5
229586 at chromodomain helicase DNA binding protein 9 CHD9
212616 at chromodomain helicase DNA binding protein 9 CHD9
1569183 a at choroideremia (Rab escort protein 1) CHM
226368 at Carbohydrate (chondroitin 4) sulfotransferase 11 CHST11
1554839 at cell death-inducing DFFA-like effector c CIDEC
229069 at cytokine induced protein 29 kDa CIP29
212752 at cytoplasmic linker associated protein 1 CLASP1
217528_at CLCA family member 2, chloride channel regulator CLCA2
206166_s at CLCA family member 2, chloride channel regulator CLCA2
206164 at CLCA family member 2, chloride channel regulator CLCA2
206165 s at CLCA family member 2, chloride channel regulator CLCA2
219761 at C-type lectin domain family 1, member A CLEC1A
226425 at CAP-GLY domain containing linker protein family, member 4 CLIP4
228751 at CDC-like kinase 4 CLK4
204577 s at clusterin associated protein I CLUAP1
225009 at CKLF-like MARVEL transmembrane domain containing 4 CMTM4
210769 at cyclic nucleotide gated channel beta 1 CNGBI
228437 at cornichon homolog 4 (Drosophila) CNIH4
203642 s at COBL-like I COBLLI
203654 s at coilin COIL
209081 s at collagen, type XVIII, alpha 1 COL18A1
225288 at collagen, type XXVII, alpha 1 COL27A1
213492_at collagen, type 11, alpha 1 COL2AI
217404 s at collagen, type 11, alpha 1 COL2A1
211980 at collagen, type IV, alpha i COL4A1
211964 at collagen, type IV, alpha 2 COL4A2
226024 at copper metabolism (Murr1) domain containing 1 COMMD1
COX11 homolog, cytochrome c oxidase assembly protein
203551 s at (yeast) COX11
1569353 at CP110 protein CP110
224829 at cytoplasmic polyadenylation element binding protein 4 CPEB4
241765 at carboxypeptidase M CPM
241706 at copine VIII CPNE8
1560494 a at CPX chromosome region, candidate 1 CPXCRI
Crm, cramped-like (Drosophila) /// hematological and
225172 at neurological expressed 1-like CRAMP1L /// HN1L
242855_at cysteine rich BMP regulator 2 (chordin-like) CRIM2
223475 at cysteine-rich secretory protein LCCL domain containing 1 CRISPLD1
212180 at v-crk sarcoma virus CT1O oncogene homolog (avian)-like CRKL
209283_at crystallin, alpha B CRYAB
206982 at crystallin, beta Al CRYBA1
206777 s at crystallin, beta B2 // crystallin, beta B2 pseudogene I CRYBB2 /// CRYBB2P1
222048 at crystallin, beta B2 pseudogene I CRYBB2P1
1556006 s at Casein kinase 1, alpha 1 CSNK1A1
casein kinase 2, beta polypeptide /// lymphocyte antigen 6
201390_s_at complex, locus G5B CSNK2B /// LY6G5B
206994 at cystatin S CST4
211122 s at chemokine (C-X-C moti fIigand 11 CXCL11
215726 s at cytochrome b5 type A (microsomal) CYB5A
231704 at Cytochrome P450, family 3, subfamily A, polypeptide 4 CYP3A4
211843 x at cytochrome P450, family 3, subfamily A, polypeptide 7 CYP3A7
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205939 at cytochrome P450, family 3, subfamily A, polypeptide 7 CYP3A7
210096 at cytochrome P450, family 4, subfamily B, polypeptide 1 CYP4B1
206539 s at cytochrome P450, family 4, subfamily F, polypeptide 12 CYP4F12
210576 at cytochrome P450, family 4, subfamily F, polypeptide 8 CYP4F8
225020 at DAB2 interacting protein DAB21P
208335 s at Duffy blood group, chemokine receptor DARC
222488 s at dynactin 4 (p62) DCTN4
DCN1, defective in cullin neddylation 1, domain containing 3 (S.
239648 at cerevisiae) DCUN1D3
221039 s at development and differentiation enhancing factor 1 DDEF1
224796 at development and differentiation enhancing factor 1 DDEF1
224790 at development and differentiation enhancing factor 1 DDEF1
221630 s at DEAD (Asp-Glu-Ala-Asp) box polypeptide 4 DDX4
224433 s at DEAD (Asp-Glu-Ala-Asp) box polypeptide 54 DDX54
218986 s at DEAD (Asp-Glu-Ala-Asp) box polypeptide 60 DDX60
226867 at DENN/MADD domain containing 4C DENND4C
212504 at DIP2 disco-interacting protein 2 homolog C (Drosophila) DIP2C
1565681 s at DIP2 disco-interacting protein 2 homolog C (Drosophila) DIP2C
206090 s at disrupted in schizophrenia 1 DISCI
1557633 at hypothetical locus DKFZp434K191 DKFZp434KI91
213661 at regeneration associated muscle protease DKFZP586H2123
1561961 at putative PHD finger protein 2 pseudogene DKFZp686A1627
219908 at dickkopf homolog 2 (Xenopus laevis) DKK2
201681 s at discs, large homolog 5 (Drosophila) DLG5
229738 at dynein, axonemal, heavy chain 10 DNAH10
220636 at dynein, axonemal, intermediate chain 2 DNA12
202500 at DnaJ (Hsp40) homolog, subfamily B, member 2 DNAJB2
234094 x at DnaJ (Hsp40) homolog, subfamily C, member 21 DNAJC21
238336 s at DnaJ (Hsp4O) homolog, subfamily C, member 21 DNAJC21
238335 at DnaJ (Hsp4O) homolog, subfamily C, member 21 DNAJC21
238337_s at DnaJ (Hsp4O) homolog, subfamily C, member 21 DNAJC21
224611 s at DnaJ (Hsp40) homolog, subfamily C, member 5 DNAJC5
224613 s at DnaJ (Hsp40) homolog, subfamily C, member 5 DNAJC5
224612 s at DnaJ (Hsp4O) homolog, subfamily C, member 5 DNAJC5
1554258 a at DnaJ (Hsp40) homolog, subfamily C, member 5 beta DNAJC5B
232798 at DnaJ (Hsp4O) homolog, subfamily C, member 5 beta DNAJC5B
204720 s at DnaJ (Hsp4O) homolog, subfamily C, member 6 DNAJC6
223958_s at dynein, axonemal, light chain 1 DNALI
243802 at dynein heavy chain domain 2 DNHD2
40612 at dopey family member I DOPEY1
213271 s at dopey family member 1 DOPEY1
213267 at dopey family member 1 DOPEYI
236442 at D4, zinc and double PHD fingers, family 3 DPF3
227018 at dlpeptidyl-peptidase 8 DPP8
235075 at desmoglein 3 (pemphigus vulgaris antigen) DSG3
219291 at DTW domain containing 1 DTWD1
227336 at deltex homolog 1 (Drosophila) DTX1
212611 at deltex 4 homolog (Drosophila) DTX4
dual specificity phosphatase 11 (RNA/RNP complex 1-
202703 at interacting) DUSP11
219963 at dual specificity phosphatase 13 DUSP13
203693 s at E2F transcription factor 3 E2F3
226952.at ELL associated factor 1 EAF1
219551 at ELL associated factor 2 EAF2
extracellular matrix protein 2, female organ and adipocyte
206101 at specific ECM2
208091 s at EGFR-coamplified and overexpressed protein ECOP
233839 at EF-hand calcium binding domain 6 EFCAB6
226800_at EF-hand calcium binding domain 7 EFCAB7
225656 at EF-hand domain (C-terminal) containing I EFHC1
202711 at ephrin-B1 EFNB1
226911 at EGF-like, fibronectin type Ill and laminin G domains EGFLAM
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219232 s at eal nine homolog 3 (C. elegans) EGLN3
222847 s at egi nine homolog 3 (C. elegans) EGLN3
232361 s at ets homologous factor EHF
222932 at ets homologous factor EHF
extracellular leucine-rich repeat and fibronectin type Ill domain
1559072 a at containing 2 ELFN2
elongation of very long chain fatty acids (FEN1/Elo2,
213712 at SUR4/Elo3, yeast)-like 2 ELOVL2
200878 at endothelial PAS domain protein 1 EPAS1
220120 s at erythrocyte membrane protein band 4.1 like 4A EPB41L4A
225417 at enhancer of polycomb homolog 1 (Drosophila) EPC1
225838_at enhancer of polycomb homolog 2 (Drosophila) EPC2
202894_at EPH receptor B4 EPHB4
221680 s_at ets variant gene 7 (TEL2 oncogene) ETV7
226420_at ecotropic viral integration site 1 EV11
204713_s_at coagulation factor V (proaccelerin, labile factor) F5
231029 at coagulation factor V (proaccelerin, labile factor) F5
1566124 a at fatty acid binding protein 6, Heal (gastrotropin) FABP6
1566123 at fatty acid binding protein 6, ileal (gastrotropin) FABP6
224217 s at Fas (TNFRSF6) associated factor I FAF1
225319 s at family with sequence similarity 104, member A FAM104A
229268 at family with sequence similarity 105, member B FAM105B
223386 at family with sequence similarity 118, member B FAM118B
212371 at family with sequence similarity 152, member A FAM152A
family with sequence similarity 27, member El /// family with
sequence similarity 27, member E3 /// family with sequence FAM27E1 / FAM27E2 ///
1553590 at similarity 27, member E2 FAM27E3
227563 at family with sequence similarity 27, member E3 FAM27E3
family with sequence similarity 62 (C2 domain containing)
224699 s at member B FAM62B
1553750 a at family with sequence similarity 76, member B FAM76B
235349 at family with sequence similarity 82, member A FAM82A
226129 at family with sequence similarity 83, member H FAM83H
236029 at FAT tumor suppressor homolog 3 (Drosophila) FAT3
1558964 at FAT tumor suppressor homolog 3 (Drosophila) FAT3
236525 at F-box protein 36 FBXO36
229419 at F-box and WD repeat domain containing 7 FBXW7
211734 s at Fc fragment of IgE, high affinity 1, receptor for; alpha polypeptide FCER1A
205117 at fibroblast growth factor 1 (acidic) FGF1
208240 s at fibroblast growth factor 1 (acidic) FGF1
1552721_aat fibroblast growth factor 1 (acidic) FGF1
fibroblast growth factor receptor 2 (bacteria-expressed kinase,
keratinocyte growth factor receptor, craniofacial dysostosis 1,
Crouzon syndrome, Pfeiffer syndrome, Jackson-Weiss
203638 s at syndrome) FGFR2
fibroblast growth factor receptor 2 (bacteria-expressed kinase,
keratinocyte growth factor receptor, craniofacial dysostosis 1,
Crouzon syndrome, Pfeiffer syndrome, Jackson-Weiss
208228 s at syndrome) FGFR2
fibroblast growth factor receptor 3 (achondroplasia,
204379 s at thanatophoric dwarfism) FGFR3
202949 s at four and a half LIM domains 2 FHL2
219383 at protor-2 FLJ14213
1555486 a at protor-2 FLJ14213
231152 at Hypothetical protein FLJ20309 FLJ20309
221229 s at hypothetical protein FLJ20628 FU20628
219455 at hypothetical protein FLJ21062 FLJ21062
1554919 s at hypothetical protein FLJ21062 FLJ21062
237298 at FLJ26850 protein FLJ26850
hypothetical protein FLJ36032 /// hypothetical protein
237131 at LOC100132502 FLJ36032 /// LOC100132502
I
262
Appendix: Genes Associated with K-means Cluster 7
1563750_at FLJ43944 protein FLJ43944
215017 s at formin binding protein 1-like FNBPiL
222693 at fibronectin type Ill domain containing 3B FNDC3B
225032 at fibronectin type il domain containing 3B FNDC3B
225924 at folliculin interacting protein 2 FNIP2
200090 at famesyltransferase, CAAX box, alpha FNTA
228188_at FOS-like antigen 2 FOSL2
225262 at FOS-like antigen 2 FOSL2
202724 s at forkhead box 01 FOXO1
230645 at FERM domain containing 3 FRMD3
225481 at FERM domain containing 6 FRMD6
225464 at FERM domain containing 6 FRMD6
226045 at fibroblast growth factor receptor substrate 2 FRS2
1553622 a at fibrous sheath interacting protein 1 FSIP1
217077 s at gamma-aminobutyric acid (GABA) B receptor, 2 GABBR2
209990 s at gamma-aminobutyric acid (GABA) B receptor, 2 GABBR2
211679 x at gamma-aminobutyric acid (GABA) B receptor, 2 GABBR2
209991 x at gamma-aminobutyric acid (GABA) B receptor, 2 GABBR2
205044 at gamma-aminobutyric acid (GABA) A receptor, pi GABRP
206669 at lutamate decarboxylase 1 (brain, 67kDa) GAD1
205219 s at galactokinase 2 GALK2
216411 s at galactokinase 2 GALK2
203066 at B cell RAG associated protein GALNAC4S-6ST
214855 s at GTPase activating Rap/RanGAP domain-like I GARNL1
213049 at GTPase activating Rap/RanGAP domain-like 1 GARNL1
238581 at guanylate binding protein 5 GBP5
226214 at glycerophosphodiester phosphodiesterase I GDE1
206156 at gap junction protein, beta 5, 31.1kDa GJB135
207387 s at glycerol kinase GK
223378 at GLIS family zinc finger 2 GLIS2
224861 at Guanine nucleotide binding protein (G protein), q polypeptide GNAQ
224862 at Guanine nucleotide binding protein (G protein), q polypeptide GNAQ
224863 at Guanine nucleotide binding protein (G protein), q polypeptide GNAQ
202615 at Guanine nucleotide binding protein (G protein), q polypeptide GNAQ
205184 at guanine nucleotide binding protein (G protein), gamma 4 GNG4
1555867 at guanine nucleotide binding protein (G protein), gamma 4 GNG4
1555765 a at guanine nucleotide binding protein (G protein), gamma 4 GNG4
227022 at glucosamine-6-phosphate deaminase 2 GNPDA2
201567 s at golgi autoantigen, golgin subfamily a, 4 GOLGA4
2010_ at golgin B1, golgi integral membrane protein GOLGB1
213020 at golgi SNAP receptor complex member 1 GOSR1
213021 at golgi SNAP receptor complex member 1 GOSR1
212510 at glycerol-3-phosphate dehydrogenase 1-like GPDIL
206582 s at G protein-coupled receptor 56 GPR56
223582 at G protein-coupled receptor 98 GPR98
213170 at glutathione peroxidase 7 GPX7
229616 s at GRAM domain containing 2 GRAMD2
207299 s at glutamate receptor, metabotropic 1 GRMI
222102 at glutathione S-transferase A3 GSTA3
208066_s at general transcription factor IIB GTF2B
228179 at hyaluronan synthase 3 HAS3
235264 at host cell factor C2 HCFC2
231043 at primary ciliary dyskinesia protein 1 hCG 17324
234040 at helicase, lymphoid-specific HELLS
223556 at helicase, lymphoid-specific HELLS
240486 at Helicase with zinc finger HELZ
223572 at hedgehog acyltransferase-like HHATL
210387 at histone cluster 1, H2bg HIST1H2BG
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Probeset ID Gene Name Gene Symbol
I - iMISTr14UAA /// UI14UA //
207046 at
histone cluster 1, H4i /// histone cluster 1, H4a / histone cluster
1, H4d /// histone cluster 1, H4f /// histone cluster 1, H4k /
histone cluster 1, H4j /// histone cluster 1, H4c /// histone cluster
1, H4h /// histone cluster 1, H4b /// histone cluster 1, H4e ///
histone cluster 1, H41 /// histone cluster 2, H4a /// histone cluster
4. H4 /// histone cluster 2. H4b
HIST1 H4C / HIST1 H4D ///
HIST1 H4E /// HIST1 H4F ///
HIST1H4H /// HIST1H41 ///
HIST1 H4J /// HIST1 H4K ///
HIST1 H4L /// HIST2H4A //
HIST2H4B // HIST4H4
204512 at human immunodeficiency virus type I enhancer binding protein i HIVEP1
237324_s_at hexokinase domain containing 1 HKDC1
237323 at hexokinase domain containing 1 HKDC1
227614 at hexokinase domain containing 1 HKDC1
220585 at hexokinase domain containing 1 HKDC1
235944 at hemicentin 1 HMCN1
226887 at heat shock 70kDa protein 14 HSPA14
205543_at heat shock 70kDa protein 4-like HSPA4L
intercellular adhesion molecule 4 (Landsteiner-Wiener blood
207194_s_at group) ICAM4
231733 at ICEBERG caspase-1 inhibitor ICEBERG
204569_at intestinal cell (MAK-like) kinase ICK
214059 at Interferon-induced protein 44 IF144
1555464 at interferon induced with helicase C domain I IFIH1
216020 at Interferon induced with helicase C domain 1 IFIH1
208173 at interferon, beta 1, fibroblast IFNBI
203627 at insulin-like growth factor 1 receptor IGF1R
202409 at insulin-like growth factor 2 (somatomedin A) IGF2
202718 at insulin-like growth factor binding protein 2, 36kDa IGFBP2
231148 at IGF-like family member 2 IGFL2
immunoglobulin heavy locus /// immunoglobulin heavy constant
gamma 1 (G1 m marker) /// immunoglobulin heavy constant
gamma 2 (G2m marker) /// immunoglobulin heavy constant mu IGH@ /// IGHG1 / IGHG2 /// IGHM
211430_s at /// immunoglobulin heavy variable 4-31 /// IGHV4-31
214677 x at immunoglobulin lambda locus IGL@
207695 s at immunoglobulin superfamily, member 1 IGSF1
206999 at interleukin 12 receptor, beta 2 IL12RB2
1561853 a at interleukin 23 receptor IL23R
243541 at interleuldn 31 receptor A IL31RA
212195 at interleukin 6 signal transducer (gpl30, oncostatin M receptor) ILST
235583_at immunoglobulin-like domain containing receptor 1 ILDR1
205070 at inhibitor of growth family, member 3 ING3
218783 at integrator coniplex subunit 7 INTS7
228946_at intumed planar cell polarity effector homolog (Drosophila) INTU
229161 at IQ motif containing G IQCG
239412 at interferon regulatory factor 5 IRF5
205483_s_at ISG15 ubiquitin-like modifier ISG15
205176 s at integrin beta 3 binding protein (beta3-endonexin) ITGB3BP
202746 at Integral membrane protein 2A ITM2A
202747 s at integral membrane protein 2A ITM2A
203723 at inositol 1,4,5-trisphosphate 3-kinase B ITPKB
231183 s at Jagged 1 (Alagille syndrome) JAG1
201548 s at jumonji, AT rich interactive domain 1B JARID1B
211202 s at jumonji, AT rich interactive domain 1B JARIDIB
201549 x at jumonjli, AT rich interactive domain 1B JARIDIB
201465 s at jun oncogene JUN
233644 at katanin p60 subunit A-like 2 KATNAL2
1552897 a at potassium voltage-gated channel, subfamily G, member 3 KCNG3
211806 s at potassium Inwardly-rectifying channel, subfamily J, member 15 KCNJ15
243209 at potassium voltage-gated channel, KOT-like subfamily, member 4 KCNQ4
206077 at Kell blood group, metallo-endopeptidase KEL
36612 at KIAA0280 KIAA0280
212357 at KIAA0280 KIAA0280
I
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213242 x at KIAA0284 KIAA(J284
212068 s at KIAAQ515 KIAA0515
204711_at KIAA0753 KIAA0753
209379 s at KIAA1 128 KIAA1 128
232046 at KIAA1217 KIAA1217
221736 at KIAA1219 KIAA1219
224678 at KIAA1219 KIAA1219
neuroblastoma breakpoint family, member 14 /// neuroblastoma
breakpoint family, member 1 / KIAA1245 /// neuroblastoma
breakpoint family, member 11 /// neuroblastoma breakpoint
family, member 15 // neuroblastoma breakpoint family, member KIAA1245 / LOC100132406///
20 / neuroblastoma breakpoint family, member 9 /// NBPF1 /// NBPF10 /// NBPF11 /
neuroblastoma breakpoint family, member 10 / neuroblastoma NBPF14 /// NBPFI /// NBPF16 /
breakpoint family, member 8 /// CG10522-PA-Ike /// CLIP-190- NBPF20 /// NBPF8 /// NBPF9 ///
like /// neuroblastoma breakpoint family, member 16 /similar to RP3-377D14.1 /// XXyac-
226740 x at NBPF9 YX1 5516.1
221874_at KIAA 324 KIAA1 324
226248 s at KIAA1324 K AA1324
229628 s at KIAA1 529 KIAA1529
229627 at KIAA1 529 KIAA1529
231956 at KIAA1618 KIAA1618
229878 at KIAA1731 KIAA1731
216807 at KIAA1751 KIAA1751
228446 at KIAA2026 KIAA2026
223933 at kinesin family member 5A KIF5A
205318 at kinesin family member 5A KIF5A
226534 at KIT ligand KITLG
202393 s at Kruppel-like factor 10 KLF10
225133 at Kruppel-like factor 3 (basic) KLF3
209211 at Kruppel-like factor 5 (intestinal) KLFS
225755 at kelch domain containing 8B KLHDC8B
223250_at kelch-like 7 (Drosophila) KLHL7
202055 at karyopherin alpha 1 (importin alpha 5) KPNA1
202056 at karyopherin alpha I (importin alpha 5) KPNAI
202057 at karyopherin alpha 1 (importin alpha 5) KPNA1
213741 s at karyopherin alpha 1 (importin alpha 5) KPNA1
222585 x at lysine-rich coiled-coil 1 KRCC1
201650 at keratin 19 KRT19
207908 at keratin 2 (epidermal ichthyosis bullosa of Siemens) KRT2
222681 at KTEL (Lys-Tyr-Glu-Leu) containing 1 KTELC1
204584_at LI cell adhesion molecule L1CAM
201552 at lysosomal-associated membrane protein 1 LAMP1
201553 s at lysosomal-associated membrane protein I LAMP1
212446 s at LAGI homolog, ceramide synthase 6 LASS6
204428 s at lecithin-cholesterol acyltransferase LCAT
1559224_at late cornified envelope 1E LCEIE
1559226 x at late comified envelope 1 E LCE1E
228454 at ligand dependent nuclear receptor corepressor LCOR
232893 at LMBR1 domain containing 2 LMBRD2
238037 at leishmanolysin-like (metallopeptidase M8 family) LMLN
227569 at ligand of numb-protein X 2 LNX2
microtubule associated seine/threonine kinase family member 4
225613 at / hypothetical protein LOC100128443 LOCI 00128443/ MAST4
microtubule associated serine/threonine kinase family member 4
225611 at /// hypothetical protein LOC100128443 LOC100128443 /// MAST4
229296 at hypothetical protein LOC100128501 LOC100128501
232849 at hypothetical protein LOC149692 /// similar to hCG2018847 LOC100128988 /// LOC149692
240366 at hypothetical protein LOCIO0129562 LOC100129562
215229 at Hypothetical protein LOC100129973 LOC100129973
transmembrane protein 164 / hypothetical protein
223201 s at LOC100130886 LOCI 00130886 /// TMEM164
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220486 x at
transmembrane protein 164 /// hypothetical protein
LOC100130886 LOCI 00130886 /// TMEM164
231589 at similar to LOCI 00126053 protein LOC100130940
hypothetical LOC653110 /// hypothetical protein LOC728449 /// LOC100 132646 /// LOC653110 ///
1557094 at hypothetical protein LOC100132646 LOC728449
low density lipoprotein-related protein I (alpha-2-macroglobulin
receptor) /// similar to low density lipoprotein-related protein 1
200784 s at (alpha-2-macroglobulin receptor) LOC100134190 /// LRPI
low density lipoprotein-related protein 1 (alpha-2-macroglobulin
receptor) /// similar to low density lipoprotein-related protein 1
200785_s_at (alpha-2-macroglobulin receptor) LOC100134190 / LRP1
231377 at similar to Ab2-183 LOCI 58830
213510 x at TL132 protein LOC220594
227124 at Hypothetical protein LOC221710 LOC221710
244209 at hypothetical protein LOC282992 LOC282992
226793 at hypothetical LOC283267 LOC283267
229130 at hypothetical protein LOC285535 LOC285535
1569923 s at hypothetical protein LOC285708 LOC285708
hypothetical protein LOC286434 /// similar to Serine/threonine-
protein kinase PRKX (Protein kinase PKX1) /// hypothetical LOC286434 /// LOC389906 /
protein LOC441528 /// similar to hCG 1981372 /// similar to LOC441528 /// LOC728687 ///
222031_at LOC389906 protein LOC729162
1556167 at hypothetical protein LOC339766 LOC339766
1556168_s at hypothetical protein LOC339766 LOC339766
1568658_at hypothetical gene supported byAK075484; BC014578 LOC339804
230022 at hypothetical protein MGC34761 /// secretory protein LOC348174 LOC348174 /// MGC34761
226608 at similar to RIKEN cDNA 4921524J17 LOC388272
230815 at similar to KIF27C LOC389765
241975 at Hypothetical gene supported by BX647608 LOC399959
236001 at hypothetical gene supported by BCOI 5790; BC041634 LOC400573
237585 at hypothetical protein LOC441054 LOC441054
225355 at hypothetical LOC54492 LOC54492
1554447 at hypothetical LOC554203 LOC554203
1558404 at Hypothetical protein LOC644242 LOC644242
215625 at hypothetical protein LOC644450 LOC644450
1566145 s at hypothetical protein LOC644450 LOC644450
221235 s at hypothetical LOC644617 LOC644617
TBC1 domain family, member 3 /// TBC1 domain family, member
3B /// TBC1 domain family, member 3C /// similar to TBC1
domain family, member 3C /// similar to TBC1 domain family LOC653380 /// LOC653498 /
member 3 (Rab GTPase-activating protein PRC17) (Prostate LOC729837 /f TBC1 D3 /
cancer gene 17 protein) (TRE1 7 alpha protein) /// TBC1 domain TBC1D3B /// TBC1D3C /
family, member 3G /// TBC1 domain family, member 3H f/ TBC1 TBC1D3E /// TBC1D3F ///
209403 at domain family, member 3F /// TBC1 domain family, member 3E TBC1D3G f/I TBC1D3H
RRN3 RNA polymerase I transcription factor homolog (S.
243124 at cerevisiae) pseudogene LOC653390
1557862 at hypothetical LOC654841 LOC654841
227866 at Hypothetical LOC729436 LOC729436
220244 at loss of heterozygosity, 3, chromosomal region 2, gene A LOH3CR2A
202822_at LIM domain containing preferred translocation partner in lipoma LPP
238653 at Leucine-rich repeats and immunoglobulin-like domains 2 LRIG2
218816 at leucine rich repeat containing 1 LRRC1
230793 at leucine rich repeat containing 16A LRRC16A
219573 at leucine rich repeat containing 16A LRRC16A
208140_s at leucine rich repeat containing 48 LRRC48
212978 at leucine rich repeat containing 8 family, member B LRRC8B
223817 at leucine-rich repeats and IQ motif containing 1 LRRIQ1
202729 s at latent transforming growth factor beta binding protein I LTBPI
204682_at latent transforming growth factor beta binding protein 2 LTBP2
231306 at lysozyme-like 4 LYZL4
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1208037 s at mucosal vascular addressin cell adhesion molecule 1
229475_at maelstrom homolog (Drosophila) MAEL
242794 at mastermind-like 3 (Drosophila) MAML3
205448 sat mitogen-activated protein kinase kinase kinase 12 MAP3K12
mitogen-activated protein kinase kinase kinase 7 interacting
227357 at protein 3 MAP3K7IP3
mitogen-activated protein kinase kinase kinase 7 interacting
1552928 s at protein 3 MAP3(71P3
1558732_at mitogen-activated protein kinase kinase kinase kinase 4 MAP4K4
228262 at MAP7 domain containing 2 MAP7D2
221824 s at membrane-associated ring finger (C3HC4) 8 MARCH8
227839 at methyl-CpG binding domain protein 5 MBDS
226076 s at methyl-CpG binding domain protein 6 MBD6
220397 at Mdml nuclear protein homolog (mouse) MDM1
201987 at mediator complex subunit 13 MED13
202610 s at mediator complex subunit 14 MED14
218846 at mediator complex subunit 23 MED23
202016 at mesoderm specific transcript homolog (mouse) MEST
238773 at methyltransferase 5 domain containing 1 METT5D1
220007 at methyltransferase like 8 METTL8
1554667 s at methyltransferase like 8 METTL8
230534 at hypothetical protein MGC15634 MGC15634
228077 at hypothetical protein MGC3207 MGC3207
224020 at hypothetical LOC79100 MGC4473
220930_s at hypothetical protein MGC5590 MGC5590
microtubule associated monoxygenase, calponin and LIM
212473 s at domain containing 2 MICAL2
microtubule associated monoxygenase, calponin and LIM
212472_at domain containing 2 MICAL2
225475 at mesoderm induction early response I homolog (Xenopus taevis) MIERI
228961 at mesoderm induction early response 1, family member 3 MIER3
1554449 at mesoderm induction early response 1, family member 3 MIER3
226066 at microphthalmia-associated transcription factor MITF
218259 at MKIlmyocardin-like 2 MKL2
242984 at muskelin 1, intracellular mediator containing kelch motifs MKLN1
222415 at myeloid/lymphold or mixed-lineage leukemia 3 MLL3
213708 s at MAX-like protein X MLX
203414 at monocyte to macrophage differentation-associated MMD
226844 at MOB1, Mps One Binder kinase activator-like 2B (yeast) MOBKL2B
213000 at MORC family CW-type zinc finger 3 MORC3
203780 at myelin protein zero-like 2 MPZL2
230518 at myelin protein zero-like 2 MPZL2
37408 at mannose receptor, C type 2 MRC2
201717 at mitochondrial ribosomal protein L49 MRPL49
225810 at myotubularin related protein 10 MTMR10
202197 at myotubularin related protein 3 MTMR3
224430 s at mitochondrial translation optimization 1 homolog (S. cerevisiae) MTO1
223731 at MYCBP associated protein MYCBPAP
231947_at myc target I MYCT1
1564072 at _ myosin, heavy chain 16 pseudogene MYH16
218926_at myoneurin MYNN
236718 at myosin X MYO10
1552578 a at myosin Il1B MYO3B
227761 at myosin VA (heavy chain 12, myoxin) MYO5A
225299 at myosin VB MYO5B
235367 at myopalladin MYPN
214156 at myosin VIIA and Rab interacting protein MYRIP
210341'at myeln transcription factor 1 MYT1
32069 at NEDD4 binding protein 1 N4BP1
214775 at Nedd4 binding protein 3 N48P3
209272 at NGFI-A binding protein 1 (EGR1 binding protein 1) NAB1
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1565906 at NAD synthetase 1 NADSYN1
225111 s at N-ethylmaleimide-sensitive factor attachment protein, beta NAPB
218330 s at neuron navigator 2 NAV2
219588 s at non-SMC condensin Il complex, subunit G2 NCAPG2
210774 s at nuclear receptor coactivator 4 NCOA4
NDC80 homolog, kinetochore complex component (S.
204162_at cerevisiae) NDC80
230123 at NECAP endocytosis associated 2 NECAP2
219502 at nei endonuclease Vill-like 3 (E. coli) NEIL3
225270 at neogenin homolog 1 (chicken) NEO1
218888 s at neuropilin (NRP) and tolloid (TLL)-like 2 NETO2
224984 at nuclear factor of activated T-cells 5, tonicity-responsive NFAT5
215228_at nescient helix loop helix 2 NHLH2
202007 at nidogen 1 NIDI
202008 s at nidogen 1 NID1
225752 at non imprinted in Prader-Willi/Angelman syndrome 1 NIPA1
205006 s at N-myristoyltransferase 2 NMT2
206023 at neuromedin U NMU
227870 at neighbor of Punc E11 NOPE
207309 at nitric oxide synthase 1 (neuronal) NOS1
225911 at nephronectin NPNT
thyroid hormone receptor, alpha (erythroblastic leukemia viral (v-
erb-a) oncogene homolog, avian) /// nuclear receptor subfamily
31637 s at 1, group D, member 1 NRID /// THRA
thyroid hormone receptor, alpha (erythroblastic leukemia viral (v-
erb-a) oncogene homolog, avian) /// nuclear receptor subfamily
204760 s at 1, group D, member 1 NR1D1 /// THRA
225768 at nuclear receptor subfamily 1, group D, member 2 NRID2
209750 at nuclear receptor subfamily 1, group D, member 2 NR1 D2
229838 at nucleobindin 2 NUCB2
214136_at nudix (nucleoside diphosphate linked moiety X)-type motif 13 NUDT13
204435 at nucleoporin like I NUPL1
233085 s at oligonucleotide/oligosaccharide-binding fold containing 2A OBFC2A
222872 x at oligonucleotide/oligosaccharide-binding fold containing 2A OBFC2A
203446 s at oculocerebrorenal syndrome of Lowe OCRL
2-oxoglutarate and iron-dependent oxygenase domain
221090 s at containing 1 OGFOD1
212768 s at olfactomedin 4 OLFM4
olfactory receptor, family 52, subfamily K, member 3
232829 at pseudogene OR52K3P
228676 at oral cancer overexpressed 1 ORAOV1
219073 s at oxysterol binding protein-like 10 OSBPLIO
208158 s at oxysterol binding protein-like 1A OSBPL1A
209485 s at oxysterol binding protein-like 1A OSBPL1A
1554646 at oxysterol binding protein-like 1A OSBPL1A
1553432 s at otoancorin OTOA
223835 x at orthopedia homeobox OTP
220403 s at p53-regulated apoptosis-inducing protein I P53AIPI
220001_at peptidyl arginine deiminase, type IV PAD14
211413 s at peptidyl arginine deiminase, type IV PAD14
219461_at p21(CDKN1A)-activated kinase 6 PAK6
1555310_a at p21(CDKN1A)-activated kinase 6 PAKS
202760 s at PALM2-AKAP2 PALM2-AKAP2
228735 s at Pantothenate kinase 2 (Hallervorden-Spatz syndrome) PANK2
229043 at PAP associated domain containing 5 PAPD5
202239 at poly (ADP-ribose) polymerase family, member 4 PARP4
219148 at PDZ binding kinase PBK
219656 at protocadherin 12 PCDH12
228863_at protocadherin 17 PCDH17
214937 x at pericentriolar material 1 PCM1
238792 at pecanex homolog (Drosophila) PCNX
229287 at pecanex homolog (Drosophila) PCNX
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239100 x at pecanex homolog (Drosophila)
213173 at pecanex homolog (Drosophila) PCNX
phosphodiesterase 4C, cAMP-specific (phosphodiesterase El
231478 at dunce homolog, Drosophila) PDE4C
phosphodiesterase 4C, cAMP-specific (phosphodiesterase El
206791 s at dunce homolog, Drosophila) PDE4C
211093 at phosphodiesterase 6C, cGMP-specific, cone, alpha prime PDE6C
214174 s at PDZ and LIM domain 4 PDLIM4
214175 x at PDZ and LIM domain 4 PDLIM4
206803 at prodynorphin PDYN
205251 at period homolog 2 (Drosophila) PER2
220576 at post-GPI attachment to proteins I PGAP1
244321 at post-GPI attachment to proteins 1 PGAP1
204048 s at phosphatase and actin regulator 2 PHACTR2
238693 at polyhomeotic homolog 3 (Drosophila) PHC3
226508 at polyhomeotic homolog 3 (Drosophila) PHC3
222688 at phytoceramidase, alkaline PHCA
222689 at phytoceramidase, alkaline PHCA
232262 at phosphatidylinositol glycan anchor biosynthesis, class L PIGL
212688 at phosphoinositide-3-kinase, catalytic, beta polypeptide PlK3CB
212239 at phosphoinositide-3-kinase, regulatory subunit 1 (alpha) PIK3R1
211580 s at phosphoinositide-3-kinase, regulatory subunit 3 (gamma) PIK3R3
202392 s at phosphatidylserne decarboxylase PISD
238649 at phosphatidylinositol transfer protein, cytoplasmic 1 PITPNCI
1559261_a at polycystic kidney disease 1 -like 2 PKD1 L2
244444 at polycystic kidney disease 1-like 2 PKD1 L2
63305 at PBX/knotted 1 homeobox 2 PKNOX2
222171 s at PBX/knotted I homeobox 2 PKNOX2
220952_s at pleckstrin homology domain containing, family A member 5 PLEKHA5
219700 at plexin domain containing I PLXDCI
211766 s at pancreatic lipase-related protein 2 PNLIPRP2
201578 at podocalyxin-like PODXL
209578 s at protein 0-fucosyltransferase 2 POFUT2
204835 at polymerase (DNA directed), alpha 1 POLAI
212836 at polymerase (DNA-directed), delta 3, accessory subunit POLD3
219380 x at polymerase (DNA directed), eta POLH
1557700 at Polymerase (DNA directed), eta POLH
210910 s at POM (POM121 homolog, rat) and ZP3 fusion POMZP3
209147 s at phosphatidic acid phosphatase type 2A PPAP2A
protein phosphatase 1A (formerly 2C), magnesium-dependent,
210407 at alpha isoform PPMIA
201602 s at protein phosphatase 1, regulatory (inhibitor) subunit 12A PPP1R12A
201957 at protein phosphatase 1, regulatory (Inhibitor) subunit 128 PPPIR12B
225124 at protein phosphatase 1, regulatory (inhibitor) subunit 9B PPP1 R9B
protein phosphatase 2 (formerly 2A), regulatory subunit B",
209632 at alpha PPP2R3A
1558027 s at protein kinase, AMP-activated, beta 2 non-catalytic subunit PRKAB2
203680 at protein kinase, cAMP-dependent, regulatory, type 11, beta PRKAR2B
202178 at protein kinase C, zeta PRKCZ
204304 s at prominin i PROM
223685 s at PRP18 pre-mRNA processing factor 18 homolog (S. cerevisiae) PRPF18
1559397 s at proline rich 14 PRR14
213951_s_at PSMC3 interacting protein PSMC31P
212222 at proteasome (prosome, macropain) activator subunit 4 PSME4
218371 s at paraspeckle component 1 PSPC1
209815 at patched homolog I (Drosophila) PTCH1
prostaglandin-endoperoxide synthase 1 (prostaglandin G/H
205127 at synthase and cyclooxygenase) PTGS1
236539 at protein tyrosine phosphatase, non-receptor type 22 (lymphoid) PTPN22
200635 s at protein tyrosine phosphatase, receptor type, F PTPRF
228336 at PWWP domain containing 2A PWWP2A
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212012 at peroxidasin homolog (Drosophila) PXDN
212013 at peroxidasin homolog (Drosophila) PXDN
240413~at pyrin and HIN domain family, member 1 PYHIN1
203884 s at RABII family interacting protein 2 (class 1) RAB11FIP2
59697 at RAB15, member RAS onocogene family RAB15
213440 at RAB1A, member RAS oncogene family RABIA
203885 at RAB21, member RAS oncogene family RAB21
220955_ xat RAB23, member RAS oncogene family RAB23
227842 at RAB30, member RAS oncogene family RAB30
221014 s at RAB33B, member RAS oncogene family RAB33B
204028 s at RAB GTPase activating protein 1 RABGAP1
RAB, member of RAS oncogene family-like 2B / RAB, member
219151 s at of RAS oncogene family-like 2A RABL2A /// RABL2B
218785 s at RAB, member RAS oncogene family-like 5 RABL5
206591 at recombination activating gene 1 RAGI
224880 at v-ral simian leukemia viral oncogene homolog A (ras related) RALA
226389 s at Rap guanine nucleotide exchange factor (GEF) 1 RAPGEF1
219752 at RAS protein activator like 1 (GAPI like) RASAL1
1553186 x at RAS and EF-hand domain containing RASEF
1553185 at RAS and EF-hand domain containing RASEF
231328 s at RAS guanyl releasing protein 4 RASGRP4
212332 at retinoblastoma-like 2 (p130) RBL2
225236 at RNA binding motif protein 18 RBM18
219754 at RNA binding motif protein 41 RBM41
212397 at radixin RDX
206036 s at v-rel reticuloendotheliosis viral oncogene homolog (avian) REL
205923 at reelin RELN
222629 at REV1 homolog (S. cerevisiae) REV1
239142_at Rieske (Fe-S) domain containing RFESD
236305 at Rieske (Fe-S) domain containing RFESD
203224 at riboflavin kinase RFK
205823 at regulator of G-protein signaling 12 RGS12
209637 s at regulator of G-protein signaling 12 RGS12
216317 x at Rh blood group, CcEe antigens RHCE
215819 s at Rh blood group, CcEe antigens / Rh blood group, D antigen RHCE /// RHD
241771 at RIMS binding protein 2 RIMBP2
206137 at regulating synaptic membrane exocytosis 2 RIMS2
202129 s at RIO kinase 3 (yeast) RIOK3
236224 at Ras-like without CAAX 1 RITI
233488 at ribonuclease, RNase A family, 7 RNASE7
212724 at Rho family GTPase 3 RND3
228153_at ring finger 144B RNF144B
220270 at ring finger protein 17 RNF17
204669 s at ring finger protein 24 RNF24
zinc finger and BTB domain containing 8 1/ zinc finger and BTB
235142 at domain containing 8-like RPI-2705.1 /// ZBTB8
1569532 a at MSFL2541 RP11-216L13.5
230897 at hypothetical protein LOC728621 RP4-692D3,1
227849 at Retinitis pigmentosa 9 (autosomal dominant) RP9
retinitis pigmentosa 9 (autosomal dominant) / retinitis
227640 s at pigmentosa 9 pseudogene RP9 / RP9P
223945 x at retinitis pigmentosa 9 pseudogene RP9P
227035 x at retinitis pigmentosa 9 pseudogene RP9P
221634 at ribosomal protein L23a pseudogene 7 RPL23AP7
1556684 at ribonuclease P RNA component HI RPPH1
213414 s at ribosomal protein S19 RPS19
204633_s at ribosomal protein S6 kinase, 90kDa, polypeptide 5 RPS6KA5
231100 at Ras-related associated with diabetes RRAD
230093 at radial spoke head I homolog (Chlamydomonas) RSPHI
202301 s at arginine/serine-rich coiled-coil 2 RSRC2
202302 s at arginine/serine-rich coiled-coil 2 RSRC2
210222 s at reticulon 1 RTN1
I
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227072 at rotatin RTTN
1554413_ sat RUN domain containing 2B / RUN domain containing 2C RUNDC2B /// RUNDC2C
201845 s at RINGI and YY1 binding protein RYBP
202853 s at RYK receptor-like tyrosine kinase RYK
205485 at ryanodine receptor 1 (skeletal) RYR1
214370 at S100 calcium binding protein A8 S100A8
202917 s at S100 calcium binding protein A8 S100A8
223512 at SAR1 gene homolog B (S. cerevisiae) SAR1B
242935 at SET binding factor 2 SBF2
205725 at secretoglobin, family 1A, member 1 (uteroglobin) SCGB1A1
206799 at secretoglobin, family 1D, member 2 SCGBID2
229057 at sodium channel, voltage-gated, type 11, alpha subunit SCN2A
206381 at sodium channel, voltage-gated, type II, alpha subunit SCN2A
202071 at syndecan 4 SDC4
1558675 s at serologically defined colon cancer antigen 1 SDCCAGI
240024 at SEC14-like 2 (S. cerevisiae) SEC14L2
219499 at Sec61 alpha 2 subunit (S. cerevisiae) SEC61A2
230215 at Sec6l alpha 2 subunit (S. cerevisiae) SEC61A2
228747 at Sec61 alpha 2 subunit (S. cerevisiae) SEC61A2
trafficking protein particle complex 2 / spondyloepiphyseal
219351_at dysplasia, late, pseudogene / zinc finger protein 547 SEDLP / TRAPPC2 / ZNF547
sema domain, immunoglobulin domain (1g), short basic domain,
203071 at secreted, (semaphorin) 38 SEMA3B
sema domain, immunoglobulin domain (Ig), short basic domain,
35666_at secreted, (semaphorin) 3F SEMA3F
sema domain, immunoglobulin domain (lg), short basic domain,
219689 at secreted, (semaphorin) 3G SEMA3G
sema domain, seven thrombospondin repeats (type 1 and type 1
like), transmembrane domain (TM) and short cytoplasmic
223610 at domain, (semaphorin) 5B SEMA5B
202318 s at SUMO1/sentrin specific peptidase 6 SENP6
208999 at septin 8 SEPT8
217272_s at serpin peptidase inhibitor, clade B (ovalbumin), member 13 SERPINB13
211361_s at serpin peptidase inhibitor, clade B (ovalbumin), member 13 SERPINB13
serpin peptidase inhibitor, clade E (nexin, plasminogen activator
1568765 at inhibitor type 1), member 1 SERPINE1
serpin peptidase inhibitor, clade E (nexin, plasminogen activator
202628 s at inhibitor type 1), member 1 SERPINE1
202657 s at SERTA domain containing 2 SERTAD2
212465 at SET domain containing 3 SETD3
219482 at SET domain containing 4 SETD4
214199 at surfactant, pulmonary-associated protein D SFTPD
226112 at sarcoglycan, beta (43kDa dystrophin-associated glycoprotein) SGCB
Src homology 3 domain-containing guanine nucleotide exchange
227197 at factor SGEF
212989 at sphingomyelin synthase i SGMSI
SH2 domain protein 1A, Duncan's disease (lymphoproliferative
210116 at syndrome) SH2D1A
1553177 at SH2 domain containing 1B SH2D1B
231823 s at SH3 and PX domains 2B SH3PXD2B
225056_at signalnduced proliferation-associated 1 like 2 SIPAiL2
216899_s at src kinase associated phosphoprotein 2 SKAP2
solute carrier family 13 (sodium-dependent dicarboxylate
230686 s at transporter), member 3 SLC13A3
solute carrier family 13 (sodium-dependent dicarboxylate
230687 at transporter), member 3 SLC13A3
solute carrier family I (glial high affinity glutamate transporter),
202800 at member 3 SLCIA3
solute carrier family 22 (organic cation/ergothioneine
205896_at transporter), member 4 SLC22A4
solute carrier family 2 (facilitated glucose transporter), member
227176 at 13 SLC2A13
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23456i1 at
solute carrier family 2 (facilitated glucose transporter), member
13 SLC2AI3
solute carrier family 2 (facilitated glucose transporter), member
234268 at 13 SLC2A13
solute carrier family 2 (facilitated glucose transporter), member
1552695 a at 13 SLC2A13
204204_at solute carrier family 31 (copper transporters), member 2 SLC3IA2
213083 at solute carrier family 35, member D2 SLC35D2
1569112 at solute carrier family 44, member 5 SLC44A5
1552779 a at solute carrier family 44, member 5 SLC44A5
1552278 a at solute carrier family 46 (folate transporter), member 1 SLC46A1
1552279 a at solute carrier family 46 (folate transporter), member 1 SLC46A1
211123 at solute carrier family 5 (sodium iodide symporter), member 5 SLC5A5
solute carrier family 6 (neurotransmitter transporter, dopamine),
206836 at member 3 SLC6A3
solute carrier family 7 (cationic amino acid transporter, y+
212295 s at system), member 1 SLC7A1
solute carrier family 7 (cationic amino acid transporter, y+
225516 at system), member 2 SLC7A2
solute carrier family 7 (cationic amino acid transporter, y+
system), member 6 / transient receptor potential cation
203580 s at channel, subfamily V, member 6 SLC7A6 / TRPV6
solute carrier family 9 (sodium/hydrogen exchanger), member 3
209830_s at regulator 2 SLC9A3R2
205396 at SMAD family member 3 SMAD3
235451 at SMAD family member 5 SMAD5
225219 at SMAD family member 5 SMAD5
225223 at SMAD family member 5 SMAD5
204790 at SMAD family member 7 SMAD7
SWI/SNF related, matrix associated, actin dependent regulator
215294 s at of chromatin, subfamily a, member 1 SMARCA1
201664 at structural maintenance of chromosomes 4 SMC4
215623 x at structural maintenance of chromosomes 4 SMC4
220369_at SMEK homolog 1, suppressor of meki (Dictyostelium) SMEK1
229730 at smoothelin-like 2 SMTNL2
209481_at SNF related kinase SNRK
syntrophin, beta 2 (dystrophin-associated protein Al, 59kDa,
227312 at basic component 2) SNTB2
205482 x at sorting nexin 15 SNX15
213827 at sorting nexin 26 SNX26
231194 at sorting nexin 32 SNX32
1554181 at sorting nexin 32 SNX32
223027 at sorting nexin 9 SNX9
223028 s at sorting nexin 9 SNX9
226178 at suppressor of cytokine signaling 4 SOCS4
1552792 at suppressor of cytokine signaling 4 SOCS4
204367 at Sp2 transcription factor SP2
238035 at Sp3 transcription factor SP3
sperm protein associated with the nucleus, X-linked, family
member Al / SPANX family, member C /// SPANX family, SPANXA1 /// SPANXA2 ///
224032 x at member E /// SPANX family, memberA2 SPANXC /// SPANXE
200795 at SPARC-like 1 (mast9, hevin) SPARCL1
231178 at spermatogenesis associated 4 SPATA4
218324 s at spermatogenesis associated, serine-rich 2 SPATS2
228900 at sperm antigen with calponin homology and coiled-coil domains 1 SPECCI
205185 at serine peptidase inhibitor, Kazal type 5 SPINK5
sparclosteonectin, cwcv and kozal-like domains proteoglycan
202363 at (testican) I SPOCKI
226075 at splA/ryanodine receptor domain and SOCS box containing 1 SPSB1
219964 at suppression of tumorigenicity 7 like ST7L
233141 s at suppression of tumorigenicity 7 like ST7L
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1552739 s at Isuppression of tumorigenicity 7 like SIL
222801 s at stromal antigen 3-like 4 STAG3L4
227108 at StAR-related lipid transfer (START) domain containing 9 STARD9
AFFX-
HUMISGF3A/M97935
MA at signal transducer and activator of transcription 1, 91kDa STAT1
AFFX-
HUMISGF3A/M97935
MB at signal transducer and activator of transcription 1, 91kDa STAT1
AFFX-
HUMISGF3A/M97935
3 at signal transducer and activator of transcription 1, 91 kDa STAT1
200887_s at signal transducer and activator of transcription 1, 91kDa STATI
204595 s at stanniocalcin 1 STC1
227461 at stonin 2 STON2
231969 at storkhead box 2 STOX2
226822 at storkhead box 2 STOX2
234317 s at storkhead box 2 STOX2
212354rat sulfatase I SULFi
211470 s at sulfotransferase family, cytosolic, IC, member 2 SULT1C2
222566 at suppressor of variegation 4-20 homolog 1 (Drosophila) SUV420H1
212990 at synaptojanin 1 SYN
230611 at synaptophysin-like 2 SYPL.2
SYS1 Golgi-localized integral membrane protein homolog (S.
224668 at cerevisiae) SYS1
209198 s at synaptotagmin XI SYT11
209197 at synaptotagmin XI SYT1 1
214348 at tachykinin receptor 2 TACR2
1555724_s at transgelin TAGLN
tetratricopeptide repeat, ankyrin repeat and coiled-coil containing
224952 at 2 TANC2
tetratricopeptide repeat, ankyrin repeat and coiled-coil containing
208425 s at 2 TANC2
207616 s at TRAF family member-associated NFK8 activator TANK
227611 at threonyl-tRNA synthetase-like 2 TARSL2
201813s at TBC1 domain family, member 5 TBC1D5
231997 at tubulin folding cofactor E-like TBCEL
218520 at TANK-binding kinase I TBKI
226388 at transcription elongation factor A (SIl), 3 TCEA3
227705_at transcription elongation factorA (Sil)-llke 7 TCEAL7
transcription factor 12 (HTF4, helix-loop-helix transcription
208986_at factors 4) TCF12
transmembrane 4 L six family member 19 // Tctexl domain
228606 at containing 2 TCTEX1D2 /// TM4SF19
228285 at tudor domain containing 9 TDRD9
1243 198 _at testis expressed 9 TEX9
232383 at transcription factor EC TFEC
tissue factor pathway inhibitor (lipoprotein-associated
213258 at coagulation inhibitor) TFPI
208249 s at TDP-glucose 4,6-dehydratase TGDS
209747 at transforming growth factor, beta 3 TGFB3
Transforming growth factor, beta receptor I (activin A receptor
236561 at type l-like kinase, 53kDa) TGFBR1
transforming growth factor, beta receptor I (activin A receptor
224793 s at type Il-like kinase, 53kDa) TGFBR1
219231 at trimethylguanosine synthase homolog (S. cerevisiae) TGSI
219292 at THAP domain containing, apoptosis associated protein 1 THAP1
thrombospondin, type I, domain containing 1 /// thrombospondin,
219477 s at type 1, domain containing 1 pseudogene THSD1 /// THSD1P
222835 at thrombospondin, type 1, domain containing 4 THSD4
222904 s at transmembrane channel-like 5 TMC5
213096 at transmembrane and coiled-coil domain family 2 TMCC2
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212507 at transmembrane protein 131 TMEM131
228624 at transmembrane protein 144 TMEM144
226752at transmembrane protein 157 TMEM157
1552826_a at transmembrane protein 163 TMEM163
218962- s at transmembrane protein 168 TMEM168
215241 at transmembrane protein 16C TMEM168
223784 at transmembrane protein 27 TMEM27
222892 s at transmembrane protein 40 TMEM4
226361 at transmembrane protein 42 TMEM42
203662 s at tropomodulin I TMOD1
226600_at transmembrane and tetratricopeptide repeat containing 3 TMTC3
1560017 at transmembrane and tetratricopeptide repeat containing 3 TMTC3
201645 at tenascin C (hexabrachion) TNC
231775 at tumor necrosis factor receptor superfamily, member 1Oa TNFRSF10A
205388 at troponin C type 2 (fast) TNNC2
242314 at Trinucleotide repeat containing 6C TNRC6C
228834_at transducer of ERBB2, 1 TOB1
238494 at TNF receptor-associated factor 3 interacting protein I TRAF31P1
217147 s at T cell receptor associated transmembrane adaptor 1 TRAT1
219725 at triggering receptor expressed on myeloid cells 2 TREM2
204391 x at tripartite motif-containing 24 TRIM24
211002 s at tripartite motif-containing 29 TRIM29
236175 at tripartite motif-containing 55 TRIM55
236972 at tripartite motif-containing 63 TRIM63
219405 at tripartite motif-containing 68 TRIM68
223132 s at tripartite motIf-containing 8 TRIM8
221012 s at tripartite motif-containing 8 TRIM8
209778 at thyroid hormone receptor interactor 11 TRIP11
223838_at testis specific, 10 TSGA10
230997 at tetratricopeptide repeat domain 21A TTC21A
231479 at tetratricopeptide repeat domain 33 TTC33
240369 at Tetratricopeptide repeat domain 7A TTC7A
228882 at tubby homolog (mouse) TUB
226747_at thioredoxin domain containing 16 TXNDC16
208957 at thioredoxin domain containing 4 (endoplasmic reticulum) TXNDC4
205694 at tyrosinase-related protein 1 TYRPI
238462 at ubiquitin associated and SH3 domain containing, B UBASH3B
228353 x at ubiquitin associated and SH3 domain containing, B UBASH3B
228359 at ubiquitin associated and SH3 domain containing, B UBASH3B
238587 at ubiquitin associated and SH3 domain containing, B UBASH3B
225787 at ubiquitin-conjugating enzyme E2F (putative) UBE2F
212760 at ubiquitin protein ligase E3 component n-recognin 2 UBR2
234982 at ubiquitin protein ligase E3 component n-recognin 3 UBR3
208884 s at ubiquitin protein ligase E3 component n-recognin 5 UBR5
242669 at Ubiquitin-fold modifier 1 UFM1
UDP glucuronosyltransferase I family, polypeptide A10 // UDP
glucuronosyltransferase 1 family, polypeptide A8 /// UDP
glucuronosyltransferase I family, polypeptide A6 /// UDP
glucuronosyltransferase 1 family, polypeptide A9 /// UDP
glucuronosyltransferase I family, polypeptide A4 /// UDP UGTIA1 /// UGT1A10 // UGT1A4
204532 x at glucuronosyltransferase 1 family, polypeptideAl /// UGT1A6 /// UGT1A8 /// UGT1A9
214817 at unc-13 homolog A (C. elegans) UNC13A
235261 at unc-45 homolog B (C. elegans) UNC45B
218757 s at UPF3 regulator of nonsense transcripts homolog B (yeast) UPF3B
1553263 at Usher syndrome IG (autosomal recessive) USH1G
209475_at ubiquitin specific peptidase 15 USP15
226033 at ubiquitin specific peptidase 31 USP31
244871 s at ubiquitin specific peptidase 32 USP32
232033 at ubiquitin specific peptidase 37 USP37
226730 s at ubiquitin specific peptidase 37 USP37
226729 at ubiquitin specific peptidase 37 USP37
229351 at ubiquitin specific peptidase 49 USP49
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VAMP (vesicle-associated membrane protein)-associated protein
B and C VAPB
213243_at vacuolar protein sorting 13 homolog B (yeast) VPS13B
222437 s at vacuolar protein sorting 24 homolog (S. cerevislae) VPS24
217837 s at vacuolar protein sorting 24 homolog (S. cerevisiae) VPS24
209553 at vacuolar protein sorting 8 homolog (S. cerevisiae) VPS8
202112 at von Willebrand factor VWF
203599 s at WW domain binding protein 4 (formin binding protein 21) WBP4
232964 at Williams Beuren syndrome chromosome region 19 WBSCR19
204728 s at WD repeat and HMG-box DNA binding protein 1 WDHD1
216228 s at WD repeat and HMG-box DNA binding protein 1 WDHD1
214662 at WD repeat domain 43 WDR43
212880 at WD repeat domain 7 WDR7
242204 at WAP four-disulfide core domain 5 WFDC5
228953 at WAS protein homology region 2 domain containing 1 WHDC1
227411 at Wilms tumor 1 interacting protein WTIP
212637 s at WW domain containing E3 ubiquitin protein ligase 1 WWP1
212638 s at WW domain containing E3 ubiquitin protein ligase 1 WWP1
1554062 at Xg blood group XG
222581 at xenotropic and polytropic retrovirus receptor XPRI
1555785 a at 5'-3' exoribonuclease 1 XRN1
224895 at Yes-associated protein 1, 65kDa YAP1
212342 at Yip1 domain family, member 6 YIPF6
205092 x at zinc finger and BTB domain containing 1ZBTB1
204847 at zinc finger and BTB domain containing 11 ZBTBII
227111 at zinc finger and BTB domain containing 34 ZBTB34
227047 x at zinc finger and BTB domain containing 4 ZBTB4
203026 at zinc finger and BTB domain containing 5 ZBTB5
228970 at zinc finger and BTB domain containing 8 opposite strand ZBTB80S
231899 at zinc finger CCCH-type containing 12C ZC3H12C
221193 s at zinc finger, CCHC domain containing 10 ZCCHC10
224858 at zinc finger, DHHC-type containing 5 ZDHHC5
222451 s at zinc finger, DHHC-type containing 9 ZDHHC9
226807 at zinc finger protein I homolog (mouse) ZFPI
201368 at zinc finger protein 36, C3H type-like 2 ZFP36L2
242400 at zinc finger protein 90 homolog (mouse) ZFP90
226344 at zinc finger, matrin type 1 ZMATI
235620_ xat zinc finger, MYM-type 5 ZMYM5
206744 s at zinc finger, MYM-type 5 ZMYM5
205739 x at zinc finger protein 107 ZNF107
204523_at zinc finger protein 140 ZNF140
205497_at zinc finger protein 175 ZNF175
244024_at zinc finger protein 182 ZNF182
204234 s at zinc finger protein 195 ZNF195
203985_at zinc finger protein 212 ZNF212
233461 x at zinc finger protein 226 ZNF226
203248 at zinc finger protein 24 ZNF24
242919_at zinc finger protein 253 ZNF253
206900 x at zinc finger protein 253 ZNF253
228920. at zinc finger protein 260 ZNF260
1558700 s at zinc finger protein 260 ZNF260
230063 at zinc finger protein 264 ZNF264
219540 at zinc finger protein 267 ZNF267
209989 at zinc finger protein 268 ZNF268
212366 at zinc finger protein 292 ZNF292
212368 at zinc finger protein 292 ZNF292
232497_at zinc finger protein 3 ZNF3
219604 sat zinc finger protein 3 ZNF3
200867 at zinc finger protein 313 ZNF313
211678 s at zinc finger protein 313 2NF313
229551 x at zinc finger protein 367 ZNF367
228711_at zinc finger protein 37A ZNF37A
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242761 s at zinc finger protein 420 ZNF420
238614 x at zinc finger protein 430 ZNF430
206829 x at zinc finger protein 430 ZNF430
226113 at zinc finger protein 436 ZNF436
226114 at zinc finger protein 436 ZNF436
228138 at zinc finger protein 498 ZNF498
221626 at zinc finger protein 506 ZNF506
1568720 at zinc finger protein 506 ZNF506
244861 at zinc finger protein 527 ZNF527
228099 at zinc finger protein 550 ZNF550
226509 at zinc finger protein 641 ZNF641
225945 at zinc finger protein 655 ZNF655
223898_at zinc finger protein 670 ZNF670
242923 at Zinc finger pr n 678 ZNF678
1554922 at zinc finger protein 678 ZNF678
232563 at zinc finger protein 684 ZNF684
244398 x at zinc finger protein 684 ZNF684
239482 x at zinc finger protein 708 ZNF708
1559746 a at zinc finger protein 718 ZNF718
1553269 at zinc finger protein 718 ZNF718
225848 at zinc finger protein 746 ZNF746
240079 at Zinc finger protein 81 ZNF81
231902 at Zinc finger protein 827 ZNF827
228046 at Zinc finger protein 827 ZNF827
1564962 at zinc finger protein 92 ZNF92
237335 at zona pellucida glycoprotein 1 (sperm receptor) ZP1
206507 at zinc finger and SCAN domain containing 12 ZSCAN12
217098 s at zinc finger and SCAN domain containing 12 ZSCAN12
1552851 at zinc finger and SCAN domain containing 4 ZSCAN4
1552852 a at zinc finger and SCAN domain containing 4 ZSCAN14
212601 at zinc finger, ZZ-type with EF-hand domain 1 ZZEF1
230260 s at
224216 at
236321 at
244587 at
244172 at
229087 s at
AFFX-M27830 M at
244533 at
238113 at _______________________ ____________
216943 at
1559240 at
213663 s at
243132 at
1566424 at _______________________ ____________
214384 s at _________________________________ _____
242212 at _______________________ ____________
11555580 at__________________________________ ____
1231013 at__________________________________ ____
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1561895 at ICDNA clone IMAGE:4791 521
228465_at CDNA clone IMAGE:5175565 ---
1561386 at CDNA FLJ34378 fis, clone FEBRA2018051
228603 at Transcribed locus
226886 at Clone 25028 mRNA sequence
239258 at Transcribed locus -
239277 at Transcribed locus
212985_at MRNA; cDNA DKFZp434EO33 (from clone DKFZp434E033) ---
236472 at Transcribed locus
1560738 at CDNA clone IMAGE:5300703
238098 at Transcribed locus
239045_at Transcribed locus
1559631 at Homo sapiens, clone IMAGE:4045663, mRNA
234388_at Rearranged T-cell receptor alpha-chain mRNA, variable region --
1564937_at Transcribed locus 
-
1564933_at CDNA: FLJ20963 fis, clone ADSH00818
1559102 at CDNA clone IMAGE:4791593
239200 at Transcribed locus
1559103 s at CDNA clone IMAGE:4791593
237127 at Transcribed locus
1556210 at CDNA FLJ38810 fs, clone LIVER2006251
242073_at Transcribed locus
242014 at Transcribed locus
230764 at CDNA FLJ30669 fis, clone FCBBF1000684 --
235109 at CDNA FLJ40581 fis, clone THYMU2007729
230139_at CDNA FLJ43345 fis, clone NT2R13008228
231034 s at Transcribed locus
235561 at Transcribed locus 
-
230786 at Transcribed locus
230048_at Transcribed locus
234998 at CDNA clone IMAGE:5313062
225239 at CDNA FLJ26120 fis, clone SYNO0419
243444 at Transcribed locus
236126 at activin A receptor, type IIB ACVR2B
202381 at ADAM metallopeptidase domain 9 (meltrin gamma) ADAM9
201034 at adducin 3 (gamma) ADD3
204333 s at aspartylglucosaminidase AGA
202834_at angiotensinogen (serpin peptidase inhibitor, clade A, member 8) AGT
226519 s at alanine-glyoxylate aminotransferase 2-like 2 AGXT2L2
232488_at alanine-glyoxylate aminotransferase 2-like 2 AGXT2L2
200849 s at S-adenosylhomocysteine hydrolase-like 1 AHCYL1
243352_at alpha-kinase 1 ALPK1
202920 at ankyrin 2, neuronal ANK2
210486 at ankyrin repeat and MYND domain containing 1 ANKMY1
1557116 at apolipoprotein L, 6 APOL6
219716 at apolipoprotein L, 6 APOL6
1555279 at armadillo repeat containing 8 ARMC8
219094_at armadillo repeat containing 8 ARMC8
241082 at Asparagine synthetase ASNS
205047 s at asparagine synthetase ASNS
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203304n at
BMP and activin membrane-bound inhibitor homolog (Xenopus
laevis) BAMBI
225446 at bromodomain and WD repeat domain containing 1 BRWD1
225399 at chromosome 1 open reading frame 19 Clorfl9
239999 at Chromosome 21 open reading frame 34 C21orf34
1559901 s at chromosome 21 open reading frame 34 C21 orf34
1557828 a at Chromosome 5 open reading frame 28 C5orf28
226614 s at chromosome 8 open reading frame 13 C8orf 13
219060 at chromosome 8 open reading frame 32 C8orf32
221865 at chromosome 9 open reading frame 91 C9orf91
210817 s at calcium binding and coiled-coil domain 2 CALCOCO2
235076 at calcium binding and coiled-coil domain 2 CALCOCO2
203538 at calcium modulating ligand CAMLG
228641_at caspase recruitment domain family, member 8 CARD8
202402 s at cysteinyl-tRNA synthetase CARS
240983 s at cysteinyl-tRNA synthetase CARS
213626 at carbonyl reductase 4 CBR4
227558 at chromobox homolog 4 (Pc class homolog, Drosophila) CBX4
223084 s at cyclin D-type binding-protein 1 CCNDBP1
224649 x at cyclin Y CCNY
222156 x at cell cycle progression 1 CCPG1
221156 x at cell cycle progression 1 CCPG1
221511 x at cell cycle progression 1 CCPG1
213856 at CD47 molecule CD47
CD55 molecule, decay accelerating factor for complement
201925 s at (Cromer blood group) CD55
225527 at CCAAT/enhancer binding protein (C/EBP), gamma CEBPG
219270 at ChaC, cation transport regulator homolog 1 (E. coli) CHAC1
1554015 a at chromodomain helicase DNA binding protein 2 CHD2
1554014 at chromodomain helicase DNA binding protein 2 CHD2
217556 at chloride channel 4 CLCN4
205149 s at chloride channel 4 CLCN4
205148 s at chloride channel 4 CLCN4
214769 at chloride channel 4 CLCN4
203629 s at component of oligomeric golgi complex 5 COGS
217127 at cystathionase (cystathionine gamma-lyase) CTH
206085 s at cystathionase (cystathionine gamma-lyase) CTH
238509 at Cullin 1 CUL1
226745 at cytochrome P450, family 4, subfamily V, polypeptide 2 CYP4V2
228391 at cytochrome P450, family 4, subfamily V, polypeptide 2 CYP4V2
225442 at discoidin domain receptor tyrosine kinase 2 DDR2
223140_s at DEAH (Asp-Glu-Ala-His) box polypeptide 36 DHX36
214992 s at deoxyribonuclease 11, lysosomal DNASE2
226875 at dedicator of cytokinesis 11 DOCK11
206115 at early growth response 3 EGR3
202021 x at eukaryotic translation initiation factor 1 EIF1
212227 x at eukaryotic translation initiation factor 1 ElF1
212130_x_at eukaryotic translation initiation factor I EIF1
221539 at eukaryotic translation initiation factor 4E binding protein 1 EIF4EBPI
235745 at endoplasmic reticulum to nucleus signaling 1 ERN1
214447 at v-ets erythroblastosis virus E26 oncogene homolog I (avian) ETS1
227410 at family with sequence similarity 43, memberA FAM43A
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225978 at family with sequence similaity 80, member B
1558212_at hypothetical LOC401491 FLJ35024
228702 at hypothetical L0C378805 FLJ43663
202304 at fibronectin type III domain containing 3A FNDC3A
FSHD region gene 1 / FSHD region gene I family, member B
/// similar to FRGI protein (FSHD region gene I protein) /// FRG1 l FRG1B /
235535 x at hypothetical protein LOC100134091 LOCI 00134091 /// LOC642236
fucosyltransferase 1 (galactoside 2-alpha-L-fucosyltransferase,
206109 at H blood group) FUT1
1552943 at gamma-aminobutyric acid (GABA) A receptor, gamma 1 GABRG1
241805 at gamma-aminobutyric acid (GABA) A receptor, gamma 1 GABRG1
213018 at GATA zinc finger domain containing 1 GATAD1
219668 at ganglioside-induced differentiation-associated protein 1-like 1 GDAP1 Li
224839 s at glutamic pyruvate transaminase (alanine aminotransferase) 2 GPT2
221050 s at GTP binding protein 2 GTPBP2
hexose-6-phosphate dehydrogenase (glucose 1-
226160 at dehydrogenase) H6PD
209102 s at HMG-box transcription factor 1 HBP1
238021 s at hCG1815491 hCG 1815491
238022 at hCG1815491 hCG 1815491
205659 at histone deacetylase 9 HDAC9
homocysteine-inducible, endoplasmic reticulum stress-inducible,
217168 s at ubiquitin-like domain member 1 HERPUD1
228697 at histidine triad nucleotide binding protein 3 HINT3
holocarboxylase synthetase (biotin-(proprionyl-Coenzyme A-
207833 s at carboxylase (ATP-hydrolysing)) ligase) HLCS
heterogeneous nuclear nbonucleoprotein D (AU-rich element
205183 at RNA binding protein 1, 37kDa) HNRNPD
200799 at heat shock 70kDa protein 1A // heat shock 70kDa protein 1 B HSPA1A /// HSPA1 B
202147 s at interferon-related developmental regulator 1 IFRD1
210587_at inhibin, beta E INHBE
226267 at Jun dimerization protein 2 JDP2
203205_at jumonji domain containing 2A JMJD2A
226352 at junction-mediating and regulatory protein JMY
235353 at KIAA0746 protein KIAA0746
223756 at KIAA1310 KIAA1310
204411 at kinesin family member 21B KIF21B
217906 at kelch domain containing 2 KLHDC2
226158 at kelch-like 24 (Drosophila) KLHL24
Lymphocyte cytosolic protein 2 (SH2 domain containing
244556 at leukocyte protein of 76kDa) LCP2
235360 at hypothetical LOC100131989 LOC100131989
236653 at Hypothetical protein LOC148189 LOC148189
1558256 at hypothetical protein LOC148189 LOC148189
235191 at Hypothetical protein LOC148189 LOC148189
226682_at hypothetical LOC283666 LOC283666
242329 at hypothetical LOC401317 LOC401317
solute carrier family 3 (activators of dibasic and neutral amino
200924 s at acid transport), member 2 /// hypothetical protein LOC442497 LOC442497 /// SLC3A2
243631 at hypothetical LOC727815 LOC727815
239241 at hypothetical LOC727869 LOC727869
228993 s at hypothetical LOC92482 LOC92482
220622 at leucine rich repeat containing 31 LRRC31
226851 at lysophospholipase-like 1 LYPLAL1
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230174 at lysophospholipase-lie 1I LYPLAL1
208785 s at microtubule-associated protein 1 light chain 3 beta MAP1LC3B
213671 s at methionyl-tRNA synthetase MARS
238977 at minichromosome maintenance complex component 6 MOM6
1554730 at multiple C2 domains, transmembrane 1 MCTP1
213126 at mediator complex subunit 8 MED8
213696 s at mediator complex subunit 8 MED8
242176 at Myocte enhancer factor 2A MIEF2A
232194 at methyltransferase like 4 METTL4
204101 at myotubularin MITMI
242639 at NMDA receptor regulated 2 NARG2
1553992 s at neighbor of BROAI gene 2 NBR2
1568805 at nuclear receptor coactivator 7 NCOA7
neurofibromin 1 (neurofibromatoss von Recklinghausen
210631 at disease, Watson disease) NF1
200758 s at nuclear factor (erythroid-derived 2)-like I NFE2L1
200759 x at nuclear factor (erythroid-derived 2)like I NFE2L1
214179 s at nuclear factor (erythroid-derived 2)-like 1 NFE2L1
226490 at NHS-like 1 NHSL1
234321 x at NHS-like 1 NHSL1
225105 at overexpressed in colon carcinoma-I 0CC-1
201800 s at oxysterol binding protein OSBP
226670 s at poly(A) binding protein, cytoplasmic 1-like PABPC1L
221941 at polyamine oxidase (exo-N4-amino) PAOX
50400 at polyamine oxidase (exo-N4-amino) PAOX
210023 s at polycomb group ring finger I PCGF1
202731 at programmed cell death 4 (neoplastic transformation inhibitor) PDCD4
202730 s at programmed cell death 4 (neoplastic transformation inhibitor) PDCD4
212594 at programmed cell death 4 (neoplastic transformation inhibitor) PDCD4
226452 at pyruvate dehydrogenase kinase, isozyme 1 PDK1
219132 at pellino homolog 2 (Drosophila) PEL12
1554822 at putative homeodomain transcription factor 2 PHTF2
202328 s at polycystic kidney disease I (autosomal dominant) PKD1
202925 s at pleiomorphic adenoma gene-like 2 PLAGL2
227385 at phosphatidic acid phosphatase type 2 domain containing 2 PPAPDC2
220892 s at phosphoserine aminotransferase 1 PSAT1
225796 at PX domain containing serinelthreonine kinase PXK
1552275_s at PX domain containing serine/threonine kinase PXK
1552274 at PX domain containing serinelthreonine kinase PXK
213878 at Pyridine nucleotide-disulphide oxidoreductase domain 1 PYROXD1
212932 at RAB3 GTPase activating protein subunit 1 (catalytic) RAB3GAP1
229894 s at RAB43, member RAS oncogene family RAB43
221808 at RAB9A, member RAS oncogene family RAB9A
202034 x at R1-inducible coiled-coil 1 RB1CC1
227425 at RALBPI associated Eps domain containing 2 REPS2
226948 at rhomboid domain containing 1 RHBDD1
226945 at rhomboid domain containing 1 RHBDDI
1570253 a at Ras homolog enriched in brain like 1 RHEBL1
212120 at ras homolog gene family, member ( RHOQ
212122 at ras homolog gene family, member Q RHOQ
235199 at Iring finger protein 125 RNF125
280
Appendix: Genes Associated with K-means Cluster 8
226104_at ring finger protein 170 RNF170
212155 at ring finger protein 187 RNFI187
202684 s at RNA (guanine-7-) methyltransferase RNMT
221726 at ribosomal protein L22 RPL22
204351 at S100 calcium binding protein P SlooP
1569495 at sodium channel and clathrin linker I SCLTI
214790 at SUMO1/sentrin specific peptidase 6 SENP6
226673_at SH2 domain containing 3C SH2D3C
214095 at serine hydroxymethyltransferase 2 (mitochondrial) SHMT2
214437 s at serine hydroxymethyltransferase 2 (mitochondrial) SHMT2
214096 s at serine hydroxymethyltransferase 2 (mitochondrial) SHMT2
Solute carrier family i (glutamate/neutral amino acid
244377 at transporter), member 4 SLC1A4
solute carrier family 2 (facilitated glucose transporter), member 3
/// solute carrier family 2 (facilitated glucose transporter),
222088_s at member 14 SLC2A14 /// SLC2A3
solute carrier family 2 (facilitated glucose transporter), member 3
/// solute carrier family 2 (facilitated glucose transporter),
216236 s at member 14 SLC2A14 /// SLC2A3
202499 s at solute carrier family 2 (facilitated glucose transporter), member 3 SLC2A3
202497 x at solute carrier family 2 (facilitated glucose transporter), member 3 SLC2A3
204394 at solute carrier family 43, member 1 SLC43A1
solute carrier family 7 (cationic amino acid transporter, y+
212292 at system), member I SLC7AI
solute carrier family 7, (cationic amino acid transporter, y+
217678 at system) member 11 SLC7A11
solute carrier family 7, (cationic amino acid transporter, y+
209921 at system) member 11 SLC7A11
solute carrier family 7, (cationic amino acid transporter, y+
207528 s at system) member 11 SLC7A11
222071 s at solute carrier organic anion transporter family, member 4C1 SLCO4C1
SWl/SNF related, matrix associated, actin dependent regulator
229511 at of chromatin, subfamily e, member 1 SMARCE1
227408 s at sorting nexin 26 SNX25
210677 at sterol O-acyltransferase 2 SOAT2
221489_s at sprouty homolog 4 (Drosophila) SPRY4
222750 s at steroid 5 alpha-reductase 3 SRD5A3
218800 at steroid 5 alpha-reductase 3 SRD5A3
203217 s at ST3 beta-galactoside alpha-2,3-sialyltransferase 5 ST3GAL5
203438 at stanniocalcin 2 STC2
203439_s at stanniocalcin 2 STC2
202557 at stress 70 protein chaperone, microsome-associated, 60kDa STCH
202558_s_at stress 70 protein chaperone, microsome-associated, 60kDa STCH
228867_at TatD DNase domain containing 3 TATDN3
235069_at TatD DNase domain containing 3 TATDN3
200803 s at testis enhanced gene transcript (BAX inhibitor 1) TEGT
204276 at thymidine kinase 2, mitochondrial TK2
204277 s at thymidine kinase 2, mitochondrial TK2
238063_at transmembrane protein 154 TMEM154
220169 at transmembrane protein 156 TMEM156
224566 at trophoblast-derived noncoding RNA TncRNA
218145 at tribbles homolog 3 (Drosophila) TRIB3
1555788_a at tribbles homolog 3 (Drosophila) TRIB3
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1558967 s at Tripartite motif-containing 26 TRIM26
207001 x at TSC22 domain family, member 3 TSC22D3
208763 s at TSC22 domain family, member 3 TSC22D3
226181 at tubulin, epsilon 1 TUBE1
230891_at Tubulin, epsilon 1 TUBE1
235749 at UDP-glucose ceramide glucosyltransferase-like 2 UGCGL2
226135 at UHRF1 (ICBP90) binding protein I UHRFIBPI
201671 x at ubiquitin specific peptidase 14 (tRNA-guanine transglycosylase) USP14
223167 s at ubiguitin specific peptidase 25 USP25
211760 s at vesicle-associated membrane protein 4 VAMP4
211527 x at vascular endothelial growth factor A VEGFA
212171 x at vascular endothelial growth factor A VEGFA
209822 s at very low density lipoprotein receptor VLDLR
223026 s at vacuolar protein sorting 29 homolog (S. cerevisiae) VPS29
200628 s at tryptophanyl-tRNA synthetase WARS
213836 s at WD repeat domain, phosphoinositide interacting 1 WIPl1
226182 s at WNT1 inducible signaling pathway protein 3 WISP3
210200 at WW domain containing E3 ubiquitin protein ligase 2 WWP2
200670 at X-box binding protein 1 XBP1
218911 at YEATS domain containing 4 YEATS4
228402 at zinc finger, BED-type containing 3 ZBED3
218645 at zinc finger protein 277 ZNF277
215022 x at zinc finger protein 33B ZNF33B
244552 at zinc finger family member 788 ZNF788
225131 at zinc finger, RAN-binding domain containing 1 ZRANB1
236987 at
241435 at
234759 at
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|227395_at CDNA FLJ38498 fis, clone FELNG2000241
233820 at CDNA: FLJ22542 fis, clone HS100196
231370 at Transcribed locus
227458 at Transcribed locus
234997 x at CDNA clone IMAGE:4794941
240867 at Transcribed locus
231894 at CDNA FLJ12277 fis, clone MAMMA1001711
241592_at Transcribed locus
241815 at Transcribed locus
227004_at Transcribed locus ---
238892 at Transcribed locus
238087_at Transcribed locus
238492 at CDNA FLJ33148 fis, clone UTERU2000238
235027_at CDNA FLJ41146 fis, clone BRACE2036900 ---
Primary neuroblastorna cDNA, ctone:Nbla00798, full Insert
227247 at sequence
226779 at CDNA FLJ37302 fis, clone BRAMY2016009
235344 at CDNA FLJ42306 fis, clone TRACH2001646
1556331_a at CDNA clone IMAGE:5259142
227191 at Transcribed locus
241887 at CDNA FLJ41537 fis, clone BRTHA2017985
1556580 a at CDNA FLJ30798 fis, clone FEBRA2001161 -
236798_at CDNA FLJ32438 fis, clone SKMUS2001402 ---
239210 at Transcribed locus
230096 at Transcribed locus
Transcribed locus, strongly similar to NP_002900.2 regenerating
239209 at islet-derived 1 alpha precursor [Homo sapiens]
228442_at Transcribed locus ---
230211 at Transcribed locus
236935 at CDNA clone IMAGE:4813920
229114_at CDNA clone IMAGE:4801326
243868 at Transcribed locus ---
Transcribed locus, weakly similar to NP_608540.1 CG2839
239329 at CG2839-PA [Drosophila melanogaster]
236279 at Transcribed locus --
229027 at Transcribed locus
1559544 s at CDNA clone IMAGE:5787947 ---
236402 at CDNA FLJ42263 fis, clone TKIDN2014570
228812_at Transcribed locus ---
1561026 a at CDNA FLJ23762 fis, clone HEP 8324
Transcribed locus, moderately similar to XP_001499650.1
PREDICTED: similar to protein xylosyltransferase [Equus
236190 at caballus] ---
243308 at Transcribed locus ---
236198 at Transcribed locus ---
229810 at Transcribed locus ---
243990 at Transcribed locus ---
230230 at Transcribed locus ---
242978 x at Transcribed locus ---
227682 at Transcribed locus
230860 at Transcribed locus ---
242723 at Transcribed locus
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215970 at
Transcribed locus, moderately similar to NP_062056.1 actin
alpha cardiac 1 [Rattus norvegicus
230795 at Transcribed focus --
238078 at Transcribed locus --
227755 at CDNA clone IMAGE:4077090 -
243590_at CDNA FLJ25435 fis, clone TST08040 ---
Transcribed locus, weakly similar to NP_060312.1 hypothetical
239069 s at protein LOC55652 [Homo sapiens] --
235949 at Transcribed locus
231688 at Transcribed locus -
230333 at Transcribed locus -
230334 at CDNA clone IMAGE:40078968 --
Transcribed locus, strongly similar to NP_006393.2 hepatitis B
237065 s at virus x-interacting protein [Homo sapiens]
244749 at Homo sapiens, clone IMAGE:5218412, mRNA
Transcribed locus, strongly similar to NP_001028856.1
228174 at chaperonin subunit 6a (zeta) [Rattus norvegicus]
228275 at CDNA FLJ32438 fis, clone SKMUS2001402
235884 at Transcribed locus --
226128 at CDNA FU40817 fis, clone TRACH2010639
213396 s at Transcribed locus
226520 at Primary neuroblastoma cDNA, clone:Nbla11485
1560258 a at Homo sapiens, clone IMAGE:5590287, mRNA
1557232 at CDNA clone IMAGE:4797260
226641 at CDNA FLJ11570 fis, clone HEMBA1003309
1568807 a at CDNA clone IMAGE:4825606 -
225847 at arylacetamide deacetylase-like 1 AADACL1
nephronophthisis 3 (adolescent) /// acyl-Coenzyme A
225573 at dehydrogenase family, member 11 ACAD11 /l NPHP3
213198 at activin A receptor, type IB ACVR1B
205327 s at activin A receptor, type IIA ACVR2A
ADAM metallopeptidase domain 17 (tumor necrosis factor,
213532 at alpha, converting enzyme) ADAM17
217748 at adiponectin receptor 1 ADIPOR1
228042 at ADP-ribosylarginine hydrolase ADPRH
238054 at ADP-rlbosylhydrolase like 1 ADPRHL1
239439 at AF4/FMR2 family, member 4 AFF4
230520 at androgen-induced I AIGI
205771 s at A kinase (PRKA) anchor protein 7 AKAP7
asparagine-linked glycosylation 10 homolog B (yeast, alpha-1,2-
238475 at glucosyltransferase) ALGIOB
228356 at ankyrin repeat domain 11 ANKRD11
202442 at adaptor-related protein complex 3, sigma 1 subunit AP3S1
221031 s at apolipoprotein L domain containing 1 APOLD1
202211 at ADP-ribosylation factor GTPase activating protein 3 ARFGAP3
ADP-ribosylation factor guanine nucleotide-exchange factor
202956 at 1 (brefeldin A-inhibited) ARFGEF1
230141 at AT rich interactive domain 4A (RBP1-like) ARIDA
205062 x at AT rich interactive domain 4A (RBP1-like) ARIDA
212614 at AT rich interactive domain 5B (MRFI-like) ARIDSB
ariadne homolog, ubiquitin-conjugating enzyme E2 binding
201880 at protein, 1 (Drosophila) ARIH1
222442 s at ADP-ribosylation factor-like 8B ARL88
1552632_a_at arylsulfatase G ARSG
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209517 s at ash2 (absent. small, or ) etc-lk Dosni
_ _ ,
1554980 a at activating transcription factor 3 ATF3
202672 s at activating transcription factor 3 ATF3
221504 s at ATPase, H+ transporting, lysosomal 50/57kDa, V1 subunit H ATP6V1 H
238723 at ataxin 3 ATXN3
233182 x at Ataxin 3 ATXN3
205416 s at ataxn 3 ATXN3
225557 at AXIN1 up-regulated 1 AXUD1
211692 s at BCL2 binding component 3 BBC3
223227 at Bardet-Biedi syndrome 2 BBS2
205263 at B-cell CLUlymphoma 10 BCLIO
201169 s at basic helix-loop-helix domain containing, class B, 2 BHLHB2
201170 s at basic helix-loop-helix domain containing, class B, 2 BHLHB2
221479 s at BCL2/adenovirus E1B 19kDa interacting protein 3-like BNIP3L
221478 at BCL2/adenovirus EIB 19kDa interacting protein 3-like BNIP3L
221703_at BRCA1 interacting protein C-terminal helicase 1 BRIP1
227669 at brain protein 44 BRP44
223174_at BTB (POZ) domain containing 10 BTBD1O
1559975 at B-cell translocation gene 1, anti-proliferative BTGI
200920_s at B-cell translocation gene 1, anti-proliferative BTG1
200921 s at B-cell translocation gene 1, anti-proliferative BTGI
228354 at chromosome 10 open reading frame 83 C1Oorf83
242515 x at chromosome 11 open reading frame 17 C11orfl7
223268 at chromosome 11 open reading frame 54 C11orf54
213508.at chromosome 14 open reading frame 147 C14orfI47
1568699_at chromosome 14 open reading frame 179 C14orfl79
235369 at chromosome 14 open reading frame 28 C14orf28
238647 at chromosome 14 open reading frame 28 C14orf28
230296 at Chromosome 16 open reading frame 52 C16orf52
226456 at chromosome 16 open reading frame 75 C16orf75
230012 at chromosome 17 open reading frame 44 C17orf44
217640 x at chromosome 18 open reading frame 24 C18orf24
228989 at chromosome 18 open reading frame 56 C18orf56
224443 at chromosome 1 open reading frame 97 C1orf97
224444 s at chromosome 1 open reading frame 97 C1orf97
219951_s at chromosome 20 open reading frame 12 C20orf12
226835 s at chromosome 20 open reading frame 199 C20orfI99
224915 x at chromosome 20 open reading frame 199 C20orf 199
226227 x at chromosome 20 open reading frame 199 C200rf199
235686 at chromosome 2 open reading frame 60 C2orf6O
1555906 s at chromosome 3 open reading frame 23 C3orf23
227856 at chromosome 4 open reading frame 32 C4orf32
1552370 at chromosome 4 open reading frame 33 C4orf33
220088 at complement component 5a receptor I C5AR1
229886 at chromosome 5 open reading frame 34 C5orf34
219381 at chromosome 5 open reading frame 42 C5orf42
243118 at chromosome 6 open reading frame 182 C6orf182
chromosome 6 open reading frame 182 pseudogene ///
1554019 s at chromosome 6 open reading frame 182 C6orf182 // C6orf182P
chromosome 6 open reading frame 35/// hypothetical
218453 s at LOC730074 C6orf35 /// LOC730074
220755 s at chromosome 6 open reading frame 48 C6orf48
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220050 at achromosome 9 open reading frame 9 C9orf9
218168 s at chaperone, ABC1 activity of bc1 complex homolog (S. pombe) CABC1
214933 at calcium channel, voltage-dependent, P/Q type, alpha 1A subunit CACNAIA
219714_s at calcium channel, voltage-dependent, alpha 2/delta subunit 3 CACNA2D3
240982 at cysteinyl-tRNA synthetase CARS
calcium/calmodulin-dependent serine protein kinase (MAGUK
238698 at family) CASK
calcium/calmodulin-dependent serine protein kinase (MAGUK
238699 s at family) CASK
calcium/calmodulin-dependent serine protein kinase (MAGUK
211208 s at family) CASK
205467 at caspase 10, apoptosis-related cysteine peptidase CASP10
212586 at calpastatin CAST
core-binding factor, runt domain, alpha subunit 2; translocated
207625 s at to, 2 CBFA2T2
1554606 at coiled-coil domain containing 100 CCDC100
226449 at coiled-coil domain containing 100 CCDC100
227157 at coiled-coil domain containing 111 CCDC111
234995 at coiled-coil domain containing 52 CCDC52
chemokine (C-C motif) ligand 3 /// chemokine (C-C motif) ligand
3-like 1 /// chemokine (C-C motif) ligand 3-like 3 /// similar to C-C
motif chemokine 3-like 1 precursor (Small-inducible cytokine A3-
like 1) (Tonsillar lymphocyte LD78 beta protein) (LD78-beta(1-
70)) (GO/G1 switch regulatory protein 19-2) (GOS19-2 protein) CCL3 /// CCL3L1 / CCL3L3 ///
205114 s at (PAT 464.2) LOC728830
217988 at cyclin BI interacting protein 1 CCNBIIP1
208796 s at cyclin G1 CCNG1
202769 at cyclin G2 CCNG2
202770 s at cyclin G2 CCNG2
223834 at CD274 molecule CD274
204489 s at CD44 molecule (Indian blood group) CD44
212063 at CD44 molecule (Indian blood group) CD44
206508_at CD70 molecule CD70
207176 s at CD80 molecule CD80
205288 at CDC14 cell division cycle 14 homolog A (S. cerevisiae) CDC14A
CDC14 cell division cycle 14 homolog B (S. cerevisiae) ///
221555 x at CDC14 cell division cycle 14 homolog C (S. cerevisiae) CDC14B /// CDC14C
CDC14 cell division cycle 14 homolog B (S. cerevisiae) /
221556_at CDC14 cell division cycle 14 homolog C (S. cerevisiae) CDC14B /// CDC14C
212501 at CCAAT/enhancer binding protein (C/EBP), beta CEBPB
1552472 a at centaurin, beta 2 CENTB2
239413 at centrosomal protein 152kDa CEPI52
215882 at Centrosomal protein 152kDa CEP152
215170 s at centrosomal protein 152kDa CEP152
210564 x at CASP8 and FADD-like apoptosis regulator CFLAR
224600 at CGG triplet repeat binding protein 1 CGGBP1
224599 at CGG triplet repeat binding protein 1 CGGBP1
225026 at chromodomain helicase DNA binding protein 6 CHD6
238075 at CHK1 checkpoint homolog (S. pombe) CHEK1
213060 s at chitinase 3-like 2 CHI3L2
219492 at cysteine-rich hydrophobic domain 2 CHIC2
219634 at carbohydrate (chondroitin 4) sulfotransferase 11 CHST11
226372 at Carbohydrate (chondroitin 4) sulfotransferase 11 CHST11
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214683 s at CDC-like kinase 1 dLKI
201943 s at carboxypeptidase D CPD
224831 at cytoplasmic polyadenylation element binding protein 4 CPEB4
228365 at copine Vill CPNE8
201990 s at cAMP responsive element binding protein-like 2 CREBL2
201989 s at cAMP responsive element binding protein-like 2 CREBL2
222235 s at chondroitin sulfate N-acetylgalactosaminyltrarsferase 2 CSGALNACT2
204971 at cystatin A (stefin A) CSTA
210163 at chemokine (CX-C Motif) ligand 11 CXCL11
1553905_at chromosome X open reading frame 22 CXorf22
225804 at cytochrome b5 domain containing 2 CYB5D2
DCN1, defective in cullin neddylation 1, domain containing 1 (S.
218583 s at cerevisiae) DCUN1D1
224791at development and differentiation enhancing factor I DDEF1
209383 at DNA-damage-inducible transcript 3 DDIT3
202887_sat DNA-damage-inducible transcript 4 DDIT4
222793_at DEAD (Asp-Glu-Ala-Asp) box polypeptide 58 DDX58
203695 s at deafness, autosomal dominant 5 DFNA5
229097 at diaphanous homolog 3 (Drosophila) DIAPH3
220997 s at diaphanous homolog 3 (Drosophila) DIAPK3
226026 at disrupted in renal carcinoma 2 DIRC2
222253 s at POM121-like protein DKFZP434P211
231412 at hypothetical gene supported by BX538329 DKFZp686L14188
203791 at Dmx-like I DMXLI
203810_at DnaJ (Hsp4O) homolog, subfamily B, member 4 DNAJB4
227166 at DnaJ (Hsp4O) homolog, subfamily C, member 18 DNAJC18
205003 at dedicator of cytokinesis 4 DOCK4
212538 at dedicator of cytokinesis 9 DOCK9
213391_at dpy-1 9-like 4 (C. elegans) DPY19L4
201022 s at destrin (actin depolymerizing factor) DSTN
219469 at dynein, cytoplasmic 2, heavy chain 1 DYNC2H1
203279 at ER degradation enhancer, mannosidase alpha-like 1 EDEM1
204841_s at early endosome antigen 1 EEA1
225885 at early endosome antigen 1 EEAI
227404_s at Early growth response 1 EGR1
201693 s at early growth response I EGRI
201694 s at early growth response 1 EGR1
205249 at early growth response 2 (Krox-20 homolog, Drosophila) EGR2
227930_at Eukaryotic translation initiation factor 2C, 4 EIF2C4
ectonucleotide pyrophosphatase/phosphodiesterase 2
209392 at (autotaxin) ENPP2
ectonucleotide pyrophosphatase/phosphodiesterase 4 (putative
204160_s at function) ENPP4
217886 at epidermal growth factor receptor pathway substrate 15 EPS15
235276 at Epithelial stromal interaction 1 (breast) EPST1
v-erb-a erythroblastic leukemia viral oncogene homolog 4
214053 at (avian) ERBB4
213938 at ELKS/RAB6-interacting/CAST family member 2 ERC2
241252 at establishment of cohesion 1 homolog 2 (S. cerevisiae) ESCO2
226432 at ethanolamine kinase 1 ETNK1
219017 at ethanolamine kinase 1 ETNK1
235056 at ets variant gene 6 (TEL oncogene) ETV6
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230183 at exostoses (multiple) I EXT1
224785 at family with sequence similarity 100, member B FAM00B
214889 at family with sequence similarity 149, member A FAM149A
222291 at family with sequence similarity 149, member A FAM149A
215719 x at Fas (TNF receptor superfamily, member 6) FAS
204781 s at Fas (TNF receptor superfamily, member 6) FAS
204780 s at Fas (TNF receptor superfamily, member 6) FAS
216252 x at Fas (TNF receptor superfamily, member 6) FAS
228149 at hypothetical protein FLJ31818 FLJ31818
235291 s at hypothetical protein LOC643977 FLJ32255
235292 at hypothetical protein LOC643977 FU32255
227298 at hypothetical gene supported by AK095117 FLJ37798
222225 at 60S ribosomal pseudogene FLJ45055
209189 at v-fos FBJ murine osteosarcoma viral oncogene homolog FOS
FERM and PDZ domain containing 2 / FERM and PDZ domain FRMPD2 /// FRMPD2L1 ///
239275 at containing 2 like 2 /// FERM and PDZ domain containing 2 like 1 FRMPD2L2
1562625 at FRY-like FRYL
203725 at growth arrest and DNA-damage-inducible, alpha GADD45A
210872_x_at growth arrest-specific 7 GAS7
202832 at GRIP and coiled-coil domain containing 2 GCC2
204224 s at GTP cyclohydrolase 1 (dopa-responsive dystonia) GCH1
221279 at ganglioside-induced differentiation-associated protein 1 GDAP1
226271 at ganglioside-induced differentiation-associated protein 1 GDAP1
226269 at ganglioside-induced differentiation-associated protein 1 GDAPI
229868 s at Growth differentiation factor 15 GDF15
221577 x at growth differentiation factor 15 GDF15
204472 at GTP binding protein overexpressed in skeletal muscle GEM
214681 at glycerol kinase GK
212335 at glucosamine (N-acetyl)-6-sulfatase (Sanfilippo disease ID) GNS
207183 at G protein-coupled receptor 19 GPR19
223767 at G protein-coupled receptor 84 GPR84
1552685 a at grainyhead-like 1 (Drosophila) GRHL1
215766 at Glutathione S-transferase Al GSTA1
208579 x at H2B histone family, member S H2BFS
HECT domain and ankyrin repeat containing, E3 ubiquitin
227471 at protein ligase 1 HACE1
205012 s at hydroxyacylglutathione hydrolase HAGH
38037 at heparin-binding EGF-like growth factor HBEGF
203821 at heparin-binding EGF-like growth factor KBEGF
200833 s at RAP1B, member of RAS oncogene family / hCG1757335 hCG_1757335 /// RAP1 B
215071 s at histone cluster 1, H2ac HIST1H2AC
214502 at histone cluster 1, H2bj HIST1 H2BJ
209806 at histone cluster 1, H2bk HISTIH2BK
212642 s at human immunodeficiency virus type I enhancer binding protein 2 HIVEP2
3-hydroxymethyl-3-methylglutaryl-CoenzymeA lyase
202772 at (hydroxymethylglutaricaciduria) HMGCL
Heterogeneous nuclear ribonucleoprotein D (AU-rich element
213359 at RNA binding protein 1, 37kDa) HNRNPD
intercellular adhesion molecule 1 (CD54), human rhinovirus
202638 s at receptor ICAM1
201631 s at immediate early response 3 IER3
I
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204439 at interferon-induced protein 44-like IF144L
226757_at interferon-induced protein with tetratricopeptide repeats 2 IFIT2
219971 at interleukin 21 receptor IL21R
220054_at interleukin 23, alpha subunit p19 IL23A
206502 s at insulinoma-associated 1 INSMI
238488 at importin 11 IPO11
231779 at interleukin-1 receptor-associated kinase 2 IRAK2
202531 at interferon regulatory factor 1 IRF1
221449 s at integrin alpha FG-GAP repeat containing I ITFG1
203710 at inositol 1,4,5-triphosphate receptor, type 1 ITPR1
216944 s at inositol 1,4,5-triphosphate receptor, type 1 ITPRI
209898_x at intersectin 2 ITSN2
209099 x at jagged I (Alagille syndrome) JAGI
216268 s at jagged 1 (Alagille syndrome) JAG1
1562031 at Janus kinase 2 (a protein tyrosine kinase) JAK2
205841 at Janus kinase 2 (a protein tyrosine kinase) JAK2
212447 at kelch repeat and BTB (POZ) domain containing 2 KBTBD2
219615_s at potassium channel, subfamily K, member 5 KCNK5
203288 at KIAA0355 KIAA0355
202386_s at KIAA0430 KIAA0430
1554132 a_at KIAA1128 KIAA1128
225327 at KIAA1 370 KIAAI 370
222139 at KIAA1466 gene KIAA1466
225506_at KIAA1468 KIAA1468
227638 at KIAA1632 KIAA1632
236108_at KIAA1 632 KIAA1 632
228453 at KIAA1632 KIAA1632
225068 at kelch-like 12 (Drosophila) KLHL12
219157 at kelch-like 2, Mayven (Drosophila) KLHL2
210635 s at kelch-like 20 (Drosophila) KLHL20
228328 at kelch-like 28 (Drosophila) KLHL28
220238 s at kelch-like 7 (Drosophila) KLHL7
220239 at kelch-like 7 (Drosophila) KLHL7
233329 s at lysine-rich coiled-coil 1 KRCC1
218303 x at lysine-rich coiled-coil 1 KRCCI
208071 s at leukocyte-associated immunoglobulin-like receptor 1 LAIR1
210644 s at leukocyte-associated immunoglobulin-like receptor 1 LAIRI
200771 at laminin, gamma 1 (formerly LAMB2) LAMC1
227013 at LATS, lare tumor suppressor, homolog 2 (Drosophila) LATS2
213371_at LIM domain binding 3 LDB3
223800 s at LIM and senescent cell antigen-like domains 3 LIMS3
235809 at lin-54 homolog (C. elegans) LIN54
200704 at lipopolysaccharide-induced TNF factor LITAF
1557558 s at Hypothetical protein LOC100131664 LOC100129196
229699 at hypothetical protein LOCI00129550 LOC100129550
ubiquitously transcribed tetratricopeptide repeat gene, Y-linked
211149_at /// hypothetical protein LOC100130224 LOC100130224 / UTY
238014 at similar to hCG1646803 LOC100131211
237085 x at similar to hCG1656091 /// hypothetical protein LOC100134805 LOC1 00132357 /// LOC100134805
neighbor of BRCA1 gene 1 /// similar to neighbor of BRCA1
201384 s at gene 1 LOC100133166 // NBR1
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213256 at
membrane-associated ring finger (C3HC4) 3 /// similar to
membrane-associated rinq finger (C3HC4) 3 LOC100133609 /// MARCH3
213195 at hypothetical protein LOC201229 LOC201229
235584 at hypothetical protein LOC285033 LOC285033
224158 s at hypothetical LOC286144 LOC286144
225603 s at hypothetical LOC286144 LOC286144
225600 at hypothetical LOC286144 LOC286144
225599 s at hypothetical LOC286144 LOC286144
226924 at hypothetical LOC400657 LOC400657
227969 at hypothetical gene supported by BC040598 LOC400960
236555 at hypothetical LOC643749 LOC643749
1559532 at hypothetical LOC646450 LOC646450
1565935 at prematurely terminated mRNA decay factor-like LOC91431
205953 at leucine-rich repeats and immunoglobulin-like domains 2 LRIG2
219338 s at leucine rich repeat containing 49 LRRC49
215222 x at microtubule-actin crosslinking factor 1 MACF1
208634 s at microtubule-actin crosslinking factor 1 MACF1
208786 s at microtubule-associated protein 1 light chain 3 beta MAP1LC3B
mitogen-activated protein kinase kinase kinase 7 interacting
212184 s at protein 2 MAP3K71P2
228468 at microtubule associated serine/threonine kinase-like MASTL
227833 s at methyl-CpG binding domain protein 6 MBD6
226225 at mutated in colorectal cancers MCC
230498 at melanin-concentrating hormone receptor I MCHR1
211675 s at MyoD family inhibitor domain containing MDFIC
213761 at Mdm1 nuclear protein homolog (mouse) MDM1
212209_at mediator complex subunit 13-like MED13L
212208_ at mediator complex subunit 13-like MED13L
212207 at mediator complex subunit 13-like MED13L
212535 at myocyte enhancer factor 2A MEF2A
238158 at meiosis expressed gene 1 homolog (mouse) MEIG1
1558960 a at Milk fat globule-EGF factor 8 protein MFGE8
1555363 s at hypothetical protein MGC39821 MGC39821
235868 at Meningioma expressed antigen 5 (hyaluronidase) MGEA5
224725 at mindbomb homolog 1 (Drosophila) MIB1
MID1 interacting protein 1 (gastrulation specific G12 homolog
218251 at (zebrafish)) MIDiIP1
218071 s at makorin, ring finger protein, 2 MKRN2
238975 at methylmalonic aciduria (cobalamin deficiency) cblB type MMAB
227747 at myelin protein zero-like 3 MPZL3
210224 at major histocompatibility complex, class I-related MR1
243010 at musashi homolog 2 (Drosophila) MS12
5,10-methenyltetrahydrofolate synthetase (5-
formyltetrahydrofolate cyclo-ligase) / suppressor of
217104 at tumorigenicity 20 MTHFS /// ST20
244734 at Methenyltetrahydrofolate synthetase domain containing MTHFSD
233665_x_at mitochondrial translation optimization 1 homolog (S. cerevisiae) MTOI
218716 x at mitochondrial translation optimization 1 homolog (S. cerevisiae) MTO1
222014 x at mitochondrial translation optimization 1 homolog (S. cerevisiae) MTOI
228846 at MAX dimerization protein 1 MXD1
226275 at MAX dimerization protein I MXDI
225301 s at myosin VB MYO5B
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228242 at NEDD4 binding protein 2 N4BP2
214906 x at NEDD4 binding protein 2-like 1 N4BP2L1
217197 x at NEDD4 binding protein 2-like I N4E1P2L1
214887 at NEDD4 binding protein 2-like 1 N4BP2L1
213375 s at NEDD4 binding protein 2-like 1 N4BP2LI
1565908 at NAD synthetase 1 NADSYN1
neural precursor cell expressed, developmentally down-
213012 at regulated 4 NEDD4
212299_at NIMA (never in mitosis gene a)- related kinase 9 NEK9
Nuclear factor of activated T-celis, cytoplasmic, calcineurin-
226991 at dependent 2 NFATC2
201146 at nuclear factor (erythroid-derived 2)-like 2 NFE2L2
202215 s at nuclear transcription factor Y, gamma NFYC
212483 at Nipped-B homolog (Drosophila) NIPBL
209798 at nuclear protein, ataxia-telanglectasia locus NPAT
238843 at nephronophthisis 1 (juvenile) NPHP1
204538 x at nuclear pore complex interacting protein NPIP
N-acetyineuraminate pyruvate lyase (dihydrodipicolinate
240440 at synthase) NPL
N-acetyineuraminate pyruvate lyase (dihydrodipicolinate
223405 at synthase) NPL
nuclear receptor subfamily 3, group C, member 1 (glucocorticoid
216321_s at receptor) NR3C1
202340 x at nuclear receptor subfamily 4, group A, member 1 NR4AI
216248 s at nuclear receptor subfamily 4, group A, member 2 NR4A2
209959 at nuclear receptor subfamily 4, group A, member 3 NR4A3
223011 s at OCIA domain containing 1 OCIAD1
222945 x at oleoyl-ACP hydrolase OLAH
202073_at optineurin OPTN
221864 at ORAl calcium release-activated calcium modulator 3 ORA13
235197 s at osteopetrosis associated transmembrane protein 1 OSTM1
204088_at purinergic receptor P2X, ligand-gated ton channel, 4 P2RX4
230100_x at p21/Cdc42/Rac1 -activated kinase 1 (STE20 homolog, yeast) PAK1
200897 s at palladin, cytoskeletal associated protein PALLID
218809 at pantothenate kinase 2 (Hallervorden-Spatz syndrome) PANK2
219543 at phenazine biosynthesis-like protein domain containing PBLD
214118_x at pericentriolar material 1 PCM1
202174 s at pericentriolar material I PCMI
protein-L-isoaspartate (D-aspartate) 0-methyltransferase
232382_s_at domain containing 1 PCMTD1
221918 at PCTAIRE protein kinase 2 PCTK2
220049 s at programmed cell death 1 ligand 2 PDCD1 LG2
phosphodlesterase 4B, cAMP-specific (phosphodiesterase E4
203708_at dunce homolog, Drosophila) PDE4B
213228_at phosphodiesterase 8B PDE8B
219891 at pyroglutamyl-peptidase I PGPEPI
227949 at phosphatase and actin regulator 3 PHACTR3
40446 at PHD finger protein 1 PHFI
202928_s at PHD finger protein 1 PHF1
1554153 a at PHD finger protein 21A PHF21A
203278 s at PHD finger protein 21A PHF21A
51146 at phosphatidylinositol glycan anchor biosynthesis, class V PIGV
221756_at phosphoinositide-3-kinase interacting protein 1 PIK31P1
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209193 at pim-1 oncogene PIM1
229414 at phosphatidylinositol transfer protein, cytoplasmic 1 PITPNC1
pleckstrin homology domain containing, family G (with RhoGef
226122 at domain) member 1 PLEKHG1
204286 s at phorbol-12-myristate-13-acetate-induced protein 1 PMAIP1
204285 s at phorbol-12-myristate-13-acetate-induced protein 1 PMAIP1
223269 at polymerase (RNA) IlIl (DNA directed) polypeptide G (32kD)-like POLR3GL
219926 at popeye domain containing 3 POPDC3
1569675 at POU class 2 associating factor 1 POU2AF1
212230 at phosphatidic acid phosphatase type 2B PPAP2B
peroxisome proliferator-activated receptor gamma, coactivator 1
219195 at alpha PPARGC1A
226472 at peptidylprolyl isomerase (cyclophilin)-like 4 PPIL4
protein phosphatase 1A (formerly 2C), magnesium-dependent,
203966 s at alpha isoform PPM1A
236302 at protein phosphatase 1 E (PP2C domain containing) PPM1 E
202014 at protein phosphatase 1, regulatory (inhibitor) subunit 15A PPP1R15A
37028 at protein phosphatase 1, regulatory (inhibitor) subunit 15A PPPI R15A
protein phosphatase 2 (formerly 2A), regulatory subunit B",
209633 at alpha PPP2R3A
205053 at primase, DNA, polypeptide 1 (49kDa) PRIM1
prion protein (p27-30) (Creutzfeldt-Jakob disease, Gerstmann-
201300 s at Strausler-Scheinker syndrome, fatal familial insomnia) PRNP
pleckstrin homology, Sec7 and coiled-coil domains 1(cytohesin
202880 s at 1) PSCD1
205048 s at phosphoserine phosphatase PSPH
200732 s at protein tyrosine phosphatase type IVA, member 1 PTP4A1
225074 at RAB2B, member RAS oncogene family RAB2B
228003 at RAB30, member RAS oncogene family RAB30
230075 at RAB39B, member RAS oncogene family RAB39B
238695 s at RAB39B, member RAS oncogene family RAB39B
213531 s at RAB3 GTPase activating protein subunit 1 (catalytic) RAB3GAP1
213530 at RAB3 GTPase activating protein subunit I (catalytic) RAB3GAP1
228432 at RAB3A interacting protein (rabin3) RAB31P
223471 at RAB3A interacting protein (rabin3) RAB31P
213313 at RAB GTPase activating protein 1 RABGAP1
205023 at RAD51 homolog (RecA homolog, E. coil) (S. cerevisiae) RAD51
204146 at RAD51 associated protein 1 RAD51AP1
1553285 s at RAD9 homolog B (S. cerevisiae) RAD9B
1564688 a at RAD9 homolog B (S. cerevisiae) RAD9B
57540 at ribokinase RBKS
219222 at ribokinase RBKS
212331 at retinoblastoma-like 2 (p130) RBL2
226430 at RELT-like 1 RELL1
208070 s at REV3-like, catalytic subunit of DNA polymerase zeta (yeast) REV3L
209085_x at replication factor C (activator 1) 1, 145kDa RFC1
208021 s at replication factor C (activator 1) 1, 145kDa RFCi
207234 at regulatory factor X, 3 (influences HLA class 11 expression) RFX3
222630 at regulatory factor X domain containing 2 RFXDC2
RANBP2-like and GRIP domain containing 5 // RANBP2-like
and GRIP domain containing 4 /// RANBP2-like and GRIP
domain containing 8 // RANBP2-like and GRIP domain RGPD4 Il/ RGPD5 /// RGPD6 ///
212842 x at containing 6 RGPD8
209324 s at regulator of G-protein signaling 16 RGS16
I
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209325 s at regulator of G-protein signaling 16 RGS16
232053 x at rhomboid domain containing 2 RHBDD
222995 s at rhomboid domain containing 2 RHBDD2
202130 at RIO kinase 3 (east) RIHK3
202131sat RIO kinase 3 (yeast) RIOK3
221215 s at receptor-interacting serine-threonine kinase 4 RIPK4
243463 s at Ras-like without CAAX 1 RIT1
236223 s at Ras-like without CAAX 1 RITi
239843 at Ras-like without CAAX 1 RIT1
233166 at ribonuclease H2, subunit B RNASEH2B
218761_at ring finger protein 111 RNF111
201779 s at ring finger protein 13 RNF13
201780_s_at ring finger protein 13 RNF13
214898 at RODi regulator of differentiation 1 (S. pombe) ROD1
214697 s at ROD1 regulator of differentiation 1 (S. pombe) RODI
224618 at ROD1 regulator of differentiation 1 (S. pombe) ROD1
224835 at hypothetical protein KIAA1434 RP5-1022P6.2
1554319 at ribosomal protein 56 kinase, 9OkDa, polypeptide 5 RPS6KA5
204635 at ribosomal protein S6 kinase, 90kDa, polypeptide 5 RPS6KA5
200802 at seryl-tRNA synthetase SARS
213988 s at spermidine/spermine N1-acetyltransferase 1 SAT1
210592 s at spermidine/spermine NI-acetyltransferase 1 SATI
203455 s at spermidine/spermine N1-acetyltransferase 1 SAT1
215670 s at SCAN domain containing 2 SCAND2
226619 at SUMO1/sentrin specific peptidase 1 SENP1
223444 at SUMOI/sentrin specific peptidase 7 SENP7
Sep (0-phosphoserine) tRNA:Sec (selenocysteine) tRNA
235516 at synthase SEPSECS
209000_s at septin 8 SEPT8
214539 at serpin peptidase inhibitor, clade B (ovalbumin), member 10 SERPINB10
223196 s at sestrin 2 SESN2
223195 s at sestrin 2 SESN2
227210 at Scmlike with four mbt domains 2 SFMBT2
207351 s at SH2 domain protein 2A SH2D2A
223744 s at sialic acid acetylesterase SIAE
solute carrier family 12 (potassium/chloride transporters),
226741_at member 6 SLC12A6
solute carrier family 1 (glutamate/neutral amino acid transporter),
212810 s at member 4 SLC1A4
solute carrier family 24 (sodium/potassium/calcium exchanger),
206081 at member 1 SLC24A1
218284 at SMAD family member 3 SMAD3
205398 s at SMAD family member 3 SMAD3
SWI/SNF related, matrix associated, actin dependent regulator
206542 s at of chromatin, subfamily a, member 2 SMARCA2
210357 s at spermine oxidase SMOX
225220 at small nucleolar RNA host gene (non-protein coding) 8 SNHG8
229618_at sorting nexin 16 SNX16
215522 at sortilln-related VPS1O domain containing receptor 3 SORCS3
225564 at spermatogenesis associated 13 SPATA1 3
226353 at signal peptide peptidase-like 2A SPPL2A
1554053 at serine palmitoyltransferase, long chain base subunit 1 SPTLC1
229067 at SLIT-ROBO Rho GTPase activating protein 2 pseudogene 1 SRGAP2P1
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1568957 x at SLIT-ROBO Rho GTPase acgaiaooti suoene 1 SRGAP2P1
1568955 at SLIT-ROBO Rho GTPase activating protein 2 pseudogene 1 SRGAP2Pi
1558254 s at SFRS protein kinase 2 SRPK2
203182 s at SFRS protein kinase 2 SRPK2
236123 at Suppression of tumorigenicity 7 like ST7L
231521 at Stromal antigen 3-like 4 STAG3L4
218994 s at stromal antigen 3-like 4 STAG3L4
225636 at signal transducer and activator of transcription 2, 113kDa STAT2
signal transducer and activator of transcription 3 (acute-phase
225289_at response factor) STAT3
40420 at serine/threonine kinase 10 STKIO
228394_at serine/threonine kinase 10 STK1 0
203047 at serine/threonine kinase 10 STK10
202695 s at serine/threonine kinase 17a STK17A
36019 at serine/threonine kinase 19 STK19
204090 at serine/threonine kinase 19 STK1 9
201060 x at stomatin STOM
212800 at syntaxin 6 STX6
212799 at syntaxin 6 STX6
227407 at transmembrane anterior posterior transformation 1 TAPT1
1569566 at TBC1 (tre-2/USP6, BUB2, cdc16) domain family, member 1 TBC1 D1
218584 at tectonic family member 1 TCTN1
206438 x at tectonic family member 2 TCTN2
201174 s at telomeric repeat binding factor 2, interacting protein TERF21P
205486 at testis-specific kinase 2 TESK2
219596 at THAP domain containing 10 THAP1 0
230185 at THAP domain containing 9 THAP9
220986 s at tigger transposable element derived 6 TIGD6
47608 at tight junction associated protein 1 (peripheral) TJAP1
204872 at transducin-like enhancer of split 4 (E(spl) homolog, Drosophila) TLE4
212621 at transmembrane protein 194 TMEM194
212619 at transmembrane protein 194 TMEM194
241364 at Transmembrane protein 57 TMEM57
228549 at Transmembrane protein 63A TMEM63A
232023 at transmembrane protein 67 TMEM67
226483 at transmembrane protein 68 TMEM68
202644 s_at tumor necrosis factor, alpha-induced protein 3 TNFAIP3
202643 s at tumor necrosis factor, alpha-induced protein 3 TNFAIP3
206025 s at tumor necrosis factor, alpha-induced protein 6 TNFAIP6
206026 s at tumor necrosis factor, alpha-induced protein 6 TNFAIP6
209295 at tumor necrosis factor receptor superfamily, member 1Ob TNFRSFIOB
210405 x at tumor necrosis factor receptor superfamily, member 1Ob TNFRSF10B
207643 s at tumor necrosis factor receptor superfamily, member 1A TNFRSF1A
211786 at tumor necrosis factor receptor superfamily, member 9 TNFRSF9
206907 at tumor necrosis factor (ligand) superfamily, member 9 TNFSF9
tankyrase, TRF1-interacting ankyrin-related ADP-ribose
202561 at polymerase TNKS
229257 at trinucleotide repeat containing 18 TNRC18
209670 at T cell receptor alpha constant TRAC
202124 s at trafficking protein, kinesin binding 2 TRAK2
225537 at trafficking protein particle complex 6B TRAPPC6B
I
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223924 at tetratricopeptide repeat domain 25
226175 at tetratricopeptide repeat domain 9C TTC9C
219201 s at twisted gastrulation homolog 1 (Drosophila) TWSG1
201010 s at thioredoxin interacting protein TXNIP
201009 s at thioredoxin interacting protein TXNIP
226700_at U2 small nuclear RNA auxiliary factor 1-like 4 U2AF1L4
222421 at ubiquitin-conjugating enzyme E2H (UBC8 homolog, yeast) UBE2H
226637_at Ubiquitin-conjugating enzyme E2H (UBC8 homolog, yeast) UBE2H
222420 s at ubiquitin-conjugating enzyme E2H (UBC8 homolog, yeast) UBE2H
226681 at Ubiquitin-conjugating enzyme E2H (UBC8 homolog, yeast) UBE2H
217799 x at ubiquitin-conjugating enzyme E2H (UBC8 homolog, yeast) UBE2H
226921 at ubiquitin protein ligase E3 component n-recognin 1 UBR1
212756_sat ubiquitin protein ligase E3 component n-recognin 2 UBR2
230029 x at ubiquitin protein ligase E3 component n-recognin 3 UBR3
244121 at Ubiquitin protein ligase E3 component n-recognin 3 UBR3
211950_at ubiquitin protein ligase E3 component n-recognin 4 UBR4
1555888 at Ubiquitin protein ligase E3 component n-recognin 5 UBR5
208883 at ubiquitin protein ligase E3 component n-recognin 5 UBR5
212840 at UBX domain containing 7 UBXD7
224638_at signal peptide peptidase 3 UNQ1887
226505 x at ubiquitin specific peptidase 32 USP32
206405 x at ubiquitin specific peptidase 6 (Tre-2 oncogene) USP6
238164 at USP6 N-terminal like USP6NL
201099_at ubiquitin specific peptidase 9, X-linked USP9X
225093at utrophin UTRN
203992 s at ubiquitously transcribed tetratricopeptide repeat, X chromosome UTX
203991 s at ubiquitously transcribed tetratricopeptide repeat, X chromosome UTX
210322 x at ubiquitously transcribed tetratricopeptide repeat gene, Y-linked UTY
213480 at vesicle-associated membrane protein 4 VAMP4
210512_s at vascular endothelial growth factor A VEGFA
218396 at vacuolar protein sorting 13 homolog C (S. cerevisiae) VPS13C
228024 at Vacuolar protein sorting 37 homolog A (S. cerevisiae) VPS37A
225378 at vacuolar protein sorting 37 homolog A (S. cerevisiae) VPS37A
222390_at WW domain containing adaptor with coiled-coil WAC
220917 s at WD repeat domain 19 WDR19
229516_at WD repeat domain 31 WDR31
218851 s at WD repeat domain 33 WDR33
226668 at WD repeat, sterile alpha motif and U-box domain containing 1 WDSUB1
212340 at Yipl domain family, member 6 YIPF6
222408 s at yippee-like 5 (Drosophila) YPEL5
217783 s at yippee-like 5 (Drosophila) YPEL5
225512 at zinc finger and BTB domain containing 38 ZBTB38
227809 at zinc finger CCCH-type containing 6 ZC3H6
241372 at zinc finger CCCH-type containing 6 ZC3H6
218020 s at zinc finger, ANI-type domain 3 ZFAND3
243312 at Zinc finger protein 107 ZNF107
213452 at zinc finger protein 184 ZNFI84
233070 at zinc finger protein 197 ZNF197
215239 x at zinc finger protein 273 ZNF273
225382 at zinc finger protein 275 ZNF275
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Probeset ID Gene Name Gene Symbol
228460 at zinc finger protein 319 ZNF319
212557 at zinc finger protein 451 ZNF451
232272 at zinc finger protein 624 ZNF624
206583 at zinc finger protein 673 ZNF673
227080 at zinc finger protein 697 ZNF697
238510 at zinc finger protein 720 ZNF720
1560853 x at zinc finger prtein 826 ZNF826
1564963 x at zinc finger protein 92 ZNF92
219676 at zinc finger and SCAN domain containing 16 ZSCAN16
226208 at zinc finger, SWIM-type containing 6 ZSWIM6
232515 at
208144 s at
222968 at
1562474_at
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237147 at Transcribed locus
237753 at Transcribed locus --
210230 at CDNA: FLJ23438 fis, clone HRC13275
Transcribed locus, moderately similar to XP_001162191.1
PREDICTED: complement component 4A isoform 2 [Pan
235856_at troglodytes] 
---
235378 at Transcribed locus
235534 at CDNA clone IMAGE:5723825 ---
235352 at CDNA FLJ31593 fis, clone NT2R12002481
235661 at Transcribed locus
1563057 at Homo sapiens, clone IMAGE:3451831, mRNA
1559668 s at Homo sapiens, clone IMAGE:2905626, mRNA
235230 at CDNA FLJ34317 fis, clone FEBRA2008475
236683 at Transcribed locus
235924 at CDNA FLJ42287 fis, clone TLIVE2005866
Transcribed locus, strongly similar to XP_001102200.1
231379_at PREDICTED: hypothetical protein [Macaca mulatta]
1556332 at CDNA FLJ38412 fis, clone FEBRA2009385
244503 at Transcribed locus
217490_at MRNA; cDNA DKFZp564P073 (from clone DKFZp564P073)
242866 x at Transcribed locus
243695 at Transcribed locus
243283 at Transcribed locus ---
243397 at Transcribed locus
1555893_at CDNA clone IMAGE:5267578 ---
Transcribed locus, strongly similar to XP_001141494.1
231378 at PREDICTED: hypothetical protein [Pan troglodytes]
236709_at Transcribed locus
233529 at Transcribed locus -
239896 at Clone TESTIS-809 mRNA sequence
239605 x at Transcribed locus
238725 at Transcribed locus
213448 at CDNA FLJ31688 fis, clone NT2R12005520
1559667 at Homo sapiens, clone IMAGE:2905626, mRNA
221725 at CDNA clone IMAGE:3030163
241434 at Transcribed locus
241390 at Transcribed locus ---
1562770_at Homo sapiens, clone IMAGE:5228125, mRNA
235053 at CDNA FLJ30257 fis, clone BRACE2002467
Transcribed locus, strongly similar to XP_001718768.1
229917 at PREDICTED: similar to hCG2014417 [Homo sapiens] -
Transcribed locus, strongly similar to XP_531001.1
228231 at PREDICTED: hypothetical protein [Pan troglodytes] --
238717 at CDNA FLJ31114 fis, clone IMR322000379 ---
1560590 s at Homo sapiens, clone IMAGE:2905626, mRNA -
1567575 at Trapped 3' terminal exon, clone C2C4 ---
1558444 at CDNA FU35140 fis, clone PLACE6009524 
-
226002 at CDNA clone IMAGE:4801326 ---
229715 at CDNA FLJ41663 fis, clone FEBRA2027297
235592_at CDNA FLJ36210 fis, clone THYMU2000155
228910 at Transcribed locus ---
233479_at CDNA FLJ 12362 fis, clone MAMMA1 002360
239988 at Transcribed locus I -_I
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225499 at Clone CDABPO105 mRNA sequence
226282 at Full length insert cDNA clone ZE03FO6 ---
230828 at Transcribed locus --
1569339 s at Transcribed locus ---
228717_at Transcribed locus --
236766 at Transcribed locus -
1558438 a at Immunoglobulin epsilon chain ---
225685 at CDNA FLJ31353 fis, clone MESAN2000264
1559214 at MRNA full length insert cDNA clone EUROIMAGE 839551 --
239310 at Transcribed locus
227184 at Transcribed locus ---
1564381 s at CDNA FLJ 10952 fis, clone PLACE1 000374
226478_at CDNA FLJ34764 fis, clone NT2NE2002311
1564479 a at CDNA FLJ37609 fis, clone BRCOC2011010 -
1557021 s at CDNA clone IMAGE:5268292 --
Homo sapiens, clone IMAGE:4284850, mRNA /// CDNA
226832 at FU39749 fis, clone SMINT2017599
1556938 a at CDNA FLJ38433 fis, clone FEBRA2014578
1558512 at CDNA FLJ33400 fis, clone BRACE2009828 -
Transcribed locus, strongly similar to NP_060631.2 NAD
1568802 at synthetase 1 [Homo sapiens] --
1563898 at CDNA FLJ34764 fis, clone NT2NE2002311
232320 at CDNA: FLJ22706 fis, clone HS113163 ---
Periodontal ligament cell specific protein 2 mRNA, partial
235506 at sequence
240454 at Transcribed locus
227749 at Transcribed locus -
227252 at Transcribed locus -
227333 at CDNA: FLJ23546 fis, clone LNG08361
228811 at Transcribed locus --
230343 at Transcribed locus --
235046 at Transcribed locus -
237063 at Transcribed locus
233413 at CDNA FLJ13457 fis, clone PLACE1 003343
231584 s at Transcribed locus
231637 at Transcribed locus
1563086 at CDNA clone IMAGE:5526877
231558 at Transcribed locus -
233116 at CDNA FLJ25090 fis, clone CBL08887
224261 at Transcribed locus --
239332 at Homo sapiens, clone IMAGE:3897156, mRNA
1559462_at Homo sapiens, clone IMAGE:6155889, mRNA -
229746 x at CDNA FLJ10952 fis, clone PLACEI 000374
229754 at CDNA clone IMAGE:4862812 ---
Transcribed locus, strongly similar to XP_001134971.1
243721 at PREDICTED: hypothetical protein [Pan troglodytes]
229202 at Transcribed locus -
236806 at Transcribed locus
235080_at Transcribed locus -
229242 at Transcribed locus
231150 at Transcribed locus
244026 at Transcribed locus -
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1558845 at CDNA FLJ40376 fis, clone TEST12035121
230606 at CDNA FLJ40933 fis, clone UTERU2007081 -
1563949 at MRNA; cDNA DKFZp547L204 (from clone DKFZp547L204) --
1556138 a at Full length insert cDNA clone ZC33A09
230483 at Transcribed locus ---
Transcribed locus, strongly similar to NP_006493.1 polymerase
237877 at (DNA directed), eta [Homo sapiens]
Transcribed locus, strongly similar to NP_004827.4 eukaryotic
1568804 at translation initiation factor 2-alpha kinase 3 [Homo sapiens] --
239578 at Transcribed locus 
--
230856_at Transcribed locus ---
242667 at Transcribed locus --
225176_at CDNA FLJ42149 fis, clone THYMU 1000692
1559372 at Homo sapiens, clone IMAGE:5743964, mRNA
230330_at CDNA FLJ30011 fis, clone 3NB692000276
205434 s at AP2 associated kinase 1 AAKi
225522_at AP2 associated kinase 1 AAK1
215465 at ATP-binding cassette, sub-family A (ABC1), member 12 ABCA12
207321 s at ATP-binding cassette, sub-family B (MDR/TAP), member 9 ABCB9
214209 s at ATP-binding cassette, sub-family B (MDR/TAP), member 9 ABCB9
205566 at abhydrolase domain containing 2 ABHD2
213935 at abhydrolase domain containin 5 ABHD5
213497_at ankyrin repeat and BTB (POZ) domain containing 2 ABTB2
209608 s at acetyl-Coenzyme A acetyltransferase 2 ACAT2
201630 s at acid phosphatase 1, soluble ACP1
243140 at Actin, alpha 2, smooth muscle, aorta ACTA2
206833_s at acylphosphatase 2, muscle type ACYP2
244194 at ADAM metallopeptidase domain 22 ADAM22
209122_at adipose differentiation-related protein ADFP
212500 at 2-aminoethanethiol (cysteamine) dioxygenase ADO
217419 x at agrin AGRN
212285.s at agrin AGRN
1555736 a at angiotensin Il receptor-associated protein AGTRAP
225059 at angiotensin 11 receptor-associated protein AGTRAP
220289_s at absent in melanoma 1-like AIM1L
205633 s at aminolevulinate, delta-, synthase I ALAS1
207381_at arachidonate 12-lipoxygenase, 12R type ALOX1 2B
amyotrophic lateral sclerosis 2 (juvenile) chromosome region,
1553956 at candidate 4 ALS2CR4
228840 at angiomotin like 1 AMOTL1
218167 at archaelysin family metallopeptidase 2 AMZ2
205390_s at ankyrin 1, erythrocytic ANKI
207087 x at ankyrin 1, erythrocytic ANKI
205389 s at ankyrin 1, erythrocytic ANK1
240363 at ankyrin 1, erythrocytic ANKI
208353_x at ankyrin 1, erythrocytic ANK1
208352 x at ankyrin 1, erythrocytic ANKI
205391 x at ankyrin 1, erythrocytic ANK1
218769 s at ankyrin repeat, family A (RFXANK-like), 2 ANKRA2
220144 s at ankyrin repeat domain 5 ANKRD5
230683 at Ankyrin repeat domain 60 ANKRD60
201301 s at annexin A4 ANXA4
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203350 at adaptor-related protein complex 1, gamma 1 subunit AP1G1
211554 s at apoptotic peptidase activating factor 1 APAF1
204859 s_at apoptotic peptidase activating factor 1 APAF1
209462 at amyloid beta (M) precursor-like protein 1 APLP1
apolipoprotein B mRNA editing enzyme, catalytic polypeptide-
206632 s at like 3B APOBEC3B
222658 s at aprataxin APTX
218527 at aprataxin APTX
ADP-ribosylation factor guanine nucleotide-exchange factor 2
215931 s at (brefeldin A-inhibited) ARFGEF2
226638 at Rho GTPase activating protein 23 ARHGAP23
209539 at Rac/Cdc42 guanine nucleotide exchange factor (GEF) 6 ARHGEF6
218964 at AT rich interactive domain 3B (BRIGHT-like) ARID3B
1560219 at Ankyrin repeat and SOCS box-containing 3 ASB3
212815 at activating signal cointegrator I complex subunit 3 ASCC3
231269 at activating signal cointegrator 1 complex subunit 3 ASCC3
209693 at astrotactin 2 ASTN2
215407 s at astrotactin 2 ASTN2
1554816 at astrotactin 2 ASTN2
201444 s at ATPase, H+ transporting, lysosomal accessory protein 2 ATP6AP2
212062 at ATPase, class 11, type 9A ATP9A
1559249 at ataxin 1 ATXN1
205415 s at ataxin3 ATXN3
202686 s at AXL receptor tyrosine kinase AXL
217904 s at beta-site APP-cleaving enzyme 1 BACEI
222462 s at beta-site APP-cleaving enzyme 1 BACE1
222675 s at BAll-associated protein 2-like I BAIAP2L1
227371 at BAll-associated protein 2-like 1 BAIAP2L1
BAll-associated protein 2-like 1 /hypothetical protein
227372 s at LOC100128461 BAIAP2L1 1/ LOC100128461
203728 at BCL2-antagonistkiller I BAK1
208478 s at BCL2-associated X protein BAX
211833 s at BCL2-associated X protein BAX
218471 s at Bardet-Biedl syndrome I BBS1
229603 at Bardet-Biedl syndrome 12 BBS12
212745 s at Bardet-Biedl syndrome 4 BBS4
212744 at Bardet-Biedl syndrome 4 BBS4
228787 s at breast carcinoma amplified sequence 4 BCAS4
220588 at breast carcinoma amplified sequence 4 BCAS4
branched chain keto acid dehydrogenase El, alpha polypeptide
229957 at // transmembrane protein 91 BCKDHA /// TMEM91
212312 at BCL2-like 1 BCL2L1
239367_at brain-derived neurotphic factor BDNF
206382 s at brain-derived neurotrophic factor BDNF
213709 at basic helix-3oop-helix domain containing, class B, 9 BHLHB9
207655 s at B-call linker BLNK
225049 at biogenesis of lysosome-related organelles complex-1, subunit 2 BLOCIS2
202201 at biliverdin reductase B (flavin reductase (NADPH)) BLVRB
205574 x at bone morphogenetic protein 1 BMP1
202701 at bone morphogenetic protein 1 BMP1
205289 at bone morphogenetic protein 2 BMP2
226580 at breast cancer metastasis-suppressor 1-like BRMS1L
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224484 s at breast cancer metastasis-suppressor 1-like BRMS1L
201235 s at BTG family, member 2 BTG2
225334 at chromosome 10 open reading frame 32 ClOorf32
203481 at chromosome 10 open reading frame 6 C10orf6
227735 s at chromosome 10 open reading frame 99 C1Oorf99
219099 at chromosome 12 open reading frame 5 C12orf5
211034 s at chromosome 12 open reading frame 51 C12orff5
237701 at chromosome 12 open reading frame 54 C12orf54
240354 at chromosome 12 open reading frame 54 C12orf54
240353_s at chromosome 12 open reading frame 54 C12orf54
1557681 s at chromosome 14 open reading frame 174 C14orfl74
232316_at chromosome 14 open reading frame 174 C14orf174
1557680 at chromosome 14 open reading frame 174 CI4orfl74
242608_x at Chromosome 14 open reading frame 44 C14orf44
220173 at chromosome 14 open reading frame 45 C14orf45
213512 at chromosome 14 open reading frame 79 C14orf79
227544 at chromosome 14 open reading frame 83 C14orf83
223407_at chromosome 16 open reading frame 48 C16orf48
218183 at chromosome 16 open reading frame 5 Ct6orf5
223960_s at chromosome 16 open reading frame 5 C16orf5
217508 s at chromosome 18 open reading frame 25 C18orf25
1553651 at chromosome 18 open reading frame 54 C18orf54
221335 x at chromosome 19 open reading frame 61 C19orf61
227359_at chromosome 1 open reading frame 102 CIorf102
220193 at chromosome 1 open reading frame 113 Clorf13
220476 s at chromosome 1 open reading frame 183 Corfl183
233693 at chromosome 1 open reading frame 201 Ciorf201
1553741_at chromosome 1 open reading frame 211 Clorf211
226813 at chromosome 1 open reading frame 57 Clorf57
1561331_at chromosome 1 open reading frame 99 C1orf99
224693 at chromosome 20 open reading frame 108 C20orfi 08
224690 at chromosome 20 open reading frame 108 C20orf108
230955 s at chromosome 20 open reading frame 112 C20orf 112
230954 at chromosome 20 open reading frame 112 C20orf112
234031 at chromosome 20 open reading frame 112 C20orflI2
225224_at chromosome 20 open reading frame 112 C20orf112
chromosome 20 open reading frame 112 / hypothetical protein
1558679 at LOC284804 C20orf 112 / LOC284804
225890 at chromosome 20 open reading frame 72 C20orf72
223706 at chromosome 22 open reading frame 23 C22orf23
217767_at complement component 3 C3
241666_ at chromosome 3 open reading frame 23 C3orf23
1555905 a at chromosome 3 open reading frame 23 C3orf23
1553158 at chromosome 3 open reading frame 34 C3orf34
239697 x at chromosome 3 open reading frame 67 C3orf67
complement component 4A (Rodgers blood group) ///
208451 s at complement component 4B (Childo blood group) C4A /// C4B
complement component 4A (Rodgers blood group) /
214428_x at complement component 4B (Childo blood group) C4A /// C4B
223204 at chromosome 4 open reading frame 18 C4orfl8
218518 at chromosome 5 open reading frame 5 C5orf5
226936 at chromosome 6 open reading frame 173 C6orf173
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228007 at Chromosome 6 open reading frame 204 C6orf204
236504 x at chromosome 6 open reading rame 52 6orf52
239417 x at chromosome 6 open reading frame 52 C6orf52
219655 at chromosome 7 open reading frame 10 C7orflO
1556571 at Chromosome 8 open reading frame 38 C8orf38
236047 at chromosome 8 open reading frame 5 C8orf5
228211 at chromosome 9 open reading frame 102 C9orf512
59437 at chromosome 9 open reading frame 116 C9orfl16
1557866 at chromosome 9 open reading frame 117 C9orf 117
1557867 s at chromosome 9 open reading frame 117 C9orf117
226027 at chromosome 9 open reading frame 119 C9orf 119
207839 s at chromosome 9 open reading frame 127 C9orf127
235776 x at Chromosome 9 open reading frame 44 C9orf44
1557666_s at chromosome 9 open reading frame 98 C9orf98
230976 at chromosome 9 open reading frame 98 C9orf98
calcium/calmodulin-dependent protein kinase (CaM kinase) |1
210404 x at beta CAMK28
calcium/calmodulin-dependent protein kinase (CaM kinase) I
209956 s at beta CAMK2B
227328 at Calmodulin binding transcription activator 1 CAMTA1
213268 at calmodulin binding transcription activator 1 CAMTA1
1555370 a at calmodulin binding transcription activator 1 CAMTA1
211890 x at calpain 3, (p94) CAPN3
220168 at cancer susceptibility candidate I CASC1
calcium/calmodulin-dependent serine protein kinase (MAGUK
207620 s at family) CASK
caspase 1, apoptosis-related cysteine peptidase (interleukin 1,
209970 x at beta, convertase) CASP1
caspase 1, apoptosis-related cysteine peptidase (interleukin 1,
211366 x at beta, convertase) CASP1
caspase 1, apoptosis-related cysteine peptidase (interleukin 1,
211367 s at beta, convertase) CASP1
caspase 1, apoptosis-related cysteine peptidase (interleukin 1,
211368 s at beta, convertase) CASP1
207467 x at calpastatin CAST
208908 s at calpastatin CAST
243386 at castor zinc finger 1 CASZ1
242069 at chromobox homolog 5 (HP1 alpha homolog, Drosophila) CBX5
1554022 at coiled-coil domain containing 13 CCDCI3
1554023 s at coiled-coil domain containing 13 CCDC13
232989 s at coiled-coil domain containing 136 CCDC136
227091 at coiled-coil domain containing 146 CCDC146
1553839 at coiled-coil domain containing 149 CCDC149
241360 at coiled-coil domain containing 15 CCDC15
230807 at coiled-coil domain containing 151 CCDC151
232362 at coiled-coil domain containing 18 CCDC18
1553666 at coiled-coil domain containing 34 CCDC34
226287 at coiled-coil domain containing 34 CCDC34
227783 at coiled-coil domain containing 57 CCDC57
241943 at coiled-coil domain containing 58 CCDC58
218288_s at coiled-coil domain containing 90B CCDC90B
222577 at Coiled-coil domain containing 90B CCDC90B
238682 at coiled-coil domain containing 96 CCDC96
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225824_at cyclin K CCNK
1552509 a at CD300 molecule-like family member g CD300LG
206120 at CD33 molecule CD33
1554519 at CD80 molecule CD80
203904_x at CD82 molecule CD82
205685 at CD86 molecule CD86
203794_at CDC42 binding protein kinase alpha (DMPK-like) CDC42BPA
214721 x at CDC42 effector protein (Rho GTPase binding) 4 CDC42EP4
218062_x at CDC42 effector protein (Rho GTPase binding) 4 CDC42EP4
carcinoembryonic antigen-related cell adhesion molecule 1
209498 at (biliary glycoprotein) CEACAM1
carcinoembryonic antigen-related cell adhesion molecule 1
211889 x at (biliary glycoprotein) CEACAM1
carcinoembryonic antigen-related cell adhesion molecule 1
206576 s at (biliary glycoprotein) CEACAMI
carcinoembryonic antigen-related cell adhesion molecule 1
211883 x at (biliary glycoprotein) CEACAM1
carcinoembryonic antigen-related cell adhesion molecule 1
210610 at (biliary glycoprotein) CEACAMI
205910_s at carboxyl ester lipase (bile salt-stimulated lipase) CEL
1553970 s.at carboxyl ester lipase (bile salt-stimulated lipase) CEL
207412_x at carboxyl ester lipase pseudogene CELP
cadherin, EGF LAG seven-pass G-type receptor 2 (flamingo
204029 at homolog, Drosophila) CELSR2
34206_at centaurin, delta 2 CENTD2
206210 s at cholesteryl ester transfer protein, plasma CETP
236588 at Craniofacial development protein 1 CFDP1
208485 x at CASP8 and FADD-like apoptosis regulator CFLAR
209508_x_at CASP8 and FADD-like apoptosis regulator CFLAR
214486_x at CASP8 and FADD-like apoptosis regulator CFLAR
211317 s at CASP8 and FADD-like apoptosis regulator CFLAR
211316 x at CASP8 and FADD-llke apoptosis regulator CFLAR
211862 x at CASP8 and FADD-like apoptosis regulator CFLAR
204605 at cell growth regulator with ring finger domain 1 CGRRF1
225031_at chromodomain helicase DNA binding protein 6 CHD6
207568.at cholinergic receptor, nicotinic, alpha 6 CHRNA6
32094 at carbohydrate (chondroitin 6) sulfotransferase 3 CHST3
209834 at carbohydrate (chondroltin 6) sulfotransferase 3 CHST3
223786_at carbohydrate (N-acetylglucosamine 6-0) sulfotransferase 6 CHST6
226736_at churchill domain containing I CHURCI
219398 at cell death-inducing DFFA-like effector c CIDEC
221698_s at C-type lectin domain family 7, member A CLEC7A
ceroid-lipofuscinosis, neuronal 8 (epilepsy, progressive with
222874_s at mental retardation) CLN8
cerold-lipofuscinosis, neuronal 8 (epilepsy, progressive with
219340 s at mental retardation) CLN8
ceroid-lipofuscinosis, neuronal 8 (epilepsy, progressive with
223912 s at mental retardation) CLN8
204576 s at clusterin associated protein 1 CLUAP1
1554522 at cyclin M2 CNNM2
1564008_at Collagen, type XXVII, alpha 1 COL27AI
225293_at collagen, type XXVII, alpha 1 COL27A1
203325 s at collagen, type V, alpha 1 COL5A1
218760 at coenzyme Q6 homolog, monooxygenase (S. cerevisiae) COQ6
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204662 at CP110 Drotein CP110
224828_at cytoplasmic polyadenylation element binding protein 4 CPEB4
243403 x at carboxypeptidase M CPM
201988 s at cAMP responsive element binding protein-like 2 CREBL2
219139 s at ciliary rootlet coiled-coil, rootletin-ke 2 CROCCL2
231102 at carnitine 0-octanoyltransferase CROT
204573 at camitine 0-octanoyltransferase CROT
209716 at colony stimulating factor 1 (macrophage) CSF1
221673 s at casein kinase 1, gamma 1 CSNK1GI
226888 at casein kinase 1, gamma 1 CSNK1G1
231920 s at casein kinase 1, gamma 1 CSNKIG1
204736 s at chondroitin sulfate proteoglycan 4 CSPG4
214297 at chondroitin sulfate proteoglycan 4 CSPG4
203947 at cleavage stimulation factor, 3pre-RNA, subunit 3, 77kDa CSTF3
225525 at KIAAI671 protein/// hypothetical protein LOCI 00131004 CTA-221G9.4 /// LOC100131004
203081 at catenin, beta interacting protein 1 CTNNBIP1
208862 s at catenin (cadherin-associated protein), delta 1 CTNNDI
211240 x at catenin (cadherin-associated protein), delta 1 CTNND1
206126 at chemokine (C-X-C motif) receptor5 CXCR5
217889 s at cytochrome b reductase 1 CYBRD1
215785 s at cytoplasmic FMRI interacting protein 2 CYFIP2
226632 at cytoglobin CYGB
221903 s at cylindromatosis (turban tumor syndrome) CYLD
206153 at cytochrome P450, family 4, subfamily F, polypeptide 11 CYP4F11
210452 x at cytochrome P450, family 4, subfamily F, polypeptide 2 CYP4F2
cytochrome P450, family 4, subfamily F, polypeptide 3 //
206514 s at cytochrome P450, family 4, subfamily F, polypeptide 2 CYP4F2 /// CYP4F3
206515 at cytochrome P450, family 4, subfamily F, polypeptide 3 CYP4F3
224522 s at dephospho-CoA kinase domain containing DCAKD
226093 at DCPI decapping enzyme homolog B (S. cerevisiae) DCP1B
exonuclease domain containing 1 /// DCN1, defective in cullin
213365 at neddylation 1, domain containing 3 (S. cerevisiae) DCUN1D3 /// EXOD1
203409 at damage-specific DNA binding protein 2, 48kDa DDB2
207169 x at discoidin domain receptor tyrosine kinase 1 DDR1
208779 x at discoidin domain receptor tyrosine kinase 1 DDR1
210749 x at discoidin domain receptor tyrosine kinase 1 3DR1
1007 s at discoidin domain receptor tyrosine kinase I DDR1
227485 at DEAD/H (Asp-Glu-Ala-Asp/His) box polypeptide 26B DDX26B
221080 s at DENNIMADD domain containing IC DENNDiC
218102 at 2-deoxyribose-5-phosphate aldolase homolog (C. elegans) DERA
47553 at deaffness, autosomal recessive 31 DFNB31
221887 s at deafness, autosomal recessive 31 DFNB31
211272 s at diacyiglycerol kinase, alpha 8OkDa DGKA
203385 at diacylglycerol kinase, alpha 8OkDa DGKA
214079 at dehydrogenase/reductase (SDR family) member 2 DHRS2
206463 s at dehydrogenase/reductase (SOR family) member 2 DHRS2
235466 s at Dispatched homolog 1 (Drosophila) DISPI
229579 s at dispatched homolog 2 (Drosophila) DISP2
214724 at DX dmain cntainin 1 DIXDC1
DMC1 dosage suppressor of mckl homolog, meiosis-specific
208386 x at homologous recombination (yeast) IDMVC1
I
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208382 s at
DMC1 dosage suppressor of mck1 homolog, meiosis-specific
homologous recombination (yeast) DMC1
208086_s at dystrophin (muscular dystrophy, Duchenne and Becker types) DMD
37996 s at dystrophia myotonica-protein kinase DMPK
217066 s at dystrophia myotonica-protein kinase DMPK
230893 at DnaJ (Hsp40) homolog, subfamily C, member 21 DNAJC21
226309 at dynein, axonemal, light chain 1 DNAL1
204008 at dynein, axonemal, light chain 4 DNAL4
219452_at dipeptidase 2 DPEP2
236055 at DEAQ box polypeptide 1 (RNA-dependent ATPase) DQX1
218627 at damage-regulated autophagy modulator DRAM
232059 at Down syndrome cell adhesion molecule like 1 DSCAML1
218854 at dermatan sulfate epimerase DSE
218585s at denticleless homolog (Drosophila) DTL
deltex homolog 2 (Drosophila) /// hypothetical protein
215732 s at LOC100134197 DTX2 /l LOC100134197
203367 at dual specificity phosphatase 14 DUSP14
201908 at dishevelled, dsh homolog 3 (Drosophila) DVL3
238116 at dynein, light chain, roadblock-type 2 DYNLRB2
201999 s at dynein, light chain, Tctex-type 1 DYNLT1
207232 sat DAZ interacting protein 3, zinc finger DZIP3
213186_at DAZ interacting protein 3, zinc finger DZIP3
204947 at E2F transcription factor I E2FI
228033 at E2F transcription factor 7 E2F7
219424 at Epstein-Sarr virus induced gene 3 E813
206758 at endothelin 2 EDN2
204840 s at early endosome antigen 1 EEA1
1562815_at EF-hand calcium binding domain 6 EFCAB6
231026 at EF-hand domain (C-terminal) containing I EFHC1
219833 s at EF-hand domain (C-terminal) containing 1 EFHC1
207768 at eary growth response 4 EGR4
225645_at Ets homologous factor EHF
208289 s at etoposide induced 2.4 mRNA E124
242470 at EP300 interacting inhibitor of differentiation 2B EID2B
225164 s at eukaryotic translation initiation factor 2 alpha kinase 4 EIF2AK4
202461 at eukaryotic translation initiation factor 2B, subunit 2 beta, 39kDa EIF2B2
E74-like factor 3 (ets domain transcription factor, epithelial-
210827 s at specific ) ELF3
214446 at elongation factor, RNA polymerase 11, 2 ELL2
226099 at elongation factor, RNA polymerase 11, 2 ELL2
226982 at elongation factor, RNA polymerase 11, 2 ELL2
228307 at elastin microfibril interfacer 3 EMILIN3
201341 at ectodermal-neural cortex (with BTB-like domain) ENC1
201340 s at ectodermal-neural cortex (with BTB-like domain) ENCI
229292 at erythrocyte membrane protein band 4.1 like 5 EPB41 L5
223253 at ependymin related protein 1 (zebrafish) EPDR1
203499_at EPH receptor A2 EPHA2
232164 s at epiplakin 1 EPPKI
232165 at epiplakin 1 EPPK1
202609 at epidermal growth factor receptor pathway substrate 8 EPS8
218180 s at EPS8-like 2 EPS8L2
235104 at endoplasmic reticulum aminopeptidase 2 ERAP2
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219759 at endoplasmic reticulum aminopeptidase 2 ERAP2
225369 at endothelial cell adhesion molecule ESAM
205225 at estrogen receptor 1 ESR1
224225 s at ets variant gene 7 (TEL2 oncogene) ETV7
exocyst complex component 3-like /// hypothetical protein
LOC653319 /// hypothetical protein LOC100130525 /// EXOC3L / LOC100130525 ///
1558041 a at hypothetical protein LOC100134333 LOC100134333 /// LOC653319
203358 s at enhancer of zeste homolog 2 (Drosophila) EZH2
221664 s at F11 receptor F11R
224097 s at F11 receptor F11R
204714 s at coagulation factor V (proaccelerin, labile factor) F5
205756 s at coagulation factor Vill, procoagulant component (hemophilia A) F8
coagulation factor VIII-associated (intronic transcript) 1 /
coagulation factor Vill-associated (intronic transcript) 2 ///
203274 at coagulation factor Vlll-associated (intronic transcript) 3 F8A1 /// F8A2 /// F8A3
212400 at family with sequence similarity 102, member A FAM102A
226584 s at family with sequence similarity 110, member A FAM110A
228678 at family with sequence similarity 116, member B FAM116B
218532 s at family with sequence similarity 134, member B FAM134B
218510 x at family with sequence similarity 134, member B FAM134B
1554547 at family with sequence similarity 13, member C1 FAM13C1
major histocompatibility complex, class I, B I// major
histocompatibility complex, class I, C /// MHC class I polypeptide FAM20B /// HLA-B /// HLA-C /I
related sequence A /l MHC class I polypeptide-related sequence MICA /// MICB /// XXbac-
211911 x at B // family with sequence similarity 20, member B BPG181B23.1
1554367 at family with sequence similarity 26, member C FAM26C
ribosomal protein L23a pseudogene 7 /// family with sequence FAM41C l MGC70863 //
232899 at similarity 41, member C // similar to RPL23AP7 protein RPL23AP7
218023 s at family with sequence similarity 53, member C FAM53C
family with sequence similarity 62 (C2 domain containing)
224698 at member B FAM62B
227951 s at family with sequence similarity 98, member C FAM98C
220255 at Fanconi anemia, complementation group E FANCE
1556131_s at Fas (TNFRSF6) binding factor 1 FBF1
1555288 s at Fas (TNFRSF6) binding factor I FBF1
228427 at F-box protein 16 FBXO16
225736 at F-box protein 22 FBXO22
225737 s at F-box protein 22 FBXO22
219784 at F-box protein 31 FBXO31
219785 s at F-box protein 31 FBXO31
222729 at F-box and WD repeat domain containing 7 FBXW7
218751 s at F-box and WD repeat domain containing 7 FBXW7
Fc fragment of IgG binding protein / similar to IgGFc-binding
protein precursor (FcgammaBP) (Fcgamma-binding protein
203240 at antigen) FCGBP //I LOC100133944
228220_at FCH domain only 2 FCHO2
203620 s at FCH and double SH3 domains 2 FCHSD2
207813 s at ferredoxin reductase FDXR
222676 at hypothetical protein LOC644975 FLJ30064
223443 s at hypothetical protein FLJ32065 FLJ32065
223950 s at FLYWCH-type zinc finger 1 FLYWCH1
234106 s at FLYWCH-type zinc finger 1 FLYWCH1
222692 s at fibronectin type Ill domain containing 3B FNDC3B
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218880_at FOS-like antigen 2 FOSL2
227964 at FERM domain containing 8 FRMD8
238486 at fibroblast growth factor receptor substrate 2 FRS2
229137 at Fucosidase, alpha-L- 1, tissue FUCAI
202838_at fucosidase, alpha-L- 1, tissue FUCA1
205674x at FXYD domain containing ion transport regulator 2 FXYD2
207434_s at FXYD domain containing ion transport regulator 2 FXYD2
225998 at GRB2-associated binding protein 1 GABi
207112 s at GRB2-associated binding protein 1 GAB1
40225 at cyclin G associated kinase GAK
202281 at cyclin G associated kinase GAK
UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-
220296 at acetylgalactosaminyttransferase 10 (GaINAc-TIO) GALNTIO
UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-
219013 at acetylgalactosaminyltransferase 11 (GaINAc-T11) GALNTI1
1552474_a at guanidinoacetate N-methyltransferase GAMT
205354_at guanidinoacetate N-methyltransferase GAMT
235310_at germinal center expressed transcript 2 GCET2
204867_at GTP cyclohydrolase I feedback regulator GCHFR
221576 at growth differentiation factor 15 GDF15
32502 at glycerophosphodiester phosphodiesterase domain containing 5 GDPD5
213343 s at glycerophosphodiester phosphodiesterase domain containing 5 GDPD5
209919_x at gamma-glutamyltransferase 1 GGT1
208284 x at gamma-glutamyltransferase 1 GGT1
207131 x at gamma-glutamyltransferase 1 GGT1
211417 x at gamma-glutamyltransferase 1I GGTI
gamma-glutamyltransferase 1 /// gamma-glutamyltransferase 3
pseudogene /// gamma-glutamyltransferase light chain 2 ///
gamma-glutamyltransferase light chain 3 /// gamma- GGT1 /// GGT2 /// GGT3P /
215603 x at glutamyltransferase 2 GGTLC2 /// GGTLC3
236225 at gamma-glutamyltransferase 6 GGT6
211416 x at gamma-glutamyltransferase light chain 1 GGTLC1
211767 at GINS complex subunit 4 (SIdS homolog) GINS4
235029_at GINS complex subunit 4 (Sd5 homolog) GINS4
218030 at G protein-coupled receptor kinase interactor 1 GITI
201667 at gap junction protein, alpha 1, 43kDa GJA1
226868_at glycosyltransferase 8 domain containing 3 GLT8D3
232021 at glycosyltransferase 8 domain containing 3 GLT8D3
226177 at glycolipid transfer protein GLTP
35820_at GM2 ganglioside activator GM2A
212737 at GM2 ganglioside activator GM2A
209727 at GM2 ganglioside activator GM2A
guanine nucleotide binding protein (G protein), alpha 15 (Gq
205349 at class) GNA15
201057_s at golgin B1, golgi integral membrane protein GOLGB1
223319 at gephyrin GPHN
220773 s at gephyrin GPHN
65718 at G protein-coupled receptor 124 GPR124
221814 at G protein-coupled receptor 124 GPR124
212070 at G protein-coupled receptor 56 GPR56
219936 s at G protein-coupled receptor 87 GPR87
222830 at grainyhead-like 1 (Drosophila) GRHL1
232116 at grainyhead-like 3 (Drosophila) GRHL3
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216041 x at granulin GRN
211284 s at granulin GRN
200678 x at granulin GRN
209945 s at glycogen synthase kinase 3 beta GSK3B
211630 s at glutathione synthetase GSS
201415 at glutathione synthetase GSS
219484 at host cell factor C2 HCFC2
1556181 at hCG20426 hCG 20426
1556182 x at hCG20426 hCG 20426
226446 at hairy and enhancer of split 6 (Drosophila) HES6
219687 at hedgehog acyltransferase HHAT
major histocompatibility complex, class I, B /// major
histocompatibility complex, class I, C /// MHC class I polypeptide
related sequence A / MHC class I polypeptide-related sequence HLA-B / H LA-C // MICA/// MICB
205904 at B /// XXbac-BPG181B23.1
226878 at major histocompatibility complex, class 11, DO alpha HLA-DOA
204755 x at hepatic leukemia factor HLF
204753 s at hepatic leukemia factor HLF
230914 at hepatocyte nuclear factor 4, alpha HNF4A
223647 x at HscB iron-sulfur cluster co-chaperone homolog (E. coli) HSCB
1554122 a at hydroxysteroid (17-beta) dehydrogenase 12 HSD17B12
1554121 at hydroxysteroid (17-beta) dehydrogenase 12 HSD17B12
220081 x at hydroxysteroid (17-beta) dehydrogenase 7 HSD17B7
209512 at hydroxysteroid dehydrogenase like 2 HSDL2
209513 s at hydroxysteroid dehydrogenase like 2 HSDL2
1559128 at hydroxysteroid dehydrogenase like 2 HSDL2
219284 at HSPB (heat shock 27kDa) associated protein 1 HSPBAP1
201655 s at heparan sulfate proteoglycan 2 HSPG2
inhibitor of DNA binding 2, dominant negative helix-loop-helix
protein // inhibitor of DNA binding 2B, dominant negative helix-
213931 at loop-helix protein ID2 /// ID2B
210354 at interferon, gamma IFNG
231179 at inositol hexaphosphate kinase 3 IHPK3
235202 x at IKK interacting protein IKIP
236249 at IKK interacting protein IKIP
227295 at IKK interacting protein IKIP
204912 at interleukin 10 receptor, alpha IL10RA
239522 at interleukin 12 receptor, beta 1 IL12RBI
1552584 at interleukin 12 receptor, beta 1 IL12RB1
201888 s at interleukin 13 receptor, alpha 1 IL13RA1
220056 at interleukin 22 receptor, alpha 1 IL22RA1
226218 at interleukin 7 receptor IL7R
207008 at interleukin 8 receptor, beta IL8RB
202794 at inositol polyphosphate-1-phosphatase INPP1
205376 at inositol polyphosphate-4-phosphatase, type I1, 105kDa INPP4B
241393 at Intracisternal A particle-promoted polypeptide IPP
1554740_a at intracistemal A particle-promoted polypeptide IPP
208436 s at interferon regulatory factor 7 IRF7
209075 s at iron-sulfur cluster scaffold homolog (E. coli) ISCU
219361 s at interferon stimulated exonuclease gene 20kDa-like 1 ISG20L1
1556151 at Integrin alpha FG-GAP repeat containing 1 ITFG1
I
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integrin, alpha 2b (platelet glycoprotein lIb of lIb/Illa complex,-
antigen CD41) IlTGA2B
205786_s at integrin, alpha M (complement component 3 receptor 3 subunit) ITGAM
integrin, alpha V (vitronectin receptor, alpha polypeptide, antigen
202351 at CD51) ITGAV
213076 at inositol 1,4,5-trisphosphate 3-kinase C ITPKC
211360 s at inositol 4,5-triphosphate receptor, type 2 ITPR2
209907 s at intersectin 2 ITSN2
205842 s at Janus kinase 2 (a protein tyrosine kinase) JAK2
212495_at jumonji domain containing 2B JMJD2B
212496 s at jumonji domain containing 2B JMJD2B
230126_s at Jumonji domain containing 2B JMJD2B
226918 at junctophilin 4 JPH4
238789_at KN motif and ankyrin repeat domains 1 KANK1
227713 at katanin p60 subunit A-like 1 KATNAL1
1554234 at katanin p60 subunit A-like 2 KATNAL2
210119 at potassium inwardly-rectifying channel, subfamily J, member 15 KONJ15
223658_at potassium channel, subfamily K, member 6 KCNK6
235857 at potassium channel tetramerisation domain containing 11 KCTD11
202181 at KIAA0247 KIAA0247
204308 s at KIAA0329 KIAA0329
213304 at KIAA0423 KIAA0423
204546-at KIAA0513 KIAA0513
1554440 at KIAA0513 KIAA0513
212359 s at KIAA0913 KIAA0913
209378_s at KIAA1128 KIAA1128
221738 at KIAA1219 KIAA1219
235301 at KIAA1 324-like KIAA1324L
244317 at KIAA1324-like KIAA1324L
228476 at KIAA1407 KIAA1407
226222 at KIAA1432 KIAA1432
226221_at KIAA1432 KIAA1432
241347 at KIAA1618 KIAA1618
232155_at KIAA1618 KIAA1618
228409 at KIAA1881 KIAA1881
225878_at Kinesin family member 1 B KIF1 B
229921 at Kinesin family member 5A KIF5A
1556012_at kelch domain containing 7A KLHDC7A
227582 at kelch domain containing 9 KLHDC9
221221_s at kelch-like 3 (Drosophila) KLHL3
209854 s at kalllkreln-related peptidase 2 KLK2
219692_at kringle containing transmembrane protein 2 KREMEN2
212236 x at keratin 17 KRT17
205157 s at keratin 17 KRT17
209016 s at keratin 7 KRT7
235252 at Kinase suppressor of ras 1 KSR1
210150 s at laminin, alpha 5 LAMA5
219407 s at laminin, gamma 3 LAMC3
224951 at LAG1 homolog, ceramide synthase 5 LASS5
1560531 at late cornified envelope 1 B LCE11B
228762 at LFNG 0-fucosylpeptide 3-beta-N-acetylglucosaminyltransferase LFNG
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203236_s_at lectin, galactoside-binding, soluble, 9 (galectin 9) LGALS9
212658 at lipoma HMGIC fusion partner-like 2 LHFPL2
205266 at leukemia inhibitory factor (cholinergic differentiation factor) LIF
202193 at LIM domain kinase 2 LIMK2
213526 s at lin-37 homolog (C. elegans) LIN37
219760 at lin-7 homolog B (C. elegans) LIN7B
likely ortholog of mouse lung-inducible Neutralized-related
232593 at C3HC4 RING domain protein LINCR
244881 at leishmanolysin-like (metallopeptidase M8 family) LMLN
229611 at leishmanolysin-like (metallopeptidase M8 family) LMLN
212089 at lamin A/C LMNA
1554600 s at lamin A/C LMNA
203411 s at lamin A/C LMNA
224089 at hypothetical protein PR03077 / similar to PR03077 LOC100128663 // PR03077
240058 at hypothetical protein LOC100129597 LOC100129597
242035 at hypothetical protein LOC100129951 LOC100129951
ubiquitously transcribed tetratricopeptide repeat gene, Y-linked
208067 x at /// hypothetical protein LOC100130224 LOC 100130224 / UTY
240616 at hypothetical protein LOC100131110 LOC100131110
1564257 at hypothetical LOC100132116 LOC100132116
psoriasis susceptibility 1 candidate 3 / similar to psoriasis LOC100133342 // LOC100133375
238997 at susceptibility 1 candidate 3 /// PSORS1C3
mature T-cell proliferation 1 1// similar to mature T-cell
210212 x at proliferations I LOC100133946 / MTCP1
237731 at hypothetical protein LOC154092 LOC154092
236076 at hypothetical protein LOC257396 LOC257396
1556477 a at hypothetical protein LOC283485 LOC283485
1556476 at hypothetical protein LOC283485 LOC283485
239777 at hypothetical protein LOC283551 LOC283551
237460 x at hypothetical protein LOC283551 LOO283551
237032 x at hypothetical protein LOC283567 LOC283567
230245 s at hypothetical protein LOC283663 LOC283663
1557114 a at hypothetical protein LOC284385 LOC284385
227270 at hypothetical protein LOC285550 LOC285550
222196 at hypothetical protein LOC286434 LOC286434
1566147 a at hypothetical LOC375010 LOC375010
230435_at hypothetical LOC375190 LOC375190
236915 at hypothetical protein LOC441054 LOC441054
235416 at hypothetical protein LOC643201 LOC643201
1570445_a at hypothetical protein LOC643201 LOC643201
228158 at similar to lymphocyte-specific protein 1 LOC645166
1569517 at hypothetical LOC646482 LOC646482
1559322 at hypothetical protein LOC727916 LOC727916
228198 s at fumarylacetoacetate hydrolase domain containing 2 pseudogene LOC729234
208107 s at exonuclease NEF-sp LOC81691
215215 s at exonuclease NEF-sp LOC81691
231300 at hypothetical protein LOC90835 LOC90835
223099 s at Ion peptidase 2, peroxisomal LONP2
219019 at leucine-rich repeats and death domain containing LRDD
221640 s at leucine-rich repeats and death domain containing LRDD
35974 at lymphoid-restricted membrane protein LRMP
204674 at lymphoid-restricted membrane protein LRMP
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201412 at low density lipoprotein receptor-related protein 10 LRP10
1562939 at leucine rich repeat containing 16A LRRC16A
239471 at leucine rich repeat containing 28 LRRC28
227423 at leucine rich repeat containing 28 LRRC28
220003_at leucine rich repeat containing 36 LRRC36
229962 at leucine rich repeat containing 37, memberA3 LRRC37A3
229231 at leucine rich repeat containing 37B LRRC37B
230600_at leucine rich repeat containing 46 LRRC46
230601 s at leucine rich repeat containing 46 LRRC46
226717 at leucine rich repeat containing 51 LRRC6
229232 at leucine rich repeat containing 57 LRRC57
203523 at lymphocyte-specific protein i LSP1
202018 s at lactotransferrin LTF
52169 at protein kinase LYK5 LYK5
228954_at LysM, putative peptidoglycan-binding, domain containing 4 LYSMD4
204857_at MADI mitotic arrest deficient-like I (yeast) MADILI
213627_at melanoma antigen family D, 2 MAGED2
1556315 a at male germ cell-associated kinase MAK
220302 at male germ cell-associated kinase MAK
209166 s at mannosidase, alpha, class 2B, member 1 MAN281
203778_at mannosidase, beta A, lysosomal MANBA
203151 at microtubule-associated protein 1A MAPIA
205447 s at mitogen-activated protein kinase kinase kinase 12 MAP3K12
206571 s at mitogen-activated protein kinase kinase kinase kinase 4 MAP4K4
218181 s at mitogen-activated protein kinase kinase kinase kinase 4 MAP4K4
212271_at mitogen-activated protein kinase 1 MAPK1
210059_s at mitogen-activated protein kinase 13 MAPK13
210058 at mitogen-activated protein kinase 13 MAPK13
210075 at membrane-associated ring finger (C3HC4) 2 MARCH2
217373 x at Mdm2 p53 binding protein homolog (mouse) MDM2
211832 s at Mdm2 p53 binding protein homolog (mouse) MDM2
237891 at Mdm2 p53 binding protein homolog (mouse) MDM2
205385 at Mdm2 p53 binding protein homolog (mouse) MDM2
205386 s at Mdm2 p53 binding protein homolog (mouse) MDM2
232533_at methyltransferase like 8 METTL8
239304 at major facilitator superfamily domain containing 4 MFSO4
242372 s at major facilitator superfamily domain containing 4 MFSD4
1554732 at hypothetical protein MGC24125 MGC24125
1569318 at hypothetical protein MGC39821 MGC39821
1554222 at hypothetical gene MGC45922 MGC45922
244616 x at Hypothetical protein MGC5370 MGC5370
217542 at Hypothetical protein MGC5370 MGC5370
225160 x at hypothetical protein MGC5370 MGC5370
229711 s at hypothetical protein MGC5370 MGC5370
220449 at hypothetical protein MGC5566 MGC5566
1569144 a at Similar to RIKEN cDNA 2310002J15 gene MGC59937
228658 at myocardial infarction associated transcript (non-protein coding) MIAT
55081 at MICAL-like 1 MICALL1
221779 at MICAL-like 1 MICALLI
241478 at MICAL-like 2 MICALL2
219332 at MICAL-like 2 MICALL2
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1555862 s at MICAL-like 2 MICALL2
212748 at megakaryoblastic leukemia (translocation) 1 MKL1
218883 s at MLF1 interacting protein MLFIIP
229305 at MLF1 interacting protein MLF1 IP
229304 s at MLFI interacting protein MLF1 IP
200948 at myeloid leukemia factor 2 MLF2
207329 at matrix metallopeptidase 8 (neutrophil collagenase) MMP8
219265 at MOB1, Mps One Binder kinase activator-like 2B (yeast) MOBKL2B
219959 at molybdenum cofactor sulfurase MOCOS
212755 at MON2 homolog (S. cerevisiae) MON2
212754 s at MON2 homolog (S. cerevisiae) MON2
218853 s at motile sperm domain containing 1 MOSPD1
210528 at major histocompatibility complex, class I-related MRI
210223 s at major histocompatibility complex, class I-related MR1
207566 at major histocompatibility complex, class I-related MR1
207565 s at major histocompatibility complex, class I-related MR1
5,10-methenyltetrahydrofolate synthetase (5-
formyltetrahydrofolate cyclo-ligase) /// suppressor of
203433 at tumorigenicity 20 MTHFS /// ST20
1553436 at mucin 19, oligomeric MUC19
204673 at mucin 2, oligomeric mucus/gel-forming MUC2
214385 s at mucin 5AC, oligomeric mucus/gel-forming MUC5AC
213906 at v-myb myeloblastosis viral oncogene homolog (avian)-like 1 MYBL1
206394 at myosin binding protein C, fast type MYBPC2
213067 at myosin, heavy chain 10, non-muscle MYH10
216222 s at myosin X MYO10
201976 s at myosin X MYO10
244350 at myosin X MYO10
211916 s at myosin IA MYO1A
217409 at myosin VA (heavy chain 12, myoxin) MYO5A
241966 at myosin VA (heavy chain 12, myoxin) MYO5A
204527 at myosin VA (heavy chain 12, myoxin) MYO5A
243843 at NEDD4 binding protein 2-like 1 N4BP2LI
214748_at NEDD4 binding protein 2-like 2 N4BP2L2
218840 s at NAD synthetase 1 NADSYNI
232946 s at NAD synthetase 1 NADSYN1
214440 at N-acetyttransferase 1 (arylarnine N-acetyltransferase) NAT1
227249 at NudE nuclear distribution gene E homolog 1 (A. nidulans) NDE1
200632 s at N-myc downstream regulated gene 1 NDRG1
210720 s at N-terminal EF-hand calcium binding protein 3 NECAB3
1557170 at NIMA (never In mitosis gene a- related kinase 8 NEK8
208926 at sialidase 1 (lysosomal sialidase) NEU
236677 at neurogtobin NGB
Nance-Horan syndrome (congenital cataracts and dental
228933 at anomalies) NHS
1561082 at nidogen I NIDi
203045 at ninjurin 1 NINJ
221933 at neuroligin 4, X-llnked NLGN4X
1554125 a at neuroligin 4, Y-linked NLGN4Y
236295 s at NLR family, CARD domain containing 3 NLRC3
219680 at NLR family member X1 NLRX1
1553695 a at NLR family member X1 NLRXI
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non-metastatic cells 7, protein expressed in (nucleoside-
227556 at diphosphate kinase) NME7
218902_at Notch homolog 1, translocation-associated (Drosophila) NOTCHI
212377 s at Notch homolog 2 (Drosophila) NOTCH2
202443 x at Notch homolog 2 (Drosophila) NOTCH2
N-acetyineuraminate pyruvate lyase (dihydrodipicolinate
221210 s at synthase) NPL
225949 at nuclear receptor binding protein 2 NRBP2
242426_at neuregulin 4 NRG4
209983 s at neurexin 2 NRXN2
202395_at N-ethylmaleimide-sensitive factor NSF
1562019 at 5'-nucleotidase domain containing 4 NT5DC4
1562020 s at 5'-nucleotidase domain containing 4 NT5DC4
213061 s at N-terminal asparagine amidase NTAN1
213062 at N-terminal asparagine amidase NTAN1
231914 at nudix (nucleoside diphosphate linked moiety X)type motif 14 NUDT14
219347 at nudix (nucleoside diphosphate linked moiety X)-type motif 15 NUDT15
236930 at Numb homolog (Drosophila) NUMB
209230 s at nuclear protein 1 NUPR1
208316 s at oculocerebrorenal syndrome of Lowe OCRL
236245 at outer dense fiber of sperm tails 3-like 1 ODF3L1
231656 x at oxysterol binding protein-like 10 OSBPL10
209627 s at oxysterol binding protein-like 3 OSBPL3
209626 s. at oxysterol binding protein-like 3 OSBPL3
procollagen-proline, 2-oxoglutarate 4-dioxygenase (proline 4-
202733 at hydroxylase), alpha polypeptide il P4HA2
220402 at p53-regulated apoptosis-inducing protein 1 P53AIPI
201651 s at protein kinase C and casein kinase substrate in neurons 2 PACSIN2
226507 at p2l/Cdc42/Rac1 -activated kinase 1 (STE20 homolog, yeast) PAKI
203859_s at paralemmin PALM
226649_at pantothenate kinase I PANKI
226435_at papilin, proteoglycan-like sulfated glycoprotein PAPLN
224941 at pregnancy-associated plasma protein A, pappalysin 1 PAPPA
242123 at progestin and adipoQ receptor family member VIl PAQR7
213204 at p53-associated parkin-like cytoplasmic protein PARC
221526 x at par-3 partitioning defective 3 homolog (C. elegans) PARD3
229350 x at poly (ADP-rlbose) polymerase family, member 10 PARP1O
219034 at poly (ADP-ribose) polymerase family, member 16 PARP16
205253 at pre-B-cell leukemia homeobox 1 PBX1
239585 at P300/CBP-associated factor PCAF
203845 at p300/CBP-associated factor PCAF
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Probeset ID Gene Name Gene Symbol
209079 x at
protocadherin gamma subfamily C, 3 /// protocadherin gamma
subfamily B, 4 /// protocadherin gamma subfamily A, 8 ///
protocadherin gamma subfamily A, 12 /// protocadherin gamma
subfamily C, 5 / protocadherin gamma subfamily C, 4 /
protocadherin gamma subfamily B, 7 /// protocadherin gamma
subfamily B, 6 /// protocadherin gamma subfamily B, 5 /
protocadherin gamma subfamily B, 3 /// protocadherin gamma
subfamily B, 2 / protocadherin gamma subfamily B, 1 ///
protocadherin gamma subfamily A, 11 /// protocadherin gamma
subfamily A, 10 /// protocadherin gamma subfamily A, 9 /
protocadherin gamma subfamily A, 7 /// protocadherin gamma
subfamily A, 6 /// protocadherin gamma subfamily A, 5 /
protocadherin gamma subfamily A, 4 /// protocadherin gamma
subfamily A, 3 /// protocadherin gamma subfamily A, 2 ///
protocadherin gamma subfamily A, 1
PCDHGA1 /// PCDHGA10 ///
PCDHGA11 /// PCDHGA12 ///
PCDHGA2 /// PCDHGA3 /
PCDHGA4 /PCDHGA5 /
PCDHGA6 /// PCDHGA7 ///
PCDHGA8 /// PCDHGA9 ///
PCDHGB1 /// PCDHGB2 ///
PCDHGB3 /// PCDHGB4 ///
PCDHGB5 /// PCDHGB6 ///
PCDHGB7 /// PCDHGC3 ///
PCDHGC4 /PCDHGC5
protocadherin gamma subfamily C, 3 /// protocadherin gamma
subfamily B, 4 /// protocadherin gamma subfamily A, 8 ///
protocadherin gamma subfamily A, 12 /// protocadherin gamma
subfamily C, 5 /// protocadherin gamma subfamily C, 4 /
protocadherin gamma subfamily B, 7 /// protocadherin gamma PCDHGA1 / PCDHGA10/
subfamily B, 6 / protocadherin gamma subfamily B, 5 /// PCDHGA11 / PCDHGA12 /
protocadherin gamma subfamily B, 3 /// protocadherin gamma PCDHGA2 / PCDHGA3 ///
subfamily B, 2 / protocadherin gamma subfamily B, 1 / PCDHGA4 / PCDHGA5 /
protocadherin gamma subfamily A, 11 /// protocadherin gamma PCDHGA6 / PCDHGA7 /
subfamily A, 10 / protocadherin gamma subfamily A, 9 / PCDHGA8 / PCDHGA9 ///
protocadherin gamma subfamily A, 7 /// protocadherin gamma PCDHGB1 / PCDHGB2 /
subfamily A, 6 / protocadherin gamma subfamily A, 5 / PCDHGB3 /// PCDHGB4 /
protocadherin gamma subfamily A, 4 / protocadherin gamma PCDHGB5 / PCDHGB6 1/
subfamily A, 3 / protocadherin gamma subfamily A, 2 // PCDHGB7 1/ PCDHGC3 /
205717 x at protocadherin gamma subfamily A, 1 PCDHGC4 /// PCDHGC5
protocadherin gamma subfamily C, 3 /// protocadherin gamma
subfamily B, 4 /// protocadherin gamma subfamily A, 8 ///
protocadherin gamma subfamily A, 12 /// protocadherin gamma
subfamily C, 5 / protocadherin gamma subfamily C, 4 /
protocadherin gamma subfamily B, 7 /// protocadherin gamma PCDHGA1 /// PCDHGA 1 /
subfamily B, 6 /11 protocadherin gamma subfamily B, 5 / PCDHGA11 / PCDHGA12 ///
protocadherin gamma subfamily B, 3 /// protocadherin gamma PCDHGA2 /// PCDHGA3 /
subfamily B, 2 /// protocadherin gamma subfamily B, 1 /// PCDHGA4 /// PCDHGA5 /
protocadherin gamma subfamily A, 11 / protocadherin gamma PCDHGA6 /// PCDHGA7 ///
subfamily A, 10 /1 protocadherin gamma subfamily A, 9 /// PCDHGA8 / PCDHGA9 /
protocadherin gamma subfamily A, 7 /// protocadherin gamma PCDHGB1 /// PCDHGB2 ///
subfamily A, 6 / protocadherin gamma subfamily A, 5 / PCDHGB3 / PCDHGB4 /
protocadherin gamma subfamily A, 4 / protocadherin gamma PCDHGB5 / PCDHGB6 ///
subfamily A, 3 / protocadherin gamma subfamily A, 2 /// PCDHGB7 / PCDHGC3 ///
211066 x at protocadherin gamma subfamily A, 1 PCDHGC4 / PCDHGC5
201202 at proliferating cell nuclear antigen PCNA
225069 at Phosphate cytidylyltransferase 1, choline, alpha PCYT1A
200788 s at phosphoprotein enriched in astrocytes 15 PEA15
235627 at profilin family, member 4 PFN4
239725 at post-GPI attachment to proteins 1 PGAPI
213469 at post-GPI attachment to proteins 1 PGAP1
241801 at post-GPI attachment to proteins 1 PGAP1
232287 at piggyBac transposable element derived 3 PGBD3
209652 s at placental growth factor PGF
220944 at peptidoglycan recognition protein 4 PGLYRP4
222125 s at hypoxia-inducible factor prolyl 4-hydroxylase PH4
218634 at pleckstrin homology-like domain, family A, member 3 PHLDA3
1557948_at pleckstrin homology-like domain, family B, member 3 PHLDB3
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223207 x at phosphohistidine phosphatase 1 PHPT1
225683 x at phosphohistidine phosphatase I PHPTI
209345_s at phosphatidylinositol 4-kinase type 2 alpha Pl4K2A
203035 s at protein inhibitor of activated STAT, 3 PIAS3
212240_s at phosphoinositide-3-kinase, regulatory subunit 1 (alpha) PIK3R1
202743 at phosphoinositide-3-kinase, regulatory subunit 3 (gamma) PIK3R3
1558770_a at phosphoinositide-3-kinase, regulatory subunit 6 PIK3R6
1561849-at polycystic kidney disease 1-like 2 PKD1L2
202732 at protein kinase (cAMP-dependent, catalytic) inhibitor gamma PKIG
209785 s at phospholipase A2, group IVC (cytosolic, calcium-independent) PLA2G4C
1552476_s_at phospholipase C, delta 3 PLCD3
234971 x at phospholipase C, delta 3 PLCD3
202789 at phospholipase C, gamma 1 PLCG1
201050 at phospholipase D famiy, member 3 PLD3
pleckstrin homology domain containing, family F (with FYVE
219566_at domain) member 1 PLEKHF1
pleckstrin homology domain containing, family G (with RhoGef
220073 s at domain) member 6 PLEKHG6
204436_at peckstrin homology domain containing, family 0 member 2 PLEKHO2
204958 at polo-like kinase 3 (Drosophila) PLK3
204519 s at plasma membrane proteolipid (plasmolipin) PLLP
201215 at plastin 3 (T isoform) PLS3
213030 s at plexin A2 PLXNA2
208890 s at plexin 82 PLXNB2
211472 at Plexin B2 PLXNB2
205957 at plexin B3 PLXNB3
210707_x at postmeiotic segregation increased 2-like 11 PMS2L11
222879_s at polymerase (DNA directed), eta POLH
1557701 s at polymerase (DNA directed), eta POLH
231115 at polymerase (DNA directed), eta POLH
233852_at polymerase (DNA directed), eta POLH
219510 at polymerase (DNA directed), theta POLQ
228343 at POU class 2 homeobox 2 POU2F2
229750 at POU class 2 homeobox 2 POU2F2
236044 at phosphatidic acid phosphatase type 2 domain containing 1A PPAPDC1A
242218 at peroxisome proliferator-activated receptor delta PPARD
protein tyrosine phosphatase, receptor type, f polypeptide
214978 s at (PTPRF), interacting protein (liprin), alpha 4 PPFIA4
203407 at periplakin PPL
204566 at protein phosphatase 1 D magnesium-dependent, delta isoform PPM1 D
229484 at protein phosphatase IJ (PP2C domain containing) PPM1J
223733 s at protein phosphatase 4, regulatory subunit 1-like PPP4R1 L
210670 at pancreatic polypeptide PPY
243669 s at proline-rich acidic protein 1 PRAPI
235668 at PR domain containing 1, with ZNF domain PRDM1
228964 at PR domain containing 1, with ZNF domain PRDM1
217192 s at PR domain containing 1, with ZNF domain PRDMI
1553681 a at perforin 1 (pore forming protein) PRF1
214617 at perforin 1 (pore forming protein) PRF1
225968 at prickle homolog 2 (Drosophila) PRICKLE2
201835 s at protein kinase, AMP-activated, beta 1 non-catalytic subunit PRKAB1
201834 at protein kinase, AMP-activated, beta 1 non-catalytic subunit PRKAB1
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214474 at protein kinase, AMP-activated, beta 2 non-catalytic subunit
225278 at protein kinase, AMP-activated, beta 2 non-catalytic subunit PRKAB2
202801 at protein kinase, cAMP-dependent, catalytic, alpha PRKACA
204060 s at protein kinase, X-linked /// protein kinase, Y-linked PRKX /// PRKY
206279_at protein kinase, Y-linked PRKY
203650 at protein C receptor, endothelial (EPCR) PROCR
214203 s at proline dehydrogenase (oxidase) I PRODH
211661 x at platelet-activating factor receptor PTAFR
206278 at platelet-activating factor receptor PTAFR
230019 s at patched domain containing 2 PTCHD2
206060 s at protein tyrosine phosphatase, non-receptor type 22 (lymphoid) PTPN22
221840 at protein tyrosine phosphatase, receptor type, E PTPRE
200636 s at protein tyrosine phosphatase, receptor type, F PTPRF
211320 s at protein tyrosine phosphatase, receptor type, U PTPRU
228014 at peptidyl-tRNA hydrolase 1 homolog (S. cerevisiae) PTRH1
223540 at poliovirus receptor-related 4 PVRL4
216249 at Pvt1 oncogene homolog (mouse) PVT1
1558290 a at Pvt1 oncogene homolog (mouse) PVT1
1562153 a at PvtI oncogene homolog (mouse) PVT1
1552599 at peroxisomal, testis specific 1 PXT1
216748 at pyrin and HIN domain family, member 1 PYHINI
217267 s at RAB7A, member RAS oncogene family RAB7A
222742 s at RAB, member RAS oncogene family-like 5 RABL5
205024 s at RAD51 homolog (RecA homolog, E. coli) (S. cerevisiae) RAD51
209849 s at RAD51 homolog C (S. cerevisiae) RAD51C
206066 s at RAD51 homolog C (S. cerevisiae) RAD51C
205130 at renal tumor antigen RAGE
214435 x at v-ral simian leukemia viral oncogene homolog A (ras related) RALA
209050 s at ral guanine nucleotide dissociation stimulator RALGDS
53987 at RAN binding protein 10 RANBP10
221809 at RAN binding protein 10 RANBP10
238622 at RAP2B, member of RAS oncogene family RAP2B
213923 at RAP2B, member of RAS oncogene family RAP2B
215688 at Ras protein-specific guanine nucleotide-releasing factor 1 RASGRF1
208206 s at RAS guanyl releasing protein 2 (calcium and DAG-regulated) RASGRP2
226696 at retinoblastoma binding protein 9 RBBP9
232860 x at RNA binding motif protein 41 RBM41
regulator of chromosome condensation (RCC1) and BTB (POZ)
204759 at domain containing protein 2 RCBTB2
218124 at retinal saturase (all-trans-retinol 13,14-reductase) RETSAT
1566472 s at retinol saturase (all-trans-retinol 13,14-reductase) RETSAT
1053 at replication factor C (activator 1) 2, 40kDa RFC2
212968 at RFNG 0-fucosylpeptide 3-beta-N-acetylglucosaminyltransferase RFNG
212646 at raftlin, ipid raft linker i RFTNI
238810 at regulatory factor X, 3 (influences HLA class |1 expression) RFX3
209568_s at ral guanine nucleotide dissociation stimulator-like 1 RGL1
242079 at regulator of G-protein signaling 12 RGS12
219202 at rhomboid 5 homolog 2 (Drosophila) RHBDF2
210430 x at Rh blood group, CcEe antigens /// Rh blood group, D antigen RHCE /// RHD
210586 x at Rh blood group, D antigen RHD
227644 at regulating synaptic membrane exocytosis 4 RIMS4
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209882 at Ras-like without CAAX 1I RIT1
1553127_a at ring finger protein 168 RNF168
36564 at ring finger protein 19B RNF91B
213038_at ring finger protein 19B RNF19B
210706 s at ring finger protein 24 RNF24
204668 at ring finger protein 24 RNF24
207223 s at ROD1 regulator of differentiation 1 (S. pombe) RODi
224617_at ROD1 regulator of differentiation 1 (S. pombe) ROD1
226009 at deleted in a mouse model of primary ciliary dyskinesia RPII-529110.4
1553976 a at deleted in a mouse model of primary ciliary dyskinesia RP11-529110.4
210115 at ribosomal protein L39-like RPL39L
203379 at ribosomal protein S6 kinase, 90kDa, polypeptide 1 RPS6KA1
204802 at Ras-related associated with diabetes RRAD
204803_s at Ras-related associated with diabetes RRAD
201890 at ribonucleotide reductase M2 polypeptide RRM2
223342_at ribonucleotide reductase M2 B (TP53 inducible) RRM2B
223713 at radial spoke head 3 homolog (Chlamydomonas) RSPH3
201844_s at RING1 and YY1 binding protein RYBP
202598 at S100 calcium binding protein A13 S10OA13
225272 at spermidine/spermine N1-acetyltransferase family member 2 SAT2
233914 s at SET binding factor 2 SBF2
226169 at SET binding factor 2 SBF2
226549 at SH3-binding domain kinase 1 SBK1
226548 at SH3-binding domain kinase 1 SBK1
216399 s at S phase cyclin A-associated protein in the ER SCAPER
204030 s at schwannomin interacting protein 1 SCHIP1
222849 s at secernin 3 SCRN3
41329_at SCY1-like 3 (S. cerevisiae) SCYL3
205607 s at SCY1 -like 3 (S. cerevisiae) SCYL3
201286_at syndecan 1 SDC1
201287 s at syndecan 1 SDCi
201093 x at succinate dehydrogenase complex, subunit A, flavoprotein (Fp) SDHA
succinate dehydrogenase complex, subunit A, flavoprotein
222021 x at pseudogene 1 SDHALP1
232895 s at SEC14-like 2 (S. cerevisiae) SEC14L2
218703 at SEC22 vesicle trafficking protein homolog A (S. cerevisiae) SEC22A
200945_s at SEC31 homolog A (S. cerevisiae) SEC31A
serpin peptidase inhibitor, clade A (alpha-I antiproteinase,
206325 at antitrypsin), member 6 SERPINA6
serpin peptidase inhibitor, clade E (nexin, plasminogen activator
202627 s at inhibitor type 1), member 1 SERPINE1
serpin peptidase inhibitor, clade F (alpha-2 antiplasmin, pigment
202283 at epithelium derived factor), member 1 SERPINF1
223394_at SERTA domain containing 1 SERTAD1
202656 s at SERTA domain containing 2 SERTAD2
218346 s at sestrin 1 SESN1
1561923 a-at Splicing factor 3B, 14 kDa subunit SF3114
209260_at stratifin SFN
33322 i at stratifin SFN
226373 at sideroflexin 5 SFXN5
224391 s at sialic acid acetylesterase SIAE
218765 at SID1 transmembrane family, member 2 SIDT2
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56256_at SID1 transmembrane family, member 2 SIDT2
220000 at sialic acid binding Ig-like lectin 5 SIGLEC5
218436 at SIL1 homolog, endoplasmic reticulum chaperone (S. cerevisiae) SIL1
sirtuin (silent mating type information regulation 2 homolog) 2 (S.
220605 s at cerevisiae) SIRT2
solute carrier family 12 (potassium/chloride transporters),
209402 s at member 4 SLC12A4
solute carrier family 12 (potassium/chloride transporters),
218066 at member 7 SLC12A7
205317 s at solute carrier family 15 (H+/peptide transporter), member 2 SLC1 5A2
219593 at solute carrier family 15, member 3 SLC15A3
201920_at solute carrier family 20 (phosphate transporter), member 1 SLC2OA1
204587 at solute carrier family 25 (mitochondrial carrier, brain), member 14 SLC25A14
1559977 a at solute carrier family 25, member 34 SLC25A34
226737 at solute carrier family 25, member 42 SLC25A42
236436 at solute carrier family 25, member 45 SLC25A45
226679 at solute carrier family 26, member 11 SLC26A11
242271 at solute carrier family 26, member 9 SLC26A9
solute carrier family 2 (facilitated glucose/fructose transporter),
204429 s at member 5 SLC2A5
207035 at solute carrier family 30 (zinc transporter), member 3 SLC30A3
solute carrier family 35 (UDP-glucuronic acid/UDP-N-
209712 at acetylgalactosamine dual transporter), member D1 SLC35D1
solute carrier family 35 (UDP-glucuronic acid/UDP-N-
209711 at acetylgalactosamine dual transporter), member D1 SLC35D1
solute carrier family 35 (UDP-glucuronic acid/UDP-N-
209713 s at acetylgalactosamine dual transporter), member D1 SLC35D1
1568623 a at solute carrier family 35, member E4 SLC35E4
235763 at solute carrier family 44, member 5 SLC44A5
solute carrier family 6 (neurotransmitter transporter, serotonin),
207519 at member 4 SLC6A4
solute carrier family 6 (neurotransmitter transporter, serotonin),
242009 at member 4 SLC6A4
solute carrier family 7 (cationic amino acid transporter, y+
system), member 6 /// transient receptor potential cation
203579 s at channel, subfamily V, member 6 SLC7A6 /// TRPV6
solute carrier family 9 (sodium/hydrogen exchanger), member 1
209453 at (antiporter, Na+/H+, amiloride sensitive) SLC9A1
solute carrier family 9 (sodium/hydrogen exchanger), member 3
201349 at regulator i SLC9A3RI
214860 at solute carrier family 9 (sodium/hydrogen exchanger), member 7 SLC9A7
1558217 at schlafen family member 13 SLFNI3
205397 x at SMAD family member 3 SMAD3
205187 at SMAD family member 5 SMAD5
205188 s at SMAD family member 5 SMAD5
220263 at SMAD family member 5 opposite strand SMAD50S
SWI/SNF related, matrix associated, actin dependent regulator
203874 s at of chromatin, subfamily a, member 1 SMARCA1
SWI/SNF related, matrix associated, actin dependent regulator
203875 at of chromatin, subfamily a, member 1 SMARCA1
Smg-6 homolog, nonsense mediated mRNA decay factor (C.
214940 s at elegans) SMG6
218685 s at single-strand-selective monofunctional uracil-DNA glycosylase 1 SMUG1
223684 s at single-strand-selective monofunctional uracil-DNA glycosylase 1 SMUG1
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229175 at SET and MYND domain containing 4 SMYD4
1560228_at snail homolog 3 (Drosophila) SNA13
syntrophin, beta 2 (dystrophin-associated protein Al, 59kDa,
226685 at basic component 2) SNTB2
220140_s at sorting nexin 11 SNX11
53912_at sorting nexin 11 SNX11
202358 s at sorting nexin 19 SNX19
202113 s at sorting nexin 2 SNX2
202114 at sorting nexin 2 SNX2
225624 at sorting nexin 29 SNX29
225608_at sorting nexin 29 SNX29
218087 s at sorbin and SH3 domain containing I SORBSI
222513 s at sorbin and SH3 domain containing I SORBS1
228720_at sortilin-related VPS10 domain containing receptor 2 SORCS2
203509 at sortilin-related receptor, L(DLR class) A repeats-containing SORL1
230707 at sortilin-related receptor, L(DLR class) A repeats-containing SORL1
sperm protein associated with the nucleus, X-linked, family
member Al /// SPANX family, member C /// SPANX family,
member E /// SPANX family, member F1 /// SPANX family, SPANXA1 /// SPANXA2 /
member BI /// SPANX family, member A2 /// SPANX family, SPANXB1 /l SPANXB2 l
220922_s at member B2 SPANXC /// SPANXE /// SPANXF1
219583 s at spermatogenesis associated 7 SPATA7
234929 s at spermatogenesis associated 7 SPATA7
224864 at steroid receptor RNA activator 1 SRA1
224130 s at steroid receptor RNA activator 1 SRA1
202440 s at suppression of tumorigenicity 5 ST5
signal transducing adaptor molecule (SH3 domain and ITAM
203544 s at motif) 1 STAM
204548 at steroidogenic acute regulatory protein STAR
223103 at StAR-related lipid transfer (START) domain containing 10 STARD10
232322 x at StAR-related lipid transfer (START) domain containing 10 STARD10
213820 s at StAR-related lipid transfer (START) domain containing 5 STARD5
signal transducer and activator of transcription 3 (acute-phase
208991 at response factor) STAT3
signal transducer and activator of transcription 3 (acute-phase
208992 s at response factor) STAT3
201061 s at stomatin STOM
221701 s at stimulated by retinoic acid gene 6 homolog (mouse) STRA6
1569334 at stimulated by retinoic acid gene 6 homolog (mouse) STRA6
1569335 a at stimulated by retinoic acid gene 6 homolog (mouse) STRA6
212112 s at syntaxin 12 STX12
203330_s at syntaxin 5 STX5
244041 at syntaxin 6 STX6
214441_at syntaxin 6 STX6
1552618 at syntaxin 6 STX6
233555 s at sulfatase 2 SULF2
224724 at sulfatase 2 SULF2
sulfotransferase family, cytosolic, 1A, phenol-preferring, member
215299 x at 1 SULT1A1
sulfotransferase family, cytosolic, 1A, phenol-preferring, member
203615 x at 1 SULT1A1
sulfotransferase family, cytosolic, 1A, phenol-preferring, member
207122 x at 2 SULT1A2
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211385 x at
sulfotransferase family, cytosolic, 1A, phenol-preferring, member
2 SULT1A2
218242 s at suppressor of variegation 4-20 homolog 1 (Drosophila) SUV420H1
202565 s at supervillin SVIL
209447 at spectrin repeat containing, nuclear envelope 1 SYNE1
202761 s at spectrin repeat containing, nuclear envelope 2 SYNE2
242774 at spectrin repeat containing, nuclear envelope 2 SYNE2
219992 at tachykinin 3 (neuromedin K, neurokinin beta) TAC3
TAF3 RNA polymerase 11, TATA box binding protein (TBP)-
235154 at associated factor, 140kDa TAF3
TAF3 RNA polymerase 1I, TATA box binding protein (TBP)-
235119 at associated factor, 140kDa TAF3
205547 s at transgelin TAGLN
tetratricopeptide repeat, ankyrin repeat and coiled-coil containing
225308 s at 1 TANC1
210458 s at TRAF family member-associated NFKB activator TANK
209154 at Taxi (human T-cell leukemia virus type 1) binding protein 3 TAXIBP3
215464_s at Taxi (human T-cell leukemia virus type 1) binding protein 3 TAX1BP3
220260 at TBC1 domain family, member 19 TBC1D19
223375 at TBC1 domain family, member 22B TBC1D22B
212796 s at TBC1 domain family, member 2B TBCID2B
201814 at TBC1 domain family, member 5 TBC1D5
211462 s at transducin (beta)-like 1Y-linked TBLIY
230438 at T-box 15 TBX15
227321 at opposite strand transcription unit to STAG3 tcag7.1177
1566208 at transcription elongation factor A (S1l), 1 TCEA1
205797 s at t-complex 11 (mouse)-like 1 TCP11L1
205796 at t-complex 11 (mouse)-like 1 TCP11L1
215356 at tudor domain containing 12 TDRD12
206715 at transcription factor EC TFEC
transforming growth factor, beta receptor I (activin A receptor
206943 at type Il-like kinase, 53kDa) TGFBR1
226625 at transforming growth factor, beta receptor IlIl TGFBR3
204731 at transforming growth factor, beta receptor IlIl TGFBR3
207911 s at transglutaminase 5 TGM5
202338 at thymidine kinase 1, soluble TK1
206271 at toll-like receptor 3 TLR3
217730 at transmembrane BAX inhibitor motif containing 1 TMBIM1
238590 x at transmembrane protein 107 TMEM107
224495 at transmembrane protein 107 TMEM107
227172 at transmembrane protein 116 TMEM116
219460 s at transmembrane protein 127 TMEM127
237020 at transmembrane protein 146 TMEM146
223106 at transmembrane protein 14C TMEM14C
213272 s at transmembrane protein 159 TMEM159
223503 at transmembrane protein 163 TMEMI63
228505 s at transmembrane protein 170 TMEM170
224916_at trarsmembrane protein 173 TMEli-3
224929_at transmembrane protein 173 TMEM173
226860 at transmembrane protein 19 TMEM19
230467 at transmembrane protein 52 TMEM52
218562 s at transmembrane protein 57 TMEM57
225271 at transmembrane protein 63B TMEM63B
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241342 at transmembrane protein 65 TMEM65
238229 at transmembrane protein 67 TMEM67
1552765_at transmembrane protein 67 TMEM67
1563646aat transmembrane protein 67 TMEM67
1569377 at transmembrane protein 67 TMEM67
209294xat tumor necrosis factor receptor superfamily, member Ob TNFRSFOB
208023at tumor necrosis factor receptor superfamily, member 4 TNFRSF4
221085 at tumor necrosis factor (ligand) superfamily, member 15 TNFSF15
tumor necrosis factor (ligand) superfamily, member 4 (tax-
207426 s at transcriptionally activated glycoprotein 1, 34kDa) TNFSF4
220655_at TNFAIP3 interacting protein 3 TNIP3
215271 at tenascin N TNN
210886 x at TP53 activated protein 1 TP53AP1
210609 s at tumor protein p53 inducible protein 3 TP5313
231978_at two pore segment channel 2 TPCN2
204140 at trsylprotein sulfotransferase I TPST1
242473_at TNF receptor-associated factor 4 TRAF4
202368 s at translocation associated membrane protein 2 TRAM2
202369 s at translocation associated membrane protein 2 TRAM2
218403 at TP53 regulated inhibitor of apoptosis 1 TRIAP1
202504 at tripartite motif-containing 29 TRIM29
213885 at tripartite motif-containing 3 TRIM3
213884_s at tripartite motif-containing 3 TRIM3
204911 s at tripartite motif-containing 3 TRIM3
203846 at tripartite motif-containing 32 TRIM32
227102 at tripartite motif-containing 35 TRIM35
209129 at thyroid hormone receptor interactor 6 TRIP6
220623 s at testis specific, 10 TSGA10
222220 s at translin-associated factor X interacting protein 1 TSNAXIP1
223314 at tetraspann 14 TSPAN14
225775_at tetraspanin 33 TSPAN33
214672 at tubulin tyrosine ligase-like family, member 5 TTLL5
210806 at tubulin tyrosine ligase-like family, member 5 TTLL5
230924 at tubulin tyrosine ligase-like family, member 6 TTLL6
214983_at testis-specific transcript, Y-linked 15 TTTY15
224674 at tweety homolog 3 (Drosophila) TTYH3
205807_s at tuftelin 1 TUFT1
221964 at tubby like protein 3 TULP3
205854_at tubby like protein 3 TULP3
225791_at ubiquitin-conjugating enzyme E2F (putative) UBE2F
225783 at ubiquitin-conjugating enzyme E2F (putative) UBE2F
231948 s at ubigultin-conjugating enzyme E2F (putative) UBE2F
238528_at ubiquitin protein ligase E3 component n-recognin I UBR1
227716 at UBX domain containing 5 UBXD5
232206 at unc-51-like kinase 4 (C. elegans) ULK4
231149 s at unc-51-like kinase 4 (C. elegans) ULK4
1553183_at uromodulin-like 1 UMODL1
227453 at unc-13 homolog A (C. elegans) UNC13A
229337 at ubiquitin specific peptidase 2 USP2
211702 s at ubiquitin specific peptidase 32 USP32
244133 at ubiquitin specific peptidase 49 USP49
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201100 s at ubiquitin specific peptidase 9. X-linked OSP9X
226029 at vang-like 2 (van gogh, Drosophila) VANGL2
222436 s at vacuolar protein sorting 24 homolog (S. cerevisiae) VPS24
44111 at vacuolar protein sorting 33 homolog B (yeast) VPS33B
221704 s at vacuolar protein sorting 37 homolog B (S. cerevisiae) VPS37B
235569 at vacuolar protein sorting 37 homolog D (S. cerevisiae) VPS37D
242957 at von Willebrand factor C and EGF domains VWCE
224562 at WAS protein family, member 2 WASF2
224715 at WD repeat domain 34 WDR34
203855 at WD repeat domain 47 WDR47
218505 at WD repeat domain 59 WDR59
221981 s at WD repeat domain 59 WDR59
230193 at WD repeat domain 66 WDR66
214061 at WD repeat domain 67 WDR67
236381 s at WD repeat domain 8 WDR8
219322 s at WD repeat domain 8 WDR8
222799 at WD repeat domain 91 WDR91
222778 s at Wolf-Hirschhorn syndrome candidate 1 WHSC1
202134 s at WW domain containing transcription regulator 1 WWTRI
209375 at xeroderma pigmentosum, complementation group C XPC
224894_at Yes-associated protein 1, 65kDa YAP1
213342 at Yes-associated protein 1, 65kDa YAP1
225629 s at zinc finger and BTB domain containing 4 ZBTB4
218348 s at zinc finger CCCH-type containing 7A ZC3H7A
226897 s at zinc finger CCCH-type containing 7A ZC3H7A
220104 at zinc finger CCCH-type, antiviral 1 ZC3HAV1
225072 at zinc finger, CCHC domain containing 3 ZCCHC3
220933 s at zinc finger, CCHC domain containing 6 ZCCHC6
235698 at zinc finger protein 90 homolog (mouse) ZFP90
226124_at zinc finger protein 90 homolog (mouse) ZFP90
223387 at zinc finger, FYVE domain containing I ZFYVE1
223388 s at zinc finger, FYVE domain containing 1 ZFYVE1
203651 at zinc finger, FYVE domain containing 16 ZFYVE16
1555609 a at zinc finger, matrin type 3 ZMAT3
1552947 x at zinc finger protein 114 ZNF114
1552946 at zinc finger protein 114 ZNF114
235810 at zinc finger protein 182 ZNF182
205437 at zinc finger protein 211 ZNF211
219266 at zinc finger protein 350 ZNF350
235414 at zinc finger protein 383 ZNF383
226111 s at zinc finger protein 385A ZNF385A
223589 at zinc finger protein 416 ZNF416
219826 at zinc finger protein 419 ZNF419
58367 s at zinc finger protein 419 ZNF419
1553193 at zinc finger protein 441 ZNF441
1553192 at zinc finger protein 441 ZNF441
229766 at zinc finger protein 445 ZNF445
238493 at zinc finger protein 506 ZNF506
225021 at zinc finger protein 532 ZNF532
235200 at zinc finger protein 561 ZNF561
230205 at zinc finger protein 561 ZNF561
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1553957_at zinc finger protein 564 ZNF564
222851 at zinc finger protein 654 ZNF654
219239 s at zinc finger protein 654 ZNF654
241348 at zinc finger protein 654 ZNF654
219849 at zinc finger protein 671 ZNF671
227670 at zinc finger protein 75a ZNF75A
227284_at zinc finger protein 766 ZNF766
216486 x at zinc finger protein 79 ZNF79
216482_x at zinc finger protein 79 ZNF79
214138 at zinc finger protein 79 ZNF79
235170 at zinc finger protein 92 ZNF92
223382 s at zinc and ring finger 1 ZNRFI
223383 at zinc and ring finger 1 ZNRF1
231092 s at Zinc and ring finger I ZNRFI
231442 at zona pellucida binding protein 2 ZPBP2
238299 at
214912_at
230781 at
244397_at
244834 at
217426 at
240279 at
241663 at
239129 at
202648 at
243217 at
242017 at
1556744 a at
1556743 at
213662_at
225767 at
229219 s at
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